Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Completion Date,Start Date,Trial Duration,Primary Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
1,NCT04425538,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,,Completed,No Results Available,COVID-19,Drug: Infliximab,Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections,Tufts Medical Center|National Institutes of Health (NIH),All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,17,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000564,22-Jan-21,1-Jun-20,235,22-Jan-21,11-Jun-20,,18-Feb-21,"Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04425538
2,NCT04452435,Safety and Efficacy of C21 in Subjects With COVID-19,,Completed,Has Results,COVID-19,Drug: C21|Drug: Placebo,Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)|Change From Baseline in Body Temperature|Change From Baseline in IL-6|Change From Baseline in IL-10|Change From Baseline in TNF|Change From Baseline in CA125|Change From Baseline in Ferritin|Number of Subjects Not in Need of Oxygen Supply|Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation|Time to Need of Mechanical Invasive or Non-invasive Ventilation|Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation)|Adverse Events,Vicore Pharma AB|Orphan Reach,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 2,206,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VP-C21-006|2020-001502-38,13-Oct-20,21-Jul-20,84,13-Oct-20,30-Jun-20,30-Apr-21,30-Apr-21,"Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India|Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India|Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India|First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India|Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India|Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India|Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India|Respiratory Medicine, University College Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04452435/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04452435
3,NCT04445272,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,,Completed,No Results Available,COVID-19,Drug: Tocilizumab,To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function,Fundacion SEIMC-GESIDA|Roche Pharma AG|Dynamic Science S.L.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,495,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BREATH-19 (FSG011-20),23-Dec-20,22-May-20,215,23-Dec-20,24-Jun-20,,3-Feb-21,"Hospital Universitario de CabueÃ±es, GijÃ³n, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de DÃ©u de Manresa, Manresa, Barcelona, Spain|Hospital de MatarÃ³, MatarÃ³, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario MarquÃ©s Valdecilla, Santander, Cantabria, Spain|Hospital PÃºblico General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, CÃ¡diz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, AlcorcÃ³n, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, MÃ³stoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, MÃ³stoles, Madrid, Spain|Hospital Universitario Infanta SofÃ­a, San SebastiÃ¡n De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra SeÃ±ora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital ClÃ­nic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de MÃ¡laga, MÃ¡laga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT04445272
4,NCT04355741,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",,Completed,No Results Available,COVID-19,Other: Exposure,Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.,"Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de SÃ£o Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar UniversitÃ¡rio SÃ£o JoÃ£o|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research",All,"18 Years and older Â  (Adult, Older Adult)",,115,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,COVID19_Microbiota,16-Jul-20,20-Apr-20,87,1-Jul-20,21-Apr-20,,25-Aug-20,"Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de SÃ£o Francisco Xavier, Lisbon, Portugal|Centro Hospitalar UniversitÃ¡rio SÃ£o JoÃ£o, Oporto, Portugal",,https://ClinicalTrials.gov/show/NCT04355741
5,NCT04578158,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,,Completed,No Results Available,COVID-19,Drug: Standard COVID-19 care|Dietary Supplement: Quercetin Phytosome,Percentage of subjects with COVID-19 disease progression,Liaquat University of Medical & Health Sciences,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LUMHS/REC/894,15-Apr-21,29-Sep-20,198,28-Mar-21,8-Oct-20,,22-Apr-21,"Liaquat University Hospital, JÄmshoro, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT04578158
6,NCT04466644,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),,Completed,No Results Available,COVID-19,Diagnostic Test: ELISA|Diagnostic Test: RT-PCR,Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs|Ratio of asymptomatic immunized (IgG) population|To validate saliva specimens as a biological sample for COVID-19 testing,Igenomix,All,"18 Years and older Â  (Adult, Older Adult)",,340,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,IGX2-COV-JC-20-04|20201490,25-Aug-20,8-Jun-20,78,24-Aug-20,10-Jul-20,,14-Sep-20,"Boston IVF Fertility Clinic, Boston, Massachusetts, United States|Utah Fertility Clinic, Pleasant Grove, Utah, United States",,https://ClinicalTrials.gov/show/NCT04466644
7,NCT04610554,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,,Completed,No Results Available,COVID-19 Pneumonia,,Lung diffusing capacity for nitric oxide (DLNO)|Lung diffusing capacity for carbon monoxide (DLco),"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",All,"Child, Adult, Older Adult",,74,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SARS-CoV-2_DLNO,12-Oct-20,14-May-20,151,12-Oct-20,30-Oct-20,,30-Oct-20,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",,https://ClinicalTrials.gov/show/NCT04610554
8,NCT04342637,COVID-19 Endoscopy Survey,COVID-19 Endo,Completed,No Results Available,COVID-19,Other: Practice details,Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number,Al-Azhar University,All,"30 Years to 70 Years Â  (Adult, Older Adult)",,163,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,WES-2,1-May-20,10-Apr-20,21,25-Apr-20,13-Apr-20,,20-May-20,"Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT04342637
9,NCT04404179,Setting up a COVID-19 Care Facility at a Prison in Pakistan,,Completed,No Results Available,COVID-19,Other: COVID-19 FACILITY,Recovery|Mortality|ICU admission,"Services Institute of Medical Sciences, Pakistan",All,"Child, Adult, Older Adult",,69,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CovJ,2-May-20,27-Mar-20,36,2-May-20,27-May-20,,29-May-20,"Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan",,https://ClinicalTrials.gov/show/NCT04404179
10,NCT04716426,APTâ„¢ T3X on the COVID-19 Contamination Rate,,Completed,Has Results,COVID-19,Drug: Tetracycline hydrochloride 3%|Drug: Placebo,COVID-19 Contamination Rate.|Number of Participants With Adverse Events|Average Number of Adverse Events|Days Over Which an Adverse Event Was Reported|Other Virus or Bacteria Contamination Rate.,University of Nove de Julho|Santa Casa de MisericÃ³rdia de Porto Alegre,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",4.485.847,25-Mar-21,28-Jan-21,56,25-Mar-21,20-Jan-21,8-Apr-21,8-Apr-21,"Santa Casa de MisericÃ³rdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04716426/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04716426
11,NCT04389658,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),CONDITION,Completed,No Results Available,COVID-19,,Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA/IgM and IgG) population|Description of demographic characteristics,Igenomix,All,"Child, Adult, Older Adult",,1526,Industry,Observational,Observational Model: Other|Time Perspective: Retrospective,IGX1-COV-XS-20-01,25-Aug-20,7-May-20,110,10-Jun-20,15-May-20,,9-Oct-20,"Igenomix, Paterna, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04389658
12,NCT04558372,Genosvid Diagnostic Test for Early Detection of COVID-19,,Completed,No Results Available,COVID-19,Other: exhaled breath sampling,Diagnostic accuracy of electronic nose signal in COVID-19,Gadjah Mada University,All,"4 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,1999,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",1.6/2020,12-Dec-20,1-Apr-20,255,12-Dec-20,22-Sep-20,,29-Dec-20,"RS Bhayangkara Tk I R.Said Soekanto, Jakarta, Indonesia|Saiful Anwar, Malang, Indonesia|Dr Sardjito Hospital, Yogyakarta, Indonesia|Bambanglipuro Hospital, Yogyakarta, Indonesia|Bhayangkara Tk III Polda DIY, Yogyakarta, Indonesia|RS Akademik UGM, Yogyakarta, Indonesia|RSPAU Hardjolukito, Yogyakarta, Indonesia|RST Tk III Dr Soetarto, Yogyakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04558372
13,NCT04392141,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,,Completed,Has Results,COVID-19,Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,Mortality Rate|SpO2|Length of Hospitalization|Lymphocyte Count|Serum Lactate Dehydrogenase,Kermanshah University of Medical Sciences,All,"10 Years and older Â  (Child, Adult, Older Adult)",Phase 1|Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1399.062,1-Nov-20,1-Apr-20,214,1-Nov-20,18-May-20,20-Apr-21,20-Apr-21,"Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04392141
14,NCT04418284,Online Learning of Veterinary Anatomy During COVID-19 Pandemic,,Completed,No Results Available,COVID-19,Other: survey,Measure the students' interest in studying anatomy on-line.|Assess the easiness of using technology during studying anatomy online|Assess the student satisfaction regarding the provided study materials,South Valley University,All,"17 Years to 35 Years Â  (Child, Adult)",,1517,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,20-Feb,5-Nov-20,5-Jun-20,153,5-Nov-20,5-Jun-20,,16-Mar-21,"South Valley University, QinÄ, Egypt",,https://ClinicalTrials.gov/show/NCT04418284
15,NCT04449718,Vitamin D Supplementation in Patients With COVID-19,,Completed,No Results Available,COVID-19,Dietary Supplement: Vitamin D|Dietary Supplement: Placebo,Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity,University of Sao Paulo,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30959620.4.0000.0068,7-Oct-20,1-Jun-20,128,7-Oct-20,29-Jun-20,,17-Nov-20,"Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04449718
16,NCT04324489,DAS181 for Severe COVID-19: Compassionate Use,,Completed,No Results Available,COVID-19,Drug: DAS181,Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death,"Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAS181-SARS-CoV-2,30-Apr-20,6-Mar-20,55,16-Apr-20,27-Mar-20,,5-May-20,"Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04324489
17,NCT04370262,Multi-site Adaptive Trials for COVID-19,,Completed,No Results Available,COVID-19,Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo,Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity,Northwell Health,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,233,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-0268,7-Sep-20,7-Apr-20,153,7-Sep-20,30-Apr-20,,11-Dec-20,"Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",,https://ClinicalTrials.gov/show/NCT04370262
18,NCT04474496,Impact of COVID-19 on Marshallese Communities in the U.S.,,Completed,Has Results,COVID-19,Other: Assessing the impact of COVID-19,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure|Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure|Effects of COVID-19 on General Health Status|Effects of COVID-19 on Access to Healthcare Services|Effects of COVID-19 on Dietary Habits|Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)|Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)|Effects of COVID-19 on Weight|Effects of COVID-19 on HbA1c (Glycated Hemoglobin)|Barriers to Type 2 Diabetes Management Due to COVID-19|COVID-19 Screening|COVID-19 Testing|COVID-19 Vaccine Willingness/Hesitancy|Trusted Sources of COVID-19 Information|Effects of COVID-19 on Housing|Effects of COVID-19 on Employment|Effects of COVID-19 on Income|Sources of Stress During COVID-19,University of Arkansas|Patient-Centered Outcomes Research Institute,All,"18 Years and older Â  (Adult, Older Adult)",,120,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,261131,30-Nov-20,27-Jul-20,126,30-Nov-20,16-Jul-20,5-Apr-21,5-Apr-21,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04474496/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04474496
19,NCT04335123,Study of Open Label Losartan in COVID-19,,Completed,No Results Available,COVID-19,Drug: Losartan,"Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg",University of Kansas Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,34,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00145514,17-Aug-20,4-Apr-20,135,21-Jun-20,6-Apr-20,,10-May-21,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04335123
20,NCT04321421,Hyperimmune Plasma for Critical Patients With COVID-19,COV19-PLASMA,Completed,No Results Available,COVID-19,Other: hyperimmune plasma,death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response,Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,49,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRCCSSanMatteoH,7-May-20,17-Mar-20,51,28-Apr-20,25-Mar-20,,28-May-20,"Catherine Klersy, Pavia, PV, Italy|Ospedale Asst Carlo Poma Mantova, Mantova, Italy",,https://ClinicalTrials.gov/show/NCT04321421
21,NCT04646109,Ivermectin for Severe COVID-19 Management,,Completed,Has Results,COVID-19,Drug: Ivermectin,Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity,Afyonkarahisar Health Sciences University|NeuTec Pharma,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,66,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVMC_03,2-Sep-20,11-May-20,114,2-Sep-20,27-Nov-20,27-Jan-21,27-Jan-21,"Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|YÄ±ldÄ±rÄ±m BeyazÄ±t University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, Ä°stanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT04646109
22,NCT04306497,TCM Differentiation and Treatment Protocol of COVID-19,TDATPOC,Completed,No Results Available,COVID-19,Drug: TCM prescriptions,The relief of main symptoms/ disappearance rate of time|Chest CT absorption|Evaluation standard of comprehensive curative effect|Virus antigen negative conversion rate|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score,"Jiangsu Famous Medical Technology Co., Ltd.",All,"18 Years to 80 Years Â  (Adult, Older Adult)",,340,Industry,Observational,Observational Model: Cohort|Time Perspective: Other,JSZYJ202001,30-May-20,22-Jan-20,129,30-Apr-20,13-Mar-20,,4-Jun-20,"Huai'an fourth people's Hospital, Huaian, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04306497
23,NCT04364022,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,COPEP,Completed,No Results Available,Prevention of COVID-19,Drug: Lopinavir/ritonavir,"21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale","Calmy Alexandra|University Hospital, Geneva",All,"16 Years and older Â  (Child, Adult, Older Adult)",Phase 3,326,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CCER 2020-00864,24-Mar-21,23-Apr-20,335,24-Mar-21,27-Apr-20,,12-Apr-21,"Instituto Nacional de Infectiologia Evandro Chagas, Fiocruz, Rio De Janeiro, Brazil|UniversitÃ¤tsspital Basel and SwissTPH, Basel, Switzerland|HÃ´pitaux Universitaires de GenÃ¨ve, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland",,https://ClinicalTrials.gov/show/NCT04364022
24,NCT04382066,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,APLICOV-PC,Completed,No Results Available,COVID-19,Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day,Frequency of occurrence of Neutropenia â‰¥ grade 3|Frequency of occurrence of Thrombocytopenia â‰¥ grade 3|Frequency of occurrence of Anemia â‰¥ grade 3|Frequency of occurrence of Lymphopenia â‰¥ grade 3|Frequency of occurrence of CPK increase â‰¥ grade 3|Frequency of occurrence of Increase ALT and / or AST â‰¥ grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin â‰¥ grade 3|Frequency of occurrence of Neurotoxicity â‰¥ grade 3|Frequency of occurrence of QT-QTc interval extension â‰¥ grade 3|Frequency of occurrence of Other adverse events â‰¥ grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and / or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy,PharmaMar|Apices Soluciones S.L.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,46,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APL-D-002-20|2020-001993-31,23-Dec-20,12-May-20,225,23-Dec-20,11-May-20,,28-Dec-20,"Hospital Universitario Hm MonteprÃ­ncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital RamÃ³n Y Cajal, Madrid, Spain|Hospital ClÃ­nico San Carlos, Madrid, Spain|Hosptial Quironsalud Madrid, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04382066
25,NCT04382092,Co-infection Management in COVID-19 Critically Ill,,Completed,No Results Available,COVID-19,Diagnostic Test: FilmArray Pneumonia,% of COVID-19 co-infections|% of antibiotic switches following FA results,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain|BioMÃ©rieux,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,32,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2019/14MAR/124,24-Apr-20,23-Mar-20,32,24-Apr-20,11-May-20,,11-May-20,"Cliniques Universitaires Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04382092
26,NCT04352582,COVID-19 and Vaccination Attitudes,VACAT,Completed,No Results Available,COVID-19,Other: Survey,How vaccination and other attitudes are affected by COVID,"University Hospital, Geneva|University of Zurich|University of Lausanne",All,"Child, Adult, Older Adult",,1194,Other,Observational,Observational Model: Other|Time Perspective: Prospective,VACAT,30-Apr-20,14-Apr-20,16,30-Apr-20,20-Apr-20,,13-Nov-20,"Survey, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04352582
27,NCT04370808,VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection,VITACOV,Completed,No Results Available,COVID-19,Other: Exposure,Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.,"University of Lisbon|Cardiovascular Centre of Universidade de Lisboa (CCUL)|Faculty of Medicine of Universidade de Lisboa (FMUL)|Centro Hospitalar UniversitÃ¡rio Lisboa Norte (CHULN)|Centro Hospitalar UniversitÃ¡rio SÃ£o JoÃ£o (CHUSJ)|CINTESIS - Center for Health Technology and Services Research|NOVA Medical School of Universidade NOVA de Lisboa|HeartGenetics, Genetics and Biotechnology SA|Instituto Gulbenkian de CiÃªncia (IGC)",All,"18 Years and older Â  (Adult, Older Adult)",,517,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,VITACOV,31-Jan-21,1-Aug-20,183,1-Jan-21,1-May-20,,28-Apr-21,"Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar UniversitÃ¡rio Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de SÃ£o JoÃ£o, Oporto, Portugal",,https://ClinicalTrials.gov/show/NCT04370808
28,NCT04832061,Respiratory Supports and COVID-19 Mortality,,Completed,No Results Available,COVID-19,Other: Respiratory supports,rate of in-hospital mortality|rate of escalation from non-invasive ventilation to invasive mechanical ventilation,Yale University,All,"18 Years and older Â  (Adult, Older Adult)",,2300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2000028070,20-Apr-21,1-Apr-21,19,20-Apr-21,5-Apr-21,,13-May-21,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04832061
29,NCT04344145,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,,Completed,No Results Available,COVID-19,,Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations,UniversitÃ© Libre de Bruxelles,All,"18 Years and older Â  (Adult, Older Adult)",,693,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,PSY-ENCOVID19,29-May-20,16-Apr-20,43,25-May-20,14-Apr-20,,9-Sep-20,"HÃ´pital de Warquignies, Boussu, Hainaut, Belgium|HÃ´pital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium|HÃ´pital de Lobbes, Lobbes, Hainaut, Belgium|HÃ´pital de Mons, Mons, Hainaut, Belgium|Erasme Hospital CUB, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04344145
30,NCT04343768,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",COVIFERON,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B,Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization,Shahid Beheshti University of Medical Sciences,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Different Interferons in COVID,27-Apr-20,9-Apr-20,18,27-Apr-20,13-Apr-20,,5-May-20,"Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT04343768
31,NCT04344015,COVID-19 Plasma Collection,,Completed,No Results Available,COVID-19,Other: Plasma Donation,Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures,Thomas Jefferson University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,206,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20D.346,2-Jun-20,13-Apr-20,50,2-Jun-20,14-Apr-20,,10-May-21,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04344015
32,NCT04391712,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,,Completed,No Results Available,COVID-19,Device: MLS Laser|Other: Regular Inpatient Medical Care,Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels,Lowell General Hospital,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020.01,16-Jul-20,30-Apr-20,77,15-May-20,18-May-20,,5-Aug-20,"Lowell General Hospital, Lowell, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04391712
33,NCT04432324,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),,Completed,No Results Available,COVID-19,Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment,Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS â‰¤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Length of Time to Clinical Progression|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS),"Instituto Grifols, S.A.|Grifols Therapeutics LLC",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC2004|2020-001696-32,3-Mar-21,2-Jun-20,274,3-Mar-21,16-Jun-20,,10-Mar-21,"Hospital Universitario Infanta SofÃ­a, San SebastiÃ¡n De Los Reyes, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04432324
34,NCT04542694,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,,Completed,Has Results,COVID-19,Drug: Favipiravir|Drug: Standard of care,Rate of Clinical Status Improvement|Time to Clinical Improvement|Rate of Viral Elimination by Day 10|Time Before the End of Fever|Change in the Level of Lung Damage According to CT|Rate of Transfer to the Intensive Care Unit|Rate of the Use of Non-invasive Lung Ventilation|Rate of the Use of Mechanical Ventilation|Mortality,"Promomed, LLC",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FAV052020,20-Aug-20,21-May-20,91,10-Aug-20,9-Sep-20,5-Nov-20,5-Nov-20,"State Clinical Hospital â„–50, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital â„–1, Smolensk, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04542694/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04542694
35,NCT04492475,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),,Completed,No Results Available,COVID-19,Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir,"Time to recovery for patients with baseline ordinal score 4, 5, and 6|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in hemoglobin|Change from baseline in international normalized ratio (INR)|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of invasive mechanical ventilation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of non invasive ventilation or high flow oxygen use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of study product administration|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change from baseline in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale for patients with baseline ordinal score 4 and 5|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Time to recovery for patients with a baseline ordinal score of 4 and 5",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 3,969,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-3,21-Dec-20,5-Aug-20,138,21-Dec-20,30-Jul-20,,9-Feb-21,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael CosÃ­o Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y NutriciÃ³n Salvador ZubirÃ¡n - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04492475/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04492475
36,NCT04401579,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),,Completed,Has Results,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin International Normalized Ratio (INR)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Duration of Oxygen Use|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Oxygen Use|Mean Change in the Ordinal Scale|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|14-day Participant Mortality|28-day Participant Mortality|Time to an Improvement of One Category Using an Ordinal Scale|Time to an Improvement of Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First|Change From Baseline in C-reactive Protein (CRP)|Change From Baseline in D-dimer Concentration",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 3,1033,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-2,31-Jul-20,8-May-20,84,31-Jul-20,26-May-20,26-Apr-21,26-Apr-21,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y NutriciÃ³n Salvador ZubirÃ¡n - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael CosÃ­o Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, CataluÃ±a, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, CataluÃ±a, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/SAP_003.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04401579
37,NCT04280705,Adaptive COVID-19 Treatment Trial (ACTT),,Completed,Has Results,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 3,1062,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,21-May-20,21-Feb-20,90,21-May-20,21-Feb-20,25-Sep-20,9-Dec-20,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|UniversitÃ¤tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y NutriciÃ³n Salvador ZubirÃ¡n - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael CosÃ­o Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, CataluÃ±a, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, CataluÃ±a, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT04280705
38,NCT04547127,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),,Completed,No Results Available,COVID-19,Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment,All-Cause Mortality Rate|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by NEWS â‰¤ 2 Maintained for 24 hours|Time to Hospital Discharge|Time to ICU Discharge|Duration of All Oxygen Use|Duration of Mechanical Ventilation|Absolute Value Change from Baseline in Ordinal Scale|Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale,"Instituto Grifols, S.A.|Grifols Therapeutics LLC",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC2003|2020-001299-14,4-Feb-21,29-Apr-20,281,4-Feb-21,14-Sep-20,,3-Mar-21,"Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|FundaciÃ³n Jimenez Diaz, Madrid, Spain|Hospital ClÃ­nico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Complejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital ClÃ­nico Universitario de Santiago -CHUS, Santiago, Spain|Hospital Universitari Joan XXIII, Tarragona, Spain",,https://ClinicalTrials.gov/show/NCT04547127
39,NCT04459520,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,,Completed,No Results Available,COVID-19,Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario,Behavioral Intentions|Personal Decisions Subscale|Social Expectations Subscale|Voting Behavior Question|Protest Question|Transportation,"University of California, Los Angeles",All,"18 Years to 110 Years Â  (Adult, Older Adult)",Not Applicable,1400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,IRB#20-000980,29-Jul-20,23-Jul-20,6,28-Jul-20,7-Jul-20,,20-Aug-20,"UCLA Health Department of Medicine, Quality Office, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04459520
40,NCT04358536,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,,Completed,No Results Available,COVID-19,Device: CovX,Identification of COVID-19,Dascena,All,"18 Years and older Â  (Adult, Older Adult)",,230,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,4202002,17-Apr-20,1-Apr-20,16,17-Apr-20,24-Apr-20,,24-Apr-20,"Dascena, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT04358536
41,NCT04475107,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,,Completed,No Results Available,COVID-19,Drug: Pyronaridine-Artesunate|Drug: Placebo,"Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*|Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline|Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*|Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Time to achieve normalization of body temperature, post-dose|Time to achieve normalization of respiratory rate, post-dose|Time to achieve normalization of oxygen saturation, post-dose",Shin Poong Pharmaceutical Co. Ltd.,All,"19 Years and older Â  (Adult, Older Adult)",Phase 2,113,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SP-PA-COV-201,15-Apr-21,9-Jul-20,280,25-Mar-21,17-Jul-20,,21-Apr-21,"Korea University Ansan Hospital, Ansan, Korea, Republic of|Chungnam national University Hospital, Daejeon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyungpook National University Hospital, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Sahmyook Medical Center, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Eunpyeong St. Marys' Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04475107
42,NCT04641988,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19),COROBIOCHIC,Completed,No Results Available,COVID-19,,hs-cTnT|NT-proBNP,"University Hospital, Montpellier",All,"18 Years to 99 Years Â  (Adult, Older Adult)",,111,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0625,30-Jun-20,1-Feb-20,150,1-Mar-20,24-Nov-20,,24-Nov-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04641988
43,NCT04331171,Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,COVID CALL 15,Completed,No Results Available,COVID-19,Device: Web application users,To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population,Weprom|Institut Pasteur|Assistance Publique - HÃ´pitaux de Paris|DOCAPOST|Direction GÃ©nÃ©rale de l'Offre de Soins,All,"18 Years and older Â  (Adult, Older Adult)",,12000000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,WP-2020-02,15-Nov-20,17-Mar-20,243,15-Nov-20,2-Apr-20,,8-Apr-21,"All French Emergency services, Le Mans, France",,https://ClinicalTrials.gov/show/NCT04331171
44,NCT04355936,Telmisartan for Treatment of COVID-19 Patients,,Completed,No Results Available,COVID-19 Drug Treatment,Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,"C reactive protein|Admission to intensive care unit (ICU)|Occurrence of mechanical ventilation|Death|Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first)|Time from randomization to discharge|Proportion of patients not requiring supplemental oxygen at day 15|Significative differences in serum lactate dehydrogenase","Laboratorio Elea Phoenix S.A.|Carlos R. Rojo, MD|Facultad de Medicina, Universidad de Buenos Aires, UBA",All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,400,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001,30-Nov-20,19-May-20,195,2-Nov-20,21-Apr-20,,24-Dec-20,"Hospital de ClÃ­nicas 'JosÃ© de San MartÃ­n', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital EspaÃ±ol de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04355936
45,NCT04380688,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,CALAVI US,Completed,No Results Available,COVID-19,Drug: Acalabrutinib,Occurrence of Adverse Events and Serious Adverse Events|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (SpO2/FiO2)|Time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale|Time to SpO2 > 94% on room air|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862,AstraZeneca|Acerta Pharma BV,All,"18 Years to 130 Years Â  (Adult, Older Adult)",Phase 2,62,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D822FC00003,16-Nov-20,13-Jun-20,156,16-Nov-20,8-May-20,,2-Dec-20,"Research Site, Anniston, Alabama, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Newport Beach, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT04380688
46,NCT04346199,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,CALAVI,Completed,No Results Available,COVID-19,Drug: Acalabrutinib,Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC),AstraZeneca|Acerta Pharma BV,All,"18 Years to 130 Years Â  (Adult, Older Adult)",Phase 2,177,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D822FC00001,17-Nov-20,12-Jun-20,158,17-Nov-20,15-Apr-20,,2-Feb-21,"Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Monte Grande, Argentina|Research Site, Ramos MejÃ­a, Argentina|Research Site, Botucatu, Brazil|Research Site, FlorianÃ³polis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, RibeirÃ£o Preto, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Curico, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Villejuif Cedex, France|Research Site, Frankfurt, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, KÃ¶ln, Germany|Research Site, Bangalore, India|Research Site, New Delhi, India|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Shinjuku-ku, Japan|Research Site, D.F, Mexico|Research Site, Monterrey, Mexico|Research Site, MÃ©xico, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Cape Town, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Ankara, Turkey|Research Site, Bakirkoy, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Umraniye, Turkey",,https://ClinicalTrials.gov/show/NCT04346199
47,NCT04771013,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,,Completed,No Results Available,COVID-19,Biological: Thymic peptides,Time to Participant Recovery|Number of Participants with Treatment Related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)|Number of Participants with Treatment Related Side Effects as Assessed by the General Assessment of Side Effects (GASE)|Overall Survival Defined as the Time From the Start of Treatment until Death due to any Reason,Universidad CatÃ³lica de Honduras|Pontificia Universidad Catolica de Chile,All,"21 Years and older Â  (Adult, Older Adult)",Phase 2,22,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEC-01-2021|COM-2020-01,14-May-21,10-Feb-21,93,14-May-21,25-Feb-21,,18-May-21,"Hospital de Santa BÃ¡rbara Integrado, Santa BÃ¡rbara, Honduras",,https://ClinicalTrials.gov/show/NCT04771013
48,NCT04521309,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,,Completed,No Results Available,COVID-19,Biological: SARS-CoV-2 antibody based IVIG therapy,28 Days mortality|Requirement of supplemental oxygen support|Number of days on assisted ventilation|Days to step down|Days to Hospital Discharge|Adverse events during hospital stay|Change in C-Reactive Protein (CRP) levels|Change in neutrophil lymphocyte ratio|Change in Ferritin levels|Change in lactate dehydrogenase (LDH) levels|Change in radiological (X-ray) findings|Days to negative SARS-CoV-2 Polymerase Chain Reaction (PCR) test|Anti-SARS-CoV-2 Antibody|Change in fever|Change in Sodium levels|Change in Potassium levels|Change in Chloride levels|Change in Bicarbonate levels,Dow University of Health Sciences|Higher Education Commission (Pakistan),All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,biotech001,8-Feb-21,19-Jun-20,234,26-Jan-21,20-Aug-20,,24-Mar-21,"Dow University of Health Sciences, Karachi, Sindh, Pakistan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04521309/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04521309
49,NCT04381884,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,,Completed,No Results Available,COVID-19 Drug Treatment,Drug: IVERMECTIN (IVER PÂ®) arm will receive IVM 600 Âµg / kg once daily plus standard care. CONTROL arm will receive standard care.,Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2,Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de InvestigaciÃ³n Veterinaria Tandil CIVETAN|Hospital de PediatrÃ­a Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes,All,"18 Years to 69 Years Â  (Adult, Older Adult)",Phase 2,45,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVM-AR-1,29-Sep-20,18-May-20,134,29-Sep-20,11-May-20,,5-Oct-20,"Hospital de Cuenca Alta, CaÃ±uelas, Buenos Aires, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones ClÃ­nicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier MuÃ±iz, Ciudad Autonoma de Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04381884
50,NCT04345523,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,ConPlas-19,Completed,No Results Available,COVID-19,Other: Blood and derivatives.|Drug: Standard of Care,"Category Changes in the ""7-Ordinal Scale""|Time to category 5, 6 or 7 of the "" 7-Ordinal scale""|Time to an improvement of one category from admission in the ""7-Ordinal scale""|Status at day 30 in the ""11-Ordinal scale""|Status at day 15 and 30 in the ""11-Ordinal scale""|Time to first deterioration|Mean change in the ranking in the ""7-Ordinal scale"" from baseline to days 3,5,8,11,15,29 and 60|Mean change in the ranking in the ""11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60.|Mortality of any cause at 15 days|Mortality of any cause at 28 days (day 29)|Mortality of any cause at 60 days|Oxygenation free days|Ventilator free days|Duration of hospitalization (days)|Infusion-related adverse events|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load|Incidence of thrombotic arterial events|Incidence of thrombotic venous events|rate of rehospitalizations",Cristina AvendaÃ±o SolÃ¡|Instituto de Salud Carlos III|Puerta de Hierro University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,350,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ConPlas-19,5-Apr-21,3-Apr-20,367,5-Feb-21,14-Apr-20,,13-May-21,"Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, AragÃ³n, Spain|Hospital Universitario MÃºtua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital General de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Donostia, Donostia, Spain|Hospital Doctor Josep Trueta, Girona, Spain|Hospital Doctor NegrÃ­n, Las Palmas, Spain|Complejo Asistencial Universitario de LeÃ³n, LeÃ³n, Spain|Hospital Universitario Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, LogroÃ±o, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Hospital ClÃ­nico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Sant Joan de Deu de Manresa. FundaciÃ³n Althaia, Manresa, Spain|Hospital Universitario de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|ClÃ­nica Universidad de Navarra (CUN). Sedes Pamplona y Madrid, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario MarquÃ©s de Valdecilla, Santander, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital ClÃ­nico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT04345523
51,NCT04407494,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),COVID-OLFA,Completed,No Results Available,COVID-19,"Biological: Reporting of anosmia, ageusia and other clinical symptoms",Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,809,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0176,30-Apr-20,1-Mar-20,60,1-Apr-20,29-May-20,,1-Jun-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04407494
52,NCT04456153,Atovaquone for Treatment of COVID-19,,Completed,No Results Available,COVID-19,Drug: Experimental Group|Drug: Placebo Group,Primary Analysis|Secondary Between group differences in viral load|AUC comparison|Stratified|Time to viral load drop|Ordinal scale,University of Texas Southwestern Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,61,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STU-2020-0707,31-Jan-21,22-Jul-20,193,31-Jan-21,2-Jul-20,,21-Feb-21,"University of Texas Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04456153
53,NCT04757792,Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU,,Completed,No Results Available,COVID-19 Disease,Other: File inquiry,Mortality rate,Benha University|Tanta University|Cairo University,All,"Child, Adult, Older Adult",,475,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,RC1-2-2021,11-Feb-21,6-Jun-20,250,1-Feb-21,17-Feb-21,,17-Feb-21,"Faculty of Medicine, BanhÄ, Qalubia, Egypt",,https://ClinicalTrials.gov/show/NCT04757792
54,NCT04435184,Crizanlizumab for Treating COVID-19 Vasculopathy,CRITICAL,Completed,No Results Available,COVID-19,Drug: Crizanlizumab|Other: 0.9% saline,Soluble P-selectin level|D-dimer level|VWF level|CRP level|Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials|Time to hospital discharge|Safety of Crizanlizumab as assessed by adverse events,Johns Hopkins University|Novartis|Socar Research SA|Brigham and Women's Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,50,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00249874,4-Jan-21,9-Jul-20,179,28-Nov-20,17-Jun-20,,19-Jan-21,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04435184
55,NCT04525443,Endothelial Function and COVID-19,,Completed,No Results Available,COVID-19,,Reactive hyperemia index (RHI)|Percentage of COVID-19 patients with impaired endothelial vasodilator function.|Percentage of non-COVID-19 patients with impaired endothelial vasodilator function.,"Hospital San Carlos, Madrid|Mayo Clinic",All,"Child, Adult, Older Adult",,110,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20/451,11-Feb-21,3-Jun-20,253,11-Nov-20,25-Aug-20,,26-Feb-21,"Mayo Clinic, Rochester, Minnesota, United States|Hospital ClÃ­nico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04525443
56,NCT04315298,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,,Completed,No Results Available,COVID-19,Drug: Sarilumab|Drug: Placebo,"Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of â‰¤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation â‰¥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level",Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,1912,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6R88-COV-2040,2-Sep-20,18-Mar-20,168,24-Jul-20,19-Mar-20,,1-Oct-20,"Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04315298
57,NCT04898088,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,REPAIR,Completed,No Results Available,COVID-19 Pneumonia,Biological: Mesenchymal Stem Cells Transplantation,"Expression of PARP1 gene as indicator of base excision repair|Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair|Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair|Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair",SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi|Istinye University|Liv Hospital (Ulus),All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8860/9193,30-Sep-20,1-Jan-20,273,30-Aug-20,24-May-21,,24-May-21,"Istinye University, Istanbul, Turkey|SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04898088
58,NCT04616976,COVID-19 With Convalescent Plasma,,Completed,No Results Available,COVID-19 Convalescent Plasma Treatment,Biological: convalescent plasma,28-day mortality|SARS-CoV-2 negative conversion rate,"Southeast University, China",All,"18 Years and older Â  (Adult, Older Adult)",,78,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,COVID-19 convalescent plasma,1-Nov-20,1-Jan-20,305,29-Feb-20,5-Nov-20,,5-Nov-20,"Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04616976
59,NCT04367896,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,,Completed,No Results Available,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION,Other: Survey Group,Management of Solid Organ Transplant during COVID-19 pandemic|Equity of resource distribution|Equity rank of resource distribution,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,"Child, Adult, Older Adult",,1819,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Covid-19_V1,17-Apr-20,24-Mar-20,24,17-Apr-20,29-Apr-20,,29-Apr-20,"Fondazione Policlinico Universitario ""Agostino Gemelli"", Rome, Italy",,https://ClinicalTrials.gov/show/NCT04367896
60,NCT04425252,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,CRISIS,Completed,No Results Available,COVID-19,Drug: Brequinar|Other: Standard of Care,Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration,"Clear Creek Bio, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCB-CRISIS-01,29-Dec-20,1-Aug-20,150,29-Dec-20,11-Jun-20,,19-Jan-21,"Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|University of New Mexico, Albuquerque, New Mexico, United States|Temple University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04425252
61,NCT04337996,Dynamic Evaluation of COVID-19 Diagnostic Tests,TRODVID-19,Completed,No Results Available,COVID-19,Diagnostic Test: COVID-19 diagnostic test,Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies|Positive or negative Covid-19 test|Positive or negative character of the antibodies test|Biological parameters|medical-economic comparison,Tourcoing Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RIPH_2020_6,13-Jan-21,13-Jul-20,184,13-Jan-21,8-Apr-20,,26-Jan-21,"CH Tourcoing, Tourcoing, France",,https://ClinicalTrials.gov/show/NCT04337996
62,NCT04422509,Lanadelumab for Treatment of COVID-19 Disease,COVID_LAN,Completed,No Results Available,COVID-19,Biological: lanadelumab|Other: regular care,oxygen|adverse events,Radboud University|Takeda,All,"16 Years and older Â  (Child, Adult, Older Adult)",Phase 1|Phase 2,43,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCN-AKF20.04,30-Apr-21,30-Oct-20,182,25-Feb-21,9-Jun-20,,5-May-21,"Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|UMC Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT04422509
63,NCT04389567,Famotidine Outpatient COVID-19 Treatment Study,,Completed,No Results Available,COVID-19,Drug: Famotidine,Symptomatic improvement|Peripheral blood oxygen saturation,Northwell Health|Cold Spring Harbor Laboratory,All,"18 Years and older Â  (Adult, Older Adult)",,10,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,1605914-1,25-May-20,12-May-20,13,25-May-20,15-May-20,,4-Jun-20,"Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States",,https://ClinicalTrials.gov/show/NCT04389567
64,NCT04413045,"Novel COVID-19, A National Analysis",,Completed,No Results Available,COVID-19,Other: Prevalence of COVID-19,Patient Prognosis Score|Oxygen Saturation|Laboratory Data|Radiological Features|Hospital Stay|Liver Function|Kidney Function,Assiut University,All,"Child, Adult, Older Adult",,61,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,Novel COVID-19 Prevalence,28-Jul-20,20-May-20,69,28-Jul-20,2-Jun-20,,4-Aug-20,"Assiut University Hospitals, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04413045
65,NCT04387214,COVID-19 Pandemic and Academic Performance of Veterinary Students,,Completed,No Results Available,COVID-19,Other: survey,Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students|Measure the average studying time|Evaluate on-line education during COVID-19 pandemic lockdown|Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown,South Valley University,All,18 Years to 60 Years Â  (Adult),,1426,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,20-Jan,10-Aug-20,13-Apr-20,119,10-Aug-20,13-May-20,,9-Sep-20,"South Valley University, QinÄ, Egypt",,https://ClinicalTrials.gov/show/NCT04387214
66,NCT04380519,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,Completed,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,24-Jul-20,23-Apr-20,92,10-Jul-20,8-May-20,,29-Sep-20,"Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital â„– 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|ÐÐž ""State Company ""Medsi"" based on Clinical Hospital â„–1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital â„–40"", Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT04380519
67,NCT04326920,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),SARPAC,Completed,No Results Available,COVID-19,Drug: Sargramostim|Other: Control,"Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","University Hospital, Ghent|Flanders Institute of Biotechnology",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 4,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SARPAC,26-Feb-21,24-Mar-20,339,28-Sep-20,30-Mar-20,,2-Mar-21,"AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium",,https://ClinicalTrials.gov/show/NCT04326920
68,NCT04365725,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",REMDECO-19,Completed,No Results Available,COVID-19,Drug: Remdesivir,Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).,Assistance Publique - HÃ´pitaux de Paris,All,"18 Years and older Â  (Adult, Older Adult)",,84,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP200522,12-Jun-20,5-May-20,38,12-Jun-20,28-Apr-20,,19-Apr-21,"HÃ´pital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT04365725
69,NCT04365699,Cardiovascular Effects of COVID-19,,Completed,No Results Available,COVID-19,Drug: AT-001,Proportion of subjects with decreased left ventricular ejection fraction â‰¥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction â‰¥10% from baseline at time of hospitalization,NYU Langone Health,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-00416,31-Jan-21,8-Apr-20,298,31-Jan-21,28-Apr-20,,12-May-21,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04365699
70,NCT04691921,Current Pharmacological Practices in Severe COVID-19,,Completed,No Results Available,COVID-19,Behavioral: Current clinical practices of participating physicians,Choice and indication of pharmacological agents for management of Severe COVID-19,NMC Specialty Hospital,All,"20 Years to 70 Years Â  (Adult, Older Adult)",,1055,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NMCSH,31-Jan-21,4-Jan-21,27,18-Jan-21,31-Dec-20,,16-Feb-21,"Reliance Hospital, Mumbai, Mumbai, Mahrastra, India",,https://ClinicalTrials.gov/show/NCT04691921
71,NCT04395664,Arrhythmias in Patients With COVID-19,ACOVID,Completed,No Results Available,COVID-19,Device: C3+ Holter Monitor,In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis,Herlev and Gentofte Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,H-20021500,1-Sep-20,16-Apr-20,138,1-Sep-20,20-May-20,,9-Sep-20,"Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT04395664
72,NCT04569188,Convalescent Plasma in COVID-19 Elderly Patients,RESCUE,Completed,No Results Available,COVID-19,Biological: Convalescent plasma,Death|Viral load,Azienda Socio Sanitaria Territoriale di Mantova,All,65 Years and older Â  (Older Adult),Phase 2,21,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Asstmantova,3-Sep-20,15-May-20,111,15-Aug-20,29-Sep-20,,5-Oct-20,"Transfusion Service, Mantova, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04569188/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04569188
73,NCT04492943,To Observe Whether Isoflurane Can Treat COVID-19 Patients,,Completed,No Results Available,COVID-19,,Survival Outcome|COVID-19 Testing Methods|COVID-19 Clearance,Massachusetts General Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,35,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020P001048,30-Jun-20,20-Apr-20,71,30-Jun-20,30-Jul-20,,2-Sep-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04492943
74,NCT04351243,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),,Completed,No Results Available,COVID-19,Drug: Gimsilumab|Drug: Placebo,Incidence of mortality|Incidence of subjects who are alive and not on mechanical ventilation|Number of ventilator-free days|Time to hospital discharge,"Kinevant Sciences GmbH|Roivant Sciences, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,227,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KIN-1901-2001,1-Apr-21,12-Apr-20,354,1-Dec-20,17-Apr-20,,5-Apr-21,"Banner University Medical Center, Phoenix, Arizona, United States|HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States|Banner University Medical Center, Tucson, Arizona, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Miami Cancer institute, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints Medical Center, Fort Worth, Texas, United States|Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|Baylor Scott & White Medical Center, Irving, Texas, United States|Baylor Scott & White Medical Center, Plano, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04351243
75,NCT04441996,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,,Completed,No Results Available,COVID-19,Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care,Change in Plasma Viscosity|All Cause Mortality|Bleeding and Thromboembolic Complications|Time to Treatment Failure|Duration of ICU Stay|Duration of Hospital Stay|Discharge Disposition|Change in Clinical Status|Change in Body Temperature|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate|Change in Respiratory Rate|Change in Ventilator Days|Change in Ventilator Oxygen Percent (FiO2)|Change in Positive End-Expiratory Pressure (PEEP)|Change in Vasopressor Requirements|Change in Need for Treatment from a Registered Respiratory Therapist (RRT)|Change in Sequential Organ Failure Assessment (SOFA) Score|Change in Partial Pressure of Arterial Oxygen (PaO2)/Percentage of Inspired Oxygen (FiO2) Ratio|Change in Ventilatory Ratio|Change in White Blood Count (WBC)|Change in Hemoglobin (Hb)|Change in Hematocrit (Hct)|Change in Platelet Count|Change in Mean Platelet Volume (MVP)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Bilirubin|Change in Total Protein|Change in Albumin|Change in C-reactive Protein (CRP)|Change in Interleukin 6 (IL-6)|Change in Prothrombin Time (PT)|Change in International Normalized Ratio (INR)|Change in Activated Partial Thromboplastin Time (aPTT)|Change in Anti-factor Xa (anti-Xa)|Change in Fibrinogen|Change in D-dimer,Emory University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000949,18-Mar-21,17-Jul-20,244,18-Mar-21,22-Jun-20,,29-Mar-21,"Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04441996
76,NCT04337541,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,,Completed,No Results Available,COVID-19,Other: Surgical facial mask,"The primary endpoint is the difference in SARS-CoV-2 infection between the two groups after 1 months and is a combined endpoint consisting of primary outcome components 1, 2 and/or 3:|Positive oropharyngeal/nasal swab (PCR);","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,6000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,4/2/2020,2-Jun-20,2-Apr-20,61,2-Jun-20,7-Apr-20,,3-Aug-20,"Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04337541
77,NCT04750317,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,TOFA-COV-2,Completed,No Results Available,COVID-19,Drug: Tofacitinib,Death|Mechanical ventilation,I.M. Sechenov First Moscow State Medical University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,414,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,107892,1-Sep-20,11-May-20,113,1-Aug-20,11-Feb-21,,15-Feb-21,"Sechenov First Moscow State Medical University (Sechenov University) - University Clinical Hospital, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04750317
78,NCT04382586,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,,Completed,No Results Available,COVID-19 Pulmonary Complications|COVID-19,Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo,Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale,BeiGene,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BGB-3111-219,8-Apr-21,6-Jul-20,276,2-Feb-21,11-May-20,,7-May-21,"Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04382586
79,NCT04377789,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,,Completed,No Results Available,COVID-19,Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment,Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate,Kanuni Sultan Suleyman Training and Research Hospital|Orbiteratec (funding),All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,447,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,KSSEAH--0058,31-Aug-20,20-Mar-20,164,31-Jul-20,6-May-20,,18-Feb-21,"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04377789
80,NCT04459819,Respiratory Physiotherapy in Severe COVID-19 Patients,FTR-COVID,Completed,No Results Available,COVID-19,Other: Respiratory physiotherapy,Number of physiotherapy treatments|Type of physiotherapy treatments|Time of the first physiotherapy treatment|First time standing|First time walking|First time sitting out of bed|6 minutes walking test (6MWT)|1 minute sit-to-stand test (1m-STST)|Upper extremity muscles strength|Lower extremity muscles strength|Functional independence in ADL|ICU stay length|Length of hospitalization|Duration of invasive mechanical ventilation (IMV)|Patients returned home|Patients discharged to in-patient rehabilitation|Patients transferred to other hospitals|Exitus,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",All,"18 Years to 80 Years Â  (Adult, Older Adult)",,84,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,FTR-COVID,30-Sep-20,1-Mar-20,213,30-Sep-20,7-Jul-20,,16-Feb-21,"Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",,https://ClinicalTrials.gov/show/NCT04459819
81,NCT04376398,Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,COVID,Completed,No Results Available,COVID-19,,Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain|Society for Anesthesia and Resuscitation of Belgium,All,"up to 100 Years Â  (Child, Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,COVID-ANESTHESIO,30-Aug-20,6-Apr-20,146,30-Jun-20,6-May-20,,3-Nov-20,"Cliniques Universitaires Saint Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04376398
82,NCT04836065,ESICM UNITE COVID-19 Project (UNITE-COVID),UNITE-COVID,Completed,No Results Available,COVID-19 Infection,,Number of patients admitted with confirmed COVID19 infection|Mortality (ICU)|Mortality (60-day)|Duration of hospitalization in the ICU|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients developing infections during ICU stay|Proportion of patients developing thromboembolic events during ICU stay|Proportion of patients requiring tracheotomy during ICU stay,"University Hospital, Ghent|European Society of Intensive Care Medicine",All,"18 Years and older Â  (Adult, Older Adult)",,4995,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ESICMUNITE2020,31-Dec-20,1-Jul-20,183,30-Sep-20,8-Apr-21,,8-Apr-21,"Ghent University Hospital, Ghent, Belgium",,https://ClinicalTrials.gov/show/NCT04836065
83,NCT04318418,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",CODIV-ACE,Completed,No Results Available,COVID-19,,Severe COVID-19|Death,Neuromed IRCCS,All,"Child, Adult, Older Adult",,3400,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DEP_012020,30-Jun-20,23-Mar-20,99,10-May-20,24-Mar-20,,16-Sep-20,"IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",,https://ClinicalTrials.gov/show/NCT04318418
84,NCT04463602,Desidustat in the Management of COVID-19 Patients,,Completed,No Results Available,COVID-19,Drug: Desidustat|Other: Standard of Care,Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|Laboratory Assessments|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer,Cadila Healthcare Limited,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DESI.20.004,31-Mar-21,25-Jul-20,249,25-Jan-21,9-Jul-20,,23-Apr-21,"Avant Sante Site 1, Monterrey, Mexico",,https://ClinicalTrials.gov/show/NCT04463602
85,NCT04285801,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,,Completed,No Results Available,COVID-19,,28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement,Chinese University of Hong Kong,All,"18 Years and older Â  (Adult, Older Adult)",,8,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,2020.059,25-Feb-20,14-Feb-20,11,25-Feb-20,26-Feb-20,,10-Mar-20,"Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04285801
86,NCT04365738,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,,Completed,No Results Available,COVID-19,Other: Rehabilitation,Dyspnea|Chest expansion|Fatigue severity|Visual Analog Scale for pain|Hospital anxiety and depression scale,Istanbul Bilgi University,All,28 Years to 45 Years Â  (Adult),Not Applicable,270,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,PR COVID-19,26-Apr-20,11-Mar-20,46,10-Apr-20,28-Apr-20,,28-Apr-20,"Istanbul Bilgi University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04365738
87,NCT04380792,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,SCREENING,Completed,No Results Available,COVID-19,,VTE events and complications,Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE),All,"Child, Adult, Older Adult",,2497,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,SCREENING042020,13-Oct-20,13-Apr-20,183,13-Oct-20,8-May-20,,14-Dec-20,"Manuel Monreal, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04380792
88,NCT04304053,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,HCQ4COV19,Completed,No Results Available,COVID-19,Drug: Treatment and prophylaxis|Other: Standard Public Health measures,Study 1- Clinical and virological outcome in exposed contacts|Study 1- Transmission of SARS-CoV-2 in exposed contacts|Study 2- Virological outcome in index cases|Study 2- Clinical outcome in index cases,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|Laboratorios Gebro Pharma SA|Laboratorios RubiÃ³|Institut Catala de Salut",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,2300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HCQ4COV19|2020-001031-27,15-Jun-20,18-Mar-20,89,15-Jun-20,11-Mar-20,,30-Jun-20,"Departament de Salut, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04304053
89,NCT04421404,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,CAPRI,Completed,No Results Available,COVID-19|Sars-CoV2,Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo,Mechanical Ventilation or Death Endpoint|8-Point Ordinal Scale Endpoint,"Priscilla Hsue, MD|Blood Systems Research Institute|San Francisco General Hospital|University of California, San Francisco",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,34,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-30794,30-Apr-21,9-Jun-20,325,30-Apr-21,9-Jun-20,,5-May-21,"San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04421404
90,NCT04583592,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),,Completed,No Results Available,COVID-19,Drug: Camostat Mesilate|Drug: Placebo,Disease Progression at Day 28|Survival Rate|Time to Fever Resolution|Time to Disease Progression|Resolution of Viral Shedding|Rate of Adverse Events and Serious Adverse Events|Cumulative Rate of Grade 3 and 4 Adverse Events|Rate of Discontinuation|Change in Laboratory Parameter - Platelet Count|Change in Laboratory Parameter - Potassium Level|Change in Laboratory Parameter - Aspartate Aminotransferase (AST)|Change in Laboratory Parameter - Alanine Aminotransferase (ALT)|Change in Laboratory Parameter - Alkaline Phosphatase (ALP)|Change in Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)|Change in Laboratory Parameter - Albumin|Change in Laboratory Parameter - Bilirubin|Change in Vital Signs - Heart Rate|Change in Vital Signs - Blood Pressure|Change in Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2),Sagent Pharmaceuticals Inc.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,295,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NI03-CV19-001,31-Mar-21,9-Nov-20,142,31-Mar-21,12-Oct-20,,2-Apr-21,"Palmtree Clinical Research, Inc. (Site 125), Palm Springs, California, United States|Synergy Healthcare, LLC (Site 124), Bradenton, Florida, United States|Clinical Research of Brandon, LLC (Site 123), Brandon, Florida, United States|Reliable Clinical Research, LLC (Site 100), Hialeah, Florida, United States|A+ Research (Site 112), Miami, Florida, United States|NextPhase Research Alliance at CANO HEALTH (Site 107), Miami, Florida, United States|Ezy Medical Research (Site 106), Miami, Florida, United States|Eminat LLC (Site 117), Plantation, Florida, United States|Invictus Clinical Research Group, LLC (Site 101), Pompano Beach, Florida, United States|Visionaries Clinical Research, LLC (Site 121), Atlanta, Georgia, United States|Family Care Research (Site 114), Boise, Idaho, United States|Cedar Crosse Research Center (Site 122), Chicago, Illinois, United States|Massachusetts General Hospital (Site 110), Boston, Massachusetts, United States|Oakland Medical Research Center (Site 108), Troy, Michigan, United States|Cary Research Group (Site 111), Cary, North Carolina, United States|Onsite Solutions (Site 118), Charlotte, North Carolina, United States|STAT Research (Site 109), Springboro, Ohio, United States|Toledo Institute of Clinical Research, Inc.(Site 105), Toledo, Ohio, United States|Advanced Medical Trials (Site 104), Georgetown, Texas, United States|Next Innovative Clinical Research (Site 115), Houston, Texas, United States|Rio Grand Valley Clinical Research Institute (Site 120), Pharr, Texas, United States",,https://ClinicalTrials.gov/show/NCT04583592
91,NCT04367662,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,COVID'HEMOS,Completed,No Results Available,COVID-19,Procedure: blood sampling,Clinical worsening (yes/no) of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood,"University Hospital, Rouen",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,99,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020/0104/OB,14-May-20,9-Apr-20,35,14-May-20,29-Apr-20,,9-Jun-20,"Rouen University Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT04367662
92,NCT04690387,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",,Completed,No Results Available,COVID-19,Biological: AV-COVID-19|Other: GM-CSF,Incidence and severity of adverse events (safety)|Establish optimal dose formulation|Duration of detection of antibodies against SARS-CoV-2,"Aivita Biomedical, Inc.|PT AIVITA Biomedika Indonesia|Indonesia Ministry of Health|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,27,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CL-COV-P01-ID,15-Jan-21,7-Dec-20,39,13-Jan-21,30-Dec-20,,5-Apr-21,"Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia",,https://ClinicalTrials.gov/show/NCT04690387
93,NCT04410159,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,GARGLES,Completed,Has Results,COVID-19,Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water,Number of Participants With Early Viral Clearance|Number of Participants With Negative RT-PCR Results|Number of Patients That Progress to More Severe Disease|Number of Patients With Abnormal Radiological Findings|Number of Patients With Abnormal Laboratory Findings,Universiti Sains Islam Malaysia|Universiti Kebangsaan Malaysia Medical Centre,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USIMalaysia,6-Jul-20,22-Jun-20,14,29-Jun-20,1-Jun-20,21-Jul-20,21-Jul-20,"Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT04410159/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04410159
94,NCT04392414,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,,Completed,No Results Available,COVID-19,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),"The number and proportion of patients with the normal body temperature (â‰¤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CovPlas-Covid19,23-Sep-20,1-May-20,145,10-Jul-20,18-May-20,,25-Sep-20,"Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04392414
95,NCT04335136,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,APN01-COVID-19,Completed,No Results Available,COVID-19,Drug: RhACE2 APN01|Drug: Physiological saline solution,All Cause-death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death,Apeiron Biologics,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",APN01-01-COVID19,26-Dec-20,30-Apr-20,240,26-Dec-20,6-Apr-20,,22-Jan-21,"Medizinische UniversitÃ¤t Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische UniversitÃ¤t Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|NordsjÃ¦llands Hospital, HillerÃ¸d, Denmark|Hvidovre Hospital, Hvidovre, Denmark|UniversitÃ¤tsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische UniversitÃ¤t MÃ¼nchen, MÃ¼nchen, Germany|Regional State Budgetary Educational Institution ""Clinical Hospital â„– 5, Barnaul"", Barnaul, Russian Federation|State Healthcare Institution ""State Clinical Hspital â„– 15 named after O.M. Filatov"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital â„–52 of Health Department of Moscow"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow"", Moscow, Russian Federation|Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Ryazan State Medical University named after I.P. Pavlov"" HD RF, Ryazan, Russian Federation|Alexandrovskaya Hospital, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint-Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "" Saratov State Medical University named after V.I. Razumovsky"" HD RF, Saratov, Russian Federation|Regional State Budgetary Healthcare Institution ""Clinical Hospital â„–1"", Smolensk, Russian Federation|State budgetary institution of Healthcare of Tver region ""Regional clinical hospital"", Tver, Russian Federation|Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems ""Healthy Ageing"", Yaroslavl, Russian Federation|Cambridge University Hospitals NHS Trust/University of Cambridge, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT04335136
96,NCT04391127,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,"Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization",Centenario Hospital Miguel Hidalgo,All,"16 Years to 90 Years Â  (Child, Adult, Older Adult)",Phase 3,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2020-A-09,6-Nov-20,4-May-20,186,6-Nov-20,18-May-20,,9-Nov-20,"Jose Manuel Arreola Guerra, Aguascalientes, Mexico",,https://ClinicalTrials.gov/show/NCT04391127
97,NCT04389645,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,,Completed,No Results Available,COVID-19,Diagnostic Test: IP-10 in CDS protocol,IP-10 levels,MeMed Diagnostics Ltd.,All,"18 Years and older Â  (Adult, Older Adult)",,52,Industry,Observational,,MM-5000-BV,12-May-20,7-Apr-20,35,12-May-20,15-May-20,,15-May-20,"Rabin Medical Center, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT04389645
98,NCT04331366,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP,Completed,Has Results,COVID-19,Device: GO2 PEEP MOUTHPIECE,Oxygen Saturation by Pulse Oximetry|Respiratory Rate|Heart Rate|Blood Pressure|Count of Participants With Subjective Work of Breathing,Emory University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,STUDY00000381,31-Aug-20,8-Apr-20,145,31-Aug-20,2-Apr-20,10-Feb-21,18-Feb-21,"Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT04331366/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04331366
99,NCT04747158,COVID-19 Convalescent Plasma Therapy,TPCC,Completed,No Results Available,SARS-CoV-2 Infection|COVID-19 Infection,Biological: Convalescent plasma,Overall survival (30-day mortality)|Median length of hospital stay|Change in clinical status|Change in inflammatory marker: ferritin|Change in inflammatory marker: D dimer|Change in inflammatory marker: leukocytes|Serum Antibody Titers|Transfer to ICU|Transfusion related events,"Universidad Nacional de AsunciÃ³n|Consejo Nacional de Ciencias y TecnologÃ­a, Paraguay|Ministerio de Salud PÃºblica y Bienestar Social, Paraguay|Centro de informaciÃ³n y recursos para el desarrollo, Paraguay",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,350,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PINV20-388,10-Jan-21,10-Aug-20,153,10-Dec-20,10-Feb-21,,2-Mar-21,"Facultad de Ciencias MÃ©dicas - Universidad Nacional de AsunciÃ³n, AsunciÃ³n, Paraguay",,https://ClinicalTrials.gov/show/NCT04747158
100,NCT04456452,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,,Completed,No Results Available,COVID-19,Biological: Ampion|Other: Standard of Care,Incidence and severity of adverse events,Ampio Pharmaceuticals. Inc.,All,"18 Years to 89 Years Â  (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AP-016,30-Nov-20,27-Jul-20,126,8-Sep-20,2-Jul-20,,13-Jan-21,"Research Site, Colorado Springs, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04456452
101,NCT04331795,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",COVIDOSE,Completed,No Results Available,COVID-19,Drug: Tocilizumab,Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline,University of Chicago,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0515,5-Jun-20,4-Apr-20,62,5-Jun-20,2-Apr-20,,9-Mar-21,"University of Chicago Medicine, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04331795
102,NCT04333225,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine,Rate of COVID-19 positive conversion|Time-to-first clinical event,Baylor Research Institute,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,020-132,30-Jun-20,3-Apr-20,88,30-Jun-20,3-Apr-20,,26-Jan-21,"Baylor University Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04333225
103,NCT04347954,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),,Completed,No Results Available,COVID-19,Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%,Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT),Stanford University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB-56134,13-Dec-20,15-Aug-20,120,13-Dec-20,15-Apr-20,,19-Jan-21,"Stanford Health Care, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04347954
104,NCT04452617,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,,Completed,No Results Available,COVID-19,,occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death|assessment of QTc interval prolongation during the treatment period compared to baseline ECG,Institut Mutualiste Montsouris,All,"18 Years and older Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,REA-03-2020,1-Jul-20,19-Mar-20,104,8-Apr-20,30-Jun-20,,1-Sep-20,"Institut Mutualiste Montsouris, Paris, France",,https://ClinicalTrials.gov/show/NCT04452617
105,NCT04583982,ImmuneSenseâ„¢ COVID-19 Study,,Completed,No Results Available,Coronavirus Disease (COVID-19)|SARS-CoV-2 Infection,Other: T-Detectâ„¢ SARS-CoV-2 Assay,Demonstrate clinical agreement of T-Detectâ„¢ SARS-CoV-2 Assay,Adaptive Biotechnologies|Covance,All,"18 Years to 89 Years Â  (Adult, Older Adult)",,180,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRO-00781,4-Dec-20,9-Oct-20,56,4-Dec-20,12-Oct-20,,29-Dec-20,"Adaptive Biotechnologies Clinical Investigational Site, Secaucus, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04583982
106,NCT04380779,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,BLEEDING,Completed,No Results Available,COVID-19,,Bleeding events and complications,Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE),All,"Child, Adult, Older Adult",,2430,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,BLEEDING042020,13-Oct-20,13-Apr-20,183,13-Oct-20,8-May-20,,14-Dec-20,"Manuel Monreal, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04380779
107,NCT04486313,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,,Completed,No Results Available,COVID-19,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,Reducing the Time to Sustained Response|Reducing the Rate of Progression,Romark Laboratories L.C.,All,"12 Years to 120 Years Â  (Child, Adult, Older Adult)",Phase 3,1092,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RM08-3008,8-Feb-21,13-Aug-20,179,8-Feb-21,24-Jul-20,,1-Apr-21,"Invesclinic US LLC, Fort Lauderdale, Florida, United States|RH Medical Urgent Care, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04486313
108,NCT04405843,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),EPIC,Completed,No Results Available,COVID-19,Drug: Ivermectin Oral Product|Drug: Placebo,Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention|Duration of fever,Centro de Estudios en InfectogÃ­a Pediatrica,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,476,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ScDi823|IVE-PA,21-Dec-20,14-Jul-20,160,21-Dec-20,28-May-20,,28-Dec-20,"Centro de Estudios en InfectologÃ­a PediÃ¡trica, Cali, Valle, Colombia",,https://ClinicalTrials.gov/show/NCT04405843
109,NCT04365634,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,,Completed,No Results Available,COVID-19,,"Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes",Tongji Hospital,All,"Child, Adult, Older Adult",,306,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,TJ20200202,1-Apr-20,2-Feb-20,59,15-Mar-20,28-Apr-20,,28-Apr-20,"Tongji Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04365634
110,NCT04355507,Computed Tomography for COVID-19 Diagnosis,STOIC,Completed,No Results Available,COVID-19,Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR),Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities,"Assistance Publique - HÃ´pitaux de Paris|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France|GE Healthcare|Orange healthcare|TheraPanacea",All,"18 Years and older Â  (Adult, Older Adult)",,10735,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP200434,16-Oct-20,1-Mar-20,229,16-Oct-20,21-Apr-20,,21-Dec-20,"Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04355507
111,NCT04397562,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,CORONA,Completed,No Results Available,COVID-19,Drug: Levilimab|Drug: Placebo,Proportion of patients with sustained clinical recovery|Proportion of patients reporting each category of 7-Category Ordinal Scale of Clinical Status|Proportion of patients transferred to the ICU|Duration of fever|Duration of hospitalization|Change in ESR|Change in serum CRP level|Change in serum IL-6 level,Biocad,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,206,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BCD-089-4,3-Aug-20,29-Apr-20,96,3-Jul-20,21-May-20,,18-Nov-20,"State Budgetary Healthcare Institution Kaluga region ""Kaluga Regional Clinical Hospital"", Kaluga, Russian Federation|State Budget Institution of the Republic of Dagestan ""Republican Clinical Hospital"", MachaÄkala, Russian Federation|A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation|City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation|City Clinical Hospital No.52, Moscow, Russian Federation|City Clinical Hospital â„– 15 named. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital â„–1 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Clinic"", Office of the President of the Russian Federation, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""North Ossetian State Medical Academy"" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation",,https://ClinicalTrials.gov/show/NCT04397562
112,NCT04400461,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,,Completed,No Results Available,COVID-19,Other: Data collection and clinical testing of subjects,Medical Research Council sum score (MRC- SS).|The Functional Status Score for the ICU (FSS-ICU)|Age|Sex|Body Mass Index|Baseline mobility|APACHE II score|Length of stay in ICU|Number of days on mechanical ventilation|Polyneuropathy diagnosis|Number of days on Neuromuscular Blockers|Episodes of prone positioning|Length of stay in hospital|Continuation of care,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,71,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,165/20,1-Mar-21,15-May-20,290,25-Feb-21,22-May-20,,13-Apr-21,"Medical ICU. Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Surgical ICU. Hospital Universitario RamÃ³n y Cajal, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04400461
113,NCT04433910,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,CAPSID,Completed,No Results Available,COVID-19,Drug: Convalesscent Plasma,"Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions",Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,106,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAPSID2020-DRK-BSD|2020-001310-38,22-Feb-21,30-Aug-20,176,21-Jan-21,16-Jun-20,,17-Mar-21,"University Hospital Ulm, Ulm, Baden-WÃ¼rttmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany|University Hospital Berlin, Charite, Berlin, Germany|Universitiy Hospital Dresden, Dresden, Germany|University DÃ¼sseldorf, DÃ¼sseldorf, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital GieÃŸen, GieÃŸen, Germany|University Hopsital Greifswald, Greifswald, Germany|StÃ¤dtisches Klinikum Karslruhe, Karlsruhe, Germany|Universtity Hospital Schleswig-Holstein, Kiel, Germany|Universtity Hospital Schleswig-Holstein, LÃ¼beck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|University Hospital TÃ¼bingen, TÃ¼bingen, Germany",,https://ClinicalTrials.gov/show/NCT04433910
114,NCT04411628,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,,Completed,No Results Available,COVID-19,Drug: LY3819253|Drug: Placebo,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253|Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load,Eli Lilly and Company|AbCellera Biologics Inc.,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",17823|J2W-MC-PYAA,26-Aug-20,28-May-20,90,26-Aug-20,2-Jun-20,,30-Oct-20,"Cedars Sinai Medical Center, Los Angeles, California, United States|Veterans Affairs Medical Center San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Alexandria Center for Life - NYC/ NYCEDC, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Unified Research Enterprise Brody School of Medicine at ECU, Greenville, North Carolina, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04411628
115,NCT04331899,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,COVID-Lambda,Completed,Has Results,COVID-19,Drug: Peginterferon Lambda-1a|Other: Placebo,Duration Until Viral Shedding Cessation|Change in Sars-CoV-2 Viral Load|Area Under the Curve of SARS-COV-2 Viral Load|Duration Until Resolution of Symptoms|Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment,Stanford University,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,55619,6-May-21,25-Apr-20,376,14-Aug-20,2-Apr-20,22-Apr-21,21-May-21,"Stanford University School of Medicine, Stanford, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04331899/Prot_ICF_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04331899/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04331899
116,NCT04623021,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,,Completed,No Results Available,COVID-19,Drug: Nafamostat Mesilate,Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of â‰¤ 2 which is maintained for 24 hours|Changes on CT scan/X-ray|Change from baseline of CRP|Time to normalize the CRP|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortality,Chong Kun Dang Pharmaceutical,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,104,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A108_02CVD2014,12-Dec-20,25-Sep-20,78,12-Dec-20,10-Nov-20,,2-Feb-21,"A108_02CVD2014 Site# 9, Barnaul, Russian Federation|A108_02CVD2014 Site# 26, Krasnoyarsk, Russian Federation|A108_02CVD2014 Site# 5, Moscow, Russian Federation|A108_02CVD2014 Site# 8, Moscow, Russian Federation|A108_02CVD2014 Site# 31, Ryazan, Russian Federation|A108_02CVD2014 Site# 25, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 30, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 4, St. Petersburg, Russian Federation|A108_02CVD2014 site#1, Ufa, Russian Federation",,https://ClinicalTrials.gov/show/NCT04623021
117,NCT04331834,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,PrEP_COVID,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Placebos,"Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank",Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios RubiÃ³|FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital PlatÃ³|Hospital de Granollers,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,275,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PrEP_COVID,31-Dec-20,3-Apr-20,272,25-Jun-20,2-Apr-20,,16-Feb-21,"ISGlobal, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04331834
118,NCT04848610,The Factors That Affect the Infection of COVID-19,,Completed,No Results Available,COVID-19 Infection,,Risk factors affecting the infection of Covid-19 in Turkish society|Difference between the protective measures taken from Covid-19 cases and healthy people,Istanbul University-Cerrahpasa,All,"18 Years and older Â  (Adult, Older Adult)",,1104,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Covid-19 Infection,25-Feb-21,18-Oct-20,130,18-Nov-20,19-Apr-21,,19-Apr-21,"Istanbul University-Cerrahpasa Florence Nightingale Nursing Faculty, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04848610
119,NCT04292899,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),,Completed,Has Results,COVID-19,Drug: Remdesivir|Drug: Standard of Care,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),Gilead Sciences,All,"12 Years and older Â  (Child, Adult, Older Adult)",Phase 3,4891,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15|ISRCTN15874265,30-Jun-20,6-Mar-20,116,9-Apr-20,3-Mar-20,31-Dec-20,31-Dec-20,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, DÃ¼sseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fÃ¼r HÃ¤matologie, Onkologie, Immunologie, MÃ¼nchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, AlcalÃ¡ De Henares, Madrid, Spain|Complejo Hospitalario Universitario A CoruÃ±a, A CoruÃ±a, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de MÃ¡laga, MÃ¡laga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de GenÃ¨ve, GenÃ¨ve 14, Switzerland|Ospedale Regionale di Locarno La CaritÃ , Lugano, Switzerland|UniversitÃ¤tsspital ZÃ¼rich, ZÃ¼rich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/Prot_000.pdf|""Statistical Analysis Plan: Part A"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_001.pdf|""Statistical Analysis Plan: Part B"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT04292899
120,NCT04370782,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms,"St. Francis Hospital, New York",All,"30 Years and older Â  (Adult, Older Adult)",Phase 4,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-21,30-Sep-20,28-Apr-20,155,30-Sep-20,1-May-20,,9-Dec-20,"St Francis Hospital, Roslyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04370782
121,NCT04539262,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",,Completed,No Results Available,COVID-19,Drug: Remdesivir (RDV)|Drug: Placebo,Time-weighted Average Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation|Composite of All-Cause Medically Attended Visits (MAVs) (Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28|Composite of COVID-19 related MAVs or Death by Day 28|Proportion of Participants Hospitalized by Day 28|Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUClast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: CLss/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: t1/2 of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Vz/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Cmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Clast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tlast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUCtau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Î»z of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Ctau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|Change in SARS-CoV-2 Viral Load From Baseline to Day 5|Change in SARS-CoV-2 Viral Load From Baseline to Day 7|Change in SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B|Time to Negative SARS-CoV-2 Polymerase Chain Reaction (PCR)|Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PROÂ©) Questionnaire,Gilead Sciences,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,156,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-553-9020,22-Mar-21,14-Sep-20,189,26-Feb-21,4-Sep-20,,9-Apr-21,"The Institute for Liver Health, Mesa, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Franco Felizarta, MD, Bakersfield, California, United States|Aurora FDRC Inc., Costa Mesa, California, United States|Elevated Health, Huntington Beach, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Western Clinical Research, Placentia, California, United States|UC Davis Health/Medical Center, Sacramento, California, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Evolution Clinical Trials, Inc., Hialeah Gardens, Florida, United States|Research in Miami, Inc., Hialeah, Florida, United States|Optimus U Corporation, Miami, Florida, United States|L & C Professional Medical Research Institute, Miami, Florida, United States|Westchester Research Center at Westchester General Hospital, Miami, Florida, United States|MedBio Trials, Miami, Florida, United States|Nuovida Research Center, Corp, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|Family Care Research, Boise, Idaho, United States|CTU Covid Research Center, New Orleans, Louisiana, United States|STAT Research, Vandalia, Ohio, United States|Inquest Clinical Research, Baytown, Texas, United States|DFW Clinical Research, Dallas, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|PCP for Life-Tidwell, Houston, Texas, United States|Providence Regional Medical Center Everett, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT04539262
122,NCT04377711,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,,Completed,No Results Available,COVID-19,Drug: Ciclesonide|Drug: Placebo,"Time to alleviation of COVID-19-related symptoms by Day 30|Percentage of patients with hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID-19 by day 30|Percentage of patients with alleviation of COVID-19-related symptoms defined as symptom-free for a continuous period of more than 24 hours (ie, later than 3 AM/PM assessments) by day 7, by day 14, and by day 30|Time to hospital admission or death|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngeal sample at day 30",Covis Pharma S.Ã .r.l.,All,"12 Years to 100 Years Â  (Child, Adult, Older Adult)",Phase 3,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALV-020-001,5-Jan-21,8-Jun-20,211,5-Jan-21,6-May-20,,15-Apr-21,"University of Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04377711
123,NCT04343989,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,,Completed,No Results Available,COVID-19,Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo,Incidence of serious adverse events associated with high and low dose of clazakizumab|Ventilator free survival|Overall patient survival|Change in clinical status|Incidence of clazakizumab-expected adverse events,NYU Langone Health,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-00392,12-Mar-21,31-Mar-20,346,3-Feb-21,14-Apr-20,,13-May-21,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04343989
124,NCT04292730,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,Completed,Has Results,COVID-19,Drug: Remdesivir|Drug: Standard of Care,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),Gilead Sciences,All,"12 Years and older Â  (Child, Adult, Older Adult)",Phase 3,1113,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32|ISRCTN85762140,26-Jun-20,15-Mar-20,103,29-Apr-20,3-Mar-20,26-Jan-21,26-Jan-21,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, DÃ¼sseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fÃ¼r HÃ¤matologie, Onkologie, Immunologie, MÃ¼nchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, AlcalÃ¡ De Henares, Madrid, Spain|Complejo Hospitalario Universitario A CoruÃ±a, A CoruÃ±a, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de MÃ¡laga, MÃ¡laga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de GenÃ¨ve, GenÃ¨ve 14, Switzerland|Ospedale Regionale di Locarno La CaritÃ , Lugano, Switzerland|UniversitÃ¤tsspital ZÃ¼rich, ZÃ¼rich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/Prot_000.pdf|""Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part A_f-redact"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_001.pdf|""Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part B_f-redact"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT04292730
125,NCT04542967,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,PC-COVID-HCM,Completed,No Results Available,Severe COVID-19 Disease,Biological: Biological,Disease progression|Side effects|Mortality|Respiratory improvement|Clinical improvement|Acute adverse events (AAE),Hospital Central Militar,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Phase 2,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",047/2020,30-Sep-20,23-Jun-20,99,2-Sep-20,9-Sep-20,,10-May-21,"Hospital Central Militar, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT04542967
126,NCT04473170,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,SENTAD-COVID,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.,Abu Dhabi Stem Cells Center,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,146,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT.001.1.0.SENTAD-COVID,14-Jul-20,4-Apr-20,101,20-May-20,16-Jul-20,,16-Jul-20,"Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT04473170
127,NCT04395391,Home Usability Study of the SARS-CoV-2 (COVID-19) Test,,Completed,No Results Available,COVID-19,Diagnostic Test: SARS-CoV-2,Valid SARS-CoV-2 Test,Exact Sciences Corporation,All,"18 Years and older Â  (Adult, Older Adult)",,30,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-06,16-Jun-20,18-May-20,29,21-May-20,20-May-20,,11-Aug-20,"Exact Sciences, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04395391
128,NCT04371965,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",KILLER,Completed,No Results Available,COVID-19,Drug: Povidone-Iodine,"Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization",Poitiers University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KILLER,23-Oct-20,1-Sep-20,52,23-Oct-20,1-May-20,,26-Oct-20,"University Hospital of Poitiers, Poitiers, France",,https://ClinicalTrials.gov/show/NCT04371965
129,NCT04381962,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),ATOMIC2,Completed,No Results Available,COVID-19,Drug: Azithromycin Capsule,Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability,University of Oxford|Pfizer,All,"19 Years and older Â  (Adult, Older Adult)",Phase 3,298,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATOMIC2|2020-001740-26|282892|20/HRA/2105,20-Apr-21,3-Jun-20,321,29-Jan-21,11-May-20,,6-May-21,"Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT04381962
130,NCT04871633,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,,Completed,No Results Available,COVID-19,Drug: Remdesivir|Drug: Conventional,Hospital Stay|Ventilation,King Edward Medical University,All,"12 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,483/RC/KEMU,30-Dec-20,1-Aug-20,151,15-Nov-20,4-May-21,,4-May-21,"Mayo Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04871633
131,NCT04353596,Stopping ACE-inhibitors in COVID-19,ACEI-COVID,Completed,No Results Available,SARS-CoV-2|COVID-19,"Drug: ACE inhibitor, angiotensin receptor blocker","Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Mean and area under the curve of Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)",Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum fÃ¼r Herz-Kreislauf-Forschung (DZHK),All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,EudraCT 2020-001206-35,24-Feb-21,20-Apr-20,310,16-Feb-21,20-Apr-20,,2-Mar-21,"Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Medical University of Graz, Graz, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Klinikum Lienz, Lienz, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|University Hospital Aachen, Aachen, Germany|University Hospital Augsburg, Augsburg, Germany|Asklepios Stadtklinik Bad TÃ¶lz, Bad TÃ¶lz, Germany|Klinikum Dachau, Dachau, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|University of Freiburg, Freiburg, Germany|Klinikum Memmingen, Memmingen, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|MÃ¼nchen Klinik Bogenhausen und Schwabing, Munich, Germany|Rotkreuzklinikum Munich, Munich, Germany|Krankenhaus MÃ¼hldorf, MÃ¼hldorf, Germany|Klinikum Rosenheim, Rosenheim, Germany|Krankenhaus Weiden, Weiden, Germany",,https://ClinicalTrials.gov/show/NCT04353596
132,NCT04537117,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",,Completed,No Results Available,COVID-19,Other: Questionaire,Responses,Fayoum University,All,"Child, Adult, Older Adult",,202,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,pedodontists during Covid-19,5-May-20,20-Apr-20,15,5-May-20,3-Sep-20,,3-Sep-20,"Fayoum University, Fayoum, Egypt",,https://ClinicalTrials.gov/show/NCT04537117
133,NCT04444531,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,,Completed,No Results Available,COVID-19 Pneumonia,,Time to clinical improvement|Rate of patients with Clinical improvement at day 14|Rate of patients with Clinical improvement at day 28|Time to a 2-fold decrease of C-protein reactive from baseline|Time to a 2-fold decrease of ferritin from baseline|Time to a 2-fold decrease of Lactate Dehydrogenase from baseline|Time to a 2-fold decrease of D-dimer from baseline,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,,"Child, Adult, Older Adult",,18,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID Networking group,26-May-20,20-Mar-20,67,19-May-20,23-Jun-20,,25-Nov-20,"Policlinic Ibiza Hospital, Ibiza, Spain",,https://ClinicalTrials.gov/show/NCT04444531
134,NCT04534790,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,,Completed,No Results Available,COVID-19 Pneumonia,Radiation: Low Dose Radiotherapy,Clinical improvement|improvement of laboratory and imaging parameters,Instituto Mexicano del Seguro Social,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",PI-2020-2858,8-Jan-21,24-Jul-20,168,12-Dec-20,1-Sep-20,,9-Feb-21,"Social Secure Mexican Institute, Leon, Guanajuato, Mexico",,https://ClinicalTrials.gov/show/NCT04534790
135,NCT04568655,The Noninvasive Ventilation to COVID-19 Patients,,Completed,No Results Available,Noninvavie Ventilation to Patients With COVID-19,Device: noninvasive ventilation,success rate|the intubtion rate|blood lymphocyte|B-type natriuretic peptide|Procalcitonin|Oxygen Saturation,The First Affiliated Hospital of Guangzhou Medical University,All,"20 Years to 80 Years Â  (Adult, Older Adult)",,23,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,FAHGuangzhouYLS03,1-Jul-20,1-Feb-20,151,1-Jul-20,29-Sep-20,,29-Sep-20,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04568655
136,NCT04521010,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,,Completed,No Results Available,COVID-19 Pandemic,Other: COVID-19 pandemic,Number of days an individual person was absent,Poznan University of Medical Sciences,All,"Child, Adult, Older Adult",,700,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,3/2020/Reh,30-Apr-20,1-Jan-20,120,30-Apr-20,20-Aug-20,,20-Aug-20,"Department of Rehabilitation and Physiotherapy Rehabilitation,, PoznaÅ„, Poland",,https://ClinicalTrials.gov/show/NCT04521010
137,NCT04381858,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,,Completed,No Results Available,COVID-19 Pneumonia,Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin,Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization,Centenario Hospital Miguel Hidalgo,All,"16 Years to 90 Years Â  (Child, Adult, Older Adult)",Phase 3,196,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2020-A-10,26-Nov-20,6-May-20,204,26-Nov-20,11-May-20,,30-Nov-20,"Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico",,https://ClinicalTrials.gov/show/NCT04381858
138,NCT04357535,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,,Completed,No Results Available,COVID-19,Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB),Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria,Hakeam Abdulaziz Hakeam|Buraidah Central Hospital|King Khalid University Hospital|Princess Nourah Bint Abdulrahman University|King Faisal Specialist Hospital & Research Center,All,"18 Years and older Â  (Adult, Older Adult)",,314,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2210061,1-Aug-20,10-May-20,83,1-Jul-20,22-Apr-20,,4-Aug-20,"King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT04357535
139,NCT04244591,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,,Completed,No Results Available,COVID-19 Infections,Drug: methylprednisolone therapy|Other: Standard care,Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality,Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Glucocorticoid COVID-19,13-Apr-20,26-Jan-20,78,13-Apr-20,28-Jan-20,,16-Jun-20,"Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04244591
140,NCT04713878,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19) Pneumonia,Other: Mesenchymal stem cells,Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms,Kanuni Sultan Suleyman Training and Research Hospital,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020.05.20,15-Jul-20,8-May-20,68,30-Jun-20,19-Jan-21,,20-Jan-21,"University of Health Sciences, Istanbul, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04713878/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04713878
141,NCT04320615,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,COVACTA,Completed,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Time to Recovery|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,28-Jul-20,3-Apr-20,116,24-Jun-20,25-Mar-20,,25-Sep-20,"University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|SjÃ¦llands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|HÃ´pital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik KÃ¶ln, KÃ¶ln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,https://ClinicalTrials.gov/show/NCT04320615
142,NCT04407130,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,,Completed,No Results Available,COVID-19 Patients,Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo,Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >93% despite oxygenation|Number of days on oxygen support|Duration of hospitalization|All causes of mortality,"International Centre for Diarrhoeal Disease Research, Bangladesh",All,"40 Years to 65 Years Â  (Adult, Older Adult)",Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PR-20039,20-Nov-20,16-Jun-20,157,30-Oct-20,29-May-20,,4-Feb-21,"Icddr,B, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT04407130
143,NCT04386616,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,COVASTIL,Completed,No Results Available,COVID-19 Pneumonia,Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo,"Time to Recovery, Defined as the Time to a Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First)|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Hospital Discharge or ""Ready for Discharge""|Duration of Supplemental Oxygen|Percentage of Participants Alive and Free of Respiratory Failure|Clinical Status, Assessed Using a 7-Category Ordinal Scale|Incidence of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 14 and 28|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of â‰¤2 Maintained for 24 hours|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints|Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study","Genentech, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,410,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GA42469|2020-002713-17,12-Feb-21,2-Jun-20,255,2-Jan-21,13-May-20,,17-Feb-21,"University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|Alta Bates Summit Medical Center, Oakland, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Bay Pines VA Medical Center - NAVREF, Bay Pines, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|Northside Hospital; Peachtree Dunwoody Medical Center, Atlanta, Georgia, United States|WellStar Research Institute, Marietta, Georgia, United States|University Of Iowa Hospitals And Clinics, Coralville, Iowa, United States|DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria, Louisiana, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Lincoln Medical Mental Health Center, Bronx, New York, United States|Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics, Bronx, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center; Investigational Drug Services/Regional Research, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma, Washington, United States|Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro, RJ, Brazil|Centro De Estudos Pesquisas em Molestias Infecciosas - CPCLIN, Natal, RN, Brazil|Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Instituto do CoraÃ§Ã£o - HCFMUSP, Sao Paulo, SP, Brazil|Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases, Mexico, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario A CoruÃ±a, Coruna, LA CoruÃ±a, Spain|Hospital San Pedro, LogroÃ±o, LA Rioja, Spain|Hospital Costa del Sol; Servicio de Oncologia, Marbella, Malaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Hospital Clinico Universitario Valladolid, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT04386616
144,NCT04363736,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,MARIPOSA,Completed,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,12-Aug-20,5-May-20,99,12-Aug-20,27-Apr-20,,11-Sep-20,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04363736
145,NCT04409262,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,REMDACTA,Completed,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Time from randomization to hospital discharge or ""ready for discharge"" up to Day 28|Time to mechanical ventilation or death up to Day 28, defined as the time from randomization to the first occurrence of mechanical ventilation or death (whichever occurs first)|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status up to Day 28|Clinical status as assessed by the investigator using a 7-category ordinal scale of clinical status on Days 7, 14, 21, 28, and 60|Proportion of participants requiring initiation of mechanical ventilation post-baseline up to Day 28 and Day 60 (participants who do not require mechanical ventilation at baseline)|Proportion of participants who are alive and free of respiratory failure at (participants requiring mechanical ventilation at baseline) at Day 28 and Day 60|Duration of mechanical ventilation (participants requiring mechanical ventilation at baseline) up to Day 28|Time to death up to Days 28 and 60|Mortality on Days 14, 28, and 60 (proportions at specified timepoints)|Time to recovery up to Day 28, defined as the time from randomization to the time when a category of 2 on the 7-category ordinal scale (non-ICU hospital ward or ""ready for hospital ward"" not requiring supplemental oxygen) or better is observed|Proportion of participants who are discharged or ""ready for discharge"" up to Day 28|Proportion of participants who require initiation of mechanical ventilation post-baseline or die up to Day 28",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older Â  (Child, Adult, Older Adult)",Phase 3,649,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,8-Mar-21,16-Jun-20,265,1-Feb-21,1-Jun-20,,11-Mar-21,"Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John's Health Center, Santa Monica, California, United States|Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Medical Center, Novi, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health-Midlands, Columbia, South Carolina, United States|The Liver Institute at Methodist Dallas, Arlington, Texas, United States|Baylor Scott and White Medical Center - College Station, College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Medical Center - Irving, Irving, Texas, United States|Baylor Scott & White Hospital - Plano, Plano, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Nossa Senhora das GraÃ§as; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos ClÃ­nicos, Sao Bernardo Do Campo, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do CoraÃ§Ã£o - HCFMUSP, Sao Paulo, SP, Brazil|Medsi Clinic, Moscow, Adygeja, Russian Federation|Clinical Infectious Diseases Hospital #1; Chair of Infectious Disease and Epidemiology, Moskva, Moskovskaja Oblast, Russian Federation|City Clinical Hospital #15, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Pokrovsky City Hosptial, St Petersburg, Russian Federation|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Principe de Asturias; Medicina Interna - Servicio de Enfermedades Infecciosas, Alcala de Henares, Madrid, Spain|Hospital Universitario HM Torrelodones, Torrelodones, Madrid, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT04409262
146,NCT04374032,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,,Completed,No Results Available,COVID-19 Infection,Drug: metenkefalin + tridecactide|Drug: The standard of care,Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels,Bosnalijek D.D,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN-COVCS-01,3-Nov-20,1-May-20,186,7-Oct-20,5-May-20,,24-Dec-20,"Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Hospital Travnik, Travnik, Bosnia and Herzegovina|Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina",,https://ClinicalTrials.gov/show/NCT04374032
147,NCT04589117,Expressive Writing for COVID-19 Resilience for Parents,,Completed,No Results Available,Parents During COVID-19,Behavioral: Expressive writing,Resilience|Perceived stress|Depression symptoms|Parental stress,Duke University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00105586,2-Aug-20,27-May-20,67,2-Aug-20,19-Oct-20,,19-Oct-20,"Duke Integrative Medicine, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04589117
148,NCT04816084,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,SERUR,Completed,No Results Available,Covid19,Diagnostic Test: Anti-SARS-CoV2 Serology,Prevalence of IgG and IgM anti-SARS CoV2 antibodies,UniversitÃ© de Reims Champagne-Ardenne,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,389,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2020-004-SERUR,15-Mar-21,5-Nov-20,130,1-Dec-20,25-Mar-21,,25-Mar-21,"UniversitÃ© de Reims Champagne-Ardenne, Reims, France",,https://ClinicalTrials.gov/show/NCT04816084
149,NCT04476888,Convalescent Plasma Treatment in COVID-19,COLLATE,Completed,No Results Available,Covid19,Biological: Convalescent Plasma (CP)|Other: Drugs and supportive care,Decrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findings,Aga Khan University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CON000000000880,10-Oct-20,26-Apr-20,167,15-Sep-20,20-Jul-20,,20-Jan-21,"Aga Khan University Hospital, Karachi, Sind, Pakistan",,https://ClinicalTrials.gov/show/NCT04476888
150,NCT04371744,QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,QT-Logs,Completed,No Results Available,COVID-19,,Corrected QT (QTc) interval measurement,Assistance Publique Hopitaux De Marseille,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIL 2020-52,5-Jun-20,17-Apr-20,49,4-Jun-20,1-May-20,,9-Jun-20,"Assistance Publique HÃ´pitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT04371744
151,NCT04354870,COVID-19 PrEP HCW HCQ Study,,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine (HCQ),Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time,NYU Langone Health,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,s20-00390,1-Oct-20,3-Apr-20,181,15-Sep-20,21-Apr-20,,12-May-21,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04354870
152,NCT04589104,Expressive Writing for COVID-19 Resilience,,Completed,No Results Available,Distress Due to COVID-19,Behavioral: Expressive writing,Resilience|Perceived stress|Depression symptoms|Post-traumatic growth,Duke University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00105575,17-Aug-20,26-May-20,83,17-Aug-20,19-Oct-20,,19-Oct-20,"Duke Integrative Medicine, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04589104
153,NCT04401241,How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,MONACOVID,Completed,No Results Available,Covid19,,routine biomarkers and blood cell count are discriminant to diagnose COVID-19|Probability of COVID-19 and CRP|Probability of COVID-19 and PCT|Probability of COVID-19 and Ddimers|Probability of COVID-19 and NTproBNP|Probability of COVID-19 and cTnT-HS|Probability of COVID-19 and blood cell counts|performance of combined routine biomarkers|Assess usual biomarkers and blood cell count,Centre Hospitalier Princesse Grace,All,"18 Years and older Â  (Adult, Older Adult)",,257,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,20-06,15-May-20,1-Feb-20,104,1-May-20,26-May-20,,26-May-20,"Centre Hospitalier Princesse Grace, Monaco, MON, Monaco",,https://ClinicalTrials.gov/show/NCT04401241
154,NCT04527562,Colchicine in Moderate Symptomatic COVID-19 Patients,COLCOVIDBD,Completed,No Results Available,Covid19,Drug: Colchicine|Drug: Placebo,"Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale.|Length of hospital stay|Number of participant requiring increased amount of supplemental oxygen|Number of participants requiring mechanical ventilation|Number of participants who die",Dhaka Medical College,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,299,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",U1111-1255-3541,10-Dec-20,14-Jul-20,149,15-Nov-20,26-Aug-20,,11-Jan-21,"Dhaka Medical College Hospital, Dhaka-1000, Bangladesh",,https://ClinicalTrials.gov/show/NCT04527562
155,NCT04425889,COVID-19 Antibodies Among Healthcare Workers,,Completed,No Results Available,COVID-19|SARS-CoV 2,"Diagnostic Test: COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)",Presence of antibody,Hospital Universitario Dr. Jose E. Gonzalez,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,156,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,IF20-00008,1-Jun-20,5-May-20,27,30-May-20,11-Jun-20,,12-Jun-20,"Hospital Universitario JosÃ© E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,https://ClinicalTrials.gov/show/NCT04425889
156,NCT04459325,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,,Completed,No Results Available,COVID-19|Coronavirus Disease 2019,Biological: TigeraseÂ® and best available care|Other: Best available care,The proportion of patients with mechanical ventilation|Category change on WHO Ordinal Scale for Clinical Improvement|Proportion of patients surviving 28 days after inclusion in the study|Number of days of oxygen therapy during the treatment period|Change in C-reactive protein level|Change in oxygenation index|Change in SpO2/FiO2 index|Change in ferritin level|Change in D-dimer level|Change in neutrophil-leucocyte ratio|Change in leucocyte-C-reactive protein ratio|Change in the level of relative (%) number of lymphocytes of the general blood test,AO GENERIUM,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DRN-ALI-III|#216 eff date 27.05.2020,20-Jul-20,1-Jun-20,49,20-Jul-20,7-Jul-20,,14-Oct-20,"City Clinical Hospital #15, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|City Clinical Hospital #51, Moscow, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|N.V. Sklifosovsky Scientific Research Institute of First Aid, Moscow, Russian Federation|Siberian State Medical University (SibMed), Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04459325
157,NCT04389554,D-dimer Levels in Pregnant With COVID-19,,Completed,No Results Available,COVID-19|D-dimer,Other: Blood D-dimer assay,Compare D-dimer values of COVID-19 patients and healthy pregnant women,Kanuni Sultan Suleyman Training and Research Hospital,Female,18 Years to 45 Years Â  (Adult),,300,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,MTalmac,29-May-20,14-May-20,15,28-May-20,15-May-20,,1-Jun-20,"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey",,https://ClinicalTrials.gov/show/NCT04389554
158,NCT04329559,COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,,Completed,No Results Available,COVID-19|Liver Cirrhosis,,All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis,"Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|The Sixth People's Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People's Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine",All,"18 Years and older Â  (Adult, Older Adult)",,21,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CHESS2002,10-Feb-21,30-Mar-20,317,10-Feb-21,1-Apr-20,,24-Feb-21,"Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",,https://ClinicalTrials.gov/show/NCT04329559
159,NCT04382651,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,MAS-COVID,Completed,No Results Available,"COVID-19 Pneumonia, Impaired Respiratory Function",Drug: MAS825|Drug: Matching placebo,APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time,Novartis Pharmaceuticals|Novartis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CMAS825F12201,20-Apr-21,11-Jun-20,313,6-Jan-21,11-May-20,,13-May-21,"Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04382651
160,NCT04375761,COVID-19: Human Epidemiology and Response to SARS-CoV-2,HEROS,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2,Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys,"Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period|Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period","National Institute of Allergy and Infectious Diseases (NIAID)|Rho Federal Systems Division, Inc.",All,"Child, Adult, Older Adult",,5599,NIH|Industry,Observational,Observational Model: Family-Based|Time Perspective: Prospective,DAIT-COVID-19-001,24-Jan-21,1-May-20,268,24-Jan-21,5-May-20,,15-Feb-21,"Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Childhood Allergy Study (CAS) Site, Detroit, Michigan, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04375761
161,NCT04318301,Hypertension in Patients Hospitalized With COVID-19,HT-COVID19,Completed,No Results Available,COVID-19|Hypertension,,Rate of Death|the severity of pneumonia,Zhenhua Zen|Nanfang Hospital of Southern Medical University,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,275,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,HT-COVID19,30-Mar-20,21-Mar-20,9,28-Mar-20,23-Mar-20,,29-Apr-20,"Hankou Hospital, Hankou, Hubei, China",,https://ClinicalTrials.gov/show/NCT04318301
162,NCT04668469,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,,Completed,No Results Available,Covid19,Drug: Ivermectin|Drug: Hydroxychloroquine|Behavioral: personal protective Measures,"number of participants with improvement of clinical condition (symptoms and signs)|Reduction of recovery time, hospital stay days and mortality rate|improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart.",Benha University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Re96.2020,30-Oct-20,8-Jun-20,144,15-Sep-20,16-Dec-20,,16-Dec-20,"Benha Faculty of Medicine, Benha University, BanhÄ, Qaluopia, Egypt",,https://ClinicalTrials.gov/show/NCT04668469
163,NCT04377815,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,FORECAST,Completed,No Results Available,COVID-19|Anosmia,Other: General Public cohort,Percentage of people reporting changes in smell/taste|mortality rate|Percentage of people with change in smell/taste before other symptoms|proportion of other COVID-19 linked symptoms in people with smell and/or taste change|Percentage of people with persistent changes in smell and/or taste|Percentage of hospitalisation|co-morbidities association|prevalence of changes in smell/taste|clinical outcomes,"University College, London",All,"18 Years and older Â  (Adult, Older Adult)",,569,Other,Observational,Observational Model: Cohort|Time Perspective: Other,132311|20/HRA/1879,24-Jun-20,23-Apr-20,62,14-May-20,6-May-20,,19-Jan-21,"University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04377815
164,NCT04726865,COVID-19 Pandemic and Medical Students,,Completed,No Results Available,the Effect of COVID-19 Pandemic,Other: Naser Al-Husban,psychological stress and academic results,University of Jordan|Aysha Alkhayat|Mariam Aljweesri|Reem Alharbi|Zahraa Aljazzaf,All,18 Years to 24 Years Â  (Adult),,415,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Jordan Universities,31-Dec-20,1-Oct-20,91,20-Dec-20,27-Jan-21,,27-Jan-21,"Al-Husban University Naser, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT04726865
165,NCT04436471,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",,Completed,No Results Available,Preventive Immunization COVID-19,Biological: Gam-COVID-Vac,Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development",All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,38,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,02-Gam-COVID-Vac-2020,10-Aug-20,17-Jun-20,54,3-Aug-20,18-Jun-20,,12-Aug-20,"Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04436471
166,NCT04356534,Convalescent Plasma Trial in COVID -19 Patients,,Completed,No Results Available,SARS-CoV 2|COVID-19,Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients,Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate,"Royal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali",All,"21 Years and older Â  (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BDF/R&REC/2020-423,9-Jul-20,19-Apr-20,81,15-Jun-20,22-Apr-20,,28-Jul-20,"Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",,https://ClinicalTrials.gov/show/NCT04356534
167,NCT04622891,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,,Completed,No Results Available,Covid19,Drug: Clarithromycin 500mg|Drug: Azithromycin|Drug: Placebo,time to fever control|PCR conversion,South Valley University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",SVU-MED-CHT019-420860,30-Jul-20,1-Apr-20,120,30-Jul-20,10-Nov-20,,10-Nov-20,"south-Vally University faculty of medicine, Qena, Egypt",,https://ClinicalTrials.gov/show/NCT04622891
168,NCT04355871,Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,COVID19@Spain,Completed,No Results Available,Covid19,,Overall mortality|Mechanical ventilation,Fundacion SEIMC-GESIDA,All,"Child, Adult, Older Adult",,4035,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,COVID-19/SEIMC-FSG,17-Apr-20,18-Mar-20,30,15-Apr-20,21-Apr-20,,11-May-20,"Comp. Hosp. Univ. A CoruÃ±a, A CoruÃ±a, Spain|H. Quiron A CoruÃ±a, A CoruÃ±a, Spain|H. de Alcaniz, AlcaÃ±iz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, BreÃ±a Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de DÃ©nia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan RamÃ³n JimÃ©nez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de JaÃ©n, JaÃ©n, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, LeganÃ©s, Spain|H. San Pedro, LogroÃ±o, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion JimÃ©nez DÃ­az, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de AlcorcÃ³n, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de MÃ³stoles, Madrid, Spain|H. Univ. Gregorio MaraÃ±on, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. RamÃ³n y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, MatarÃ³, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, MondragÃ³n, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, MÃ¡laga, Spain|H. Virgen de la Victoria, MÃ¡laga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, PalamÃ³s, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San SebastiÃ¡n De Los Reyes, Spain|H. de Donostia, San SebastiÃ¡n, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ãvila, Spain",,https://ClinicalTrials.gov/show/NCT04355871
169,NCT04423978,Implications of Covid-19 on the Lifestyle Changes,,Completed,No Results Available,COVID-19,,The ratio of individuals living in the province of Reggio Emilia who completed the survey|The ratio of individuals who changed the lifestyles during the lock-down|The number and the type of support services used the most by participants,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,All,"18 Years and older Â  (Adult, Older Adult)",,1826,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,ICOLS_CovidStyle,15-Jun-20,4-May-20,42,15-Jun-20,9-Jun-20,,20-Jul-20,"Elisa Mazzini, Reggio Emilia, Italy",,https://ClinicalTrials.gov/show/NCT04423978
170,NCT04438239,Rehabilitation Needs After COVID-19 Hospital Treatment,REACT,Completed,No Results Available,Covid-19,"Other: none, this study is observational","number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome)|number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in B-ADL|level of participation in social|description of qualitative data about patients' experience",Azienda UnitÃ  Sanitaria Locale Reggio Emilia,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Other|Time Perspective: Prospective,428/2020/OSS/AUSLRE,31-Dec-20,22-Jun-20,192,31-Dec-20,18-Jun-20,,26-Jan-21,"Azienda USL-IRCCS S.Maria Nuova Hospital, Reggio Emilia, Italy",,https://ClinicalTrials.gov/show/NCT04438239
171,NCT04730323,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,,Completed,No Results Available,Covid19,Drug: Tocilizumab,Decreased Mortality in Participants|Hospital & ICU stay in days,FMH College of Medicine and Dentistry,All,"16 Years to 85 Years Â  (Child, Adult, Older Adult)",Phase 4,93,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB# FMH-05-2020-IRB-75,12-Jun-20,12-May-20,31,12-Jun-20,29-Jan-21,,29-Jan-21,"Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Punjab, Pakistan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04730323/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04730323
172,NCT04874792,Clinical Characteristics of Deceased With COVID-19,COVID-19,Completed,No Results Available,Covid19,,Clinical Characteristics|Duration from admission to death,Dhaka Medical College,All,"14 Years and older Â  (Child, Adult, Older Adult)",,282,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,ERC-DMC-ECC/2020/142,31-Dec-20,1-Jul-20,183,30-Nov-20,6-May-21,,6-May-21,"Dhaka Medical College Hospital, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT04874792
173,NCT04487119,Hematology and Clinical Picture in Pediatric COVID-19 Infection,,Completed,No Results Available,Covid19,,hematological findings|clinical presentations,Benha University,All,"up to 18 Years Â  (Child, Adult)",,29,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RC 6-7-2020,23-Aug-20,12-Aug-20,11,20-Aug-20,27-Jul-20,,9-Sep-20,"Benha Faculty of Medicine, BanhÄ, Qalubia, Egypt",,https://ClinicalTrials.gov/show/NCT04487119
174,NCT04331600,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,,Completed,No Results Available,COVID-19,Drug: Chloroquine phosphate|Other: Telemedicine,COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications,Wroclaw Medical University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WROCLAW CORONA STUDY 2020,17-Dec-20,16-Apr-20,245,17-Dec-20,2-Apr-20,,11-Feb-21,"Uniwersytecki Szpital Kliniczny, WrocÅ‚aw, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, PoznaÅ„, Ul. Szwajcarska 3, Poland",,https://ClinicalTrials.gov/show/NCT04331600
175,NCT04401202,Nigella Sativa in COVID-19,,Completed,No Results Available,COVID-19|SARS-CoV-2,Dietary Supplement: Nigella sativa oil,The proportion of patients whom had clinical recovery within 14 days after randomization|The number of days to recovery|Duration of each symptom|Rate of complications|Side effects|Hospital admission due to high disease severity,King Abdulaziz University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,173,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,266-20,31-Dec-20,21-May-20,224,31-Dec-20,26-May-20,,4-May-21,"King Abdulaziz University Hospital, Jeddah, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT04401202
176,NCT04328493,The Vietnam Chloroquine Treatment on COVID-19,VICO,Completed,No Results Available,SARS-CoV-2 Infection|COVID-19,Drug: Chloroquine phosphate,Viral clearance time|Length of hospital stay|Ventilator free days|Oxygen free days|Time to death|Adverse events|fever clearance time|Ordinal outcome scale|Development of ARDS,"Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID,10-Sep-20,7-Apr-20,156,10-Sep-20,31-Mar-20,,24-May-21,"National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,https://ClinicalTrials.gov/show/NCT04328493
177,NCT04883203,The Effect of Vitamin D Supplementation on COVID-19 Recovery,COVID-VITD,Completed,No Results Available,Covid19,Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol]|Drug: Physiological Irrigating Solution,Vitamin D supplementation and recovery delay in COVID-19 patients,University of Monastir|Loussaief Chawki|Nissaf Ben Alaya|Cyrine Ben Nasrallah|Manel Ben Belgacem|Hela Abroug|Imen Zemni|Manel Ben fredj|Wafa Dhouib,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 3,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,VITD COVIDMonastir,31-Oct-20,22-Apr-20,192,30-Sep-20,12-May-21,,12-May-21,"Asma Sriha Belguit, Monastir, Tunisia",,https://ClinicalTrials.gov/show/NCT04883203
178,NCT04382794,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,SIDIACO-RETRO',Completed,No Results Available,Covid19,Drug: Retrospective case-control analysis,Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease,"University of Milan|Papa Giovanni XXIII Hospital|IRCCS Policlinico S. Matteo|Humanitas Hospital, Italy|Ospedale dell'Angelo, Venezia-Mestre|University of Pavia",All,"18 Years and older Â  (Adult, Older Adult)",,338,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,20-May,15-Jun-20,14-May-20,32,15-Jun-20,11-May-20,,9-Jul-20,"ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy",,https://ClinicalTrials.gov/show/NCT04382794
179,NCT04877509,Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19,MicroCovAging,Completed,No Results Available,Covid19,"Biological: Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization","Selenium, Zinc and Copper, Vitamin A, D and E plasma concentrations of 229 over 50 year's patients hospitalized suffering from COVID-19.",Hospices Civils de Lyon,All,"50 Years and older Â  (Adult, Older Adult)",,229,Other,Observational,Observational Model: Cohort|Time Perspective: Other,69HCL20_0730 A067,1-May-21,1-Mar-20,426,1-Dec-20,7-May-21,,7-May-21,"Chls Cbap, Pierre-BÃ©nite, France",,https://ClinicalTrials.gov/show/NCT04877509
180,NCT04810728,Efficacy of Psidii Guava's Extract For COVID-19,,Completed,No Results Available,Covid19,Drug: Extract Psidii guava|Combination Product: Standard therapy for Covid-19 patient,Changes of inflammatory cells and marker|Recovery rate|Duration of seroconversion,Faculty of Medicine Baiturrahmah University,All,"13 Years to 59 Years Â  (Child, Adult)",Phase 3,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PSIDII0520_COV19,30-Jan-21,20-Jun-20,224,4-Dec-20,23-Mar-21,,20-Apr-21,"Faculty of Medicine, Baiturrahmah University, Padang, West Sumatera, Indonesia",,https://ClinicalTrials.gov/show/NCT04810728
181,NCT04403828,Impact of COVID-19 on Personal Protection Among Dentist in Egypt,,Completed,No Results Available,COVID 19,Other: Survey,Personal protection measures|impact of Covid-19 pandemic on type of face masks used in dental clinic,Fayoum University,All,"18 Years to 75 Years Â  (Adult, Older Adult)",,323,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,PPE in COVID-19,15-Jul-20,20-May-20,56,1-Jun-20,27-May-20,,22-Jul-20,"Faculty of Dentistry, Fayoum, Egypt",,https://ClinicalTrials.gov/show/NCT04403828
182,NCT04512118,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,,Completed,No Results Available,Presence of COVID-19 Compatible CT Abnormalities,Diagnostic Test: PET-CT of 18F-FDG,Visual analysis of pulmonary lobes|Measurement of metabolic activity,"Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,22,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,2020PI153,30-Jul-20,15-Mar-20,137,30-Jun-20,13-Aug-20,,13-Aug-20,"CHRU of Nancy, VandÅ“uvre-lÃ¨s-Nancy, Grand Est, France",,https://ClinicalTrials.gov/show/NCT04512118
183,NCT04273321,Efficacy and Safety of Corticosteroids in COVID-19,,Completed,No Results Available,COVID-19|Novel Coronavirus Pneumonia,Drug: Methylprednisolone,the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days,Beijing Chao Yang Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,86,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Methylprednisolone in COVID-19,15-Apr-20,14-Feb-20,61,15-Apr-20,18-Feb-20,,11-May-20,"Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China",,https://ClinicalTrials.gov/show/NCT04273321
184,NCT04365127,Progesterone for the Treatment of COVID-19 in Hospitalized Men,,Completed,No Results Available,COVID-19|Sars-CoV2,Drug: Progesterone 100 MG,"Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 15|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization",Sara Ghandehari|IBSA Institut Biochimique SA|Cedars-Sinai Medical Center,Male,"18 Years and older Â  (Adult, Older Adult)",Phase 1,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000611,20-Aug-20,27-Apr-20,115,20-Aug-20,28-Apr-20,,27-Jan-21,"Cedars Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04365127
185,NCT04656691,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,UNITED,Completed,No Results Available,Covid19,Drug: bamlanivimab,Efficacy - determining hospitalization rates|Safety - documenting adverse events after infusion,"Daniel Griffin|Eli Lilly and Company|Optum, Inc.|UnitedHealth Group",All,65 Years and older Â  (Older Adult),Phase 4,4000,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0081_,18-Apr-21,4-Jan-21,104,18-Apr-21,7-Dec-20,,29-Apr-21,"QueryLab, Minnetonka, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04656691
186,NCT04392245,Proctologic Practice and Covid-19,PROCTOLOCK,Completed,No Results Available,Proctologic Practice During COVID-19,,Predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities,Societa Italiana di Chirurgia ColoRettale|Gaetano Gallo|Alessandro Sturiale|Veronica De Simone|Gian Luca Di Tanna|Iacopo Giani|Ugo Grossi,All,"Child, Adult, Older Adult",,1050,Other,Observational,Observational Model: Other|Time Perspective: Prospective,1,26-Apr-20,15-Apr-20,11,26-Apr-20,18-May-20,,18-May-20,"Gallo Gallo, Catanzaro, Italy",,https://ClinicalTrials.gov/show/NCT04392245
187,NCT04347174,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,,Completed,No Results Available,COVID-19,Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Placebo,7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|Sequential Organ Failure Assessment (SOFA) scores|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death|All-cause mortality,"Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRSC20004,21-Aug-20,30-Apr-20,113,10-Aug-20,15-Apr-20,,27-Jan-21,"All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT04347174
188,NCT04670328,Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity,,Completed,No Results Available,Covid19,Diagnostic Test: not required,"complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio|PT, APTT and D-dimer",FMH College of Medicine and Dentistry,All,"17 Years to 75 Years Â  (Child, Adult, Older Adult)",,101,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,FMHCMD,31-Jul-20,1-May-20,91,31-Jul-20,17-Dec-20,,17-Dec-20,"FMH college of medicine and dentistry, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04670328
189,NCT04343781,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,COVID19PUGG2,Completed,No Results Available,SARS-CoV-2|COVID-19,Other: observation,symptoms of COVID-19 in older patients,"University Hospital, Angers",All,70 Years and older Â  (Older Adult),,353,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,ar20-0031v1,5-Apr-20,22-Mar-20,14,5-Apr-20,13-Apr-20,,16-Jun-20,"Angers University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT04343781
190,NCT04365816,NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,,Completed,No Results Available,COVID-19,Other: Interview,Evaluation of food intake at 1 month after discharge from hospital for COVID|Weight variation during the infection|Clinical signs limiting food intake|Factors limiting food intake|Implemented nutritional strategy|Pre-existing chronic disorders|Covid-19 repercussions,"University Hospital, Grenoble|University Grenoble Alps",All,"18 Years and older Â  (Adult, Older Adult)",,403,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A01120-39,10-Jul-20,30-Apr-20,71,10-Jul-20,28-Apr-20,,28-Jul-20,"Marie-France VAILLANT, Grenoble, France",,https://ClinicalTrials.gov/show/NCT04365816
191,NCT04379271,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",,Completed,No Results Available,COVID-19,Drug: IMU-838|Other: Placebo,"Proportion of patients without any need* for INV until end-of-study (EoS)|Duration of ICU treatment until EoS|28-day all-cause mortality|Time to clinical improvement|Duration of hospitalization|Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS|Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS|Proportion of patients free of INV until Days 6 and 14*|Proportion of patients free of RRT until Days 6 and 14*|Proportion of patients free ECMO until Days 6 and 14*|Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28|Proportion of patients with clinical recovery: Axillary temperature â‰¤36.6 â„ƒ, or oral temperature â‰¤37.2 â„ƒ, or rectal or tympanic temperature â‰¤37.8 â„ƒ;|Proportion of patients with clinical recovery: Respiratory frequency â‰¤24 times/min without oxygen inhalation; and|Proportion of patients with clinical recovery: Oxygen saturation â‰¥98% without oxygen inhalation|Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Duration of INV|Duration of ECMO|Duration of RRT|Duration of auxiliary oxygen therapy (including all types of oxygen therapy)|Duration of hospitalization for survivors|The rate of ICU* admission on Days 6, 14, and 28|Hospital-free days|Time from IMP treatment initiation to death|Time to first prescription of INV|Time to first prescription of RRT|Time to first prescription of ECMO|Time to first prescription of INV, RRT, and ECMO|Time to ICU admission|Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)|Time to clinical recovery|Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28|Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Adverse events (AEs) and serious AEs|Vital signs: height|Vital signs: weight|Vital signs: body temperature (ÂºC)|Vital signs: pulse rates,|Vital signs: systolic and diastolic blood pressures|Clinical laboratory parameters: blood chemistry|Clinical laboratory parameters: hematology|Clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: PQ-interval|12-lead electrocardiogram: QRS-interval|12-lead electrocardiogram: QT interval|12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)|Temperature|D-dimer|Lactate dehydrogenase (LDH)|C-reactive protein|Troponin I|Procalcitonin|Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load|Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28|Time to conversion to a negative SARS-CoV-2 (qualitative) test|Interleukin (IL)-17|Interleukin (IL)-1ÃŸ|Interleukin (IL)-6|interferon gamma (IFNÎ³)|tumor necrosis factor alpha|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: â€¢ Time to appearance of IgA and/or IgG antibodies|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: â€¢ Proportion of patients with IgA and/or IgG antibodies on Days 6, 14, and 28",Immunic AG|FGK Clinical Research GmbH,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,223,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P2-IMU-838-COV,23-Feb-21,11-Jun-20,257,12-Jan-21,7-May-20,,26-Apr-21,"Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria|UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria|University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany|Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT04379271
192,NCT04688372,Hospital COVID-19 Surge and Associated Mortality Risk,,Completed,No Results Available,Volume Outcome Relationship Among COVID-19 Inpatients in US Hospitals,Other: Surge Index,In-hospital mortality or discharge to hospice|In-hospital mortality,National Institutes of Health Clinical Center (CC)|Emory University|Harvard Medical School|National Institute of Allergy and Infectious Diseases (NIAID)|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Older Adult)",,144116,NIH|Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,BD022386,15-Feb-21,1-Oct-20,137,15-Feb-21,30-Dec-20,,6-Apr-21,"National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04688372
193,NCT04649658,Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support,PRINCESS,Completed,No Results Available,Covid19,Behavioral: Prone position,Endotracheal intubation|Mortality|Tracheostomy|Length of Respiratory Intensive Care Unit stay|Length of Hospital stay,University of Modena and Reggio Emilia,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,93,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,UModenaReggio10,30-Nov-20,1-Mar-20,274,1-Jun-20,2-Dec-20,,14-Dec-20,"Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy",,https://ClinicalTrials.gov/show/NCT04649658
194,NCT04349241,Efficacy and Safety of Favipiravir in Management of COVID-19,FAV-001,Completed,No Results Available,Coronavirus Disease (COVID-19),Drug: favipiravir|Drug: Standard of care therapy,Viral clearance|Clinical improvement|Radiological Improvement,Ain Shams University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMASU P14 / 2020,20-Jun-20,18-Apr-20,63,1-Jun-20,16-Apr-20,,25-Jun-20,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,https://ClinicalTrials.gov/show/NCT04349241
195,NCT04610502,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,SECR-01,Completed,No Results Available,Covid19,Biological: Administration of Equine immunoglobulin anti SARS-CoV-2,"To evaluate the efficacy and safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (""S"" and ""M"").|To evaluate safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (""S"" and ""M"").|Viral load|Mortality|Hospital stay|ventilatory support|blood levels of immunoglobulins against SARS-CoV-2|inflammatory markers|thrombotic marker levels|negativization period of RT-PCR on nasopharyngeal swabbing (Reverse transcription polymerase chain reaction)|SpFI (Partial saturation Oxigen/inspired fraction of Oxigen) gain|Lung Ultrasound|Adverse events",Caja Costarricense de Seguro Social|Universidad de Costa Rica|Ministry of Health Costa Rica,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R020-SABI-00259,6-Dec-20,6-Sep-20,91,6-Oct-20,30-Oct-20,,19-Mar-21,"Centro Especializado de AtenciÃ³n COVID19 (CEACO), San JosÃ©, Costa Rica|Hospital Dr. Rafael Ãngel CalderÃ³n Guardia, San JosÃ©, Costa Rica|Hospital MÃ©xico, San JosÃ©, Costa Rica|Hospital San Juan de Dios, San JosÃ©, Costa Rica",,https://ClinicalTrials.gov/show/NCT04610502
196,NCT04393805,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,HETHICO,Completed,No Results Available,COVID-19|Hypercoagulability,Drug: Low Molecular Weight Heparin,Bleeding|Thrombosis|Mortality|Worsening|LOS,Quovadis Associazione|University of Padova,All,"18 Years and older Â  (Adult, Older Adult)",,744,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HETHICO,26-Feb-21,1-Jun-20,270,26-Feb-21,19-May-20,,18-Mar-21,"Giuseppe Camporese, Padova, Italy",,https://ClinicalTrials.gov/show/NCT04393805
197,NCT04346628,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,,Completed,No Results Available,Sars-CoV2|COVID-19,Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment,Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir,Stanford University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,149,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",56032,16-Apr-21,12-Jul-20,278,16-Apr-21,15-Apr-20,,20-Apr-21,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04346628
198,NCT04374513,Community Pharmacists Behaviour During Covid-19,,Completed,No Results Available,Covid19,,community pharmacists facing covid-19,Damanhour University,All,"Child, Adult, Older Adult",,318,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Pharmacists and covid-19,1-Jul-20,2-Apr-20,90,1-Jun-20,5-May-20,,3-Feb-21,"Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT04374513
199,NCT04423003,Endoscopic Interventions in Patients With COVID-19,,Completed,No Results Available,"Change; Endoscopy, COVID-19",Procedure: Endoscopic intervention,death in time of observation,University Hospital Tuebingen,All,"Child, Adult, Older Adult",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,242/2020BO2,15-May-20,1-Mar-20,75,15-May-20,9-Jun-20,,9-Jun-20,"University Hospital of Tuebingen, Tuebingen, Germany",,https://ClinicalTrials.gov/show/NCT04423003
200,NCT04412668,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,,Completed,No Results Available,SARS-CoV-2 (COVID-19) Severe Pneumonia,Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo,"Incidence of treatment-emergent adverse events (TEAEs)|Time to hospital discharge|Time to recovery (World Health Organization [WHO] Ordinal Scale score â‰¤3)|Proportion of patients achieving recovery by Day 14 and Day 28|Duration of supplemental oxygen (O2) requirement|Number of days with fever (temperature >100.4ÂºF [38.0ÂºC])|Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60|Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score|All-cause mortality at Days 14, 28, and 60","aTyr Pharma, Inc.",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATYR1923-C-003,21-Dec-20,12-Jun-20,192,21-Dec-20,2-Jun-20,,29-Jan-21,"University of Alabama at Birmingham, Birmingham, Alabama, United States|aTyr Investigative Site, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|aTyr Investigative Site, Vineland, New Jersey, United States|aTyr Investigative Site, Toledo, Ohio, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Alliance Medical Service, Cardio Pulmonary Research, Guaynabo, Puerto Rico|Manati Medical Center, ManatÃ­, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04412668
201,NCT04477655,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,PRO-CARF,Completed,No Results Available,Covid19,Procedure: Awake prone positioning|Procedure: Standard oxygen therapy,Intubation rate|Total hours of prone position at day|Total number of prone sessions at day|Hours of the longest prone session each day|Change in oxygenation 1-hour after first prone session|Change in the ROX-index 1-hour after first prone session|Total days of prone positioning therapy|Adverse effects of prone positioning therapy|Mechanical ventilation days|Intensive care unit length of stay|Hospital length of stay|Hospital mortality,Hospital Civil de Guadalajara,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,430,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,048/20,26-Jan-21,3-May-20,268,26-Jan-21,20-Jul-20,,13-Apr-21,"Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital General de Occidente, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT04477655
202,NCT04437875,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",,Completed,No Results Available,Preventive Immunization COVID-19,Biological: Gam-COVID-Vac Lyo,The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days|Number of Participants With Adverse Events|The changing of virus neutralizing antibody titer|The changing of antigen-specific cellular immunity level,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development",All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,38,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,03-Gam-COVID-Vac Lyo-2020,10-Aug-20,17-Jun-20,54,3-Aug-20,18-Jun-20,,12-Aug-20,"Sechenov First Moscow State Medical University, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04437875
203,NCT04678739,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,,Completed,No Results Available,Covid19|Covid-19 ARDS,Drug: Remdesivir|Drug: Tocilizumab,Time to Clinical Improvement (TTCI)|Duration of ICU Stay|Mortality Rate|Time to Recovery|Hospital stay|Rate of daily Supplemental Oxygen Use|Time to Clinical Failure,M Abdur Rahim Medical College and Hospital|First Affiliated Hospital Xi'an Jiaotong University|Cox's Bazar 250 Bed District Sadar Hospital|Chattogram General Hospital,All,"16 Years to 80 Years Â  (Child, Adult, Older Adult)",Phase 3,205,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M.A.R.M.C.D./2020/1985,10-Feb-21,15-Aug-20,179,30-Jan-21,22-Dec-20,,2-Apr-21,"Chattogram General Hospital, Chittagong, Bangladesh|Cox's Bazar 250 Bed District Sadar Hospital, Cox's Bazar, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh",,https://ClinicalTrials.gov/show/NCT04678739
204,NCT04386044,Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients,,Completed,No Results Available,COVID-19|Vitamin D Deficiency,,COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19,Tameside General Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,986,Other,Observational,Observational Model: Other|Time Perspective: Other,TGH1234,8-Sep-20,1-Jun-20,99,8-Aug-20,13-May-20,,7-May-21,"Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04386044
205,NCT04530422,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,,Completed,No Results Available,Covid19,Drug: Sofosbuvir plus Ledipasvir,Therapeutic success (cured)|28 days in hospital mortality|Percentage of clinical failure of treatments|Length of hospital stay|Incidence of side effects,Almaza Military Fever Hospital,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 3,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,14,23-Jul-20,15-Apr-20,99,8-Jul-20,28-Aug-20,,28-Aug-20,"Almaza Military Fever Hospital, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04530422
206,NCT04389944,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,,Completed,No Results Available,Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection),Other: convalescent plasma application to SARS-CoV-2 infected patients,Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response,"University Hospital, Basel, Switzerland",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Req-2020-00508; me20khanna2,30-Jun-20,31-Mar-20,91,30-Jun-20,15-May-20,,4-Aug-20,"Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT04389944
207,NCT04402866,TD-0903 for ALI Associated With COVID-19,,Completed,No Results Available,Acute Lung Injury (ALI) Associated With COVID-19|Lung Inflammation Associated With COVID-19,Drug: TD-0903|Drug: Placebo,Part 2: Respiratory Failure-Free Days (RFDs)|Part 2: Clinical Status Scale|Part 2: Subjects alive and respiratory failure-free|Part 2: SaO2/FiO2 ratio,Theravance Biopharma,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,235,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0188|2020-001807-18,21-Apr-21,24-Jun-20,301,21-Apr-21,27-May-20,,19-May-21,"Theravance Biopharma Investigational Site, Duarte, California, United States|Theravance Biopharma Investigational Site, Denver, Colorado, United States|Theravance Biopharma Investigational Site, Sebring, Florida, United States|Theravance Biopharma Investigational Site, Boston, Massachusetts, United States|Theravance Biopharma Investigational Site, Fall River, Massachusetts, United States|Theravance Biopharma Investigational Site, Kalispell, Montana, United States|Theravance Biopharma Investigational Site, Glens Falls, New York, United States|Theravance Biopharma, Hyde Park, New York, United States|Theravance Biopharma Investigational Site, Columbus, Ohio, United States|Theravance Biopharma Investigational Site, Allentown, Pennsylvania, United States|Theravance Biopharma Investigational Site, Bethlehem, Pennsylvania, United States|Theravance Biopharma Investigational Site, Wenatchee, Washington, United States|Theravance Biopharma Investigational Site, Bela Vista, Brazil|Theravance Biopharma Investigational Site, Botucatu, Brazil|Theravance Biopharma Investigational Site, Caxias Do Sul, Brazil|Theravance Biopharma Investigational Site, SÃ£o JosÃ© Do Rio Preto, Brazil|Theravance Biopharma Investigational Site, Helsinki, Finland|Theravance Biopharma Investigational Site, Turku, Finland|Theravance Biopharma Investigational Site, Chisinau, Moldova, Republic of|Theravance Biopharma Investigational Site, Bucharest, Romania|Theravance Biopharma Investigational Site, Brovary, Ukraine|Theravance Biopharma Investigational Site, Kyiv, Ukraine|Theravance Biopharma Investigational Site, Kyiv, Ukraine|Theravance Biopharma Investigational Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04402866
208,NCT04480593,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Bee-Covid,Completed,No Results Available,Covid19,Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care,Composite clinical outcome with oxygen therapy dependency time or hospitalization time|Percentage of participants with adverse events during the use of propolis|Rate and severity of acute kidney injury during the study|Renal replacement therapy.|Rate of need for vasopressor use|Need for intensive care unit (ICU)|Intensive care unit (ICU) readmission|Invasive oxygenation time|Variation of plasma c-reactive protein,D'Or Institute for Research and Education|Hospital Sao Rafael,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,31099320.6.0000.0048,30-Aug-20,2-Jun-20,89,30-Aug-20,21-Jul-20,,30-Sep-20,"Hospital Sao Rafael, Salvador, BA, Brazil",,https://ClinicalTrials.gov/show/NCT04480593
209,NCT04427332,Smell and Taste Disorders in COVID-19 Patients,COVID-19 ORL,Completed,No Results Available,covid19,Other: Investigation of smell and taste disorders,Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste,University of Milano Bicocca,All,"18 Years and older Â  (Adult, Older Adult)",,376,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19 ORL,16-Oct-20,11-Jun-20,127,16-Oct-20,11-Jun-20,,27-Jan-21,"ASST Monza-Ospedale San Gerardo, Monza, Italy",,https://ClinicalTrials.gov/show/NCT04427332
210,NCT04642196,COVID-19 in Home Healthcare,,Completed,No Results Available,Covid19,,Frailty|Comorbidity,"University Hospital, Linkoeping",All,"Child, Adult, Older Adult",,155,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Home healthcare 2020,10-Oct-20,2-May-20,161,10-Oct-20,24-Nov-20,,24-Nov-20,"Dept of anesthesia, LinkÃ¶ping, Sweden",,https://ClinicalTrials.gov/show/NCT04642196
211,NCT04710771,Effect of Prone Positioning in Patients With COVID-19,,Completed,No Results Available,Covid19,Other: Prone Lying Position|Other: alternate nostril breathing,PaO2|FiO2|General Anxiety Disorder-7 Score,Sialkott College of Physical Therapy,All,"40 Years to 80 Years Â  (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,138,29-Jan-21,23-Nov-20,67,15-Jan-21,15-Jan-21,,9-Feb-21,"DHQ Hospital, Faisalabad, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04710771
212,NCT04591600,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,,Completed,No Results Available,Covid19,Drug: Ivermectin and Doxycyline|Drug: Standard of care,Mortality rate|Rate of progression disease|Time to recovery,Alkarkh Health Directorate-Baghdad,All,"16 Years to 86 Years Â  (Child, Adult, Older Adult)",Phase 1|Phase 2,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IVM-DOX,14-Oct-20,1-Jul-20,105,30-Sep-20,19-Oct-20,,19-Oct-20,"Akarkh Healt hdirectorate, Baghdad, Iraq",,https://ClinicalTrials.gov/show/NCT04591600
213,NCT04380727,Almitrine and COVID-19 Related Hypoxemia,,Completed,No Results Available,COVID-19|Hypoxic Respiratory Failure,,Changes from baseline PaO2 (mmHg)|Changes from baseline ScvO2 (%),"Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,17,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2020PI080_2,25-Apr-20,20-Mar-20,36,14-Apr-20,8-May-20,,30-Jul-20,"Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",,https://ClinicalTrials.gov/show/NCT04380727
214,NCT04434157,Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,,Completed,No Results Available,Covid-19,,Clinical complications and Mortality|Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio,Hospital Regional de Alta especialidad de Ixtapaluca|Hospital General de MÃ©xico Dr. Eduardo Liceaga,All,"Child, Adult, Older Adult",,221,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NR-09-2020,5-May-20,28-Mar-20,38,5-May-20,16-Jun-20,,16-Jun-20,"Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico",,https://ClinicalTrials.gov/show/NCT04434157
215,NCT04629222,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,,Completed,No Results Available,Ventilation Lung Scintigraphy During COVID-19 Infection,,Tracheobronchitis signs may be observed on ventilation lung scintigraphy during COVID-19 infection.,"Pierre Yves MARIE|Central Hospital, Nancy, France",All,"Child, Adult, Older Adult",,10,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,2020PI154,23-Jul-20,11-Mar-20,134,20-Jul-20,16-Nov-20,,16-Nov-20,"CHRU of Nancy, VandÅ“uvre-lÃ¨s-Nancy, France",,https://ClinicalTrials.gov/show/NCT04629222
216,NCT04408456,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,PEP-CQ,Completed,No Results Available,CoVID-19,Drug: HCQ|Other: Standard therapy,Incidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction (ADR),Postgraduate Institute of Medical Education and Research,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,325,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IEC-04/2020-1624,31-Jul-20,1-Mar-20,152,31-Jul-20,29-May-20,,4-Aug-20,"Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India",,https://ClinicalTrials.gov/show/NCT04408456
217,NCT04476823,European Pathology Laboratories and COVID-19,,Completed,No Results Available,Clinical Practice During the COVID-19 Crisis,Other: Activity,Activity,Centre Hospitalier Universitaire de Nice,All,"Child, Adult, Older Adult",,71,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,20labocovid01,31-May-20,15-Mar-20,77,31-May-20,20-Jul-20,,20-Jul-20,"CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT04476823
218,NCT04427267,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,,Completed,No Results Available,Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,Other: Personal protective equipment from biological hazard,Skin thermometry|Hygrometry under costume|Heart rate|Air thermometry|Air hygrometry,"Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""",All,18 Years to 45 Years Â  (Adult),,6,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PPE-02,27-Jun-20,3-Jun-20,24,27-Jun-20,11-Jun-20,,28-Jul-20,"Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04427267
219,NCT04516759,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,ARCADIA,Completed,No Results Available,Covid19,Drug: AZD1656|Other: Placebo,"Clinical Improvement by Day 14|*Title: Clinical Improvement at Day 7, 14 and 21|Glycaemic Control|Occurrence of Adverse Events|Occurrence of Serious Adverse Events|Duration of Hospitalisation|Time to Intubation/ Mechanical Intervention|Mortality Rate",St George Street Capital,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,156,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SGS.1656.201|2020-002211-21,12-May-21,12-Aug-20,273,25-Apr-21,18-Aug-20,,14-May-21,"Masarykova Univerzita - Fakultni Nemocnice U SV Anny V Brne (308), Brno, Czechia|Nemocnice HoÅ™ovice (309), HoÅ™ovice, Czechia|Oblastni Nemocnice KolÃ­n (306), KolÃ­n, Czechia|Klaudianova Nemonice (302), MladÃ¡ Boleslav, Czechia|Fakultni Nemocnice V Motole (303), Prague, Czechia|Thomayerova Nemonice (310), Prague, Czechia|Nemocnice TÅ™ebÃ­Ä (305), TÅ™ebÃ­Ä, Czechia|Colentina Clinical Hospital (204), Bucharest, Romania|Spitalul Clinic de Boli Infectioase Cluj-Napoca (203), Cluj-Napoca, Romania|Spitalul Clinic de Pneumoftiziologie ""Leon Daniello"" Cluj-Napoca (202), Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase ConstanÅ£a (207), ConstanÅ£a, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes Craiova (206), Craiova, Romania|Spitalul Judetean de Urgenta Deva (208), Deva, Romania|Spitalul Clinic de Boli Infectioase ""Sfanta Parascheva"" IaÅŸi (205), IaÅŸi, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes TimiÅŸoara (201), TimiÅŸoara, Romania|Barnsley Hospital NHS Foundation Trust (105), Barnsley, United Kingdom|Bolton NHS Foundation Trust (122), Bolton, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust (103), Bradford, United Kingdom|North Bristol NHS Trust (116), Bristol, United Kingdom|County Durham and Darlington NHS Foundation Trust (121), Darlington, United Kingdom|The Dudley Group NHS Foundation Trust (107), Dudley, United Kingdom|Medway NHS Foundation Trust (108), Gillingham, United Kingdom|Hull & East Yorkshire NHS Trust (102), Hull, United Kingdom|Barts Health NHS Trust (101 and 111), London, United Kingdom|Royal Free London NHS Foundation Trust (119), London, United Kingdom|St George's University Hospitals NHS Foundation Trust (114), London, United Kingdom|Penine Acute Hospitals NHS Trust (106), Salford, United Kingdom|Sheffield Hospitals NHS Foundation Trust (104), Sheffield, United Kingdom|Somerset NHS Foundation Trust (109), Taunton, United Kingdom|Walsall Healthcare NHS Trust (113), Walsall, United Kingdom",,https://ClinicalTrials.gov/show/NCT04516759
220,NCT04348214,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,SARAH,Completed,No Results Available,Coronavirus Disease (COVID-19),,Risk categorization of healthcare workers|COVID-19 infection rate among health care workers|Risk factors for COVID-19 among health care workers|Adherence of health care workers to infection prevention|Validity of the available rapid serological test for detecting COVID-19 virus infection|Clinical spectrum of COVID-19|Effectiveness of infection prevention in the health care facility|Emergency infection prevention and control needs|Isolation rate and emergency health care worker replacement needs|Rate of seroconversion,Ain Shams University,All,"18 Years and older Â  (Adult, Older Adult)",,4040,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,FMASU P18a/ 2020,1-Dec-20,22-Apr-20,223,1-Oct-20,16-Apr-20,,20-Apr-21,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,https://ClinicalTrials.gov/show/NCT04348214
221,NCT04527458,Case Fatalities in Hospitalised COVID-19 Patients in the UK,,Completed,No Results Available,Covid19,Other: Patient Characteristics|Other: COVID-19 treatments|Other: Differences in triage|Other: Surge capacity,Case fatality,University of Edinburgh|International Severe Acute Respiratory and Emerging Infection Consortium|BREATHE Health Data Research Hub,All,"Child, Adult, Older Adult",,70000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ISARIC_COVID_CF,2-Aug-20,24-Feb-20,160,2-Aug-20,26-Aug-20,,26-Aug-20,"University of Edinburgh, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT04527458
222,NCT04350736,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",,Completed,No Results Available,Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19,Drug: TD-0903|Drug: Placebo,Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax,Theravance Biopharma,All,18 Years to 50 Years Â  (Adult),Phase 1,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0183|2020-000577-24,24-Jun-20,23-Apr-20,62,24-Jun-20,17-Apr-20,,2-Sep-20,"Theravance Biopharma Investigational Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04350736
223,NCT04609969,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,COVID-VIRO,Completed,No Results Available,Covid19|SARS-CoV-2 Infection,Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIROÂ® test,Evaluation of COVID VIROÂ® diagnostic specificity|Evaluation of COVID VIROÂ® diagnostic sensitivity|Evaluation of COVID VIROÂ® diagnostic sensitivity for RT-qPCR Cycle threshold value < or > 28,Centre Hospitalier RÃ©gional d'OrlÃ©ans,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHRO-2020-18,17-Oct-20,13-Oct-20,4,17-Oct-20,30-Oct-20,,7-Dec-20,"Centre Hospitalier RÃ©gional d'OrlÃ©ans, France, OrlÃ©ans, France",,https://ClinicalTrials.gov/show/NCT04609969
224,NCT04455308,COVID-19 and Chilblains,ECCES,Completed,No Results Available,Chilblains|COVID-19,Diagnostic Test: Biological sample collection,"Level of viral exposure in ""case family"" compared to ""comparator family""|Comparison of seropositivity rates in subjects with chilblains and their age-matched controls|Comparison of SARS-CoV-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks|Antibody avidity and differentiated IgG and IgM assay by subject in the homes",Rennes University Hospital,All,"Child, Adult, Older Adult",Not Applicable,269,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,35RC20_8888_ECCES,19-Oct-20,21-Jul-20,90,19-Oct-20,2-Jul-20,,4-Nov-20,"CHU Angers, Angers, France|CHRU Brest, Brest, France|CHU Nantes, Nantes, France|CHU Rennes, Rennes, France|CHRU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04455308
225,NCT04338932,COVID-19 and Deep Venous Thrombosis,,Completed,No Results Available,COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis,,"the prevalence of a DVT in patients at the ICU.|Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood|Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood|glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood|oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood|white blood cells, red blood cells and platelets in the blood|PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L)in the blood|prevalence of co-morbidities|prevalence of vital signs at icu admission|prevalence of complications during icu stay|evaluation of treatment|evaluation of the oxygen therapy",Jessa Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,12,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,JessaH_COVID19_DVT,15-May-20,17-Apr-20,28,15-May-20,8-Apr-20,,19-May-20,"Jessa hospital, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT04338932
226,NCT04668625,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",,Completed,No Results Available,COVID-19 (SARS-CoV-2),Behavioral: Participate in a massive musical event,Incidence rate of people infected with SARS-CoV-2 8 days after randomization|SARS-CoV-2 genome sequence|Incidence rate of appearance of symptoms compatible with COVID 19|Time spent in testing the total number of participants in the study.|Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.|Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva|Presence of viable SARS-CoV-2 from cell culture|Satisfaction in relation to the test procedure,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia|Dr. Bonaventura Clotet Sala|Dr. Josep MÂª LLibre Codina|Dr. Boris Revollo Barriga|Dra. Lidia Ruiz Tabuenca|Dr. Ignacio Blanco Guillermo|Dra. Andrea Alemany Ortiz|Dr. Roger Paredes Deiros",All,18 Years to 59 Years Â  (Adult),Not Applicable,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PRIMACOV,8-Jan-21,30-Nov-20,39,20-Dec-20,16-Dec-20,,8-Feb-21,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04668625
227,NCT04518735,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),CORONA,Completed,No Results Available,Covid19,Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19,Mortality|Transfer to the Intensive Care Unit (ICU)|Thromboembolic complications|Major bleeding complications,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,All,"Child, Adult, Older Adult",,1707,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,IIBSP-COV-2020-24,30-Jun-20,1-Apr-20,90,30-Jun-20,19-Aug-20,,19-Aug-20,"Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain",,https://ClinicalTrials.gov/show/NCT04518735
228,NCT04739410,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,,Completed,No Results Available,Covid19,Drug: Ivermectin,Resolution of symptoms|Progression of the disease,FMH College of Medicine and Dentistry,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 4,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB#FMH-07-2020-IRB-766-M,30-Jun-20,1-May-20,60,30-Jun-20,4-Feb-21,,4-Feb-21,"Aijaz Zeeshan Khan Chachar, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04739410
229,NCT04789460,Relationship Between Potential Predictors and Mortality in COVID-19 Patients Ä±n Turkey,,Completed,No Results Available,Covid19,,mortality rate|need for intensive care unit rate|length stay in hospital,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",All,"18 Years and older Â  (Adult, Older Adult)",,816,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,TURKEYPROMOD,28-Mar-21,5-Mar-21,23,28-Mar-21,9-Mar-21,,24-May-21,"SBU Sultan Abdulhamid Han, Istanbul, Asia, Turkey",,https://ClinicalTrials.gov/show/NCT04789460
230,NCT04358939,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),,Completed,No Results Available,Acute Respiratory Distress Syndrome|COVID-19,Other: Prone decubitus,"Therapeutic failure within 14 days of randomization|Therapeutic failure within 28 days of randomization|Timeframe of intubation or death|Timeframe of therapeutic escalation (in case of non-invasive ventilation at two pressure levels)|Evolution of oxygenation (PaO2/FiO2 ratio or SpO2/FiO2 surrogate) over the 14 days following randomization|Evolution of the SpO2/FiO2 ratio during the first prone session|Evolution of the ROX index during the first prone session|Evolution of the World Health Organization disease severity score of COVID|Patient comfort before, during and after the first prone position session|Occurrence of skin lesions on the anterior surface of the body|Displacement of invasive devices during reversals|Days of nasal High-Flow therapy use in the general population, in non-intubated patients and in intubated patients|Days spent in the intensive care unit and in the hospital|Mortality in the intensive care unit and in the hospital|Ventilator-free-days within 28 days of randomization","University Hospital, Tours",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,405,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIGH-PRONE-COVID-19|2020-A01121-38|DR200125,21-Feb-21,27-Apr-20,300,21-Feb-21,24-Apr-20,,19-Apr-21,"Intensive Care Unit, University Hospital, Aix, Aix-en-Provence, France|Medical Intensive Care Unit, University Hospital, Amiens, Amiens, France|Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France|Intensive Care Unit, Hospital,, Blois, France|Medical Intensive Care Unit, University Hospital, Brest, Brest, France|Medical Intensive Care Unit, Hospital, BÃ©thune, BÃ©thune, France|Medical Intensive Care Unit, University Hospital, Caen, Caen, France|Intensive Care Unit, Louis Mourier-APHP, Colombes, France|Intensive Care Unit, Hospital, Dax, Dax, France|Medical Intensive Care Unit, University Hospital, Dijon, Dijon, France|Medical Intensive Care Unit, University Hospital, Grenoble, Grenoble, France|Intensive Care Unit, Hospital, La Roche-sur-Yon, La Roche-sur-Yon, France|Intensive Care Unit, Hospital, Le Mans, Le Mans, France|Intensive Care Unit, University Hospital, Lille, Lille, France|Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France|Medical Intensive Care Unit, University Hospital, Nice, NIce, France|Medical Intensive Care Unit, Hospital, OrlÃ©ans, OrlÃ©ans, France|Medical Intensive Care Unit, Tenon-APHP, Paris, France|Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France|Medical Intensive Care Unit, University Hospital, Tours, Tours, France|Surgical Intensive Care Unit, University Hospital, Tours, Tours, France|Intensive Care Unit, Hospital, Valence, Valence, France|Medical Intensive Care Unit, University Hospital, Nancy, VandÅ“uvre-lÃ¨s-Nancy, France|Intensive Care Unit, Hospital, Vannes, Vannes, France",,https://ClinicalTrials.gov/show/NCT04358939
231,NCT04438980,Glucocorticoids in COVID-19 (CORTIVID),CORTIVID,Completed,No Results Available,Covid-19 Pneumonia,Drug: Methylprednisolone|Other: Placebo,"Proportion of patients developing treatment failure|Mortality at day 28|Proportion of patients requiring ICU admission|Proportion of patients requiring rescue-therapy with tocilizumab|Length of hospital stay|Proportion of severe adverse events|Proportion of bacterial, fungal or opportunistic infections|Evolution of inflammatory biomarkers related to COVID-19|Proportion of SARS-CoV-2 clearance.",Fundacion Miguel Servet|Complejo Hospitalario de Navarra|Hospital Sant Joan DespÃ­ MoisÃ¨s Broggi,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 3,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CORTIVID,9-Apr-21,15-May-20,329,12-Mar-21,19-Jun-20,,17-May-21,"Hospital Sant Joan DespÃ­ MoisÃ¨s Broggi, Sant Joan DespÃ­, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain",,https://ClinicalTrials.gov/show/NCT04438980
232,NCT04412226,Effect of Using Barrier Devices for Intubation in COVID-19 Patients,,Completed,No Results Available,"Intubation, Intratracheal|COVID-19",Device: aerosol box|Device: transparent sheet,First pass success|Time to endotracheal intubation|Difficulty level of accessing the equipment|Difficulty level of inserting the endotracheal tube into the glottis|Clarity of the view of the patient's face,Derince Training and Research Hospital,All,"Child, Adult, Older Adult",,13,Other,Observational,Observational Model: Other|Time Perspective: Prospective,2020/56,30-Jun-20,10-Jun-20,20,30-Jun-20,2-Jun-20,,4-Dec-20,"Kocaeli Derince Training and Research Hospital, Kocaeli, Izmit, Turkey",,https://ClinicalTrials.gov/show/NCT04412226
233,NCT04707742,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,BUCOSARS,Completed,No Results Available,Covid19,Drug: BetadineÂ© bucal 100 mg/ml|Drug: OximenÂ® 3%|Drug: Clorhexidine Dental PHBÂ©|Drug: Vitis Xtra ForteÂ©|Drug: Distilled Water,Effect of 5 different mouthwashes on the SARS-Cov2 viral load.,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az|Hospital Universitario General de Villalba|Hospital Universitario Infanta Elena|Hospital Universitario Virgen de la Arrixaca|Hospital ClÃ­nico Universitario de Valencia|Dentaid SL,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,84,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Interventional,18-Nov-20,15-Jun-20,156,18-Nov-20,13-Jan-21,,13-Jan-21,"Alejandro Mira, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04707742
234,NCT04397523,Efficacy and Safety of COVID-19 Convalescent Plasma,,Completed,No Results Available,Convalescent Plasma|COVID-19|SARS-CoV 2,Biological: anti-SARS-CoV-2 convalescent plasma,"Duration of oxygenation and ventilation support|Hospital length of stay (LOS)|ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery","Institute for Transfusion Medicine of RNM|University Clinic for Infectious Diseases, North Macedonia",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITM05/2020MKD,10-May-21,30-Apr-20,375,10-May-21,21-May-20,,11-May-21,"Institute for Transfusion Medicine of RNM, Skopje, North Macedonia",,https://ClinicalTrials.gov/show/NCT04397523
235,NCT04758286,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,,Completed,No Results Available,COVID-19,Procedure: Emergency surgical procedures,Questionnaire|Physiologic assessment|Surgical follow-up,Benha University|Tanta University,All,"Child, Adult, Older Adult",Not Applicable,209,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,RC2-2-2021,11-Feb-21,1-Jul-20,225,1-Feb-21,17-Feb-21,,17-Feb-21,"Faculty of Medicine, BanhÄ, Qalubia, Egypt",,https://ClinicalTrials.gov/show/NCT04758286
236,NCT04838093,COVID-19 Testing in Patients With Vascular Disorders,,Completed,No Results Available,Covid19,Diagnostic Test: PCR,prevalence of SARS-CoV-2 infection,Medical University of Vienna,All,"Child, Adult, Older Adult",,2243,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2049/2020,1-Jan-21,1-Mar-20,306,1-Dec-20,8-Apr-21,,8-Apr-21,"Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04838093
237,NCT04427358,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,COVID-19GAOM,Completed,No Results Available,Covid-19,,"1. Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection|2. Assess quantitative evaluation of a nasopharyngeal swab SARS-CoV-2 RT-PCR test|Assessment of late stool SARS-CoV-2 RT-PCR, serological status and associated factors with death and RT-PCR results 1 month after the date of first symptom onset","University Hospital, Strasbourg, France",All,70 Years and older Â  (Older Adult),,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,7838,7-Sep-20,7-May-20,123,7-Aug-20,11-Jun-20,,25-Nov-20,"Service SSR GÃ©riatrique, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04427358
238,NCT04357808,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),SARCOVID,Completed,No Results Available,Covid-19,Drug: Sarilumab|Other: Standar of care,Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation,Maria del Rosario Garcia de VicuÃ±a Pinedo|Instituto de InvestigaciÃ³n Sanitaria Hospital Universitario de la Princesa|FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SARCOVID|2020-001634-36,4-Dec-20,13-Apr-20,235,30-Nov-20,22-Apr-20,,11-Feb-21,"Hospital Universitario de la Princesa, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04357808
239,NCT04373161,Home Pulse Oximeter Use in Patients With COVID-19,,Completed,No Results Available,Sars-CoV2|COVID-19|COVID,Device: Home Pulse Oximetry Monitoring,Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay,Swedish Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,209,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2020032301,22-Apr-20,20-Mar-20,33,22-Apr-20,4-May-20,,6-May-20,"Swedish Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04373161
240,NCT04829552,Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units,,Completed,No Results Available,Covid19,,Inpatient all-cause mortality|Rates of major bleeding events|Rates of venous thromboses|Intensive care unit/Step down unit length of stay,William Beaumont Hospitals,All,"18 Years and older Â  (Adult, Older Adult)",,704,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-219,15-Apr-20,10-Mar-20,36,15-Apr-20,2-Apr-21,,2-Apr-21,"Beaumont Health System (BHS), Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04829552
241,NCT04809480,COVID-19 and Acute Invasive Fungal Rhinosinusitis,,Completed,No Results Available,Covid19,Diagnostic Test: Fungal rhinosinusitis,Fungus detection,Al-Azhar University,All,"15 Years to 90 Years Â  (Child, Adult, Older Adult)",,56,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20- 11- 002,31-Dec-20,1-Jan-17,1460,31-Dec-20,22-Mar-21,,22-Mar-21,,,https://ClinicalTrials.gov/show/NCT04809480
242,NCT04894409,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,COVID-19,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),Device: Mouthwash and nose rinse with the AgNPs solution|Device: Mouthwashes and nose rinse in a conventional way,Incidence of SARS-CoV-2 infection in the experimental group.|Incidence of SARS-CoV-2 infection in the control group.|Number of participants with adverse reactions by AgNPs.,"Cluster de Bioeconomia de Baja California, A.C|Bionag SAPI de CV|General Hospital Tijuana",All,"20 Years to 73 Years Â  (Adult, Older Adult)",Not Applicable,231,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,CONBIOETICA-02-CEI-001-20170,29-Sep-20,24-Apr-20,158,30-Jun-20,20-May-21,,20-May-21,"Tijuana General Hospital, Tijuana, Baja California, Mexico",,https://ClinicalTrials.gov/show/NCT04894409
243,NCT04359212,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,VTE-COVID,Completed,No Results Available,"COVID-19 Disease|Thromboembolism, Venous",Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux,the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism,Quovadis Associazione|Azienda Ospedaliera di Padova,All,"18 Years and older Â  (Adult, Older Adult)",,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,VTE-COVID,31-Jul-20,1-May-20,91,30-Jun-20,24-Apr-20,,17-Sep-20,"Giuseppe Camporese, Padova, Italy",,https://ClinicalTrials.gov/show/NCT04359212
244,NCT04349592,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,,Completed,No Results Available,Covid19,Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules,Proportion of virologically cured (PCR-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events,Hamad Medical Corporation,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,456,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MRC-05-001,30-Aug-20,14-Apr-20,138,14-Aug-20,16-Apr-20,,23-Feb-21,"Hamad Medical Corporation, Doha, Qatar",,https://ClinicalTrials.gov/show/NCT04349592
245,NCT04355715,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,COVID-Scan,Completed,No Results Available,COVID 19|SARS-Cov-2,,Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion,"University Hospital, Montpellier",All,"18 Years to 99 Years Â  (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0223,20-Oct-20,1-Apr-19,568,1-Oct-20,21-Apr-20,,29-Dec-20,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04355715
246,NCT04558385,Seroconversion in COVID-19 Recovered Population,,Completed,No Results Available,Covid19,Diagnostic Test: IgG SARS CoV2,IgG SARS CoV2,Lahore General Hospital,All,"Child, Adult, Older Adult",,275,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,LGH006,31-Mar-21,1-Jul-20,273,31-Mar-21,22-Sep-20,,1-Apr-21,"Lahore General Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04558385
247,NCT04422574,COVID 19 Serology in Pulmonologists,Pneumoserocov,Completed,No Results Available,Covid 19,,covid 19 serology|risk factors for positive serology testing,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,97,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,RECHMPL20_0343,30-May-20,1-May-20,29,1-May-20,9-Jun-20,,9-Jun-20,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04422574
248,NCT04654416,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine,,Completed,No Results Available,Covid-19,Drug: Corticosteroid with or without colchicine,Outcome,ClÃ­nica MedellÃ­n - Grupo QuirÃ³nsalud,All,"18 Years and older Â  (Adult, Older Adult)",,301,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,20-Apr,20-Aug-20,20-Mar-20,153,7-Aug-20,4-Dec-20,,4-Dec-20,"ClÃ­nica MedellÃ­n - Grupo QuirÃ³nsalud, MedellÃ­n, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT04654416
249,NCT04410939,COVID-19 PCR Test Results in Asymptomatic Pregnants,,Completed,No Results Available,COVID-19|Asymptomatic Pregnant,Diagnostic Test: Reverse transcription polymerase chain reaction,Rate of positive COVID-19 cases in asymptomatic pregnant women,Istanbul Medipol University Hospital,Female,"Child, Adult, Older Adult",,179,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Retrospective,Gpolat1,21-May-20,10-Apr-20,41,20-May-20,1-Jun-20,,1-Jun-20,"Istanbul Medipol University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04410939
250,NCT04288102,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),,Completed,No Results Available,Corona Virus Disease 2019(COVID-19),Biological: UC-MSCs|Biological: Saline containing 1% Human serum albuminï¼ˆsolution without UC-MSCsï¼‰,"Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) Ã— voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|The General Hospital of Central Theater Command|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-013-D,9-Jul-20,5-Mar-20,126,12-May-20,28-Feb-20,,19-Aug-20,"General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04288102
251,NCT04343339,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,EPILOGUE,Completed,No Results Available,"Addiction, Substance|COVID-19",,Evolution of consumption|health care access,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0195,30-Sep-20,8-Apr-20,175,30-Jul-20,13-Apr-20,,8-Oct-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04343339
252,NCT04470258,Elmo Respiratory Support Project - COVID-19,,Completed,No Results Available,COVID-19|Respiratory Failure With Hypoxia,Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS|Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY,Usability tests of the Elmo system using Euristic usability principles|Evaluation of the effectiveness of the ELMO system using physiological parameters,Escola de SaÃºde PÃºblica do CearÃ¡,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,4.104.233,30-Nov-20,25-Jun-20,158,30-Aug-20,14-Jul-20,,20-Apr-21,"Hospital Leonardo Da Vinci, Fortaleza, Brazil",,https://ClinicalTrials.gov/show/NCT04470258
253,NCT04437121,Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,COV-EAT,Completed,No Results Available,Eating Behavior|COVID-19,Other: Online Survey about Dietary and Lifestyle Habits,Change in weight (child)|Behaviour (child)|Behaviour (parents)|Physical Activity Levels (child)|Screen Time (child)|Sleep Duration (child),University of Thessaly,All,"24 Months to 18 Years Â  (Child, Adult)",,397,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,COV-EAT,24-May-20,30-Apr-20,24,24-May-20,18-Jun-20,,18-Jun-20,"Department of Nutrition-Dietetics, TrÃ­kala, Thessaly, Greece","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04437121/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04437121
254,NCT04649333,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,,Completed,No Results Available,Covid19,,"The type, extent and intensity of physical activity",Medical University Innsbruck|Universitaet Innsbruck,All,"18 Years and older Â  (Adult, Older Adult)",,1336,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,20200609,31-Aug-20,15-Jun-20,77,31-Aug-20,2-Dec-20,,4-Dec-20,"Medical University Innsbruck, Innsbruck, Tyrol, Austria",,https://ClinicalTrials.gov/show/NCT04649333
255,NCT04684433,Surgery in the Time of COVID-19 Pandemic,,Completed,No Results Available,Covid19,Other: Data extraction from medical files,Surgery code|Urgency|Type of anesthesia|Delay between surgery and first symptoms|Surgery duration|Hospital stay (in days)|Intensive care unit stay (in days)|Post-op complications|Covid status before surgery|Covid status post-surgery|COVID19 Diagnosis by CT scan|COVID19 Diagnosis by swab test|COVID 19 Diagnosis by antibody test|COVID19 symptoms - dry cough|COVID19 symptoms - fever|COVID19 symptoms - myalgia|COVID19 symptoms - anosmia|COVID19 symptoms -respiratory distress|Treatment for COVID19 - Plaquenil|Treatment for COVID19 - Antivirals|Need for intubation|Death|Age|Gender|Ethnicity|BMI|Comorbidities,Brugmann University Hospital,All,"Child, Adult, Older Adult",,707,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CHUB-Farid,15-Mar-21,14-Apr-20,335,15-Mar-21,24-Dec-20,,16-Mar-21,"St Pierre, Brussels, Belgium|CHU Brugmann, Brussels, Belgium|Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium",,https://ClinicalTrials.gov/show/NCT04684433
256,NCT04358081,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,Completed,Has Results,Covid-19,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Number of Participants Who Achieved Clinical Response by Day 15|Number of Participants Who Achieved Viral Clearance|Number of Participants Discharged or Ready for Discharge|Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,27-Jul-20,1-May-20,87,27-Jul-20,22-Apr-20,17-Mar-21,2-Apr-21,"Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04358081
257,NCT04799873,Alpha-1-Antitrypsin-Deficiency in COVID-19,CORSAAR-AAT,Completed,No Results Available,Covid19,Drug: AAT( Alpha 1 Antitrypsin),Clinical course,UniversitÃ¤t des Saarlandes,All,"18 Years to 110 Years Â  (Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CORSAAR-AAT-001,1-Dec-20,8-Apr-20,237,1-Dec-20,16-Mar-21,,16-Mar-21,"Saarland University, Homburg, Saarland, Germany",,https://ClinicalTrials.gov/show/NCT04799873
258,NCT04460703,"COVID-19 Vaccine Messaging, Part 1",,Completed,No Results Available,Vaccination|COVID-19,Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message,Intention to get COVID-19 vaccine|Vaccine confidence scale|Persuade others item|Fear of those who have not been vaccinated|Social judgment of those who do not vaccinate,Yale University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,4000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2000027983,8-Jul-20,3-Jul-20,5,8-Jul-20,7-Jul-20,,21-Jul-20,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04460703
259,NCT04386694,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,,Completed,No Results Available,COVID-19|Respiratory Failure,Device: Active PBMT/sMF|Device: Placebo PBMT/sMF,Time until discharge|Survival rate|Diaphragm muscle function|Platelet count|Leukogram|Erythrogram|C-reactive protein|D-dimer|Immunoglobulin G|Immunoglobulin M|Levels of positive end-expiratory pressure (PEEP)|Fraction of inspired oxygen (FiO2)|Arterial partial pressure of oxygen (PO2)|Arterial partial pressure of oxygen (PO2)/Fraction of inspired oxygen (FiO2) ratio|Levels of tumor necrosis factor-Î± (TNF-Î±)|Levels of vitamin D,University of Nove de Julho|Hospital Tacchini/RS,All,"15 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3.985.226,17-Sep-20,18-May-20,122,17-Sep-20,13-May-20,,29-Oct-20,"Hospital Tacchini, Bento GonÃ§alves, RS, Brazil",,https://ClinicalTrials.gov/show/NCT04386694
260,NCT04460274,Forecast Number of Covid-19 Cases Worldwide,Covid19TmeSer,Completed,No Results Available,Covid-19,Other: Model Building|Other: Model validation,Number of Confirmed cases of Covid-19,Turkish Ministry of Health Izmir Teaching Hospital,All,"Child, Adult, Older Adult",,7882471,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,TurkishMOHITH-TimeSeries,20-Jun-20,31-Dec-19,172,15-Jun-20,7-Jul-20,,8-Jul-20,"Republic of Turkey, Health Sciences University, Izmir Bozyaka Education and Training Hospital, Ä°zmir, Turkey",,https://ClinicalTrials.gov/show/NCT04460274
261,NCT04859881,Risk Factors for Barotrauma in COVID-19,,Completed,No Results Available,Barotrauma|Covid19,Other: No intervention,Barotrauma development|Mortality,Hospital General Ajusco Medio|Horacio Marquez-Gonzalez|Carlos Torruco-Sotelo|Sebastian Rodriguez-Llamazares,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,262,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,HGAM01,31-Jan-21,1-Apr-20,305,31-Jan-21,26-Apr-21,,26-Apr-21,"Hospital General Ajusco Medio, Mexico city, Mexico",,https://ClinicalTrials.gov/show/NCT04859881
262,NCT04390074,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,,Completed,No Results Available,COVID-19|Critical Illness,Other: COVID-19 and Intensive Care,Chronic medications as risk factor of intensive care for COVID-19|Comorbidities as risk factor of intensive care for COVID-19|Chronic medications as risk factor of death during intensive care for COVID-19|Comorbidities as risk factor of death during intensive care for COVID-19,"Uppsala University|Center for Clinical Research Dalarna, Sweden",All,"18 Years and older Â  (Adult, Older Adult)",,9905,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,UTN: U1111-1251-8195,4-Jun-20,27-May-20,8,4-Jun-20,15-May-20,,25-Aug-20,"BjÃ¶rn AhlstrÃ¶m, Falun, Sweden",,https://ClinicalTrials.gov/show/NCT04390074
263,NCT04473248,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,,Completed,No Results Available,Covid19,Device: Spartan COVID-19 System,Asses the % agreement between predicate results and Spartan COVID-19 results.,Spartan Bioscience Inc.|Humber River Hospital|The Ottawa Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,27,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,VNV-00552,30-Aug-20,28-Jun-20,63,30-Aug-20,16-Jul-20,,13-Nov-20,"Humber River Hospital, North York, Ontario, Canada|The Univeristy of Ottawa Heart Institute, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04473248
264,NCT04853901,Remdesivir Efficacy In Management Of COVID-19 Patients,,Completed,No Results Available,Covid19,Drug: Remdesivir|Drug: Standard of care_1|Drug: Standard of care_2,Evaluation of viral clearance,Ain Shams University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 3,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMASU P56a/ 2020,1-Mar-21,27-Jul-20,217,1-Jan-21,22-Apr-21,,22-Apr-21,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,https://ClinicalTrials.gov/show/NCT04853901
265,NCT04355767,Convalescent Plasma in Outpatients With COVID-19,C3PO,Completed,No Results Available,Covid19,Biological: Convalescent Plasma|Biological: Saline,Number of patients with disease progression|Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization|Time to disease progression|Number of Hospital-free days during the 30 days following randomization|All-cause mortality,"Stanford University|National Heart, Lung, and Blood Institute (NHLBI)|Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network|University of Pittsburgh|Medical University of South Carolina",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,511,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",C3PO|1OT2HL156812-01,29-Mar-21,11-Aug-20,230,29-Mar-21,21-Apr-20,,12-May-21,"Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04355767/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04355767
266,NCT04817332,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,STOP-COVID19,Completed,No Results Available,Covid19,Drug: Brensocatib|Drug: Placebo,"Comparison of participant clinical status between treatment arms|Time to an improvement of one category from admission using 7-point ordinal scale.|Participant clinical status on 7-point ordinal scale|Mean change in the 7-point ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of â‰¤ 2 and maintained for 24 hours, whichever occurs first.|Change from baseline of National Early Warning Score (NEWS)|Number of oxygen therapy free days|Incidence and duration of new oxygen therapy use during the trial|Number of mechanical ventilator free days|Incidence and duration of new mechanical ventilation use during the trial.|Duration of hospitalisation (days).|28-day mortality|Cumulative incidence of Serious Adverse Events (SAEs)|Discontinuation or temporary suspension of treatment|Changes in white cell count (x10^9/L) over time (hospitalised participants only)|Changes in haemoglobin (g/L) over time (hospitalised participants only)|Changes in platelets (x10^9/L) over time (hospitalised participants only)|Changes in creatinine (umol/L) over time (hospitalised participants only)|Changes in total bilirubin (umol/L) over time (hospitalised participants only)|Changes in Alanine Aminotransferase (U/L) over time (hospitalised participants only)|Changes in Aspartate Aminotransferase U/L over time (hospitalised participants only)|Adverse events of special interest- hyperkeratosis, infections and dental complications",University of Dundee|NHS Tayside|Insmed Incorporated,All,"16 Years and older Â  (Child, Adult, Older Adult)",Phase 3,400,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01.01.20|2020-001643-13|281986,28-Feb-21,5-Jun-20,268,28-Feb-21,26-Mar-21,,26-Mar-21,"NHS Grampian, Aberdeen, United Kingdom|Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Cardiff & Vale University Health Board, Cardiff, United Kingdom|NHS Tayside, Dundee, United Kingdom|NHS Fife, Dunfermline, United Kingdom|Frimley Health NHS Foundation Trust, Frimley, United Kingdom|Princess Alexandra Hospital NHS Trust, Harlow, United Kingdom|NHS Highland, Inverness, United Kingdom|NHS Forth Valley, Larbert, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|University Hospitals North Midlands NHS Trust, Stoke-on-Trent, United Kingdom|NHS Lanarkshire, Wishaw, United Kingdom",,https://ClinicalTrials.gov/show/NCT04817332
267,NCT04553055,Antibiotic Misuse During COVID-19 Pandemic,,Completed,No Results Available,Covid19,Other: online questionnaires,antibiotic misuse,Beni-Suef University,All,"20 Years and older Â  (Adult, Older Adult)",,413,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,AA86,15-Sep-20,20-Jul-20,57,15-Sep-20,17-Sep-20,,10-Dec-20,"BeniSuefU, Cairo, BeniSuef, Egypt",,https://ClinicalTrials.gov/show/NCT04553055
268,NCT04547660,Convalescent Plasma for Severe COVID-19 Patients,PLACOVID,Completed,No Results Available,Covid19,Biological: Convalescent Plasma|Other: Best Supportive Care,Clinical improvement|6-point ordinal scale proportion at 14 days|6-point ordinal scale proportion at 28 days|Overall mortality|Days alive and free of respiratory support (DAFOR28)|Mechanical ventilation|PaO2/FiO2 ratio|Hospital stay|Lactate Dehydrogenase|Troponin I|C Reactive Protein|D-Dimers|Fibrinogen|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (APTT)|Tumor Necrosis Factor Alfa (TNF-Alfa)|Interleukin-6 (IL-6)|RT-PCR|Sequential Organ Failure Assessment (SOFA) score|National Early Warning Score 2 (NEWS) 2|Safety and Adverse Events,"Hospital de Clinicas de Porto Alegre|FundaÃ§Ã£o de Amparo Ã  Pesquisa do Estado do Rio Grande do Sul, Brazil|Instituto Cultural Floresta",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2020-0158,7-Jan-21,16-Jul-20,175,7-Jan-21,14-Sep-20,,9-Feb-21,"Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT04547660
269,NCT04582331,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,,Completed,No Results Available,Covid19,Other: Smartphone-based voice and self-reported symptom collection,Vocal biomarker performance in COVID-19 positive vs. healthy controls|Vocal biomarker vs. symptom burden correlation in COVID-19 positive|Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic,Sonde Health,All,"12 Years and older Â  (Child, Adult, Older Adult)",,500,Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,SH2020.COV01,12-May-21,10-Sep-20,244,12-May-21,9-Oct-20,,14-May-21,"UC San Diego Medical Center, San Diego, California, United States|Brigham & Woman's Hospital, Boston, Massachusetts, United States|Montefiore Medical Center, New York, New York, United States|Deenanath Mangeshkar Hospital & Research Centre, Pune, India",,https://ClinicalTrials.gov/show/NCT04582331
270,NCT04386564,Kidney Injury Severity and COVID-19,,Completed,No Results Available,COVID-19|Kidney Injury,Diagnostic Test: mRNA in urine test,The effect of COVID-19 severity on the severity of renal failure|The expression of viral RNA in the urine with the severity of renal failure|The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure|Assessment of the severity of renal impairment in patients who died from COVID-19|Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19|Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19,I.M. Sechenov First Moscow State Medical University,All,"18 Years and older Â  (Adult, Older Adult)",,340,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Sechenov-COVID19_AKI,1-Sep-20,15-May-20,109,1-Aug-20,13-May-20,,9-Feb-21,"Sechenov University., Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04386564
271,NCT04483830,Suloexide in the Treatment of Early Stages of COVID-19,SulES-COVID,Completed,No Results Available,Covid19,Drug: Sulodexide|Drug: Placebo,hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation,Clinedem|Alfasigma S.p.A.,All,"40 Years to 80 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,243,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Clidm/Vas/2020-05-01,7-Sep-20,5-Jun-20,94,6-Aug-20,23-Jul-20,,9-Sep-20,"Clinedem, San Luis Rio Colorado, Sonora, Mexico",,https://ClinicalTrials.gov/show/NCT04483830
272,NCT04840966,A Simplified Test to Assess Flavor in COVID-19 Patients,,Completed,No Results Available,Covid19,Diagnostic Test: Flavor test|Other: Self-assesment questionnaire,Flavor perception|Flavor perception intensity,Federico II University,All,"18 Years and older Â  (Adult, Older Adult)",,111,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PM0001/2020,15-Jan-21,5-May-20,255,15-Jan-21,12-Apr-21,,15-Apr-21,"Dipartimento di Medicina Clinica e Chirurgia, Napoli, Italy",,https://ClinicalTrials.gov/show/NCT04840966
273,NCT04650035,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak,,Completed,No Results Available,Covid19,,Number of surgical operations performed whether elective or emergency,Yarmouk University,All,"Child, Adult, Older Adult",,60,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,The Impact of COVID-19 Jordan,10-Nov-20,1-Nov-20,9,4-Nov-20,2-Dec-20,,3-Dec-20,"Yarmouk University, Irbid, Jordan",,https://ClinicalTrials.gov/show/NCT04650035
274,NCT04599959,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,,Completed,No Results Available,Covid-19,Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol,SARS-CoV-2-RNA detectability in Swab and Salivette samples,Boehringer Ingelheim,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,144,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0352-2150,20-Jan-21,26-Oct-20,86,20-Jan-21,23-Oct-20,,26-Jan-21,"Instituto Nacional de Enfermedades Respiratorias Ismael CosÃ­o Villegas, Mexico, Mexico",,https://ClinicalTrials.gov/show/NCT04599959
275,NCT04523831,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,,Completed,Has Results,Covid19,Drug: Ivermectin and Doxycycline|Drug: Standard of care,Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19,Dhaka Medical College,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,400,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ERC-DMC/ECC/2020/117,10-Sep-20,1-Jun-20,101,22-Aug-20,24-Aug-20,9-Oct-20,9-Oct-20,"Dhaka Medical College, Dhaka, Bangladesh","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04523831
276,NCT04827160,Prediction of Thrombosis Using D-dimer Trends in COVID-19,TRENDS,Completed,No Results Available,Covid19,,D-dimer trends|Thrombosis|All-cause mortality|Orotracheal intubation,"Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,280,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020308,11-Aug-20,2-Mar-20,162,11-Aug-20,1-Apr-21,,1-Apr-21,"CHRU Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT04827160
278,NCT04670003,Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application,SourceCOVID,Completed,No Results Available,Covid19,Other: users,Description of the methods of contamination of patients|Evaluation in time of the spread of the virus during the 2nd epidemic wave.|Evaluation in space of the spread of the virus during the 2nd epidemic wave.,Weprom|Kelindi,All,"18 Years and older Â  (Adult, Older Adult)",,4975,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,WP-2020-05,30-Mar-21,2-Jan-21,87,30-Mar-21,17-Dec-20,,8-Apr-21,"Institut InterrÃ©gional de CancÃ©rologie, Le Mans, France",,https://ClinicalTrials.gov/show/NCT04670003
279,NCT04358926,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),HBOTCOVID19,Completed,No Results Available,COVID-19|Desaturation of Blood,Device: Hyperbaric oxygen therapy,SpO2|NEWS Score|Inflammation level -CRP|white blood cells number|Cytokines - IL1|Cytokines - IL2|Cytokines - IL6|Cytokines - IL10|Cytokines - TNFalpha|Inflammation level - procalcitonin|Inflammation level - ferritin|Symptoms level|Number of patients with IgM seroconversion|Number of patients with IgG seroconversion|FEV1/FVC|Time to symptoms recovery|Number of patients who required invasive ventilation|Time to negative virus PCR|Mortality rate|Number of barotrauma events (safety),Assaf-Harofeh Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,120-20-ASF,1-Nov-20,30-Apr-20,185,15-Oct-20,24-Apr-20,,3-Feb-21,"Amir Hadanny, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT04358926
280,NCT04832828,Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive,,Completed,No Results Available,Covid19,Diagnostic Test: RothÂ´s Test,Oxygen Saturation|RothÂ´s test,Universidad Autonoma de Madrid,All,"12 Years to 99 Years Â  (Child, Adult, Older Adult)",,114,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PI-4321,28-Nov-20,1-Jun-20,180,28-Nov-20,6-Apr-21,,6-Apr-21,"CS EntrevÃ­as, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04832828
281,NCT04793243,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,,Completed,No Results Available,Covid19,Dietary Supplement: Vitamin D3,Baseline levels of serum vitamin D in COVID-19 patients|Correlation between D-dimer and vitamin D serum levels in COVID-19 patients|Correlation between transferrin and vitamin D serum levels in COVID-19 patients|Correlation between ferritin and vitamin D serum levels in COVID-19 patients|Effects of vitamin D3 supplementation on COVID-19 patients,University of Guadalajara,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CI-07620,24-Oct-20,17-Aug-20,68,10-Oct-20,11-Mar-21,,11-Mar-21,"Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT04793243
282,NCT04709744,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic,,Completed,No Results Available,Covid19,Drug: Vitamin D|Diagnostic Test: ELISA,Level of serum vitamin D in SLE infected with COVID-19|Vitamin D level with COVID-19 severity,Mansoura University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,38,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,RP.21.01.91,30-Dec-20,1-Apr-20,273,25-Dec-20,14-Jan-21,,15-Jan-21,"Mansoura University Hospital, Mansoura, DK, Egypt",,https://ClinicalTrials.gov/show/NCT04709744
283,NCT04529447,Response of Korean Medicine Hospital to COVID-19,,Completed,No Results Available,Covid19,Other: Survey,Satisfactory service regarding hospital response to COVID-19|Feelings of apprehension regarding hospital visits|Medical staff wearing of facial masks and hand hygiene|Cleanliness and sterilization of hospital facilities|Convenience and accessibility of hand sanitizers|Helpfulness and readability of posters and stand-up banners|Satisfaction with hospital safety measures for COVID-19|Recommendation of hospital to friends and family,Jaseng Hospital of Korean Medicine|Jaseng Medical Academy,All,"Child, Adult, Older Adult",,485,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,JMA-CT-2020-01,10-Aug-20,10-Jun-20,61,10-Aug-20,27-Aug-20,,27-Aug-20,"Jaseng Hospital of Korean Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04529447
284,NCT04584450,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,,Completed,No Results Available,Covid19,Other: Questionnaire,Post-COVID-19 Functional Status Scale (Turkish version)|Dyspnea assessment|Evaluation of daily living activities|Assessment of the structural validity of the Post-COVID-19 Functional Status Scale,Hacettepe University,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Prospective,GO 20/788,31-Dec-20,2-Sep-20,120,31-Dec-20,14-Oct-20,,29-Jan-21,"Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04584450
285,NCT04419571,Outcomes in Emergency Laparotomies During COVID-19 Pandemic,,Completed,No Results Available,COVID-19|Emergency General Surgery,Procedure: Emergency Laparotomy,30-day mortality|7-day mortality|Number of participants returning to theatre|Length of stay|Post-operative respiratory failure|Post-operative ARDS|Post-operative sepsis|ITU/HDU admission,"Barking, Havering and Redbridge University Hospitals NHS Trust",All,"18 Years and older Â  (Adult, Older Adult)",,94,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,133196,16-Jun-20,23-Mar-20,85,16-Jun-20,5-Jun-20,,23-Jul-20,"Queen's Hospital, Romford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04419571/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04419571
286,NCT04480060,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,,Completed,No Results Available,Covid19,Diagnostic Test: COVID-19 diagnostic PCR,Mortality of the COVID-19 patients,Kanuni Sultan Suleyman Training and Research Hospital,All,18 Years to 50 Years Â  (Adult),,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,KSSEAH--EDCC,14-Jul-20,10-Mar-20,126,30-Jun-20,21-Jul-20,,21-Jul-20,"Seda Yilmaz Semerci, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04480060
287,NCT04387643,Protecting Health Care Workers During the COVID-19 Outbreak,,Completed,No Results Available,Covid-19,Dietary Supplement: Ayurvedic Kadha,Physical Health|Psychological Health|Coping with distress|Self-Help,"Aarogyam UK|Samta Ayurveda Prakoshtha, India",All,18 Years to 60 Years Â  (Adult),,52,Other,Observational,Observational Model: Other|Time Perspective: Prospective,AU/SA/01,2-Apr-20,1-Mar-20,32,2-Apr-20,14-May-20,,14-May-20,"Samta Ayurveda Prakoshtha, Jaipur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT04387643
288,NCT04568525,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,,Completed,No Results Available,Covid19,Diagnostic Test: Passive Microwave Radiometry,Determine sensitivity and specificity of MWR diagnostics of pneumonia in patients with COVID-19. (diagnosed by PCR and CT),Kyrgyz State Medical Academy|University of Edinburgh|International Medical University,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,195,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,01-2/141 27,1-Aug-20,1-Jul-20,31,25-Jul-20,29-Sep-20,,29-Sep-20,"Educational - clinical - scientific medical center of KSMA, Bishkek, Chui, Kyrgyzstan",,https://ClinicalTrials.gov/show/NCT04568525
289,NCT04666753,Retrospective Study of ImmunoFormulation for COVID-19,,Completed,No Results Available,Covid19,Dietary Supplement: ImmunoFormulation,Clinical symptoms duration,Fagron Iberica S.A.U.,All,"18 Years and older Â  (Adult, Older Adult)",,40,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,IMUNO TF STUDY,29-Sep-20,2-Jul-20,89,29-Sep-20,14-Dec-20,,14-Dec-20,"Clinic Bascoy, Barcelona, Spain|ClÃ­nica Arvila Magna, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04666753
290,NCT04400058,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,,Completed,No Results Available,Covid-19,Biological: Octagam 10%|Other: Placebo,Stabilization or Improvement in Clinical Status|Descriptive Clinical Status Analysis|Clinical Status Assessment|Time to death|Mechanical Ventilation Initiation|Mechanical Ventilation Duration|SARS-CoV-2 Test Result|Incidence of all AEs|Incidence of AEs considered related to the IMP|Incidence of serious adverse events (SAEs)|Radiological findings (chest CT/chest X-ray)|Blood glucose|Blood calcium|Sodium|Potassium|Carbon dioxide|Chloride|Albumin|Total protein|Alkaline phosphatase|Alanine transaminase|Aspartate aminotransferase|Bilirubin|Blood urea nitrogen|D-dimer|Fibrinogen|PT|PTT|INR|hsCRP|Ferritin|LDH|IgG|IgM|IgA|IFE|Troponin|Red blood cell count|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|White blood cell count|White blood cell differential|Platelet count|Mean platelet volume|Platelet distribution width|SpO2|A-a gradient|Blood Pressure|Pulse|Respiration Rate|Body Temperature,Octapharma,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,208,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",GAM10-10,31-Jan-21,1-Jun-20,244,7-Jan-21,22-May-20,,10-Mar-21,"Octapharma Research Site, Sheffield, Alabama, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Newport Beach, California, United States|Octapharma Research Site, Orange, California, United States|Octapharma Research Site, San Diego, California, United States|Octapharma Research Site, Washington, District of Columbia, United States|Octapharma Research Site, Honolulu, Hawaii, United States|Octapharma Research Site, Iowa City, Iowa, United States|Octapharma Research Site, Covington, Louisiana, United States|Octapharma Research Site, Midland, Michigan, United States|Octapharma Research Site, Las Vegas, Nevada, United States|Octapharma Research Site, Minot, North Dakota, United States|Octapharma Research Site, Charleston, South Carolina, United States|Octapharma Research Site, Tyler, Texas, United States|Octapharma Research Site, Ivanovo, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Ryazan', Russian Federation|Octapharma Research Site, Ivano-Frankivs'k, Ukraine|Octapharma Research Site, Kharkiv, Ukraine|Octapharma Research Site, Kremenchuk, Ukraine",,https://ClinicalTrials.gov/show/NCT04400058
291,NCT04446104,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,,Completed,No Results Available,Covid-19,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C,"Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Adverse events and serious adverse events in control arm (Vitamin C)|Drug discontinuation due to adverse events in control arm (Vitamin C)","National University Hospital, Singapore",Male,21 Years to 60 Years Â  (Adult),Phase 3,4257,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2020/00561,31-Aug-20,13-May-20,110,31-Aug-20,24-Jun-20,,19-Oct-20,"Tuas South Dormitory, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04446104
292,NCT04450277,Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,,Completed,No Results Available,COVID-19|Emergency Surgery,Procedure: Emergency surgery,Surgical morbidity in patients with COVID-19 infection and general surgical conditions,Khoo Teck Puat Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,15,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020/00660,31-May-20,1-Apr-20,60,31-May-20,29-Jun-20,,7-Jul-20,"Khoo Teck Puat Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04450277
293,NCT04343092,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,,Completed,Has Results,COVID 19,Drug: Ivermectin (IVM),Number of Cured Patients|Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group,University of Baghdad,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO20040001,1-Jun-20,18-Apr-20,44,31-May-20,13-Apr-20,4-Nov-20,4-Nov-20,"General Directorate of Medical City, Bagdad, Baghdad, Iraq","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04343092/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04343092
294,NCT04387786,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),DACOVID,Completed,No Results Available,COVID-19|Mechanical Ventilation,Drug: Dornase Alfa,Number of participants discharged from the intensive care unit (ICU)|Number of participants who survived COVID-19|Mean change in FiO2,Feinstein Institute for Medical Research|Cold Spring Harbor Laboratory|Northwell Health,All,"18 Years to 85 Years Â  (Adult, Older Adult)",,5,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,216,4-Sep-20,31-Mar-20,157,24-Apr-20,14-May-20,,13-Nov-20,"Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States",,https://ClinicalTrials.gov/show/NCT04387786
295,NCT04734223,Neuroimaging Findings in Patients With COVID-19,,Completed,No Results Available,Neuroimaging|COVID-19,Diagnostic Test: Neuroimaging Findings in Patients With COVID-19,Frequency of acute thromboembolism in COVID-19 patients undergoing neuroimaging,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,436,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,09.25.2020/587,31-Dec-20,1-Apr-20,274,31-Dec-20,2-Feb-21,,4-Feb-21,"SaÄŸlik Bilimleri Ãœniversitesi Training and Research Hospital, DiÌ‡yarbakir, Turkey",,https://ClinicalTrials.gov/show/NCT04734223
296,NCT04713852,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients,,Completed,No Results Available,Covid19,,Mortality|Predictive value,Jessa Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,116,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-174,31-Dec-20,13-Mar-20,293,30-Sep-20,19-Jan-21,,19-Jan-21,"Jessa hospital, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT04713852
297,NCT04674553,Effect of Obesity Among COVID-19 Patients in Critical Care Settings,,Completed,No Results Available,Obesity|Covid19,,In-hospital mortality|Recovery from COVID-19|COVID-19 severity|Oxygen requirement,"Services Institute of Medical Sciences, Pakistan",All,"18 Years to 80 Years Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,16021982,10-Dec-20,10-Nov-20,30,10-Dec-20,19-Dec-20,,19-Dec-20,"Mehwish Iftikhar, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04674553
298,NCT04317040,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,SAC-COVID,Completed,No Results Available,Covid19,Drug: CD24Fc|Drug: Placebo,Improvement of COVID-19 disease status|Proportion of patients who died or had respiratory failure.|Disease progression of COVID-19|All cause of death|Proportion of clinical relapse|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of high flow oxygen therapy|Absolute lymphocyte count|Change of D-dimers,"OncoImmune, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,243,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7110-007|20200674|CD24Fc-007,20-Oct-20,24-Apr-20,179,20-Oct-20,20-Mar-20,,26-Mar-21,"Baptist Health Research Institute, Jacksonville, Florida, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04317040
299,NCT04334252,Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,,Completed,No Results Available,COVID 19,Other: Questionnaire,Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms,Jessa Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,528,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,JessaH_COVID19_prescreening,20-Dec-20,17-Apr-20,247,20-Dec-20,6-Apr-20,,6-Jan-21,"Jessa hospital, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT04334252
300,NCT04714515,Montelukast - a Treatment Choice for COVID-19,,Completed,No Results Available,Covid19|SARS-CoV-2 Infection,Drug: Montelukast|Drug: Hydroxychloroquine|Drug: Ivermectin,Patients admittance to ICU|Length of total stay at the hospital|Alleviating the symptoms of COVID-19|Interleukin levels,"University of Sargodha|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shaukat Khanum Memorial Cancer Hospital & Research Centre|Shanghai Jiao Tong University School of Medicine|Teesside University",All,"20 Years to 80 Years Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,01032020-7,20-Apr-20,20-Feb-20,60,30-Mar-20,19-Jan-21,,19-Jan-21,"Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China|Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04714515
301,NCT04605952,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,,Completed,No Results Available,Covid19,Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days,Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days,Tata Main Hospital,All,18 Years to 60 Years Â  (Adult),,201,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,152473,30-Aug-20,1-Jul-20,60,30-Aug-20,28-Oct-20,,28-Oct-20,"Dr.Deb Sanjay Nag, Jamshedpur, Jharkhand, India",,https://ClinicalTrials.gov/show/NCT04605952
302,NCT04542876,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,,Completed,No Results Available,Covid19,Drug: Guduchi Ghan Vati,Virologic clearance|Hospital Stay|Clinically relevant adverse effects|Laboratory tests,Aarogyam UK|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AYU/DSSR/03,18-Aug-20,1-May-20,109,31-Jul-20,9-Sep-20,,9-Sep-20,"Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT04542876
303,NCT04327531,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",,Completed,No Results Available,COVID-19|Physician-Patient Relations,Behavioral: turkish physicians,Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future,Kanuni Sultan Suleyman Training and Research Hospital,All,25 Years to 55 Years Â  (Adult),,200,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,turkishcovid19,28-May-20,26-Mar-20,63,22-May-20,31-Mar-20,,5-Jun-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04327531
304,NCT04506268,COVID-19 SAFE Enrollment,COVID SAFE,Completed,No Results Available,Covid19,Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email,Proportion Enrolled|Participant Age|Participant Sex|Participant Race/Ethnicity|Participant Income|Participant Education|Test Completion,University of Pennsylvania,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,412,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening",843565,30-Oct-20,9-Sep-20,51,30-Oct-20,10-Aug-20,,11-Mar-21,"Penn Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04506268
305,NCT04350320,Trial to Study the Benefit of Colchicine in Patients With COVID-19,COL-COVID,Completed,No Results Available,COVID19,Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.,Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,102,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMIB-COLVID-2020-03,30-Dec-20,30-Apr-20,244,20-Oct-20,17-Apr-20,,12-Jan-21,"Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",,https://ClinicalTrials.gov/show/NCT04350320
306,NCT04716647,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,,Completed,No Results Available,Covid19,Other: Ayurveda,Time to clinical recovery|Proportion of patient with negative conversion in nasopharyngeal swab|Clinical Outcome,Aarogyam UK|University of Warwick|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AU/2187,18-Dec-20,9-Oct-20,70,12-Dec-20,20-Jan-21,,20-Jan-21,"Aarogyam UK, Leicester, Leicestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04716647
307,NCT04368221,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,MY-CO-VID,Completed,No Results Available,Covid-19,,Opportunistic fungal co-infections.|Median time|Time between diagnosis and targeted treatment|Preventive strategies,Rennes University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,576,Other,Observational,Observational Model: Cohort|Time Perspective: Other,35RC20_8885_MY_CO_VID,23-Feb-21,4-May-20,295,23-Feb-21,29-Apr-20,,30-Mar-21,"CHU Angers, Angers, France|CHU de Brest, Brest, France|CHU de Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Marseille, Marseille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Paris - Avicenne, Paris, France|CHU Paris - Bichat, Paris, France|CHU Paris - HEGP, Paris, France|CHU Paris - Mondor, Paris, France|CHU Paris - Tenon, Paris, France|HÃ´pital LariboisiÃ¨re/ St Louis, Paris, France|HÃ´pital Necker-Enfants Malades, Paris, France|HÃ´pital PitiÃ©-SalpÃªtriÃ¨re, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04368221
308,NCT04621903,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,,Completed,No Results Available,Covid19,Other: Shanshamani Vati Plus,Time to COVID-19 symptoms relief|Prevention of severe stage of Covid19|Side effect/ adverse events|COVID-19 severity worsening|Time to negative saliva,"Aarogyam UK|University of Warwick|All India Institute of Ayurveda, Ministry of AYUSH, Government of India",All,"20 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AU/WU/ 06,3-Nov-20,8-Oct-20,26,27-Oct-20,9-Nov-20,,19-Nov-20,"Aarogyam (UK) CIC, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04621903
309,NCT04409509,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),"Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",The incidence of tracheal intubation or death prior to tracheal intubation|Proportion of subjects with death from all causes|Proportion of subjects intubated|Number and proportion of subjects with â‰¥ 2-point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale|Number and proportion of subjects within each of the categories of the NIAID|Proportion of subjects requiring continuous positive airway pressure (CPAP)|Proportion of subjects requiring bilevel positive airway pressure (BiPAP)|Proportion of subjects requiring high-flow nasal cannula (HFNC)|Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)|Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score|Change from Baseline in SOFA score and in the individual components of SOFA score|Length of hospital stay|Number and proportion of subjects experiencing Adverse Events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects with adverse events of special interest (AESIs)|Number and proportion of subjects with CSL312 induced anti-CSL312 antibodies|Maximum plasma concentration (Cmax) of CSL312|Time to maximum plasma concentration (Tmax) of CSL312|Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last) of CSL312|Terminal half-life (T1/2) of CSL312,CSL Behring,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSL312_COVID-19,12-Jan-21,1-Jul-20,195,12-Jan-21,1-Jun-20,,22-Jan-21,"Nova Clinical Research, LLC, Bradenton, Florida, United States|Theia Clinical Research, LLC, Saint Petersburg, Florida, United States|MercyOne North Iowa Medical Center, Mason City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Inspira Health Center Vineland, Vineland, New Jersey, United States|Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|PharmaTex Research, Amarillo, Texas, United States|UT Health Science Center, McGovern Medical School, Houston, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04409509
310,NCT04503434,Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,,Completed,No Results Available,Patient Preference|COVID-19,,The Picker Patient Experience Questionnaire|Open questions,Hospital Clinic of Barcelona,All,"Child, Adult, Older Adult",,517,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,Medicalitzed Hotel COVID-19,6-Jun-20,15-May-20,22,31-May-20,7-Aug-20,,7-Aug-20,"Carme HernÃ¡ndez, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04503434
311,NCT04560855,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,SECURADOM,Completed,No Results Available,Covid19,Device: Connected devices measurements,Sensitivity and Specificity of the patient's aggravation with a logistic regression model|Sensitivity and Specificity of the patient's aggravation with a cluster model|Study the evolution of daily patient parameters without aggravation over time|Subjective assessment of the connected devices,Withings,All,"18 Years and older Â  (Adult, Older Adult)",,10,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A00981-38,12-May-21,14-Sep-20,240,12-Jan-21,23-Sep-20,,20-May-21,"CHU Grenoble-Alpes, Grenoble, Auvergne-RhÃ´ne-Alpes, France|CHU d'Amiens, Amiens, Hauts-de-France, France|HÃ´pital d'Instruction des ArmÃ©es BÃ©gin, Saint-MandÃ©, Ile De France, France|HÃ´pital d'Instruction des ArmÃ©es Percy, Clamart, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT04560855
312,NCT04373759,Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,ACICOVID,Completed,No Results Available,Sars-CoV2|Covid-19,Other: Cardiopulmonary resuscitation|Other: Modified Rankin score,"Incidence of unexpected cardiac arrest|Charlson score|Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest|Etiology retained to explain cardiac arrest occurrence|Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months",Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,All,"18 Years and older Â  (Adult, Older Adult)",,186,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-CHITS-004,30-Sep-20,2-May-20,151,30-Sep-20,4-May-20,,14-Dec-20,"CHU Caen, Caen, Calvados, France|HÃ´pital PrivÃ© St Martin, Caen, Calvados, France|CH AngoulÃ¨me, AngoulÃªme, Charente, France|CH Brive, Brive-la-Gaillarde, CorrÃ¨ze, France|CHU Dijon, Dijon, CÃ´te-d'Or, France|CH Etampes, Ã‰tampes, Essonne, France|CHU Antoine BÃ©clÃ¨re AP-HP, Clamart, Haut-de-Seine, France|CHU Ambroise ParÃ© AP-HP, Boulogne-Billancourt, Hauts-de-Seine, France|CH Louis Mourier AP-HP, Colombes, Hauts-de-Seine, France|CHU Montpellier, Montpellier, HÃ©rault, France|CHU LariboisiÃ¨re AP-HP, Paris, Ile-de-France, France|CHU Saint Louis AP-HP, Paris, Ile-de-France, France|CHU St Antoine, Paris, Ile-de-France, France|Groupe Hospitalier Saint Joseph, Paris, Ile-de-France, France|CHU Necker Enfants Malades, Paris, Ile-de-France, France|CHU PitiÃ© SalpÃ©triÃ¨re, Paris, Ile-de-France, France|CHU Felix Guyon, Saint-Denis, La Reunion, France|CHR OrlÃ©ans, OrlÃ©ans, Loiret, France|CH Cahors, Cahors, Lot, France|CHRU Roger Salengro, Lille, Nord, France|CH Bethune, Beuvry, Pas-de-Calais, France|CH Lens, Lens, Pas-de-Calais, France|Grand HÃ´pital de l'Est Francilien, Jossigny, Seine-et-Marne, France|CHU Meaux, Meaux, Seine-et-Marne, France|Groupe Hospitalier Sud Ile de France, Melun, Seine-et-Marne, France|CHU Rouen, Rouen, Seine-Maritime, France|CHU Amiens Picardie, Amiens, Somme, France|HÃ´pital Nord Franche ComtÃ©, TrÃ©venans, Territoire De Belfort, France|CH Argenteuil, Argenteuil, Val-d'Oise, France|CHU Henri Mondor AP-HP, CrÃ©teil, Val-de-Marne, France|CHU Kremlin BicÃªtre, Le Kremlin-BicÃªtre, Val-de-Marne, France|CH de la DracÃ©nie, Draguignan, Var, France|CHI Frejus St Raphael, FrÃ©jus, Var, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, Var, France|CH Versailles, Le Chesnay, Yvelines, France|CHU Martinique - Fort de France, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT04373759
313,NCT04352491,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,,Completed,No Results Available,COVID 19,Other: No intervention,Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score,"Institute of Liver and Biliary Sciences, India",All,"18 Years to 75 Years Â  (Adult, Older Adult)",,347,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,ILBS-COVID-03,31-May-20,24-Apr-20,37,31-May-20,20-Apr-20,,17-Jun-20,"Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT04352491
314,NCT04462393,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,,Completed,No Results Available,COVID-19|Critical Illness,Other: Admission to ICU for COVID-19,30-day mortality|ICU mortality,Linkoeping University|Region Ã–stergÃ¶tland,All,"18 Years and older Â  (Adult, Older Adult)",,1563,Other,Observational,Observational Model: Cohort|Time Perspective: Other,SweCOVID,6-May-20,6-Mar-20,61,6-May-20,8-Jul-20,,9-Jul-20,"Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Ã–stergÃ¶tland, LinkÃ¶ping, Ã–stergÃ¶tland, Sweden",,https://ClinicalTrials.gov/show/NCT04462393
315,NCT04704388,Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care,COMEBAC,Completed,No Results Available,Covid19,,post-intensive care syndrome (PICS)|Evaluate the 3-month mortality of patients released alive from intensive care|Describe the overall state of health and the main organ sequelae of these patients|functional respiratory sequelae,Assistance Publique - HÃ´pitaux de Paris,All,"18 Years and older Â  (Adult, Older Adult)",,478,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,COMEBAC,1-Oct-20,1-Jun-20,122,1-Oct-20,11-Jan-21,,1-Apr-21,"BicÃªtre Hospital, Le Kremlin-BicÃªtre, France",,https://ClinicalTrials.gov/show/NCT04704388
316,NCT04563689,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,,Completed,No Results Available,Covid19,Other: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|Other: placebo rinse,exploratory change in viral load|number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR|number of patients with adverse events during 5 days study duration,Dentaid SL,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Not Applicable,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,COVID-POC1,23-Oct-20,18-Jun-20,127,22-Oct-20,24-Sep-20,,20-Nov-20,"Escuela odontologia. Facultad de Salud Hospital del Valle, Cali, Colombia",,https://ClinicalTrials.gov/show/NCT04563689
317,NCT04581291,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,,Completed,No Results Available,Covid19,Other: Moderate Intensity Aerobic Exercises,Immune system markers|Upper respiratory tract infection symptoms severity and progression,Istanbul Gelisim University,All,24 Years to 45 Years Â  (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Aerobic exercise, COVID-19",1-Oct-20,1-Jan-20,274,1-Jun-20,9-Oct-20,,9-Oct-20,"Motaz Alawna, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04581291
318,NCT04403932,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,COVIT-D,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),,severe COVID-19,"Hospital San Carlos, Madrid",All,"18 Years and older Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20/428-E_COVID,1-Aug-20,17-Apr-20,106,1-Jun-20,27-May-20,,1-Feb-21,"Hospital ClÃ­nico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04403932
319,NCT04475120,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,,Completed,No Results Available,Covid19,Drug: liposomal lactoferrin|Drug: SOC therapy,Rate of viral clearance Time to viral clearance|Time to clinical improvement,University of Rome Tor Vergata,All,"20 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4220,2-Jul-20,15-Apr-20,78,2-Jul-20,17-Jul-20,,14-May-21,"University of Rome Tor Vergata, Rome, Italy",,https://ClinicalTrials.gov/show/NCT04475120
320,NCT04551781,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,,Completed,No Results Available,Covid19,Drug: 20 Mg Prednisone for 14 days|Drug: control,improved,South Valley University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SVU-MED-CHT019420861,30-Jul-20,1-Apr-20,120,30-Jul-20,16-Sep-20,,16-Sep-20,"south-Vally University faculty of medicine, Qena, Kena, Egypt",,https://ClinicalTrials.gov/show/NCT04551781
321,NCT04900129,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",,Completed,No Results Available,Covid19,"Combination Product: Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%","Inhalation of Vapor with Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Sher-E-Bangla Medical College,All,"20 Years and older Â  (Adult, Older Adult)",Phase 1,43,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SBMC Barisal 2020 1896,30-Dec-20,1-Dec-20,29,30-Dec-20,25-May-21,,25-May-21,"HN Sarker, Barisal, Bangladesh","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04900129/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04900129
322,NCT04662671,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",,Completed,No Results Available,COVID19,Device: RD-X19,Primary Safety Measure|Primary Efficacy Measure|Geometric Mean Viral Load|Viral Load Reduction|Time to Clearance of Viral Infection|Proportion of Subjects Demonstrating Clearance of Viral Infection|Median Time to Alleviation of Symptoms,EmitBio Inc.|KNOWBio Inc.,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EB-P12-01,30-Jan-21,18-Nov-20,73,9-Dec-20,10-Dec-20,,11-Feb-21,"Site 2, Miami, Florida, United States|Site 1, College Station, Texas, United States",,https://ClinicalTrials.gov/show/NCT04662671
323,NCT04551898,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),,Completed,No Results Available,Covid19,Drug: BGB-DXP593|Drug: Placebo,Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples|Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Number of participants requiring hospitalization due to worsened COVID-19|Time to resolution of all COVID-19-related symptoms|All-cause mortality rate at Day 29|Number of participants experiencing Adverse Events (AEs)|Number of participants experiencing Serious Adverse Events (SAEs),BeiGene,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 2,181,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BGB-DXP593-102,25-Jan-21,2-Dec-20,54,25-Jan-21,16-Sep-20,,4-Mar-21,"Elixia, Hollywood, California, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Baptist Medical Center, Jacksonville, Florida, United States|Homestead Associates in Research Inc., Miami, Florida, United States|Medical Research Center of Miami II, Inc., Miami, Florida, United States|US Associates in Research, Miami, Florida, United States|Continental Research Network, Miami, Florida, United States|Omega Research Orlando, Orlando, Florida, United States|Revival Research Institute, LLC., Dearborn, Michigan, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|PanAmerican Clinical Research, Brownsville, Texas, United States|The Royal Prince Alfred Hospital, Camperdown, Australia|FundaÃ§Ã£o Universidade de Caxias do Sul - Instituto de Pesquisas em SaÃºde, Petropolis, Caxias Do Sul, Brazil|Hospital das ClÃ­nicas da Faculdade de Medicina de Botucatu, Botucatu, Brazil|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre, Porto Alegre, Brazil|Hospital UniversitÃ¡ro de Santa Maria / UFSM, Santa Maria, Brazil|CMPC Pesquisa Clinica, Sorocaba, Brazil|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|JM Research, Cuernavaca, Mexico|Hospital General Dr. Manuel Gea Gonzalez, Mexico, Mexico|Iecsi S.C., Monterrey, Mexico|Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C., Morelia, Mexico|Kohler & Milstein Research, MÃ©rida, Mexico|PanAmerican Clinical Research, QuerÃ©taro, Mexico|East Rand Research T/A Worthwhile Clinical Trials, Benoni, South Africa|TASK, Cape Town, South Africa|TREAD Research CC, Cape Town, South Africa|Langeberg Clinical Trials, Cape Town, South Africa|Wits Clinical Research, Soweto, South Africa",,https://ClinicalTrials.gov/show/NCT04551898
324,NCT04275245,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),Drug: Meplazumab for Injection,2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status,Tang-Du Hospital,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20200101,9-Mar-20,3-Feb-20,35,9-Mar-20,19-Feb-20,,9-Apr-21,"Tangdu Hospital, Xi'an, Shaanxi, China",,https://ClinicalTrials.gov/show/NCT04275245
325,NCT04380714,Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,,Completed,No Results Available,People Incarcerated|COVID-19,,percentage changes in the consumption of psychoactive substances|Assessment of the level of stress|Assessment of depression|Craving modification evaluation,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,700,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,RECHMPL20_0273,1-Aug-20,1-May-20,92,30-May-20,8-May-20,,29-Dec-20,"UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04380714
326,NCT04579289,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions,REMPAR-EHPAD,Completed,No Results Available,Covid19,Other: questionnaire,case of COVID 19,Rennes University Hospital,All,"Child, Adult, Older Adult",,230,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Retrospective,35RC20_8898_REMPAR-EHPAD,1-Sep-20,15-Jun-20,78,1-Sep-20,8-Oct-20,,14-Oct-20,"Centre Hospitalier Universitaire de Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT04579289
327,NCT04482361,SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,,Completed,No Results Available,COVID-19,Diagnostic Test: Presence of specific anti-SARS-CoV-2 antibodies,Prevalence of IGG for COVID-19|Changes in prevalence of IGG for COVID-19,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,All,"18 Years and older Â  (Adult, Older Adult)",,5900,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,SEROEPIDEMIOLOGY COVID IN CABA,22-Dec-20,6-Aug-20,138,22-Dec-20,22-Jul-20,,25-Jan-21,"Ministerio de Salud de la Ciudad AutÃ³noma de Buenos Aires, Ciudad AutÃ³noma de Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04482361
328,NCT04362137,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",RUXCOVID,Completed,No Results Available,Cytokine Storm (Covid-19),Drug: Ruxolitinib|Drug: Placebo,"Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care|Clinical status|Percentage of patients with at least two-point improvement from baseline in clinical status|Percentage of patients with at least one-point improvement from baseline in clinical status|Percentage of patients with at least one-point deterioration from baseline in clinical status|Time to improvement in clinical status|Mean change from baseline in the clinical status|Mortality rate|Proportion of patients requiring mechanical ventilation|Duration of hospitalization|Time to discharge or to a NEWS2 score of â‰¤2|Change from baseline in NEWS2 score|Change from baseline in SpO2/FiO2 ratio.|Proportion of patients with no oxygen therapy",Novartis Pharmaceuticals|Incyte Corporation|Novartis,All,"12 Years and older Â  (Child, Adult, Older Adult)",Phase 3,432,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CINC424J12301|INCB 18424-368|2020-001662-11,17-Oct-20,2-May-20,168,17-Oct-20,24-Apr-20,,12-Nov-20,"Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, MÃ©xico, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04362137
329,NCT04674644,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,,Completed,Has Results,COVID-19 Pandemic,Behavioral: The psychosocial effects of COVID-19 pandemic on dental professionals,The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale|The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale,Suleyman Demirel University,All,"23 Years and older Â  (Adult, Older Adult)",Not Applicable,850,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,355,23-Oct-20,16-Oct-20,7,23-Oct-20,19-Dec-20,29-Jan-21,2-Feb-21,"Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department, Isparta, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04674644/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04674644
330,NCT04366141,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,,Completed,No Results Available,COVID-19,Device: COVID-19 barrier box,"Time to tracheal intubation (TTI)|First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier Box",University of British Columbia,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,H20-01270,1-Feb-21,1-May-20,276,1-Feb-21,28-Apr-20,,24-Feb-21,"Providence Health Care, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT04366141
331,NCT04400032,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,CIRCA-19,Completed,No Results Available,Acute Respiratory Distress Syndrome|Covid19,Biological: Mesenchymal Stromal Cells,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28,Ottawa Hospital Research Institute|Stem Cell Network|Ontario Research Fund,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20200243-01H,22-Apr-21,15-May-20,342,22-Apr-21,22-May-20,,26-Apr-21,"The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04400032
332,NCT04695457,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps,PROCOPAD,Completed,No Results Available,Covid19|Nursing Home,,Identification of factors associated with the occurrence of COVID-19 outbreak in French Alps' nursing homes,Centre Hospitalier Annecy Genevois,All,"Child, Adult, Older Adult",,74,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-13,16-Nov-20,15-Jul-20,124,16-Nov-20,5-Jan-21,,5-Jan-21,"Ch Annecy Genevois, Pringy, France",,https://ClinicalTrials.gov/show/NCT04695457
333,NCT04357327,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),,Completed,No Results Available,COVID-19|SARS-CoV 2|Corona Virus Infection,Diagnostic Test: rapid salivary test,Sensibility|Specificity,UniversitÃ  degli Studi dell'Insubria,All,"Child, Adult, Older Adult",Not Applicable,122,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,68/2020,31-Jul-20,16-Apr-20,106,31-May-20,22-Apr-20,,4-Nov-20,"ASST dei Sette Laghi, Varese, VA, Italy",,https://ClinicalTrials.gov/show/NCT04357327
334,NCT04383535,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,PLASM-AR,Completed,No Results Available,SARS Virus|SARS-CoV-2|COVID-19,Other: Convalescent SARS COVID-19 plasma|Other: Placebo,Clinical status during follow-up at 30th day|Clinical status during follow-up at 7th day|Clinical status during follow-up at 14th day|Time until hospital discharge (days).|Time until discharge from ICU (days)|Time to death|Time until complete functional recovery|Percentage of participants with adverse events / serious adverse events|Percentage of patients with negative SARS-CoV-3 PCR at Day 14th|D Dimer plasma concentration at Day 14th|Ferritin plasma concentration at Day 13th|Plasma concentration of neutralizing antibodies at Day 2nd|Plasma concentration of neutralizing antibodies at Day 7th|Post-transfusion adverse reactions,Hospital Italiano de Buenos Aires,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,333,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",5565,27-Sep-20,15-May-20,135,27-Sep-20,12-May-20,,30-Sep-20,"Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04383535
335,NCT04345653,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,,Completed,Has Results,Covid19,Drug: Hydroxychloroquine Sulfate (HCQ),Recruitment Feasibility|Resource Utilization|Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events|Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.,Hackensack Meridian Health,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 2,48,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro2020-0356,10-May-21,14-Apr-20,391,5-Jun-20,14-Apr-20,10-May-21,12-May-21,"Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04345653/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04345653
336,NCT04338009,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,REPLACECOVID,Completed,Has Results,COVID-19,Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI,"Hierarchical Composite Endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation|AUC SOFA","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|University of Arizona|Department of Medicine, Hospital Nacional Carlos Alberto SeguÃ­n Escobedo, Arequipa, Peru|Department of Nephrology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hypertension Unit, Department of Pathology, Hospital EspaÃ±ol de Mendoza, National University of Cuyo, IMBECU-CONICET, Mendoza, Argentina|Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA|Division of Infectious Diseases, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada|Unidad de VIH, Hospital Civil de Guadalajara and Universidad de Guadalajara, Guadalajara, Mexico|Universidad CatÃ³lica de Buenos Aires, Buenos Aires, Argentina|Departamento de Medicina Interna, Hospital Obrero number 3 Caja Nacional de Salud, Santa Cruz de la Sierra, Bolivia|Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru|Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden|Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA|Departamento de Emergencia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Division of Cardiology, Department of Medicine, Hospital EspaÃ±ol, Buenos Aires, Argentina|Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA|Jesse Chittams, MS|Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA|Charles R Vasquez, MD",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,842810,20-Aug-20,31-Mar-20,142,20-Aug-20,8-Apr-20,9-Apr-21,9-Apr-21,"University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04338009/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04338009
337,NCT04345276,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,,Completed,No Results Available,COVID-19,Drug: Danoprevir+Ritonavir,Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event,"Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 4,10,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASC-CTP-HS-01,15-Apr-20,18-Mar-20,28,15-Apr-20,14-Apr-20,,2-Jun-20,"Huoshenshan Hostipal, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04345276
338,NCT04291729,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,,Completed,No Results Available,COVID-19,Drug: Ganovo+ritonavir+/-Interferon nebulization,Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event,"The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 4,11,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASC-CTP-NC-01,19-Mar-20,17-Feb-20,31,19-Mar-20,2-Mar-20,,13-Apr-20,"The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China",,https://ClinicalTrials.gov/show/NCT04291729
339,NCT04507282,Eosinophil and Anticoagulation in COVID-19 Patients,,Completed,No Results Available,COVID-19,Drug: LMWH,subprophylactic anticogulation level,Bursa Postgraduate Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Bursa Postgraduate Hospital,15-Jul-20,15-May-20,61,1-Jul-20,11-Aug-20,,18-Aug-20,"Bursa YÃ¼ksek Ä°htisas Hastanesi, YÄ±ldÄ±rÄ±m, Turkey",,https://ClinicalTrials.gov/show/NCT04507282
340,NCT04732819,Improving COVID-19 Vaccine Uptake in Nursing Homes,,Completed,No Results Available,COVID-19 Vaccines,Behavioral: High touch multi-pronged behavioral intervention,Patient vaccine counts|Staff vaccine counts,"Brown University|National Institute on Aging (NIA)|Hebrew SeniorLife|Insight Therapeutics, LLC|New York University",All,"Child, Adult, Older Adult",Not Applicable,25332,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,2012002872|3U54AG063546-02S2|Pro00048627,16-Apr-21,4-Jan-21,102,30-Mar-21,1-Feb-21,,3-May-21,"Mission Health, Tampa, Florida, United States|Nexion Health, Sykesville, Maryland, United States|Vetter Senior Living, Elkhorn, Nebraska, United States|Genesis HealthCare, Kennett Square, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04732819
341,NCT04342663,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",STOP COVID,Completed,No Results Available,COVID 19|Coronavirus,Drug: Fluvoxamine|Drug: Placebo,Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe),Washington University School of Medicine,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,152,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",202004023,12-Dec-20,10-Apr-20,246,20-Aug-20,13-Apr-20,,11-Jan-21,"BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04342663
342,NCT04885543,COVID-19 STAndard of Care in Sub-Saharan Africa,COVISTA,Completed,No Results Available,Covid19,,Mortality|Clinical worsening,Alliance for International Medical Action,All,"Child, Adult, Older Adult",,2495,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ALIMA02,1-Mar-21,1-Mar-20,365,1-Mar-21,13-May-21,,13-May-21,"Chu Tengandogo, Ouagadougou, Burkina Faso|Clinique Princesse Sarah, Ouagadougou, Burkina Faso|Chu Donka, Conakry, Guinea",,https://ClinicalTrials.gov/show/NCT04885543
343,NCT04587375,Diagnosis of Endocrine Dysfunctions in Covid-19,Dyhor-19,Completed,No Results Available,Covid 19,,Plasma aldosterone levels|Plasma renin levels|covid-19 infection severity|Maximum severity of Covid-19 infection|Plasma aldosterone level|Plasma ACTH level|Plasma cortisol level|Plasma T3l level|Plasma LH level|Plasma DHEA level|Plasma estradiol (female) or testosterone (male) level|Plasma FSH level|type of treatments|Clinical characteristics|radiological characteristics,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0205,30-May-20,1-Mar-20,90,1-May-20,14-Oct-20,,14-Oct-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04587375
344,NCT04467008,Covid-19 Rapid Diagnostic Tests on Blood Drop,COVID-TEST,Completed,No Results Available,Covid19,,Positivity of the rapid diagnostic test,CMC Ambroise ParÃ©,All,"Child, Adult, Older Adult",,113,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020/05,15-Aug-20,15-Jul-20,31,15-Aug-20,10-Jul-20,,10-Nov-20,"CMC Ambroise ParÃ©, Neuilly-sur-Seine, France",,https://ClinicalTrials.gov/show/NCT04467008
345,NCT04519372,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,,Completed,No Results Available,Covid19|SARS-CoV-2,Diagnostic Test: Testing for SARS-CoV-2,Proportion of SARS-CoV-2 -infected patients,"University Hospital, Basel, Switzerland",All,"18 Years and older Â  (Adult, Older Adult)",,4099,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,2020-00808,31-Mar-21,1-Apr-20,364,14-Jun-20,19-Aug-20,,18-May-21,"University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT04519372
346,NCT04382053,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,,Completed,No Results Available,"COVID 19 Pneumonia, Impaired Respiratory Function",Drug: DFV890|Drug: Standard of Care (SoC),APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)|Serum C-reactive protein (CRP) levels|Clinical status over time|Proportion of participants not requiring mechanical ventilation for survival.|Proportion of participants with at least one-point improvement from baseline in clinical status,Novartis Pharmaceuticals|Novartis,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,143,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDFV890D12201|2020-001870-32,24-Dec-20,27-May-20,211,10-Dec-20,11-May-20,,4-May-21,"Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, San Martin de Porres, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04382053
347,NCT04568863,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,MELCOVID,Completed,No Results Available,COVID-19|SARS-CoV 2|Coronavirus Infection,Drug: Melatonin intravenous|Drug: Placebo intravenous,Mortality,Pharmamel S.L.|Hospital Universitario La Paz|Instituto de InvestigaciÃ³n Hospital Universitario La Paz,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,18,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PHM-2020-001,30-Nov-20,20-Jun-20,163,30-Nov-20,29-Sep-20,,18-Mar-21,"Hospital Universitario La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04568863
348,NCT04512027,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Prolectin-M,Completed,No Results Available,COVID-19,Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|Other: Standard of Care,SarsCoV2 viral copy number|b. Disease progression will be measured on a 7-point scale at 28 days. A 2-point change will be considered disease progression.,Composite Interceptive Med Science|Pharmalectin Inc,All,18 Years to 45 Years Â  (Adult),Not Applicable,10,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CIMED - 002- 2020,16-Oct-20,15-Sep-20,31,19-Sep-20,13-Aug-20,,19-Oct-20,"Mazumdar Shaw Medical Centre, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT04512027
349,NCT04484493,Corticosteroid Nasal Spray in COVID-19 Anosmia,,Completed,No Results Available,Covid19|Anosmia,Drug: mometasone furoate nasal spray,improvement of olfaction,Benha University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC 4-7-2020,3-Nov-20,8-Aug-20,87,25-Oct-20,23-Jul-20,,13-Nov-20,"Benha University Hospital, Faculty of Medicine, BanhÄ, Qalubia, Egypt",,https://ClinicalTrials.gov/show/NCT04484493
350,NCT04406090,Endovascular Thrombectomy in COVID-19 Infected Patients,ET-COVID-19,Completed,No Results Available,Ischemic Stroke|Covid 19,Other: Mechanical Trombectomy,Intrahospital mortality|short-term morbidity|Angiographic success,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0322,30-Jun-20,1-Apr-20,90,30-Jun-20,28-May-20,,29-Jul-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04406090
351,NCT04405986,Exploring Brain Damages After COVID-19 Infection,BRAINCOV,Completed,No Results Available,SARS-CoV 2,Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex,Latency of electrophysiological response|Delay of Muscle contraction|Delay of silent period|Duration of silent period|Inhibition rate,"University Hospital, Bordeaux",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,38,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CHUBX 2020/20,10-Mar-21,19-May-20,295,10-Mar-21,28-May-20,,8-Apr-21,"CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT04405986
352,NCT04581083,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic",,Completed,No Results Available,Covid19,Diagnostic Test: RT-PCR|Diagnostic Test: LAMP|Diagnostic Test: POOL RT-PCR|Diagnostic Test: POOL LAMP,Validation|RT- PCR (Saliva)|LAMP|POOL PCR|POOL LAMP,Hunter College of City University of New York|Universidad Autonoma Juan Misael Saracho|Gobierno Autonomo Departamental De Tarija|SEDES - Tarija|CAINCO - Bolivia,All,21 Years to 64 Years Â  (Adult),,30,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,PROY - UAJMS001/2020,30-Oct-20,8-Oct-20,22,10-Oct-20,9-Oct-20,,22-Jan-21,"Universidad AutÃ³noma Juan Misael Saracho, Tarija, Bolivia",,https://ClinicalTrials.gov/show/NCT04581083
353,NCT04557241,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,,Completed,No Results Available,COVID19 Behavioral Prophylaxis,Behavioral: Brief informational infographic|Behavioral: Placebo control (non-behavioral infographic),Change in trust in science|Believability profiles|Preventive behavioral intentions,Indiana University|Indiana Clinical and Translational Sciences Institute,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,1017,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",Indiana_CTSI_Agley_2020,31-Jan-21,14-Jan-20,383,14-Jan-21,21-Sep-20,,9-Feb-21,"Digital Intervention (Prolific Study Panel), Bloomington, Indiana, United States",,https://ClinicalTrials.gov/show/NCT04557241
354,NCT04497623,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",SabanaHerons,Completed,No Results Available,Covid19,Device: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours,"Improvement or maintenance of the oxygenation level measured by PaO2|Improvement or maintenance of the oxygenation level measured by O2 Saturation|Improvement or maintenance of adequate levels of carbon dioxide measured by PaCO2|Improvement or maintenance of adequate levels of HCO3|Improvement or maintenance of adequate levels of excess base.|Improvement or maintenance of adequate levels of blood pH|Improvement or maintenance of PaO2/FiO2|Improvement or maintenance of SatO2/FiO2|Uninterrupted and faultless operation in the period of use of the ventilator|Inspiratory peak pressure> 35 cm H2O that does not have a clinical explanation other than the ventilator (such as a mucus plug)|Plateau airway pressure> 30 cm H2O that does not have a clinical explanation other than the ventilator|VT> 8 cc / kg of ideal weight that does not have a clinical explanation other than the ventilator|Decrease or increase in respiratory rate, tidal volume, PEEP, peak inspiratory pressure, FiO2, not due to a clinician order (changes not ordered by the clinical team but due to the ventilator variability)|Pneumothorax (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Pneumomediastinum (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Subcutaneous emphysema (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Hemodynamic deterioration in the hour following the start of the Unisabana-Herons ventilator that requires a 100% increase in the dose of vasopressors and that does not have a clinical explanation other than the ventilator|Cardiac arrest without a clinical explanation other than the ventilator|Death without a clinical explanation other than the ventilator|Elevation of creatinine that does not have a clinical explanation other than the ventilator|Elevation of BUN that does not have a clinical explanation other than the ventilator|Digestive bleeding without a clinical explanation other than ventilator|Stress ulcers (upper gastrointestinal tract) without a clinical explanation other than ventilator|Pneumonia associated with ventilator.|Tracheobronchitis associated with ventilator.|Critical care polyneuropathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation|Critical care myopathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation",FundaciÃ³n Neumologica Colombiana|Universidad de la Sabana|FundaciÃ³n Cardioinfantil Instituto de CardiologÃ­a|ClÃ­nica Universidad de La Sabana,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,202006-25502,20-Sep-20,28-Jul-20,54,13-Aug-20,4-Aug-20,,24-Sep-20,"Fundacion Neumologica Colombiana, BogotÃ¡, Bogota, Colombia|Universidad de la Sabana, Chia, Cundinamarca, Colombia|Clinica Universidad de la Sabana, ChÃ­a, Cundinamarca, Colombia",,https://ClinicalTrials.gov/show/NCT04497623
355,NCT04494646,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),,Completed,No Results Available,Covid19,Drug: Bardoxolone Methyl|Drug: Placebo,Incidence of Serious Adverse Events|Average number of renal replacement therapy (RRT)-free days|Average number of mechanical ventilation-free days|Incidence of All-Cause Mortality|Proportion of participants who experienced deterioration from baseline,"NYU Langone Health|Reata Pharmaceuticals, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-00591,8-Jan-21,8-Sep-20,122,8-Jan-21,31-Jul-20,,12-May-21,"HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|NYU Bellevue Hospital Center, New York, New York, United States|NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04494646
356,NCT04425850,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,IVERCAR,Completed,Has Results,Covid19,Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops),Number of Infected Subjects|Adverse Events Other Than Those Resulting From Contagion or Disease Progression,Eurnekian Public Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,229,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IVERCAR,10-Aug-20,1-Jun-20,70,10-Aug-20,11-Jun-20,19-Oct-20,19-Oct-20,"Hospital Eurnekian, Buenos Aires, Argentina","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04425850/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04425850
357,NCT04435223,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,COVIDOLIP,Completed,No Results Available,COVID-19 Severe Pneumonia|Severe Pneumonia Due to Other Pathogene,Biological: biological assays in particular on the lipid metabolism,Cholesterol concentration|LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.,Centre Hospitalier Universitaire Dijon,All,"18 Years and older Â  (Adult, Older Adult)",,62,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NGUYEN AOIc 2020,7-May-20,7-Apr-20,30,7-May-20,17-Jun-20,,23-Jun-20,"Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT04435223
358,NCT04786041,the Impact of COVID-19 Pandemic on the Incidence and Outcome of Complicated Appendicitis,,Completed,No Results Available,Covid19|Appendicitis,Procedure: laparoscopic appendectomy,complicated appendicitis,Meir Medical Center,All,"Child, Adult, Older Adult",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,MMC-0223-20,30-May-20,1-Mar-20,90,30-May-20,8-Mar-21,,8-Mar-21,"Meir medical center, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT04786041
359,NCT04896905,Rehabilitation After Covid19-Clinical Results and Predictive Factors,,Completed,No Results Available,Covid19,Other: Rehabilitation,Mobility|Functional Independence Measurement-Level (FIM)|Promis-10 (Promis= Patient reported outcome measurement information system)|Quality of life,Klinik Valens,All,"40 Years to 100 Years Â  (Adult, Older Adult)",,101,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,Covid19_2020,18-May-21,1-Oct-20,229,28-Feb-21,21-May-21,,21-May-21,"Rehabilitationszentrum Klinik Valens, Valens, SG, Switzerland",,https://ClinicalTrials.gov/show/NCT04896905
360,NCT04581044,Impact of COVID-19 on Psoriasis Practice,,Completed,No Results Available,Psoriasis|Covid19,,Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19|Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour,Cairo University,All,"25 Years and older Â  (Adult, Older Adult)",,197,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,KAPU2020 10,23-Oct-20,17-Sep-20,36,23-Oct-20,9-Oct-20,,13-Nov-20,"Department of Dermatology, Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04581044
361,NCT04503447,COVID-19 Seroprevalence Study in ITM Staff,CovAb,Completed,No Results Available,Covid19,,"SARS-CoV-2 seroprevalence ITM staff|SARS-CoV-2 seroprevalence in ITM staff, stratified by variables","Institute of Tropical Medicine, Belgium",All,"Child, Adult, Older Adult",,330,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,SARSCOV2SEROPREVALENCEITMSTAFF,9-Sep-20,1-Aug-20,39,9-Sep-20,7-Aug-20,,22-Oct-20,"Institute of Tropical Medicine, Antwerp, Belgium",,https://ClinicalTrials.gov/show/NCT04503447
362,NCT04379310,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Covid-19,Completed,No Results Available,Covid-19,Drug: ACE Inhibitors and Calcium Channel Blockers,extend of lung involvement|oxygen saturation on admission,Nisantasi University,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,54,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20200504441,8-May-20,1-May-20,7,5-May-20,7-May-20,,5-Jun-20,"Vital Hospital, Bahcelievler, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04379310
363,NCT04789512,Respiratory Muscle Strength in Volleyball Players Suffered From COVID-19,,Completed,No Results Available,Covid19,Other: Respiratory functions,Respiratory muscle strength|FEV1|FVC|FEV1/FVC|PEF|FEF2575|Fat mass|Fat mass percent|Fat-free mass|Body mass index|Predicted muscle mass|Symptom severity perceptions|Performance situations perceptions,Gazi University,Female,"15 Years to 35 Years Â  (Child, Adult)",,42,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2021-189,29-Mar-21,1-Mar-21,28,26-Mar-21,9-Mar-21,,1-Apr-21,"Gazi University, Ankara, Ã‡ankaya, Turkey",,https://ClinicalTrials.gov/show/NCT04789512
364,NCT04407559,COVID-SErology in Rheumatoid Arthritis (COVID-19),COVID-SERA,Completed,No Results Available,COVID-19|Rheumatoid Arthritis,Other: Serological analyses to be lead on a pre-existing biobank,"Evaluate the false positive results rate|Characterize the RF isotype (IgG, IgM or IgA) associated|Determine the influence of RA on the false positivity rate in subjects|Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test|Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test","University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,216,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0330,30-Sep-20,1-May-20,152,1-Sep-20,29-May-20,,29-Dec-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04407559
365,NCT04691934,Obstetric Anesthesia Experiences in COVID-19 Positive Patients,,Completed,No Results Available,Covid19|Obstetric Anesthesia,Procedure: Anesthesia management,obstetric anesthesia practices|anesthesia complications,Turkiye Yuksek Ihtisas Education and Research Hospital,Female,"18 Years and older Â  (Adult, Older Adult)",,61,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,U1111-1263-2201,25-Dec-20,11-Mar-20,289,25-Dec-20,31-Dec-20,,31-Dec-20,"University of Health Sciences Turkey, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, YÄ±ldÄ±rÄ±m, Turkey",,https://ClinicalTrials.gov/show/NCT04691934
366,NCT04544150,Gastrointestinal Manifestations Among Patients With COVID19,,Completed,No Results Available,Covid19,,frequency of GIT symptoms among patients with COVID-19 infection,Assiut University,All,"Child, Adult, Older Adult",,220,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,COVID19 and GUT,1-Sep-20,1-Jun-20,92,1-Sep-20,10-Sep-20,,10-Sep-20,"Ahmed, Al MinyÄ, Alminya, Egypt",,https://ClinicalTrials.gov/show/NCT04544150
367,NCT04563247,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,,Completed,No Results Available,Covid19,Diagnostic Test: IgG SARS CoV 2 antibodies,SARS CoV 2 IgG antibodies,Lahore General Hospital,All,20 Years to 60 Years Â  (Adult),,970,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,LGH002,8-Feb-21,1-Jul-20,222,8-Feb-21,24-Sep-20,,18-Feb-21,"Lahore General Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04563247
368,NCT04407299,COVID-19 Impact on Rheumatic Patients,,Completed,No Results Available,COVID,Behavioral: self-administered structured questionnaire,Score of five-item Brief Symptom Rating Scale (BSRS-5),Cairo University|Zagazig University,All,"16 Years and older Â  (Child, Adult, Older Adult)",,360,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,COVID-19Rheum,20-May-20,20-Apr-20,30,10-May-20,29-May-20,,15-Jul-20,"Kasr Alainy Hospital, Cairo, Non-US/Non-Canadian, Egypt",,https://ClinicalTrials.gov/show/NCT04407299
369,NCT04546191,Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,,Completed,No Results Available,Covid19,,Symptoms|Wellbeing - HRQL,Landspitali University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,1580,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,LSH-20-002,1-Sep-20,1-Jul-20,62,1-Sep-20,11-Sep-20,,16-Sep-20,"Landspitali National University Hospital, ReykjavÃ­k, Ãsland, Iceland",,https://ClinicalTrials.gov/show/NCT04546191
370,NCT04424771,Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,,Completed,No Results Available,COVID|Post Traumatic Stress Disorder,Behavioral: Maslach Burnout Inventory (MBI),Number of patients with diagnosis of PTSD.,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PTSD-COVID-19,1-Jul-20,1-Mar-20,122,30-Jun-20,11-Jun-20,,27-Jul-20,"Ospedale Perrino Asl Brindisi, Brindisi, Italy|Piazza della Vittoria 14 Studio medico - Ginecologia e Ostetricia, Genoa, Italy",,https://ClinicalTrials.gov/show/NCT04424771
371,NCT04841681,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,,Completed,No Results Available,"Covid19|Distress, Emotional",Behavioral: Video-based Psychotherapy,Change from Baseline Subjective Units of Distress (SUDS) at Right After Receiving Video-based Psychotherapy,"Indonesia University|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20-05-0546,26-Aug-20,7-Jun-20,80,25-Aug-20,12-Apr-21,,12-Apr-21,"dr. Cipto Mangunkusumo National General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04841681/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04841681
372,NCT04577235,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,,Completed,No Results Available,COVID-19,Other: severity of lung involvement with COVID-19.,The evaluation of the correlation between the baseline LUS score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit|The evaluation of the correlation between the baseline CT score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit,Gaziosmanpasa Research and Education Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",AyÅŸeV,5-Sep-20,5-Jun-20,92,5-Aug-20,6-Oct-20,,6-Oct-20,"Gaziosmanpasa Taksim Research and Education Hospital, Istanbul, GaziÌ‡osmanpaÅŸa, Turkey",,https://ClinicalTrials.gov/show/NCT04577235
373,NCT04352842,Echocardiographic Manifestation in Patient With COVID-19 ï¼ˆEARLY-MYO COVID-19ï¼‰,,Completed,No Results Available,Covid19|Echocardiography,Other: Echocardiography,Death,RenJi Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,51,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID19-Echocardiography,8-Apr-20,21-Jan-20,78,8-Apr-20,20-Apr-20,,19-May-20,"Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04352842
374,NCT04824664,The ALIGHIERI Survey: an Italian Overview of Global Impact of tHe COVID-19 pandemIc on General surgERy practIce,ALIGHIERI,Completed,No Results Available,Surgery and covid19,Other: survey,surgery volume during covid19 lockdown|surgery volume after the first covid19 lockdown,Associazione Chirurghi Ospedalieri Italiani,All,"Child, Adult, Older Adult",,400,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Survey_ACOI_COVID19,30-Dec-20,1-Jan-20,364,30-Jul-20,1-Apr-21,,1-Apr-21,"ACOI, Roma, Lazio, Italy",,https://ClinicalTrials.gov/show/NCT04824664
375,NCT04328480,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,COLCOVID,Completed,No Results Available,COVID-19,Drug: Colchicine|Other: Local standard of care,Composite outcome: New requirement for mechanical ventilation or death|Mortality|New requirement for mechanical ventilation or death from respiratory failure|New requirement for mechanical ventilation or death from non-respiratory failure|Mortality due to respiratory failure|Mortality due to non-respiratory failure|In hospital - Composite outcome|In hospital - Mortality|Composite outcome (New requirement for mechanical ventilation or death) evaluated in Non-intubated population|Mortality evaluated in Non-intubated population|Mean WHO descriptive score of COVID-19 during hospitalization|Highest WHO descriptive score of COVID-19 during hospitalization,Estudios ClÃ­nicos Latino AmÃ©rica|Population Health Research Institute,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,1279,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COLCOVID version 2.0,26-Apr-21,17-Apr-20,374,25-Apr-21,31-Mar-20,,27-Apr-21,"Sanatorio Parque, Rosario, Santa Fe, Argentina",,https://ClinicalTrials.gov/show/NCT04328480
376,NCT04554979,COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,,Completed,No Results Available,Covid19|Diarrhea,Drug: Hydroxychloroquine Pill,COVID-19 disease spectrum and duration|GIT manifestations among COVID-19 patients|Non-communicable disease and COVID-19|Seasonal change and COVID-19|Possible region specific classification for COVID-19 disease,Cairo University,All,"18 Years and older Â  (Adult, Older Adult)",,199,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,1004,15-Jul-20,1-Jun-20,44,15-Jul-20,18-Sep-20,,22-Sep-20,"Faculty of Medicine Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04554979
377,NCT04261517,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,,Completed,No Results Available,"Pneumonia, Pneumocystis|Coronavirus|COVID-19",Drug: Hydroxychloroquine,"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2",Shanghai Public Health Clinical Center,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HC-COVID-19,25-Feb-20,6-Feb-20,19,25-Feb-20,7-Feb-20,,13-Apr-20,"Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04261517
378,NCT04536285,Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,,Completed,No Results Available,Type 1 Diabetes|Covid19,,Clinical characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Laboratory characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Incidence of new onset type 1 diabetes among confirmed cases of Covid-19 infection among children and adolescents|Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt,Ain Shams University,All,"1 Year to 18 Years Â  (Child, Adult)",,36,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,FMASU P59/2020,31-Aug-20,1-May-20,122,31-Aug-20,2-Sep-20,,2-Sep-20,"Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04536285
379,NCT04361786,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,,Completed,No Results Available,COVID 19,,Biological acquired thrombophilia|Overexpression of interferon type I,"University Hospital, Montpellier|Lyon Civil Hospitals - Lyon Sud Hospital Center|University Hospital, Marseille",All,"Child, Adult, Older Adult",,10,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,RECHMPL20_0211,30-Oct-20,1-Apr-20,212,30-Jun-20,24-Apr-20,,29-Dec-20,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04361786
380,NCT04458363,Convalescent Plasma in Pediatric COVID-19,,Completed,No Results Available,COVID,Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies,"Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer",Emory University,All,"up to 22 Years Â  (Child, Adult)",Early Phase 1,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000789,1-Sep-20,4-Jul-20,59,1-Sep-20,7-Jul-20,,19-Jan-21,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04458363
381,NCT04494204,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,,Completed,No Results Available,Treatment of Covid-19 Virus Infection,Combination Product: Immunofree tablets and Reginmune capsule,Time (Days) to clinical improvement from study enrollment|Proportion of participants in each group with oxygen saturation more than 94% on room air for more than 24h|Value of coagulation indicators|Time to first negative SARS-CoV-2 PCR in NP swab|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization,PUNEET MITTAL|Nutrin GmbH,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MGCTS/20/105,20-Dec-20,7-Aug-20,135,1-Dec-20,31-Jul-20,,22-Dec-20,"Govt Medical College and Govt General Hospital (Old RIMSGGH), Srikakulam, Andhra Pradesh, India|Parul Institute of Ayurveda and Research Parul University, Vadodara, Gujrat, India|Lokmanya Hospital, Pune, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT04494204
382,NCT04383626,Fear Among Dentists During COVID-19 Pandemic,,Completed,No Results Available,COVID,,fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic,Cairo University,All,"20 Years and older Â  (Adult, Older Adult)",,216,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,COVID-19 pandemic,5-May-20,2-Mar-20,64,5-Apr-20,12-May-20,,12-May-20,"Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04383626
383,NCT04346446,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,,Completed,No Results Available,COVID,Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma,Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.,"Institute of Liver and Biliary Sciences, India",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS-COVID-02,30-May-20,20-Apr-20,40,30-May-20,15-Apr-20,,12-Jun-20,"Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT04346446
384,NCT04710329,High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients,,Completed,No Results Available,"Respiratory Distress Syndrome, Adult|Covid19",Drug: Ascorbic acid,short term mortality|Length of Intensive Care Unit Stay|vasopressor requirement|invasive mechanical ventilation requirement|PaO2/FiO2 ratio|C-reactive protein|procalcitonin|Lymphocyte count|ferritin|SOFA,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,78,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CVIT-3334,10-Feb-21,16-Jan-21,25,25-Jan-21,14-Jan-21,,15-Feb-21,"Sisli etfal training and resource hospital, Sisli, Ä°stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04710329
385,NCT04473547,COVID 19 Preventive Measures Among Mansoura Nursing Students,,Completed,No Results Available,Covid19,,"adherence level to coronavirus disease 19 preventive measures among nursing students during written exams.|number of students who develop possible covid-19 symptoms during written exams|Eye,nose,mouth,Face and mask touch frequency during written exams|nursing students knowledge level of COVID 19|COVID 19 risk perception level among nursing students undergoing written exams",Mansoura University,All,"Child, Adult, Older Adult",,144,Other,Observational,Observational Model: Other|Time Perspective: Prospective,p.0203,15-Feb-21,10-Jul-20,220,20-Aug-20,16-Jul-20,,8-Mar-21,"Faculty of Nursing Mansoura University, Mansoura, Egypt",,https://ClinicalTrials.gov/show/NCT04473547
386,NCT04359251,Different PEEP Settings of COVID-19 Induced ARDS,,Completed,No Results Available,COVID-19|Mechanical Ventilation Pressure High|Acute Respiratory Distress Syndrome,Other: Gas exchanges at different PEEP|Other: lung mechanics at different PEEP|Other: Hemodynamics changes at different PEEP,Respiratory system compliance improvement|Gas echanges improvement,"Southeast University, China",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19 PEEP titration,25-Mar-20,5-Mar-20,20,25-Mar-20,24-Apr-20,,24-Apr-20,"Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04359251
387,NCT04527601,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,,Completed,No Results Available,Extreme Prematurity|Covid19,,Number of ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019|Regional difference in ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019|Correlation between the level of lockdown restrictions and number of ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019,"Rigshospitalet, Denmark",All,22 Weeks to 28 Weeks Â  (Child),,885,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,SafeBoosC COVID-19 ELGAN study,13-Sep-20,21-Aug-20,23,13-Sep-20,26-Aug-20,,8-Oct-20,"Neonatalklinikken, Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04527601
388,NCT04487574,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,,Completed,No Results Available,SARS-CoV-2 Infection,Drug: XC221|Drug: Placebo,"Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.|Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.|Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row.|Patient rate with a negative test result for SARS-CoV-2 by Day 7Â±1, 15Â±1, 21 Â±1 and 28 Â± 1.|Duration of hospitalization.|Patient rate transferred to the intensive care unit (ICU) during hospitalization.|Duration of ICU stay.|Patient rate with ARDS during hospitalization.|Presence of a fatal outcome.|Patient rate requiring oxygen therapy by Day 2-28.|Patient rate requiring high-flow oxygen therapy by Day 2-28.|Patient rate requiring non-invasive ventilation by Day 2-28.|Patient rate requiring invasive ventilation by Day 2-28.|Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28.|The total duration of oxygen therapy by the last day of hospitalization.|The total duration of high-flow oxygen therapy by the last day of hospitalization.|The total duration of non-invasive ventilation by the last day of hospitalization.|The total duration of invasive ventilation of lungs by the last day of hospitalization.|The total duration of EMO by the last day of hospitalization.|Patient rate with Sp02 > 95% by Day 2-28.|Average alteration of Sp02 by Day 2-28 from baseline.|Average time to reach SpO2 â‰¥ 95%.|Patient rate with RR < 22 / min by Day 2-28.|Average alteration in RR by Day 2-28 from baseline.|Average time to reach RR â‰¤ 22 / min.|Patient rate with body temperature < 37.5Â°C by Day 2-28.|Average alteration in body temperature by Day 2-28 from baseline.|Average time until the patient reaches a body temperature of â‰¤37.5Â°C.|Patient rate with CT-1 according to CT data by Day 2-28.|Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value.|Average time to reach CT-1 according to CT data.|Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28.|Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline.|Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale.|Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28.|Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline.|Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.|Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28.|Mean WHO grade change by Day 2-28 from baseline.|Average time to reach the 3rd category or below according to the WHO scale.|Patient rate with a NEWS score < 2 by Day 2-28.|Average change in NEWS score by Day 2-28 from baseline.|Average time to reach a NEWS score â‰¤ 2.",RSV Therapeutics LLC,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 3,118,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",XC221-03-02-2020,29-Oct-20,25-Jul-20,96,29-Oct-20,27-Jul-20,,13-Nov-20,"Regional State Budgetary Institution of Healthcare ""City Hospital No. 5, Barnaul"", Barnaul, Altai Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow Region ""Zhukovskaya City Clinical Hospital"", Zhukovskiy, Moscow Region, Russian Federation|Municipal Budgetary Institution of Healthcare ""Central City Hospital of Novoshakhtinsk"", Novoshakhtinsk, Rostov Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 15 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University), Department of Faculty Therapy No. 2, Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 52 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 40 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Multidisciplinary Hospital"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital No. 40 of Kurortny District"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital No. 15"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Pokrovskaya Hospital"" (4th Cardiology Department), Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Pokrovskaya Hospital"", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare ""Medical-Sanitary Unit No. 2"", Tomsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT04487574
389,NCT04375098,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2,Biological: COVID-19 convalescent plasma,"Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization|Median duration of fever|Median duration of mechanical ventilation|Median length of ICU stay|Median length of admission|Hospital mortality rate (percentage)|30-day mortality (percentage)|Readmission rate (percentage)|Median length of viral clearance",Pontificia Universidad Catolica de Chile|Fundacion Arturo Lopez Perez,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200415015,17-Aug-20,4-May-20,105,17-Aug-20,5-May-20,,16-Sep-20,"Hospital ClÃ­nico Universidad CatÃ³lica, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT04375098
390,NCT04723290,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,,Completed,No Results Available,Covid19,Diagnostic Test: Serological tests for SARS Cov-2,Serological tests to know the level of antibodies against SARS CoV-2,Grand HÃ´pital de Charleroi,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,2817,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SERO-SARS-CoV-2 GHdC,31-Dec-20,20-Jun-20,194,31-Oct-20,25-Jan-21,,25-Mar-21,"Grand HÃ´pital de Charleroi, Charleroi, Hainaut, Belgium",,https://ClinicalTrials.gov/show/NCT04723290
391,NCT04334291,"International COVID19 Clinical Evaluation Registry,",HOPE COVID 19,Completed,No Results Available,COVID 19,Combination Product: Observational (registry),Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.,"IVAN J NUÃ‘EZ GIL|St Carlos Hospital, Madrid, Spain",All,"Child, Adult, Older Adult",,8168,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,20/241-E|EUPAS34399,31-May-20,23-Mar-20,69,1-May-20,6-Apr-20,,23-Feb-21,"Hospital Lclinico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04334291
392,NCT04450017,Clinical Features of Severe Patients With COVID-19,,Completed,No Results Available,SARS-CoV2,"Diagnostic Test: The demographic, clinical, laboratory, and instrumental data",Mechanical ventilation duration|Non-invasive Mechanical ventilation duration|Mortality|Ð¡omplete blood count|Biochemistry analysis|Ð¡omplete blood count dynamics|Biochemistry analysis dynamics|Computer tomography|High-sensitive troponin Ð¢|High-sensitive troponin Ð¢ dynamics|Vitamin D level|Vitamin D level dynamics|Immunogram|Immunogram dynamics,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",All,"18 Years to 90 Years Â  (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,COVID-ICU,30-Jun-20,6-Apr-20,85,30-Jun-20,29-Jun-20,,20-May-21,"Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04450017
393,NCT04598256,Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic,,Completed,No Results Available,Covid19,Procedure: Endoscopic procedure,The number of participiants who was infected with Covid-19. normalization process of Covid-19 pandemic|The time of seen covid 19 infection after the endoscopic procedures in participiants.|The characteristics of patients with Covid-19 infection.,Tepecik Training and Research Hospital,All,"1 Year to 18 Years Â  (Child, Adult)",,77,Other,Observational,Observational Model: Other|Time Perspective: Prospective,TepecikTRH1,31-Aug-20,1-Jun-20,91,31-Aug-20,22-Oct-20,,2-Nov-20,"Tepecik Trh, Ä°zmir, Ä°Ì‡zmiÌ‡r, Turkey",,https://ClinicalTrials.gov/show/NCT04598256
394,NCT04398004,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,ACHIEVE,Completed,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFÎ± ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,30-Nov-20,6-May-20,208,30-Nov-20,21-May-20,,11-Jan-21,"COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, IoÃ¡nnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, ThessalonÃ­ki, Greece",,https://ClinicalTrials.gov/show/NCT04398004
395,NCT04602351,Communication in ICU During COVID-19,,Completed,No Results Available,COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Syndrome,Behavioral: Communication,Changes in the pattern of family members visiting process|Changes in process of communication between health care workers(HCWs) and family members|Changes in process of informed consent in ICU,NMC Specialty Hospital,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,296,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,ComICU,1-May-21,22-Mar-21,40,7-Apr-21,26-Oct-20,,11-May-21,"NMC Specialty Hospital, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT04602351
396,NCT04453280,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),SARSCoV2CZImun,Completed,No Results Available,COVID|SARS-CoV-2,Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies|Diagnostic Test: SARS-CoV-2 diagnostic rapid test,Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.|Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the age and to the severity of the disease.|The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies.,"Institute of Health Information and Statistics of the Czech Republic|Ministry of Health, Czech Republic|Masaryk University|Institute for Clinical and Experimental Medicine|Brno University Hospital|St. Anne's University Hospital Brno, Czech Republic|Masaryk Memorial Cancer Institute|Regional Public Health Office of the South Moravian Region based in Brno, Czech Republic|Public Health Office of the Capital City of Prague, Czech Republic|Regional Public Health Office of the Central Bohemian Region based in Prague, Czech Republic",All,"8 Years and older Â  (Child, Adult, Older Adult)",,695,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,UZIS 2020/2,3-Jun-20,18-May-20,16,3-Jun-20,1-Jul-20,,1-Jul-20,"Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT04453280
397,NCT04690413,NOWDx Test for the Detection of Antibodies to COVID-19,,Completed,No Results Available,COVID-19|SARS-CoV-2|Coronavirus,Device: NOWDx COVID-19 Test,Percentage of clinical agreement between NOWDx COVID-19 Test and emergency use authorized or FDA cleared comparator.,"NOWDiagnostics, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,129,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NOWDx COVID-19 Antibody POC,31-Dec-20,1-Sep-20,121,31-Dec-20,30-Dec-20,,3-Mar-21,"Del Sol Research Management, LLC, Tucson, Arizona, United States|Comprehensive Clinical Research, LLC, West Palm Beach, Florida, United States|Clinical Research Solutions, LLC, Jackson, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04690413
398,NCT04479150,Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,COVIDCIR,Completed,No Results Available,Covid19|Surgery--Complications,,30-day mortality|90-day mortality|Postoperative complications|Severe complications|Lenght of stay,Hospital Universitari de Bellvitge|Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,All,"18 Years and older Â  (Adult, Older Adult)",,5307,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COVIDCIR,31-Aug-20,1-Mar-20,183,31-Aug-20,21-Jul-20,,23-Feb-21,"Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04479150
399,NCT04362813,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,CAN-COVID,Completed,No Results Available,Pneumonia and Cytokine Release Syndrome (Covid-19),Drug: Canakinumab|Drug: Placebo,"Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein (CRP)|Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs",Novartis Pharmaceuticals|Novartis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,451,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CACZ885D2310|2020-001370-30,22-Dec-20,30-Apr-20,236,16-Sep-20,27-Apr-20,,25-May-21,"Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04362813
400,NCT04374045,Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,COVIDANS,Completed,No Results Available,SARS-CoV 2,Other: ECG-Holter,"Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)|Analyse the other mathematical indices measuring autonomic balance, obtained by Holter-ECG recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia|To investigate whether the autonomic balance of patients with CoV-2 SARS correlates with the severity of their clinical condition during their hospital stay.|To investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters.",Centre Hospitalier Universitaire de Saint Etienne,All,"18 Years and older Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20CH095|2020-A01082-37,18-Jun-20,30-Apr-20,49,17-Jun-20,5-May-20,,14-Jan-21,"CHU Hopital nord, Saint-Ã‰tienne, France",,https://ClinicalTrials.gov/show/NCT04374045
401,NCT04515108,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,,Completed,No Results Available,"Pregnancy, Infections in|Covid19",Other: Clinical assessment,"complete blood count parameters (including the number of lymphocytes, Leukocytes, monocytes, platelets and red blood cells).|APGAR score|maternal and newborn length|maternal and newborn weight|body temperature",Ankara City Hospital Bilkent,Female,18 Years to 42 Years Â  (Adult),,108,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,E1-20-672,10-Aug-20,10-Mar-20,153,5-Aug-20,17-Aug-20,,17-Aug-20,"Ankara City Hospital, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04515108
402,NCT04552483,Effects of Early Use of Nitazoxanide in Patients With COVID-19,,Completed,No Results Available,Covid19|Coronavirus,Drug: Nitazoxanide|Drug: Placebo,Days with fever|Days with cough|Days with asthenia|SARS-COV-2 viral load - absolute number|SARS-COV-2 viral load - percentage|Hospital admission rate - absolute number|Hospital admission rate - percentage|Serum Interleukin-6|Serum Interleukin-1-beta|Serum Interleukin-8|Serum tumor necrosis factor (TNF)-alfa|Serum interferon-gamma|Serum monocyte chemoattractant protein (MCP)-1|Complete blood count|C-reactive protein - absolute number|C-reactive protein - percentage,"Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|ATCGen|Complexo Hospitalar Municipal de SÃ£o Caetano do Sul|Hospital de Transplante Doutor Euryclides de Jesus Zerbini|Secretaria Municipal de SaÃºde de Bauru|Santa Casa de MisericÃ³rdia de Sorocaba|Secretaria Municipal de SaÃºde de Guarulhos|Hospital e Maternidade Therezinha de Jesus|Secretaria de Estado de SaÃºde do Distrito Federal",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,392,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",SARITA-2|RBR-4nr86m|32258920.0.1001.5257,5-Sep-20,8-Jun-20,89,20-Aug-20,17-Sep-20,,3-Nov-20,"Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04552483
403,NCT04568356,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,,Completed,No Results Available,SARS CoV-2,Diagnostic Test: Direct Antigen Tests for COVID-19,Percent Positive Agreement and Negative Percent Agreement,"E25Bio, Inc.|SCRI Development Innovations, LLC",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,200,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,E25001_NEU2012,24-Sep-20,24-Apr-20,153,12-Jun-20,29-Sep-20,,19-Oct-20,"JFK Medical Center, Miami, Florida, United States|Kendall Regional, Miami, Florida, United States|Aventura Hospital and Medical Center, Miami, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04568356/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04568356/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04568356
404,NCT04603729,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,covid19,Completed,No Results Available,Covid 19 Disease,Drug: Dexamethasone 2 MG/ML|Drug: Methylprednisolone Injection,temperature (F)|oxygen saturation(%)|CRP (mg/dl)|mortality|ICU transfer,Fatima Memorial Hospital,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMH-06-2020-IRB-763-M,1-Jul-20,30-May-20,32,30-Jun-20,27-Oct-20,,27-Oct-20,"Fatima Memorial Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04603729
405,NCT04421612,COVID-19 - No Health Without Mental Health,Co-COVID-19,Completed,No Results Available,Covid19|Anxiety,Behavioral: Co-mestring (co-coping),The Patient Health Questionnaire|The Generalized Anxiety Disorder Scale|Positive and negative affect|Perceived Stress Scale|Client Satisfaction Scale,Haukeland University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,126376,1-Jan-21,2-Apr-20,274,1-Jan-21,9-Jun-20,,6-May-21,"Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT04421612
406,NCT04544176,COVID-19 Risk From Attending Outpatient Radiology Appointments,,Completed,No Results Available,Covid19,Other: Observational,A microbiological diagnosis of COVID infection.,Nottingham University Hospitals NHS Trust|University Hospital of Wales,All,"16 Years to 100 Years Â  (Child, Adult, Older Adult)",,48000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20NS031,1-Jan-21,1-Jan-20,366,30-Jun-20,10-Sep-20,,12-Feb-21,"Nottingham University Hospitals, NHS Trust, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04544176
407,NCT04358510,COVID-19 Mortality Prediction Model,,Completed,No Results Available,COVID-19|Pneumonia|Mechanical Ventilation,Device: COViage,Mortality outcome in COVID-19 ICU patients|Mortality outcome in mechanically ventilated ICU patients|Mortality outcome in pneumonia ICU patients,Dascena,All,"18 Years and older Â  (Adult, Older Adult)",,114,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,4202001,17-Apr-20,1-Apr-20,16,17-Apr-20,24-Apr-20,,24-Apr-20,"Dascena, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT04358510
408,NCT04531345,Cytokine Status of Covid-19 Patients,,Completed,No Results Available,Covid19,Diagnostic Test: Flow cytometric analysis,Cytokine levels of patients,Istanbul Training and Research Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Covid Cytokine,15-Nov-20,1-Oct-20,45,1-Nov-20,28-Aug-20,,12-Jan-21,"Istanbul Training and Reseach Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04531345
409,NCT04359810,Plasma Therapy of COVID-19 in Severely Ill Patients,,Completed,No Results Available,SARS-CoV-2 Infection,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma),"Day 28 severity outcome|Proportion of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital and 28-day mortality|Time-to-clinical improvement in-hospital|Host genetic differences at day 0|Host transcriptomic differences at days 0,7,14","Max O'Donnell|New York Blood Center|Amazon.com, Inc.|Columbia University",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,223,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AAAS9924,30-Dec-20,21-Apr-20,253,30-Dec-20,24-Apr-20,,18-May-21,"Columbia University Irving Medical Center/NYP, New York, New York, United States|Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil|Hospital Geral de Nova IguaÃ§u, Rio De Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04359810
410,NCT04491994,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,COVID-19,Completed,Has Results,Covid19|Progression,Drug: HCQ,Number of Participants With Progression|Viral Clearance,"UNICEF|Pak Emirates Military Hospital Rawalpindi, Pakistan",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 3,540,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sultan Mehmood Kamran 2,31-May-20,10-Apr-20,51,31-May-20,30-Jul-20,21-Aug-20,21-Aug-20,"Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04491994/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04491994
411,NCT04357782,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,AVoCaDO,Completed,No Results Available,COVID-19|Hypoxia,Drug: L-ascorbic acid,Incidence of adverse events|Incidence of serious adverse reactions|Incidence of adverse reactions|Ventilator-free days|ICU-free days|Hospital-free days|All-cause mortality|Change in S/F ratio during HDIVC infusion|C-reactive protein (CRP)|Lactate dehydrogenase (LDH)|D-dimer|Lymphocyte count|Neutrophil to Lymphocyte ratio (NLR)|Serum Ferritin,Hunter Holmes Mcguire Veteran Affairs Medical Center|McGuire Research Institute,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,20,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Davis 001,13-Oct-20,16-Apr-20,180,13-Oct-20,22-Apr-20,,23-Dec-20,"Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04357782
412,NCT04602871,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,COVID-19,Completed,No Results Available,Covid19,Diagnostic Test: Breath Biopsy,Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.|Correlation between Volatile Organic Compounds pattern and the course of the disease,Scentech Medical Technologies Ltd,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,108,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Cov-2-2020,30-Jan-21,3-Jul-20,211,30-Jan-21,26-Oct-20,,13-Apr-21,"Soroka Medical Center, Be'er Sheva, Israel|Meir Medical Center, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT04602871
413,NCT04347928,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,PHYSIO-COVID,Completed,No Results Available,COVID-19|ARDS|Sars-CoV2,,intrapulmonary shunt ratio|Evolution of respiratory variables|Evolution of hemodynamic stability variables,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,15,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_32|2020-A00957-32,6-Nov-20,20-Apr-20,200,6-Nov-20,15-Apr-20,,17-Nov-20,"Hopital Roger Salengro, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04347928
414,NCT04425044,AiM Covid Self Monitoring,,Completed,No Results Available,Covid19,Other: Other,Fever|Shortness of Breath|Cough|Sore Throat|Headache|Muscle/ Joint Pain|Diarrhoea|Vomiting/ Nausea|Runny Nose|Loss of Smell/Taste|Other symptoms,Aarogyam UK|University of Warwick|NMP Medical Research Institute|Mothers Touch Foundation,All,"18 Years and older Â  (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Au015,28-May-20,12-Apr-20,46,18-May-20,11-Jun-20,,11-Jun-20,"Mothers Touch Foundation, Mumbai, Maharashtra, India|NMP Medical Research Institite, Jaipur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT04425044
415,NCT04480515,Does COVID-19 Pandemic Reduce In-hospital Mortality?,,Completed,No Results Available,Covid19|In-hospital Cardiac Arrest,Other: in-hospital mortality rate,In-hospital mortality,Kanuni Sultan Suleyman Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,KSSEAH--IHM,30-Jun-20,11-Mar-20,111,15-Jun-20,21-Jul-20,,21-Jul-20,"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04480515
416,NCT04636294,Borderline COVID-19 PCR Test Result,,Completed,No Results Available,Covid19|Virus,Diagnostic Test: SARS-CoV-2 PCR,Ratio of positivity conversion after receiving a COVID-19 borderline PCR result.|Symptoms predicting COVID-19 positivity conversion after receiving a borderline PCR result.,Jessa Hospital,All,"Child, Adult, Older Adult",,30000,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,f/2020/166,15-Feb-21,1-Aug-20,198,15-Feb-21,19-Nov-20,,16-Feb-21,"Clinical Laboratory Jessa Hospital, Hasselt, Limburg, Belgium",,https://ClinicalTrials.gov/show/NCT04636294
417,NCT04347824,Predict Adverse Events by Covid-19 Nephritis,,Completed,No Results Available,Covid-19,,Time to Disease-Aggravation|Complications|Resources|Blood-test,"University Hospital Goettingen|UniversitÃ¤tsklinikum Hamburg-Eppendorf|University Hospital, Aachen|Transplantationszentrum KÃ¶ln-Merheim",All,"Child, Adult, Older Adult",,223,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,UMG_Co19-Nephritis,31-Mar-21,27-Apr-20,338,31-Dec-20,15-Apr-20,,28-Apr-21,"University Medical Center Goettingen, GÃ¶ttingen, Germany",,https://ClinicalTrials.gov/show/NCT04347824
418,NCT04595240,Semen Analysis Changes in Covid-19 Positivepatients,,Completed,No Results Available,Covid19,Diagnostic Test: semen analysis,changes of semen volume in (ML)by covid-19 from normal values.|changes of sperm concentration in (million/ml) by covid-19 from normal values.|changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.|changes of sperm motility in percentage of (A+B) by covid-19 from normal values.|changes of semen volume in (ML) by covid-19 from from the first sample|changes of sperm concentration in (million /ML) by covid-19 from from the first sample|changes of sperm morphology in percentage of normal form by covid-19 from from the first sample|changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample,Assiut University,Male,20 Years to 45 Years Â  (Adult),,100,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Semen analysis post covid-19,15-Oct-20,1-May-20,167,15-Oct-20,20-Oct-20,,20-Oct-20,"Mostafa Kamel, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04595240
419,NCT04746365,Ivermectin Role in Covid-19 Clinical Trial,IRICT,Completed,No Results Available,Covid19,Drug: ivermectin|Drug: hydroxychloroquine|Drug: Placebo,Reduction in the WHO ordinal scale of clinical status by at least two points|Time to discharge|Mortality,Elaraby Hospital|Shebin El-Kom Teaching Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",1029076|2101001,6-Feb-21,6-Dec-20,62,31-Jan-21,9-Feb-21,,9-Feb-21,"Shebin-Elkom teaching hospital, ShibÄ«n Al Kawm, Menoufia, Egypt",,https://ClinicalTrials.gov/show/NCT04746365
420,NCT04354753,AiM COVID for Covid 19 Tracking and Prediction,,Completed,No Results Available,COVID 19,Other: No Intervention,Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions,Aarogyam UK|University of Warwick|Igor Sikorsky Kyiv Polytechnic Institute|ClickMedix LLC,All,"18 Years and older Â  (Adult, Older Adult)",,80,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,AU12,17-Apr-20,28-Mar-20,20,14-Apr-20,21-Apr-20,,21-Apr-20,"Aarogyam (UK), Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04354753
421,NCT04531319,Immune Cell Subgroups in Covid 19 Patients,,Completed,No Results Available,Covid19,Diagnostic Test: Flow cytometric analysis,T cell subtype ratios|Monocyte ratio,Istanbul Training and Research Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Covid Cell,1-Oct-20,15-Aug-20,47,1-Oct-20,28-Aug-20,,12-Jan-21,"Istanbul Training and Reseach Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04531319
422,NCT04734171,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak",,Completed,No Results Available,Covid19|Fear|Loneliness,Behavioral: Digital social activity video intervention|Behavioral: Informational sheet|Behavioral: Stigma awareness video intervention,Change in total stigma score 2 weeks after the intervention|Change in total fear score 2 weeks after the intervention|Change in loneliness ordinal score 2 weeks after the intervention|Change in fear of people COVID-19+ ordinal score 2 weeks after the intervention|Change in time spent on internet ordinal score 2 weeks after the intervention|Change in social activity ordinal score 2 weeks after the intervention,Columbia University|New York State Psychiatric Institute,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AAAT0067,16-Apr-20,2-Apr-20,14,16-Apr-20,2-Feb-21,,2-Feb-21,"Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04734171
423,NCT04487873,COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,,Completed,No Results Available,Covid19|Bronchiectasis,,COVID-19 Phobia|Qol|Health anxiety|Physical activity|Quality of sleep,Hacettepe University,All,18 Years to 60 Years Â  (Adult),,74,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,GO 20/602,31-Jan-21,23-Jul-20,192,18-Dec-20,27-Jul-20,,13-May-21,"Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04487873
424,NCT04420312,Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,COVID-EP,Completed,No Results Available,Pulmonary Embolism|Covid-19,,Impact of PE on COVID-19 patients|Clinical and radiological characteristics,Groupe Hospitalier Paris Saint Joseph,All,"18 Years and older Â  (Adult, Older Adult)",,1024,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,COVID-EP|MR 4516150520,20-Apr-20,1-Mar-20,50,20-Apr-20,9-Jun-20,,25-Jun-20,"Groupe Hospitalier Paris Saint-Joseph, Paris, France",,https://ClinicalTrials.gov/show/NCT04420312
425,NCT04488588,Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,,Completed,No Results Available,Covid19|Coronavirus Disease|SARS-CoV-2,Other: Kaplan Meier analysis,number of co-morbidities in hospitalized patients with COVID-19|causes of ICU admission,Assiut University,All,36 Years to 63 Years Â  (Adult),,1064,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,AssiutU17,1-Jul-20,15-Mar-20,108,1-May-20,28-Jul-20,,28-Jul-20,"AssiutU, Assiut, Egypt|Aliae Mohamed-Hussein, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04488588
426,NCT04395300,Sleep Quality in Healthcare Personnel During COVID-19,,Completed,No Results Available,COVID-19|Sleep Quality|General Health,Other: Web Based Survey,measure sleep quality in healthcare worker|impact of covid-19 pandemic on general health|correlate between sleep quality and general health,Assiut University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,143,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,AssiutU14,16-May-20,30-Mar-20,47,30-Apr-20,20-May-20,,23-Jun-20,"AssiutU, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04395300
427,NCT04432272,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ABACCuS,Completed,No Results Available,COVID-19|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections,Biological: COVID-19 convalescent plasma,Avoidance of intubation at 28 days (group A)|Mortality (group B)|Cardio-circulatory arrest|Patient Outcome at 28 days|Renal failure|Liver failure|Cytokine Storm|Respiratory support|Vasopressor medication support|Length of ICU length of stay|Intensive Care Unit (ICU) mortality|Hospital length of stay|Ventilator free days|Intubation duration|Readmission|Serum anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality (group A)|Time from Transfusion to end of ventilator support (group B),William Beaumont Hospitals,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,71,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-198,28-Nov-20,16-Jul-20,135,13-Nov-20,16-Jun-20,,6-May-21,"William Beaumont Hospital, Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04432272
428,NCT04384471,Covid-19 Pandemic: Patients' Experience in T1D,,Completed,No Results Available,Type1diabetes|Covid19,Other: Online survey,"Self-reported acute diabetes complication|Self-reported hypoglycemia|Ability to get diabetes supplies and to access diabetes care|Concern about not having access to diabetes supplies and to access diabetes care|Impact of the pandemic situation on daily life activities|Impact on stress, anxiety and depression for adults participants|Impact on stress, anxiety and depression for children and adolescents",McGill University|Juvenile Diabetes Research Foundation|Canadian Institutes of Health Research (CIHR),All,"1 Year and older Â  (Child, Adult, Older Adult)",,384,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2021-1079,1-Jul-20,29-Apr-20,63,1-Jul-20,12-May-20,,24-Feb-21,"Institut de Recherches Cliniques de MontrÃ©al, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04384471
429,NCT04344977,Collection of Anti-SARS-CoV-2 Immune Plasma,NIAID,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),,Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 70 Years Â  (Adult, Older Adult)",,151,NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,200081|20-I-0081,3-Mar-21,1-Jun-20,275,20-Nov-20,14-Apr-20,,5-Mar-21,"Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04344977
430,NCT04500067,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",,Completed,No Results Available,Covid19|Pneumonia,Drug: IVIG,"Period duration (in days) to clinical improvement|O2 saturation (SPO2 percentage), with self-breathing|Respiratory movements rate (amount per minute), with self-breathing|Body temperature without antipyretics use|Lymphocyte count|Time from the onset of the disease to discharge, in days|Duration of the need for ventilatory support, in days|Duration of the need for intensive care, in days|Duration of need for oxygenation in days (SPO2 â‰¤ 93% with self-breathing)|The C-reactive protein (CRP) level|The tumor necrozis factor alpha (TNF-Î±) level|The interleukin-1Î² (IL-1Î²) level|The interleukin-6 (IL-6) level|The D-dimer level|The Complement (C3 component) level|The Circulating immune complexes level|The ferritin level|The procalcitonin level|IgG subtypes|Survival assessment for a 28-day follow-up period since the onset of severe pneumonia",Biopharma Plasma LLC|Lviv National Medical University|Vinnitsa National Medical University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,76,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-BV-BP,15-Sep-20,7-May-20,131,15-Sep-20,5-Aug-20,,14-Oct-20,"Site 08 - ""Central City Clinical Hospital of Ivano-Frankivsk City Council"", Ivano-Frankivs'k, Ivano-Frankivs'k Region, Ukraine|Site 02 - ""Bila Tserkva City Hospital â„–3"", Bila Tserkva, Kyiv Region, Ukraine|Site 03 - ""Lviv Regional Infectious Diseases Clinical Hospital"", Lviv, Lviv Region, Ukraine|Site 04 - ""City Clinical Infectious Diseases Hospital"", Odesa, Odesa, Odesa Region, Ukraine|Site 07 - ""Ternopil City Municipal Ambulance Hospital"", Ternopil', Ternopil' Region, Ukraine|Site 06 - ""Vinnytsia City Clinical Hospital â„–1"", Vinnitsia, Vinnitsia Region, Ukraine|Site 09 - ""Volyn Regional Clinical Hospital"", Luts'k, Volyn Region, Ukraine|Site 01 - ""Kyiv City Clinical Hospital â„–17"", Kyiv, Ukraine|Site 05 - ""Kyiv City Clinical Hospital â„–4"", Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT04500067
431,NCT04459962,Covid-19 Breath Test,,Completed,No Results Available,Covid-19 Infection,Diagnostic Test: Breath Test & Cheek Swab,To investigate/ examine the effectiveness of Nanotechnology Biomarker Tagging (NBT) in detecting COVID-19 infection using breath samples of patients with COVID-19 symptoms|-To profile the unique pattern of Volatile Organic Compounds (VOCs) found in the expired breath of COVID-19 patients using the NBT system (VOC analysis and ML).|To differentiate this unique profile from the patients that are found to be negative for COVID-19,Ancon Technologies Ltd,All,"16 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,330,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2020ATL01,7-Jan-21,29-Jun-20,192,7-Jan-21,7-Jul-20,,29-Jan-21,"Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT04459962
432,NCT04863534,Ultrasound Grayscale Analysis in ARDS covid19,Graycovid,Completed,No Results Available,Muscular Diseases|COVID-19 Acute Respiratory Distress Syndrome,Device: Ultrasound,Grayscale and mortality|Grayscale and inflammation,University of Milan,,"Child, Adult, Older Adult",,32,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Umilan1,21-Feb-21,1-Apr-20,326,21-Feb-21,28-Apr-21,,28-Apr-21,"ASST-Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy",,https://ClinicalTrials.gov/show/NCT04863534
433,NCT04393428,Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),COVID-AKI,Completed,No Results Available,COVID-19|Renal Replacement Therapy|Acute Kidney Injury,Other: [TIMP-2]*[IGFBP-7],Sensibility and specificity of urinary,"University Hospital, Montpellier",All,"18 Years to 100 Years Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0294,30-Jun-20,1-Mar-20,121,1-Jun-20,19-May-20,,29-Jul-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04393428
434,NCT04353011,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,DolPsyCOVID,Completed,No Results Available,Sars-CoV2|Chronic Pain,Other: questionnaire assesment,Hospital Anxiety and Depression Scale questionnaire|Quality of life (SF36)|self-reported questionnaire for painful|qualitive questionnaire,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,312,Other,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,2020_45|2020-A00912-37,27-Apr-20,20-Apr-20,7,27-Apr-20,20-Apr-20,,11-Dec-20,"Hopital Roger Salengro, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04353011
435,NCT04351633,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,OsPsyCOVID,Completed,No Results Available,Sars-CoV2|Osteoporosis,Other: questionnaire assesment,percentage of patient with feeling of disabilities,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,52,Other,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,2020_31|2020-A00911-38,30-Apr-20,23-Apr-20,7,30-Apr-20,17-Apr-20,,11-Dec-20,"Hopital Roger Salengro, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04351633
436,NCT04356586,Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,,Completed,No Results Available,COVID-19|Serology,,Percentage of serological positive healthcare workers|Percentage of HCW with positive Saliva-sabs,Sciensano|Jessa Hospital,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,287,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Jessa300,21-Aug-20,4-May-20,109,21-Aug-20,22-Apr-20,,7-Sep-20,"Sciensano, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04356586
437,NCT04386369,Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,APRV-COVID19,Completed,No Results Available,ARDS|COVID19,Other: Airway pressure release ventilation,Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV|Number of interventions on ventilator settings|Change in mean blood pressure|Change in heart rate|Changes in catecholamine doses|Changes in static compliance at the end of 6 hours of APRV|Variations of minute ventilation|Changes in static compliance 4 hours after stopping APRV|Proportion of patients with a decrease of the PaO2/FiO2 ratio,"Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,17,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020PI076,1-Jun-20,15-Apr-20,47,1-Jun-20,13-May-20,,14-Sep-20,"Centre Hospitalier RÃ©gional Universitaire de Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT04386369
438,NCT04358614,Baricitinib Therapy in COVID-19,,Completed,No Results Available,COVID|Pneumonia,Drug: Baricitinib 4 MG Oral Tablet,"To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|ICU admission rate|Discharge rate.",Fabrizio Cantini|Hospital of Prato,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HPrato-4,7-Apr-20,16-Mar-20,22,5-Apr-20,24-Apr-20,,24-Apr-20,"Fabrizio Cantini, Prato, Tuscany, Italy",,https://ClinicalTrials.gov/show/NCT04358614
439,NCT04794361,Management of Patients Suspected of COVID 19 With Ultra Low Dose Thoracic Scanner,COVID-19 ULD,Completed,No Results Available,Covid19,,reading of LD and ULD acquisitions,Centre Hospitalier Universitaire de NÄ«mes,All,"18 Years and older Â  (Adult, Older Adult)",,400,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,Local 2020/JF1,5-May-20,5-Mar-20,61,5-May-20,12-Mar-21,,12-Mar-21,"Julien FRANDON, NÃ®mes, France",,https://ClinicalTrials.gov/show/NCT04794361
440,NCT04373486,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,COVID-APE,Completed,No Results Available,Covid-19 With Positive RT-PCR,,Rate of positivity for Acute Pulmonary Embolism,"University Hospital, Strasbourg, France",All,"18 Years and older Â  (Adult, Older Adult)",,160,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,7840,1-May-20,3-Mar-20,59,30-Apr-20,4-May-20,,11-Jan-21,"Service de Radiologie B - NHC, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04373486
441,NCT04824625,Incidence of Infection Reported by COVID-19 in Attendees of a Commercial Music Concert,,Completed,No Results Available,Covid-19 (SARS-CoV-2),,Incidence rate of people with SARS-CoV-2|Incidence rate of consultations in primary care centers|Incidence rate of Hospital emergencies|Incidence rate of hospital admissions|Incidence rate of Intensive care units admissions|Incidence rate of mortality,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia|Festivals per la Cultura Segura AIE",All,"18 Years to 65 Years Â  (Adult, Older Adult)",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,StJordi-CoV,10-Apr-21,27-Mar-21,14,27-Mar-21,1-Apr-21,,19-Apr-21,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04824625
442,NCT04494984,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",,Completed,No Results Available,Covid19,Drug: INM005|Drug: Placebo,Clinical changes in COVID-19 symptoms|Pharmacokinetics evaluation of INM005|Time to progression of disease|Disease progression|Discharge|Intensive care unit (ICU) hospitalization|Mechanical ventilation assistance (MVA)|Mortality|Changes in viral load,Inmunova S.A.,All,"18 Years to 79 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,242,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT-INM005-01,30-Dec-20,27-Jul-20,156,23-Nov-20,31-Jul-20,,11-Feb-21,"Hospital de Cuenca Alta, CaÃ±uelas, Buenos Aires, Argentina|Hospital Alta Complejidad ""El Cruce"" Dr. NÃ©stor Carlos Kirchner, Florencio Varela, Buenos Aires, Argentina|Hospital Prof. Dr. Bernardo A. Houssay, Florida, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina|Hospital Municipal Emilio Zerboni, San Antonio de Areco, Buenos Aires, Argentina|Hospital Municipal Dr. Diego E. Thompson, San MartÃ­n, Buenos Aires, Argentina|Hospital Pablo Soria, San Salvador De Jujuy, Jujuy, Argentina|Hospital Provincial NeuquÃ©n ""Dr. Eduardo Castro RendÃ³n"", NeuquÃ©n, Neuquen, Argentina|Hospital Centro de Salud ZenÃ³n J. SantillÃ¡n, San Miguel De TucumÃ¡n, Tucuman, Argentina|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina|Hospital MuÃ±iz, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Pirovano, Ciudad Autonoma de Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina|ClÃ­nica Adventista Belgrano, Ciudad Autonoma de Buenos Aire, Argentina|ClÃ­nica Pasteleros, Ciudad Autonoma de Buenos Aire, Argentina|ClÃ­nica Zabala, Ciudad Autonoma de Buenos Aire, Argentina|FundaciÃ³n Favaloro, Ciudad Autonoma de Buenos Aire, Argentina|Hospital EspaÃ±ol de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina|Hospital G. A. Carlos G. Durand, Ciudad Autonoma de Buenos Aire, Argentina|Sanatorio Agote, Ciudad Autonoma de Buenos Aire, Argentina|Sanatorio Sagrado CorazÃ³n, Ciudad Autonoma de Buenos Aire, Argentina",,https://ClinicalTrials.gov/show/NCT04494984
443,NCT04543760,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,DeCOPO,Completed,No Results Available,Covid19,Other: Prone position|Other: Supine position,"[PaO2 / FiO2] ratio|Î”Peso measured using an esophageal balloon catheter|Concentration of CO2 at the end of expiration (EtCO2, mmHg)|Intensity of dyspnea|Tolerance of the technique|The occurrence of side effects due to PP","Hospital St. Joseph, Marseille, France",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,4/3/2020,14-Mar-21,1-Oct-20,164,15-Jan-21,10-Sep-20,,19-May-21,"Hopital Saint Joseph, Marseille, France",,https://ClinicalTrials.gov/show/NCT04543760
444,NCT04698083,"Electrocardiographic QRS Axis Shift ,Rotation and COVÄ°D-19",,Completed,No Results Available,Covid19,"Diagnostic Test: Electrocardiography ,Tomographic imaging","Differences in the electrocardiographic QRS axis shift(Â°),|Differences in the electrocardiographic rotation|Differences in the CO-RADS5/CO-RADS1-4 ratio",Ankara Education and Research Hospital,All,"Child, Adult, Older Adult",,160,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,22/7/2020-2152,5-Nov-20,22-Jul-20,106,15-Oct-20,6-Jan-21,,6-Jan-21,"Åžahbender KoÃ§, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04698083
445,NCT04401371,Distance Learning for Dental Student During COVID-19 Pandemic,,Completed,No Results Available,Distance Education Learning Environment During COVID 19 Pandemic,,assessment of distance education learning environment experiences among dental students enrolled in pediatric dentistry online course during COVID-19 crisis,Cairo University,All,"Child, Adult, Older Adult",,418,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Distance learning environment,10-May-20,1-May-20,9,10-May-20,26-May-20,,27-Jan-21,"Faculty of Dentistry, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04401371
446,NCT04679272,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients,ProCOVRA,Completed,No Results Available,Covid19|Rheumatoid Arthritis,,"Hospitalization rates for COVID-19|Critical care transfer rate for COVID-19 and death due to COVID-19|Pulmonary comorbidities, corticosteroids or DMARDs use|Age|Number of Participants with co-morbidities|Type of clinical presentation|Type of associated treatments","University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0682,1-Feb-21,1-Dec-20,62,30-Jan-21,22-Dec-20,,1-Mar-21,"UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04679272
447,NCT04802642,"Evaluation of COVID-19 Fear, Anxiety and Their Effects in Physiotherapy Technician Students",,Completed,No Results Available,Covid19|Anxiety and Fear,Other: Survey,Coronavirus anxiety scale|The Fear of COVID-19 Scale,Ufuk University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,80,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,4/25/2020,1-Mar-21,1-Jan-21,59,1-Mar-21,17-Mar-21,,17-Mar-21,"Ufuk University, Ankara, Ã‡ankaya, Turkey",,https://ClinicalTrials.gov/show/NCT04802642
448,NCT04784481,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,IVER-Leve,Completed,No Results Available,Covid19|SARS (Severe Acute Respiratory Syndrome),Drug: Ivermectin,Proportion test|Odd Ratio|Odd Ratio and logistic regression test,"Ministry of Public Health, Argentina",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,254,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5077-410-CH2020,18-Jan-21,20-Sep-20,120,20-Dec-20,5-Mar-21,,26-Apr-21,"SI.PRO.SA, Ministerio de Salud PÃºblica, TucumÃ¡n, Argentina",,https://ClinicalTrials.gov/show/NCT04784481
449,NCT04453670,Neuropathology in Adults Intensive Care Unit Patients With COVID 19,,Completed,No Results Available,COVID 19,Procedure: autopsy,"detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues|quantification of inflammation, necrosis and hemorrhage in different brain areas",University of Versailles,All,"18 Years and older Â  (Adult, Older Adult)",,7,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Obs2020,15-May-20,10-Mar-20,66,11-May-20,1-Jul-20,,1-Jul-20,"HÃ´pital Raymond PoincarÃ©, Garches, France",,https://ClinicalTrials.gov/show/NCT04453670
450,NCT04567810,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",,Completed,No Results Available,Covid19,Drug: anti-SARS-CoV-2 IgY|Drug: Placebo,Number of participants with treatment-related adverse events|Number of Participants With Vital Sign Findings Reported as TEAEs|Number of Participants With Clinically Significant Findings in Physical Examinations|Number of Participants With Clinically Significant Changes From Baseline in ECG Data|Number of participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters|Number of Participants with Presence of Serum anti-SARS-CoV-2 IgY,Stanford University,All,18 Years to 45 Years Â  (Adult),Phase 1,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CVR001,14-Dec-20,18-Sep-20,87,14-Dec-20,29-Sep-20,,21-Dec-20,"Linear Clinical Research - Harry Perkins Research Institute, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT04567810
451,NCT04560530,The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients,,Completed,No Results Available,Covid19,Radiation: Non-enhanced CT scan of the chest,pneumonia severity.|Aorta diameter|Pulmonary artery diameter|Pulmonary artery diameter TO Aorta diameter ratio|Description of the lesions found in the CT scan,Tanta University,All,"18 Years and older Â  (Adult, Older Adult)",,76,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,chest CT scan in COVID-19,1-Sep-20,1-Mar-20,184,30-Jul-20,23-Sep-20,,23-Sep-20,"Security Forces Hospital, Riyadh, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT04560530
452,NCT04531254,Back to School COVID-19 Simulation Study,,Completed,No Results Available,Covid19|Schools,Behavioral: Personal behaviours,Total number of hand-to-face contacts per participant per hour|Total number of hand-to-mucus membrane contacts per participant per hour|Total number of hand-to-non-mucus membrane contacts per participant per hour|Total number of instances where participants are within 1 and 2 meters of each other|Total number of glo germ transfers to another person|Total number of glo germ transfers to teacher|Total number of glo germ transfers to a surface|Total number of instances of hand holding per participant per hour|Total number of touches to another person per participant per hour|Total number of hand hygiene actions per participant per hour|Total number of mask removals per participant per hour|Teacher concerns measured using study-specific post-simulation questionnaire|Teacher concerns measured using semi-structured group interviews|Student concerns measured using study-specific post-simulation questionnaire|Student concerns measured using semi-structured group interviews|Identify activity types that influence touching behaviour,The Hospital for Sick Children,All,"4 Years to 18 Years Â  (Child, Adult)",,190,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1000071861,31-Aug-20,10-Aug-20,21,31-Aug-20,28-Aug-20,,8-Mar-21,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04531254
453,NCT04878900,Effects of COVID-19 in Chronic Pain,,Completed,No Results Available,Chronic Pain|Covid19,Other: Survey,General pain severity and global well-being assesment with the visual analog scale (VAS).|Perceived Stress Scale (PSS)|Pittsburgh Sleep Quality Index (PSQI)|Nottingham Health Profile (NHP),Ufuk University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,3/16/2020,1-Mar-21,1-Jan-21,59,1-Mar-21,10-May-21,,10-May-21,"Ufuk University, Ankara, Ã‡ankaya, Turkey",,https://ClinicalTrials.gov/show/NCT04878900
454,NCT04579393,Fostamatinib for Hospitalized Adults With COVID-19,,Completed,No Results Available,Coronavirus Disease 2019,Drug: Placebo|Drug: fostamatinib,"Cumulative Incidence of SAEs|Number of days in the ICU|Change in CRP, IL-6, d-dimer, ferritin, fibrinogen, absolute lymphocyte count, absolute neutrophil count, and platelet count from baseline|Ordinal scale|Days of hospitalization|Time to recovery|Number of days free of mechanical ventilation [entire hospitalization cohort 1]|Number of days on oxygen|Change in SOFA score from baseline|Days free of renal failure|Clinically relevant deep vein thrombosis|Relative change in PaO2/FiO2 or SpO2/FiO2 ratio","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,62,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",10000110|000110-H,3-May-21,8-Oct-20,207,15-Dec-20,8-Oct-20,,13-May-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States|INOVA Health Systems, Falls Church, Virginia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04579393/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04579393
455,NCT04794400,The Application of an Oxygen Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,,Completed,No Results Available,Covid19,Other: oxygen mask,Oxygenation|Carbon dioxide|SpO2|Respiratory rate,Region Skane,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2020-07078,31-Mar-21,4-Feb-21,55,31-Mar-21,12-Mar-21,,14-May-21,"SkÃ¥ne University Hospital, MalmÃ¶, SkÃ¥ne, Sweden",,https://ClinicalTrials.gov/show/NCT04794400
456,NCT04532294,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",,Completed,No Results Available,Covid19,Drug: BGB DXP593|Drug: Placebo,Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)|Number of participants experiencing Serious Adverse Events (SAEs)|Maximum observed plasma concentration (Cmax) of BGB-DXP593|Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUCt) of BGB-DXP593|AUC from time zero to infinity (AUCinf) of BGB-DXP593|AUC from time zero to Day 29 (AUC0-29) of BGB-DXP593|Time to maximum observed plasma concentration (tmax) of BGB-DXP593|Terminal half life (t1/2) of BGB-DXP593|Clearance (CL) of BGB-DXP593|Volume of distribution (Vz) of BGB-DXP593|Immunogenic response to BGB-DXP593 as assessed by the Detection of antidrug antibodies (ADA),BeiGene,All,18 Years to 60 Years Â  (Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",BGB-DXP593-101,13-Feb-21,8-Sep-20,158,15-Jan-21,31-Aug-20,,18-May-21,"Q Pharm Pty Limited, Herston, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT04532294
457,NCT04445376,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,,Completed,No Results Available,Covid19,Other: Physical Exercises,6 minute walk test|Modified Borg Dyspnea Scale|SF-36 QUESTIONNAIRE,Government College University Faisalabad,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,313,3-Oct-20,3-Jul-20,92,10-Sep-20,24-Jun-20,,8-Oct-20,"Bin Inam Rehabilitation Center., FaisalÄbad, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04445376
458,NCT04583189,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,,Completed,No Results Available,Covid19,Diagnostic Test: Performance of the test antigenic and test RT-PCR,"Comparison of the performance of the Biosynex Covid-19 Ag BSS rapid antigenic test against the RT-PCR Covid-19 reference test with the AllplexTM 2019-nCoV kit (Seegene, South Korea) in children with symptoms consistent with Covid19 infection|Sensitivity of the Biosynex Covid-19 Ag BSS rapid antigenic test compared to the RT-PCR Covid-19 reference test performed with the AllplexTM 2019-nCoV kit in children.|Comparison of the time it takes to report results between the two methods",Centre Hospitalier Intercommunal Creteil,All,"up to 18 Years Â  (Child, Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SPEEDYCOVI,25-Nov-20,1-Oct-20,55,25-Nov-20,12-Oct-20,,2-Dec-20,"Centre hospitalier intercommunal de CrÃ©teil, CrÃ©teil, France|Cabinet de ville, Nogent sur Marne, France|Cabinet Dr Cohen, Saint-Maur-des-FossÃ©s, France|Cabinet de ville 13 Villa BeausÃ©jour, Vincennes, France",,https://ClinicalTrials.gov/show/NCT04583189
459,NCT04354610,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Nancy-CovH-AKI,Completed,No Results Available,COVID 19,Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up,"Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital","Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020PI072,26-Mar-21,27-Apr-20,333,19-Dec-20,21-Apr-20,,12-May-21,"CHRU de Nancy, Nancy, France|CHRU de Nancy, VandÅ“uvre-lÃ¨s-Nancy, France",,https://ClinicalTrials.gov/show/NCT04354610
460,NCT04371471,Covid-19 Pandemic Triage Score,STC-19,Completed,No Results Available,Sars-CoV2|Covid19,Diagnostic Test: STC-19 score,STC-19 score,Groupe Hospitalier de la Rochelle RÃ© Aunis|Numa Health International,All,"18 Years and older Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020/P04/288,30-Apr-20,1-Mar-20,60,30-Apr-20,1-May-20,,25-Jun-20,"Groupe Hospitalier de la Rochelle RÃ© Aunis, La Rochelle, France",,https://ClinicalTrials.gov/show/NCT04371471
461,NCT04375644,Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),COVIDPROIMPACT,Completed,No Results Available,"Covid 19|Stress, Psychological",Other: Questionnaires on psychological quality of life,"Stress state score, during the confinement period",Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,1565,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,69HCL20_0413,15-Jul-20,7-May-20,69,15-Jul-20,5-May-20,,21-Dec-20,"GynÃ©cologie-ObstÃ©trique CHU de Angers, Angers, France|GynÃ©cologie-ObstÃ©trique HÃ´pital Pellegrin, Bordeaux, France|GynÃ©cologie-ObstÃ©trique CHRU de Brest, Brest, France|Gynaecology Department, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France|GynÃ©cologie-ObstÃ©trique HÃ´pital Antoine BÃ©clÃ¨re (APHP), Clamart, France|GynÃ©cologie-ObstÃ©trique CHU Grenoble-Alpes, HÃ´pital Couple Enfant, La Tronche, France|GynÃ©cologie-ObstÃ©trique HÃ´pital BICETRE (APHP), Le Kremlin-BicÃªtre, France|GynÃ©cologie-ObstÃ©trique HÃ´pital Jeanne de Flandre - CHRU Lille, Lille, France|GynÃ©cologie-ObstÃ©trique HÃ´pital de la MÃ¨re et de l'Enfant, Limoges, France|GynÃ©cologie-ObstÃ©trique HÃ´pital de la Croix Rousse, Lyon, France|GynÃ©cologie-ObstÃ©trique HÃ´pital La Conception, Marseille, France|GynÃ©cologie-ObstÃ©trique HÃ´pital de la PitiÃ© SalpÃªtriÃ¨re (APHP), Paris, France|GynÃ©cologie-ObstÃ©trique MaternitÃ© Port-Royal, Groupe Hospitalier Cochin-Broca- Hotel Dieu (APHP), Paris, France|GynÃ©cologie-ObstÃ©trique CHU de Poitiers, Poitiers, France|GynÃ©cologie-ObstÃ©trique CHU Reims - Institut MÃ¨re Enfant Alix de Champagne, Reims, France|GynÃ©cologie-ObstÃ©trique CHU de Rennes, Rennes, France|GynÃ©cologie-ObstÃ©trique CHU de Saint Etienne, Saint-Ã‰tienne, France|GynÃ©cologie-ObstÃ©trique HÃ´pital de Hautepierre, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04375644
462,NCT04522830,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,BTL-TML-COVID,Completed,No Results Available,SARS-CoV-2 Infection,Drug: BTL-TML-COVID|Drug: Placebo,Mean duration and severity of disease|Incidence/Safety of Adverse Events,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.|Curavit Clinical Research",All,"40 Years and older Â  (Adult, Older Adult)",Phase 2,28,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-04-0311,28-Feb-21,30-Jul-20,213,28-Feb-21,21-Aug-20,,13-Apr-21,"Intermountain Clinical Reserach, Draper, Utah, United States",,https://ClinicalTrials.gov/show/NCT04522830
463,NCT04479202,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,BOIFIM,Completed,No Results Available,Berberine|COVID-19,Drug: Berberine|Drug: Montmorrillonite,Changes in diarrhea frequency and Bristol Stool Scale|IL-6 (ng/ml)|IL-10ï¼ˆng/mlï¼‰|IL-1Î² (ng/ml)|TNF-Î± (pg/ml)|leukocyte count (10^9/l)|c reactive protein (mg/l)|procalcitonin (ng/ml),Chinese Medical Association,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 4,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Berberine treats COVID-19|XJ2020005101,23-Apr-20,8-Feb-20,75,18-Apr-20,21-Jul-20,,21-Jul-20,"Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04479202
464,NCT04712045,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,RUPERT,Completed,No Results Available,Covid19|Personal Protective Equipment,Other: New PPE|Other: Old PPE,Proportion of participants and simulated patients with contamination as assessed by ultraviolet light|Participants' perception of personal comfort and safety and safety of the patients as assessed through structured questionnaire|changes in participants perception of personal comfort and safety and safety of patients as assessed through a semi-structured questionnaire|The difference in the area of contamination between New and Standard PPE as analyzed through python script,University of Oxford,All,"Child, Adult, Older Adult",Not Applicable,67,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRAS287865,12-Dec-20,1-Aug-20,133,12-Dec-20,15-Jan-21,,15-Jan-21,"Professor Peter McCulloch, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04712045
465,NCT04663659,The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19,,Completed,No Results Available,Covid19|Diabetes Mellitus,Other: no intervention,Mortality|length of stay in intensive care,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,1559,15-May-20,15-Mar-20,61,15-May-20,11-Dec-20,,14-Dec-20,"SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04663659
466,NCT04573335,Diabetes Outcomes in COVID-19 Pandemic,,Completed,No Results Available,"Diabetes|Covid19|Isolation, Social",,All-cause mortality|COVID-19 illness,"Services Institute of Medical Sciences, Pakistan",All,"18 Years to 70 Years Â  (Adult, Older Adult)",,1282,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,16102019,30-Jul-20,1-Jun-20,59,15-Jul-20,5-Oct-20,,5-Oct-20,"Services Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04573335
467,NCT04405973,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,,Completed,No Results Available,COVID-19|SARS-CoV 2|Extracorporeal Membrane Oxygenation|ARDS,Device: vv-ECMO,overall survival|duration of ECMO treatment|duration of ventilation treatment|duration of initiation of ECMO treatment to ICU discharge,Dr. Alexander Supady|University Hospital Freiburg,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,133,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,EK-FR 329/20,30-Sep-20,19-May-20,134,30-Sep-20,28-May-20,,4-Nov-20,"University Clinic Freiburg, Freiburg, Germany",,https://ClinicalTrials.gov/show/NCT04405973
468,NCT04593654,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients,,Completed,No Results Available,Covid19|Thromboembolism,Drug: Dose of tinzaparin or dalteparin,28-day mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission|90-day mortality,Karolinska Institutet,All,"Child, Adult, Older Adult",,257,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Thromboprophylaxis COVID-19,15-Oct-20,1-Mar-20,228,15-Aug-20,20-Oct-20,,20-Oct-20,"SÃ¶dersjukhuset, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT04593654
469,NCT04573270,Mesenchymal Stem Cells for the Treatment of COVID-19,,Completed,No Results Available,Covid19|Prophylaxis,Biological: PrimePro|Other: Placebo,Survival Rates|Contraction Rates,Thomas Advanced Medical LLC|HeartStem Institute,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Pro00043080,1-Sep-20,24-Apr-20,130,20-Aug-20,5-Oct-20,,5-Oct-20,"Southern California Hospital at Culver City / Southern California Hospital at Hollywood, Culver City, California, United States",,https://ClinicalTrials.gov/show/NCT04573270
470,NCT04475562,Can the Electronic Nose Smell COVID-19?,,Completed,No Results Available,SARS-CoV Infection|Covid19,Device: Aeonose,COVID 19 positive vs negative,Maastricht University Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,219,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,eNoseCOVID,1-Jul-20,6-Apr-20,86,6-May-20,17-Jul-20,,17-Jul-20,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT04475562
471,NCT04526405,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,ThalaCoV,Completed,No Results Available,Thalassemia Major|Covid19,Diagnostic Test: SARS-CoV-2 S1/S2 IgG,Positive subjects,University of Milano Bicocca,All,"18 Years and older Â  (Adult, Older Adult)",,63,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ThalaCoV,3-Nov-20,14-Jul-20,112,3-Nov-20,25-Aug-20,,9-Nov-20,"ASST Monza - Ospedale San Gerardo, Monza, MB, Italy",,https://ClinicalTrials.gov/show/NCT04526405
472,NCT04550325,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",,Completed,No Results Available,"Covid19|Pneumonia, Viral",Biological: Kamada Anti-SARS-CoV-2,"Adverse events, serious adverse events, and deaths|AUC0-7 of Anti SARS CoV-2 antibodies|Neutralization activity","Kamada, Ltd.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Kamada Anti-SARS-CoV-2-001,26-Nov-20,5-Aug-20,113,26-Nov-20,16-Sep-20,,5-Jan-21,"Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel|Kaplan Medical Center, Reáº–ovot, Israel",,https://ClinicalTrials.gov/show/NCT04550325
473,NCT04337320,"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",,Completed,No Results Available,Covid19|Maternal-Fetal Relations,Other: newborns from covid 19 positive mothers,Evaluation of apgar status of newborns from covid 19 positive mothers,Kanuni Sultan Suleyman Training and Research Hospital|Seda Yilmaz Semerci,All,up to 15 Minutes Â  (Child),,40,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,covid19pregnancynewborn,30-May-20,15-Mar-20,76,25-May-20,7-Apr-20,,11-Jun-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04337320
474,NCT04758299,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,,Completed,No Results Available,COVID-19 Testing|Decision Making,Other: decision science-based design,choice of action to take with negative test|Likelihood of COVID-19 infection (qualitative)|Likelihood of COVID-19 infection (quantitative)|safe practices|ease of use of information rating|usefulness of information rating|helpfulness of information for what to do given positive test result|helpfulness of information for what to do given negative test result|Assess effect of the FDA authorized description of test accuracy,Barry Dewitt|Dartmouth College|University of Pittsburgh|Carnegie Mellon University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other,STUDY2020_501,30-Apr-21,13-Mar-21,48,15-Apr-21,17-Feb-21,,25-May-21,"Carnegie Mellon University, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04758299
475,NCT04514874,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,CovaÃ©,Completed,No Results Available,Covid19|SARS-CoV Infection,Other: Questionnaire,Prevalence of COVID-19 infection among French military professional aircrew|Predictive factors of COVID-19 infection|Techniques used for COVID-19 screening|Reasons for COVID-19 screening|Experienced symptoms of COVID-19|Medical care of COVID-19|Social consequences of the COVID-19 pandemic|Factors associated with pejorative consequences of the COVID-19 pandemic,Direction Centrale du Service de SantÃ© des ArmÃ©es,All,"18 Years and older Â  (Adult, Older Adult)",,479,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-COVID19-26|2020-A01459-30,5-Oct-20,1-Sep-20,34,5-Oct-20,17-Aug-20,,9-Mar-21,"Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'HÃ´pital d'Instruction des ArmÃ©es Percy, Clamart, France|Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'HÃ´pital d'Instruction des ArmÃ©es Sainte-Anne, Toulon, France",,https://ClinicalTrials.gov/show/NCT04514874
476,NCT04394000,Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,,Completed,No Results Available,COVID19|Thromboembolism,Other: thromboprofylaxis protocol|Other: standard protocol,2 week mortality|incidence of venous thromboembolism|1 week mortality|3 week mortality|1 month mortality|incidence of kidney failure|incidence of continuous renal replacement therapy (CRRT)|lowest PaO2/FiO2 (P/F) ratio|highest Sequential Organ Failure Assessment (SOFA) score|length of stay|highest bilirubin|highest ( AST|highest Aspartaat-Amino-Transferase (ALT),Jessa Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,72,Other,Observational,Observational Model: Cohort|Time Perspective: Other,Jessa_20.48,15-May-20,4-May-20,11,15-May-20,19-May-20,,19-May-20,"Jessa hospital, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT04394000
477,NCT04374123,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,,Completed,No Results Available,COVID,Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19,Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days,Instituto Ecuatoriano de Enfermedades Digestivas,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,111,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IECED-04-15-covid,15-Jun-20,20-Apr-20,56,20-May-20,5-May-20,,28-Jul-20,"Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador",,https://ClinicalTrials.gov/show/NCT04374123
478,NCT04479124,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,,Completed,No Results Available,Trauma|Covid19,Diagnostic Test: COVID-19 PCR,trauma admissions,Kanuni Sultan Suleyman Training and Research Hospital,All,"up to 50 Years Â  (Child, Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,KSSTHR-TPED,14-Jul-20,10-Mar-20,126,30-Jun-20,21-Jul-20,,21-Jul-20,"Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey",,https://ClinicalTrials.gov/show/NCT04479124
479,NCT04483375,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",,Completed,No Results Available,Coronavirus Disease 2019(COVID-19),Biological: SCTA01|Other: Placebo,Dose-limiting toxicity(DLT)|Maximal Tolerable Dose(MTD)|AUC0-t|AUC0-âˆž|t1/2|Tmax|Anti-drug antibody(ADA)|Adverse events,Sinocelltech Ltd.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SCTA01-X101,17-Nov-20,24-Jul-20,116,17-Nov-20,23-Jul-20,,23-Mar-21,"Beijing SHIJITAN Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04483375
480,NCT04542044,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,PneumoCoV-Ambu,Completed,No Results Available,Covid19|Pneumonia,Other: management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia,Secondary hospitalization(s) or death COVID-19 related|severity of COVID-19 disease|patient satisfaction with management strategies|Saved costs,"University Hospital, Geneva",All,"18 Years to 99 Years Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CCER2020-01518,30-Jun-20,2-Apr-20,89,5-May-20,9-Sep-20,,9-Sep-20,"Geneva University Hospital, Geneva, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04542044/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04542044
481,NCT04659772,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,,Completed,No Results Available,Covid19|Respiratory Failure,Drug: Clazakizumab|Drug: Placebo,Adverse Events,Ayan Sen|Mayo Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,1,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-008170,1-Feb-21,3-Dec-20,60,1-Feb-21,9-Dec-20,,3-Mar-21,"Mayo Clinic in Arizona, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04659772
482,NCT04357431,COVID-19 Among Egyptian Health Care Providers,,Completed,No Results Available,COVID,Other: self-administered questionnaire,The percentage of knowledge regarding COVID-19 information,Assiut University,All,"Child, Adult, Older Adult",,565,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,COVIDQ,30-May-20,22-Apr-20,38,26-May-20,22-Apr-20,,7-Jul-20,"Ahmed Abbas, Assiut, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04357431
483,NCT04629989,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,,Completed,No Results Available,Covid19|Hypoxemia,Other: Standard Oxygen Delivery System|Other: Double-Trunk Mask|Other: Surgical Mask,Changes in PaO2|Change in PaCO2|Change in pH|Change in respiratory rate|Change in dyspnea|Change in O2 output,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,DTM-003,5-Mar-21,13-Nov-20,112,5-Mar-21,16-Nov-20,,9-Mar-21,"Cliniques universitaires Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04629989
484,NCT04322188,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,SISCO,Completed,No Results Available,Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection,,mortality in siltuximab treated patients|the need of invasive ventilation in siltuximab patients Reduction of the need of time of ventilatory support|clinical course of patients treated with siltuximab Percentage of patients that undergo to tracheostomy|Safety Improvement of the lung function assessed by radiologic findings|the effect on inflammatory parameters|Correlation of outcomes with IL-6 levels,A.O. Ospedale Papa Giovanni XXIII,All,"18 Years and older Â  (Adult, Older Adult)",,220,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,v 2 22nd April 2020,8-May-20,19-Mar-20,50,8-May-20,26-Mar-20,,1-Jun-20,"ASST - Papa Giovanni XXIII, Bergamo, Italy",,https://ClinicalTrials.gov/show/NCT04322188
485,NCT04409249,Prognosis in Pregnant With COVID-19,,Completed,No Results Available,COVID-19|Prognostic Factors|Pregnancy,"Diagnostic Test: imaging, blood tests",the factors affecting prognosis in pregnant women diagnosed with COVID-19,Kanuni Sultan Suleyman Training and Research Hospital,Female,18 Years to 45 Years Â  (Adult),,155,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,Mtalmacprognosis,28-May-20,15-Mar-20,74,25-May-20,1-Jun-20,,2-Jul-20,"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",,https://ClinicalTrials.gov/show/NCT04409249
486,NCT04349410,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,FMTVDM,Completed,No Results Available,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status,The Camelot Foundation,All,"Child, Adult, Older Adult",Phase 2|Phase 3,1800,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FMTVDM2020,14-Sep-20,11-Apr-20,156,14-Sep-20,16-Apr-20,,12-Nov-20,"FHHI-OI-Camelot; QME, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan: Study Protocol with Statistical Analysis"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04349410
487,NCT04370249,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,VIRUS,Completed,No Results Available,Acute Respiratory Distress Syndrome|COVID-19,Other: pulmonary ultrasound,"Construction of a composite clinical-echo score (VIRUScore) predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department|Evaluate the prognostic performance of the VIRUScore on the risk of pulmonary aggravation|Evaluate the prognostic performance of the VIRUScore on the risk of severe pulmonary aggravation defined by resuscitation admission and/or death at D14 (sensitivity, specificity, positive predictive value, negative predictive value).|Construction of a decisional algorithm for triage and management of COVID-19 patients.|Search for ""ultrasound signature"" (lung fields and/or severity of involvement) associated with mild (return home) vs. moderate (oxygen therapy) vs. severe (resuscitation/death) clinical forms.|Evaluate the analytical concordance between the pulmonary ultrasound (LUScore) and the Gold-standard CT-scan (CT score)|Construction of a score predictive of aggravation in the sub-population of patients returned home",Nantes University Hospital|WINFOCUS-France,All,"18 Years and older Â  (Adult, Older Adult)",,313,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,RC20_0164,31-Aug-20,9-Apr-20,144,31-Aug-20,30-Apr-20,,24-Feb-21,"Chu de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT04370249
488,NCT04475575,Can the Electronic Nose Smell COVID-19 Antibodies?,,Completed,No Results Available,SARS-CoV Infection|Covid19,Device: Aeonose,COVID-19 antibodies vs COVID-19 negative,Maastricht University Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,222,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,eNoseCOVIDantibodies,1-Jul-20,6-Apr-20,86,30-Jun-20,17-Jul-20,,17-Jul-20,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT04475575
489,NCT04383587,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,,Completed,No Results Available,SARS-CoV 2|COVID-19,Other: Serologic testing,Prevalence of COVID19 Antibody Positivity|Ability to predict immune status/antibody positivity,Mayo Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20-004054,31-Jul-20,6-May-20,86,1-Jul-20,12-May-20,,1-Sep-20,"Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04383587
490,NCT04516928,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,SeroCovEms,Completed,No Results Available,SARS-CoV Infection|Covid19,Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire,Proportion of anti-SARS-CoV2 seropositive participants|Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants)|Correlation coefficient between medical risk factors and a positive serology|Correlation coefficient between epidemiological risk factors and a positive serology|Correlation coefficient between social risk factors and a positive serology,Direction Centrale du Service de SantÃ© des ArmÃ©es,All,"18 Years and older Â  (Adult, Older Adult)",,392,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-COVID19-29|2020-A02125-34,25-Sep-20,21-Sep-20,4,25-Sep-20,18-Aug-20,,9-Mar-21,"Antenne MÃ©dicale des Ecoles Militaires de SantÃ© de Lyon-Bron (EMSLB), Bron, France",,https://ClinicalTrials.gov/show/NCT04516928
491,NCT04479137,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,,Completed,No Results Available,"Covid-19|Risk Factor, Mortality",Diagnostic Test: PCR for COVID-19,mortality based on COVID-19,Kanuni Sultan Suleyman Training and Research Hospital,All,18 Years to 50 Years Â  (Adult),,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,KSSEAH--PPC,14-Jul-20,10-Mar-20,126,30-Jun-20,21-Jul-20,,22-Jul-20,"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04479137
492,NCT04720235,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,,Completed,No Results Available,Covid19|Corona Virus Infection,Device: Lucira COVID-19 All-In-One test kit,COVID-19 Prevalence Rate / Expected Values counts|COVID-19 Prevalence Rate / Expected Values percentages|Collection Performance/ Incidence Rate counts|Collection Performance/ Incidence Rate percentages|Sensitivity and specificity,Lucira Health Inc,All,"14 Years to 75 Years Â  (Child, Adult, Older Adult)",Not Applicable,304,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,07A-CLI-007,30-Mar-21,9-Dec-20,111,9-Mar-21,22-Jan-21,,12-Apr-21,"Neeraj Kochhar Family Medicine, Los Gatos, California, United States",,https://ClinicalTrials.gov/show/NCT04720235
493,NCT04422561,Prophylactic Ivermectin in COVID-19 Contacts,,Completed,Has Results,COVID,Drug: Ivermectin Tablets,"Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID",Zagazig University,All,"16 Years to 70 Years Â  (Child, Adult, Older Adult)",Phase 2|Phase 3,340,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ZU-IRB#6150/31-5-2020,27-Jul-20,31-May-20,57,14-Jul-20,9-Jun-20,27-Aug-20,27-Aug-20,"Zagazig University, Zagazig, Sharkia, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04422561
494,NCT04844710,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,,Completed,No Results Available,Acupuncture|Covid19,Combination Product: acupuncture and standard care|Drug: standard care,Changes of percentage of lymphocyte count|Changes of Erythrocyte sedimentation rate|Changes of Ferritin level|Changes of C-Reactive Protein level|Clinical changes,Indonesia University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KET-845/UN2.F1/ ETIK/PPM.2020,20-Nov-20,1-Sep-20,80,15-Nov-20,14-Apr-21,,14-Apr-21,"Medical Acupuncture Department FKUI-RSCM, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04844710
495,NCT04647305,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,COVPROSHIELD,Completed,No Results Available,SARS-CoV-2 Infection,Other: Closed face shield with Surgical face mask use|Other: Surgical face mask use only,COVID-19 incidence|Adherence to closed face shields use|Percentage of participants with a positive serological test at baseline|Percentage of seroconversion in the experimental group and active control group,"University of Los Andes, Columbia|United Nations",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,233,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1010166518,4-Mar-21,16-Jan-21,47,4-Mar-21,30-Nov-20,,27-Apr-21,"Universidad de los Andes, BogotÃ¡, Colombia",,https://ClinicalTrials.gov/show/NCT04647305
496,NCT04429529,"Safety of TY027, a Treatment for COVID-19, in Humans",,Completed,No Results Available,Coronavirus Disease-2019 (COVID-19),Biological: TY027|Other: 0.9% Saline,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-âˆž) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment,Tychan Pte Ltd.,All,21 Years to 50 Years Â  (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SCT-001,20-Jan-21,9-Jun-20,225,19-Nov-20,12-Jun-20,,8-Apr-21,"SingHealth Investigational Medicine Unit, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04429529
497,NCT04780373,Prognostic Score in Covid-19,,Completed,No Results Available,Covid19 Prognostic Parameters,Other: data collection,Data collection of clinical and demographical parameters of patients affected by COVID-19|Application of statistical analysis on data of patients affected by COVID-19,University of L'Aquila,All,"18 Years and older Â  (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,prot. N. 71726,1-Dec-20,1-Apr-20,244,1-Dec-20,3-Mar-21,,29-Apr-21,"University of L'Aquila, L'Aquila, Italy",,https://ClinicalTrials.gov/show/NCT04780373
498,NCT04328961,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),,Completed,No Results Available,COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2,Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid,Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,829,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",STUDY00009750|INV-016204,8-Oct-20,31-Mar-20,191,24-Sep-20,1-Apr-20,,29-Oct-20,"University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04328961
499,NCT04542213,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Covid19DPP4i,Completed,No Results Available,Hyperglycemia|Covid19,Drug: Linagliptin tablet|Drug: Insulin,Glucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levels,Hospital Regional de Alta Especialidad del Bajio,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CEI-22-2020,28-Feb-21,1-Aug-20,211,28-Feb-21,9-Sep-20,,23-Mar-21,"Hospital Regional de Alta Especialidad del BajÃ¬o, LeÃ²n, Guanajuato, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04542213/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04542213
500,NCT04745442,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,,Completed,No Results Available,Covid19|Severe Acute Respiratory Syndrome|Distress Respiratory Syndrome,Drug: Antithrombin + best available treatment|Drug: Best available treatment,"Combined variable: mortality or worsening rate with need for non-invasive mechanical ventilation or with need for invasive mechanical ventilation|Time to clinical improvement (decreased risk of developing SARS or death)|Evaluate the improvement of the oxygenation index - PaO2 / FiO2- at 24 and 48 hours.|Improvement of the analytical parameters: time (in days) until the tendency to normalization (decrease >= 20%) of DD, ferritin, LDH, PCR and IL-6; the criteria reached before will be used.|Time (in days) until improvement in oxygenation: - Time until the SpO2 / FiO2 ratio exceeds the worst SpO2 / FiO2 prior to AT treatment.|Time to radiological improvement in radiological report.|Time (in days) of non-invasive mechanical ventilation.|Time (in days) of invasive mechanical ventilation.|Mortality rate in hospital and one month after pharmacological intervention.|Percentage of patients who suffer any adverse effect related to pharmacological intervention.|Incidence of adverse events related to medication and its administration.|Incidence in the appearance of allergic type hypersensitivity|Incidence of B19 parvovirus infection|Bleeding",MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANTITROMBINA,15-Jan-21,27-Apr-20,263,20-Dec-20,9-Feb-21,,9-Feb-21,"Hospital Universitario Reina SofÃ­a, CÃ³rdoba, Spain",,https://ClinicalTrials.gov/show/NCT04745442
501,NCT04729075,"Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset",NorthCARDS,Completed,No Results Available,"ARDS, Human|Covid19",Other: ARDS and COVID19 treatments,Index Hospital Survival|Time to Mechanical Ventilator Liberation|Hospital Readmission,Northwell Health|BioSymetrics|Feinstein Institute for Medical Research,All,"Child, Adult, Older Adult",,1800,Other,Observational,Observational Model: Cohort|Time Perspective: Other,19-0598,19-Jan-21,19-Jan-21,0,19-Jan-21,28-Jan-21,,28-Jan-21,"Feinstein Institutes for Medical Research, Manhasset, New York, United States",,https://ClinicalTrials.gov/show/NCT04729075
502,NCT04374149,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,,Completed,No Results Available,Cytokine Release Syndrome|COVID19,Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib,Overall Response Rate,Prisma Health-Upstate,All,"12 Years to 80 Years Â  (Child, Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHU COVID-19-001,1-Dec-20,30-Apr-20,215,30-Sep-20,5-May-20,,25-Mar-21,"Prisma Health, Greenville, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04374149
503,NCT04840953,"Negative Pressure Therapy, Minimally Invasive and Accessible Technique in the Treatment of Massive Subcutaneous Emphysema in COVID-19 or Non Infected Critical Patients",,Completed,No Results Available,Subcutaneous Emphysema|Covid19,Device: VÃ§ac,Resolution time of emphysema with negative pressure therapy,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,All,"Child, Adult, Older Adult",,2,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ENFIVAC,1-Feb-21,1-Dec-20,62,1-Jan-21,12-Apr-21,,12-Apr-21,"Hospital General Universitario de Elche, Elche, Alicante, Spain",,https://ClinicalTrials.gov/show/NCT04840953
504,NCT04441489,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,,Completed,No Results Available,COVID-19|FDG PET/CT|Inflammation,,Primary endpoint,Centre Hospitalier Princesse Grace,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,13,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PET-COVID,27-May-20,27-Mar-20,61,3-May-20,22-Jun-20,,22-Jun-20,"Centre Hospitalier Princesse Grace, Monaco, Monaco",,https://ClinicalTrials.gov/show/NCT04441489
505,NCT04338945,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,,Completed,No Results Available,COVID,Behavioral: COVID-surgRES questionaire,Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,All,"18 Years and older Â  (Adult, Older Adult)",,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-ItaliansurgRES-SPIGC,1-May-20,15-Mar-20,47,15-Apr-20,8-Apr-20,,27-Jul-20,"U.O.C. Chirurgia Generale Universitaria ""V. Bonomo"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, UniversitÃ  di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04338945
506,NCT04383678,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,,Completed,No Results Available,COVID-19|Extracorporeal Membrane Oxygenation Complication|Acute Respiratory Distress Syndrome,Device: Extracorporeal membrane oxygenation,In-hospital mortality|Death on ECMO|Stroke|Blood stream infection|Lung complications requiring surgical treatment|Blood transfusion|Acute kidney injury|Duration of mechanical ventilation|Deep vein thrombosis|Pulmonary embolism|Length of intensive care unit stay|Length of hospital stay|Death after hospital discharge,Helsinki University Central Hospital,All,"Child, Adult, Older Adult",,132,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,COVID-19 ECMO,1-Apr-21,1-Mar-20,396,1-Apr-21,12-May-20,,20-Apr-21,"Helsinki University Hospital, Helsinki, Finland|University Hospital Jean Minjoz, BesanÃ§on, France|Nancy University Hospital, Nancy, France|Henri Mondon Unoversity Hospital, Paris, France|Robert DebrÃ© University Hospital, Reims, France|Hamburg University Heart Center, Hamburg, Germany|MÃ¼nster University Hospital, MÃ¼nster, Germany|S. Orsola Hospital, Bologna, Italy|Lecco Hospital, Lecco, Italy|Karolinska University Hospital, Stockholm, Sweden|University Hospitals of Leicester, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04383678
507,NCT04385810,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,DOCOV,Completed,No Results Available,Covid19|Sars-CoV2,Procedure: Ophthalmologic exam,Describe ophthalmologic damage to the cornea with direct exam at day 0|Describe ophthalmologic damage to the cornea with direct exam at day 7|Describe ophthalmologic damage to the cornea with direct exam at day 14|Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital|Describe ophthalmologic damage to the cornea with slit lamp exam at day 0|Describe ophthalmologic damage to the cornea with slit lamp exam at day 7|Describe ophthalmologic damage to the cornea with slit lamp exam at day 14|Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital|Describe tear film anomalies at day 0|Describe tear film anomalies at day 7|Describe tear film anomalies at day 14|Describe tear film anomalies at discharge of hospital|Describe ophthalmologic damage to the retina at day 0|Describe ophthalmologic damage to the retina at day 7|Describe ophthalmologic damage to the retina at day 14|Describe ophthalmologic damage to the retina at discharge of hospital|Describe ophthalmologic damage to the optic nerve at day 0|Describe ophthalmologic damage to the optic nerve at day 7|Describe ophthalmologic damage to the optic nerve at day 14|Describe ophthalmologic damage to the optic nerve at discharge of hospital,Fondation Ophtalmologique Adolphe de Rothschild,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,23,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,JDS_2020_13,29-Jul-20,27-Apr-20,93,29-Jul-20,13-May-20,,16-Nov-20,"Fondation Adolphe de Rothschild, Paris, France",,https://ClinicalTrials.gov/show/NCT04385810
508,NCT04493268,HYPONATREMIA IN COVID-19 PATIENTS,,Completed,No Results Available,Hyponatremia|Covid19|Corona Virus Infection,,MORTALITY|ICU HOSPITALIZATION,Hospital Nacional Profesor Alejandro Posadas,All,"1 Month to 100 Years Â  (Child, Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HYPONATREMIA IN COVID PATIENTS,21-Jul-20,7-Mar-20,136,20-Jul-20,30-Jul-20,,30-Jul-20,"Hospital Posadas, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04493268
509,NCT04480580,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,,Completed,No Results Available,Covid19|Surgery|SARS (Severe Acute Respiratory Syndrome),Diagnostic Test: SARS-CoV-2 Ab,Seroprevalence of SARS-CoV-2,University of Cagliari,All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,COVID-SURG,30-Jun-20,30-Mar-20,92,30-Apr-20,21-Jul-20,,21-Jul-20,"AOU Cagliari, Cagliari, CA, Italy",,https://ClinicalTrials.gov/show/NCT04480580
510,NCT04498936,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,,Completed,No Results Available,COVID,Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide,Change of PCR from positive to negative|Clinical improvement|Adverse events,Assiut University|Helwan University,All,"12 Years to 65 Years Â  (Child, Adult, Older Adult)",Phase 4,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19 treatment,30-Oct-20,15-Jul-20,107,30-Oct-20,5-Aug-20,,12-Nov-20,"15th May Hospital, Helwan, Cairo, Egypt|Assiut University Hospital, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04498936
511,NCT04819165,Healthcare-associated Infections in Severe COVID-19 During 2020,COVIACS,Completed,No Results Available,"Respiration, Artificial|COVID-19|Health Care Associated Infection",Other: COVID-19,Incidence of health care associated infections in each group.|The most frequent pathogens in this population associated with Incidence of health care associated infections.|Possible factors associated with Incidence of health care associated infections.|mortality in UCI|Days of ICU stay|Days of mechanical ventilation,Sanatorio Anchorena San Martin,All,"18 Years and older Â  (Adult, Older Adult)",,252,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,21-May,31-Jan-21,1-Mar-20,336,31-Dec-20,26-Mar-21,,26-Mar-21,"Sanatorio Anchorena de San Martin, San MartÃ­n, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04819165
512,NCT04596943,RGD PET/CT Imaging in COVID-19 Patients,,Completed,No Results Available,Covid19|Endothelial Dysfunction|PET Imaging,Diagnostic Test: [68Ga]Ga-DOTA-(RGD)2 PET/CT,uptake of [68Ga]Ga-DOTA-(RGD)2 in the lung parenchyma|spatial correlation with chest-CT|spatial correlation with CT-subtraction|quantitative correlation with laboratory results|explore correlation with clinical parameters,Radboud University,All,"18 Years and older Â  (Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NL73551.091.20|2020-001325-31,1-Mar-21,15-Oct-20,137,1-Feb-21,22-Oct-20,,27-Apr-21,"Radboudumc, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT04596943
513,NCT04356937,Efficacy of Tocilizumab on Patients With COVID-19,,Completed,No Results Available,SARS-CoV 2,Drug: Tocilizumab|Drug: Placebos,"The primary endpoint is the time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation|Time from investigational medication (or placebo) to at least one point worsening on clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline|Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline","Massachusetts General Hospital|Genentech, Inc.",All,"18 Years to 85 Years Â  (Adult, Older Adult)",Phase 3,243,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2020P001159,27-Aug-20,20-Apr-20,129,13-Jul-20,22-Apr-20,,16-Dec-20,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04356937
514,NCT04316299,Acute Kidney Injury in Patients Hospitalized With COVID-19,,Completed,No Results Available,COVID-19|Acute Kidney Injury|Kidney Function,,Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay,Zhenhua Zen|Nanfang Hospital of Southern Medical University,All,"18 Years and older Â  (Adult, Older Adult)",,287,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,hkyy2020-005 AKI,8-Mar-20,26-Feb-20,11,28-Feb-20,20-Mar-20,,30-Mar-20,"Hankou Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04316299
515,NCT04525742,COVID-19 Pandemic and Parents of Disabled Children,,Completed,No Results Available,COVID-19|Disabilities Multiple|Cerebral Palsy|Muscular Dystrophies,Other: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic,A questionnaire that we created will be used to determine the difficulties experienced by disabled children's parents during Covid 19 pandemic related to their medical follow-up|The Fear of COVID-19 Scale,Gaziosmanpasa Research and Education Hospital,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,309,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,105,15-Sep-20,5-Jul-20,72,30-Aug-20,25-Aug-20,,3-Nov-20,"Health Science University Gaziosmanpasa Training and Research Hospital, Ä°stanbul, Gaziosmanpasa, Turkey",,https://ClinicalTrials.gov/show/NCT04525742
516,NCT04364594,COVID-19 Search in Conjunctival Cells,COVID-T,Completed,No Results Available,COVID 19|Pulmonary Disease,Diagnostic Test: conjunctival swab,Conjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalities,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0013008/20,30-May-20,26-Mar-20,65,24-Apr-20,28-Apr-20,,23-Jul-20,"Maria Cristina Savastano, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04364594
517,NCT04407507,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",SILVERBULLET,Completed,Has Results,COVID-19,Drug: Ivermectin|Drug: Placebo,"Participants With a Disease Control Status Defined as no Disease Progression to Severe.|SARS-CoV-2 Viral Load, at 5 and 14 Days|Presence and Frequency of Symptoms Associated With the COVID-19 Disease",Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,SARS-COV-IverMX-01,29-Jan-21,1-Jul-20,212,29-Jan-21,29-May-20,21-May-21,21-May-21,"Investigacion BiomÃ©dica para el Desarrollo de FÃ¡rmacos S.A. de C.V., Zapopan, Jalisco, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04407507/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04407507/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04407507
518,NCT04495764,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,RePAiR,Completed,No Results Available,SARS-CoV-2 Infection|Anti-SARS-CoV-2 Infection,,Anti-SARS-CoV-2 antibodies|Incidence and severity of COVID-19,Davita Clinical Research,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,2504,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-M-0044-00,12-Feb-21,20-Jul-20,207,12-Feb-21,3-Aug-20,,21-Feb-21,"DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04495764
519,NCT04379661,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,,Completed,No Results Available,MS (Multiple Sclerosis)|COVID-19|Support Groups,Behavioral: Online support Group,Rate of completion|Rate of adherence|Score on the State Trait Anxiety Inventory (STAI),Columbia University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AAAS9939,31-Aug-20,7-May-20,116,7-Jul-20,7-May-20,,8-Jan-21,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04379661
520,NCT04336345,Outcomes of Patients With COVID-19 in the Intensive Care Unit,MexCOVID-19,Completed,No Results Available,Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus,,Hospital mortality|Length of stay in the intensive care unit,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,3336,4-Jun-20,1-Apr-20,64,30-Apr-20,7-Apr-20,,10-Nov-20,"Instituto Nacional de Ciencias MÃ©dicas y NutriciÃ³n Salvador ZubirÃ¡n, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico",,https://ClinicalTrials.gov/show/NCT04336345
521,NCT04387838,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,SEROSARSCOV,Completed,No Results Available,Sars-CoV2,Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire,Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.|Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.|Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.|Anti-SARS-Cov2 seroprevalence at Day 0.|Correlation between seroconversion and socio-demographic factors - sex|Correlation between seroconversion and socio-demographic factors - age|Correlation between seroconversion and professional factors - job type|Correlation between seroconversion and professional factors - personal protective equipment type|Correlation between seroconversion and non-professional factors - contact with infected individuals|Correlation between seroconversion and non-professional factors - wearing of professional equipment|Correlation between seroconversion and non-professional factors - respect of barrier gestures,Direction Centrale du Service de SantÃ© des ArmÃ©es,All,18 Years to 62 Years Â  (Adult),,845,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-COVID19-10|2020-A01028-31,15-Aug-20,14-May-20,93,15-Aug-20,14-May-20,,9-Mar-21,"HÃ´pital d'Instuction des ArmÃ©es Sainte-Anne, Toulon, France|HÃ´pital d'Instruction des ArmÃ©es Robert PicquÃ©, Villenave-d'Ornon, France",,https://ClinicalTrials.gov/show/NCT04387838
522,NCT04659876,Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19,,Completed,No Results Available,Covid19 and Mortality,Diagnostic Test: clinical features and laboratory values,Mortality,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,445,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"September 11, 2020: 550",8-Dec-20,22-Mar-20,261,1-Sep-20,9-Dec-20,,9-Dec-20,"DiyarbakÄ±r Gazi YaÅŸargil Training and Research Hospital, DiyarbakÄ±r, Turkey",,https://ClinicalTrials.gov/show/NCT04659876
523,NCT04360954,Evaluation of Antibody Tests for COVID-19,,Completed,No Results Available,COVID|Coronavirus,Diagnostic Test: Diagnostic test,Test Sensitivity|Test Specificity,Washington University School of Medicine,All,"18 Years and older Â  (Adult, Older Adult)",,461,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,202004088,8-Jul-20,23-Apr-20,76,8-Jul-20,24-Apr-20,,31-Dec-20,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04360954
524,NCT04876898,High Body Mass Index and Severity of Coronavirus,,Completed,No Results Available,COVID-19 Pneumonia,Other: prospective cohort in high body mass index patient with covid 19,pneumonia|sever pneumonia|ICU admission|length of hospital stay|clinical complication,South Valley University,All,"18 Years to 75 Years Â  (Adult, Older Adult)",,114,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BMI_COVID19,28-Feb-21,1-Jul-20,242,30-Jan-21,7-May-21,,7-May-21,"Gad sayed Gad, QinÄ, Qena, Egypt",,https://ClinicalTrials.gov/show/NCT04876898
525,NCT04355728,Use of UC-MSCs for COVID-19 Patients,,Completed,No Results Available,"Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19",Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival rate after 90 days post first infusion|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count,Camillo Ricordi|University of Miami,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1|Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20200671|20200370,31-Oct-20,25-Apr-20,189,31-Oct-20,21-Apr-20,,1-Mar-21,"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04355728
526,NCT04376710,Surgical Telemedicine in the COVID-19 Pandemic Era,,Completed,No Results Available,COVID|Surgery,Other: Completion of pre-pandemic survey|Other: Completion of survey after peak of pandemic|Other: Completion of post telemedicine encounter survey,Evaluate surgeon perceptions to telemedicine and perceived barriers to implementation|Evaluate patient perceptions to telemedicine and perceived barriers to implementation,"University of Colorado, Denver",All,"31 Days to 18 Years Â  (Child, Adult)",,180,Other,Observational,Observational Model: Other|Time Perspective: Prospective,20-1177,1-Oct-20,1-Jul-20,92,1-Oct-20,6-May-20,,28-Oct-20,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04376710
527,NCT04527354,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,,Completed,No Results Available,SARS-CoV-2 Infection|Fibrosis Lung,Drug: Treamid|Drug: Placebo,"Rate of clinically significant change in FVC and/or DLCO at Week 4 relative to the baseline value|Change in distance covered for 6 minutes (6MWD) at Weeks 2 and 4 from the baseline value (based on 6-minute walk test)|Change in the score of the Borg scale at Weeks 2 and 4 from the baseline value (based on the 6-minute walk test)|Change in forced expiratory volume for the first second (FEV1) according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FEV1/FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in DLCO according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Total Lung Capacity (TLC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Functional Residual Capacity (FRC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|The rate of reduction in the lung damage degree based on the computed tomography (CT) at Week 4 relative to the baseline value|Change in mMRC Dyspnea Score in Week 1, Week 2, Week 3, and Week 4 from the baseline value|Change in the overall score of the KBILD Questionnaire at Week 2 and Week 4 relative to the baseline value",PHARMENTERPRISES LLC,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COVID-TRE-03,10-Feb-21,1-Sep-20,162,10-Feb-21,26-Aug-20,,5-Apr-21,"Federal State-Funded Research Institution ""Research Institute of Complex Cardiovascular Diseases"", Kemerovo, Russian Federation|Federal State Budgetary Institution ""N.N. Burdenko Military Clinical Hospital"", Moscow, Russian Federation|SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation|Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI ""City Hospital â„– 62"", branch 5, Moscow, Russian Federation|State Budgetary Health Institution ""Republican Hospital named V.A.Baranov"", Petrozavodsk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Rostov State Medical University"", Rostov-on-Don, Russian Federation|LLC ""Medical Center ""Reavita Med St. Petersburg"", Saint Petersburg, Russian Federation|State autonomous healthcare institution of Yaroslavl Region ""Ð¡linical hospital for emergency medical care n. a. N.V. Solovyov"", Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT04527354
528,NCT04497818,Correlation Fear of COVID-19 & Dental Treatment Anxiety,,Completed,No Results Available,Covid19|Fear|Dental Anxiety,Other: Cross Sectional study using scientifically validated psychometric Scales,Fear of COVID-19 infection|Dental Anxiety|Correlation of Fear of COVID-19 infection & Dental Anxiety|Correlation of the nearest Dental treatment seeking time and Fear of COVID-19 infection.|Correlation of the nearest Dental treatment seeking time and Dental Anxiety|Correlation of the Age and Fear of COVID-19 infection|Correlation of the Age and Dental Anxiety.,Qassim University,All,"20 Years and older Â  (Adult, Older Adult)",,385,Other,Observational,Observational Model: Other|Time Perspective: Prospective,QassimU2,25-Jul-20,16-Jun-20,39,16-Jul-20,4-Aug-20,,4-Aug-20,"Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT04497818
529,NCT04643522,Semen Parameters and COVID-19 in Infertile Men,,Completed,No Results Available,"Sperm Count, Low|Hormone Disturbance|Covid19",Other: Clinical assessment,"Semen analyses parameters including sperm motility (total, progressive, non-progressive and immotile|Semen analyses parameters including sperm concentration|Semen analyses parameters including sperm morphology|Semen analyses parameters including semen volume|Sex-related hormone levels including testosterone|Sex-related hormone levels including follicle stimulating hormone and luteinizing hormone",Ankara City Hospital Bilkent,Male,18 Years to 40 Years Â  (Adult),,21,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,E1-20-1237,10-Oct-20,7-Jan-20,277,5-Oct-20,25-Nov-20,,30-Nov-20,"Ankara City Hospital, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04643522
530,NCT04872725,The Effect of Covid-19 Process,,Completed,No Results Available,"Covid19|Participation, Patient",Behavioral: Time management & participation & the leisure time activity,Assessment of Time Management Skills|Social Isolation Questionnaire|Interest Checklist,Istanbul Medipol University Hospital,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,531,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Covid-19 OT,30-Jul-20,1-Mar-20,151,30-Jun-20,4-May-21,,11-May-21,"Istanbul Medipol University, Beykoz, Ä°stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04872725
531,NCT04535856,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,DW-MSC,Completed,No Results Available,Covid19|Corona Virus Infection|SAR,Drug: allogeneic mesenchymal stem cell|Other: Placebo,Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change,"Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.",All,"19 Years and older Â  (Adult, Older Adult)",Phase 1,9,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DW_DWP710101|U1111-1263-1723,14-Jan-21,14-Nov-20,61,14-Jan-21,2-Sep-20,,27-Jan-21,"Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia",,https://ClinicalTrials.gov/show/NCT04535856
532,NCT04371562,Predicting Death and ICU Admission in COVID-19 Patients in ED,,Completed,No Results Available,COVID,,7-day death|7-day ICU,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,All,"18 Years and older Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,0017055/20,15-Apr-20,1-Mar-20,45,31-Mar-20,1-May-20,,5-May-20,"Marcello Covino, Roma, RM, Italy",,https://ClinicalTrials.gov/show/NCT04371562
533,NCT04318431,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,COVILLE,Completed,No Results Available,Covid19,Diagnostic Test: Data collection and rhinopharyngeal swab,Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG,Centre Hospitalier Intercommunal Creteil|Association Clinique ThÃ©rapeutique Infantile du val de Marne,All,up to 15 Years Â  (Child),Not Applicable,605,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,COVILLE|2020-A00724-35,1-Jun-20,14-Apr-20,48,12-May-20,24-Mar-20,,9-Jul-20,"Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, ChenneviÃ¨res-sur-Marne, France|14 Av renÃ© Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du GÃ©nÃ©ral Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 allÃ©e des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis BlÃ©riot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-FossÃ©s, France|Cabinet de PÃ©diatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa BeausÃ©jour, Vincennes, France",,https://ClinicalTrials.gov/show/NCT04318431
534,NCT04423991,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,IDENTIFY,Completed,No Results Available,COVID-19|Coronavirus|Mortality,Device: COViage,Mortality outcome,Dascena,All,"Child, Adult, Older Adult",Not Applicable,290,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,60820,4-Jun-20,10-Mar-20,86,4-Jun-20,9-Jun-20,,9-Jun-20,"Dascena, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT04423991
535,NCT04378712,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),,Completed,No Results Available,Covid-19|Hydrogen/Oxygen Mixed Gas|Dyspnea,Device: Hydrogen Oxygen Generator with Nebulizer|Other: Standard-of-care,The proportion of patients with improved disease severity at day 2|The proportion of patients with improved disease severity at day 3|The proportion of patients with improved disease severity at the day before hospital discharge|The change from baseline in oxygen saturation at day 2.|The change from baseline in oxygen saturation at day 3.|The change from baseline in oxygen saturation at the day before hospital discharge|The change from baseline in dyspnea scale at day 2.|The change from baseline in dyspnea scale at day 3.|The change from baseline in dyspnea scale at the day before hospital discharge.|The change from baseline in cough scale at day 2|The change from baseline in cough scale at day 3|The change from baseline in cough scale at the day before hospital discharge|The change from baseline in chest pain scale at day 2.|The change from baseline in chest pain scale at day 3.|The change from baseline in chest pain scale at the day before hospital discharge.|The change from baseline in chest distress scale at day 2.|The change from baseline in chest distress scale at day 3.|The change from baseline in chest distress scale at the day before hospital discharge.,Guangzhou Institute of Respiratory Disease,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JT202005LZ,23-Mar-20,21-Jan-20,62,23-Mar-20,7-May-20,,15-May-20,"First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04378712
536,NCT04466462,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,,Completed,No Results Available,SARS-CoV-2 Infection,,Number of participants with past SARS-CoV-2 infection|Number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for COVID-19 infection|Number of infections in health personnel based on the degree of exposure to patients infected with COVID-19.|Number of infected participants who are active smokers and/or have chronic lung disease and/ or have history of hypertension.Relationship of degree of exposure to participants infected with SARS-CoV-2 admitted to the hospital.Professional category.|Number of participants infected with SARS-CoV-2 that presented symptoms and their grade. Number of participants infected with SARS-CoV-2 who required hospitalization. Number of participants infected with SARS-CoV-2 who received treatment.|Number of family members infected from each participant with SARS-CoV-2 infection,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",All,"18 Years and older Â  (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Other,COVID-Hosp,30-Jun-20,26-May-20,35,30-Jun-20,10-Jul-20,,10-Jul-20,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04466462
537,NCT04390022,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,SAINT,Completed,Has Results,Covid-19|Coronavirus Infection|SARS-CoV-2 Infection,Drug: Ivermectin|Drug: Placebo,"Proportion of Patients With a Positive SARS-CoV-2 PCR|Median Viral Load|Fever and Cough Progression|Seroconversion at Day 21|Proportion of Drug-related Adverse Events|Levels of IgG, IgM and IgA|Frequency of Innate Immune Cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells|Results From Cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health",All,18 Years to 59 Years Â  (Adult),Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SAINT,9-Oct-20,31-Jul-20,70,17-Sep-20,15-May-20,17-Dec-20,17-Dec-20,"Clinica Universidad de Navarra, Pamplona, Navarra, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04390022
538,NCT04615676,Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus,COPREG,Completed,No Results Available,SARS-CoV2,Other: Follow-up phone call,Hospitalization,"University Hospital, Toulouse",All,"15 Years and older Â  (Child, Adult, Older Adult)",,4734,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC31/20/0141,17-Jul-20,27-Apr-20,81,17-Jul-20,4-Nov-20,,9-Nov-20,"University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04615676
539,NCT04555005,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,,Completed,No Results Available,Mindfulness|COVID-19|Healthcare Worker,Other: Mindfulness based intervention,Perceived helpfulness to reduce current stress,Instituto de InvestigaciÃ³n Hospital Universitario La Paz|Hospital Universitario La Paz,All,"Child, Adult, Older Adult",Not Applicable,1000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Mind-COVID-19,26-Apr-20,10-Mar-20,47,26-Apr-20,18-Sep-20,,18-Sep-20,"La Paz University Hospital, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04555005
540,NCT04512300,Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,,Completed,No Results Available,Dental Treatment During Covid -19,,Assessment of parental attitude toward children dental visit during Coronavirus crisis,Cairo University,All,"Child, Adult, Older Adult",,267,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Covid -19 and dental visit,25-Jun-20,15-Jun-20,10,25-Jun-20,13-Aug-20,,12-May-21,"faculty of dentistry, Cairo university , Egypt, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04512300
541,NCT04485169,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Plex,Completed,No Results Available,COVID-19|Cytokine Release Syndrome,Procedure: Therapeutic Plasma Exchange,Survival|Duration of Hospitalization|Timing of PCR negativity|Time to CRS resolution|Complications,UNICEF|Pak Emirates Military Hospital Rawalpindi,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,280,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sultan Mehmood Kamran,31-Jul-20,1-Apr-20,121,31-Jul-20,24-Jul-20,,28-Sep-20,"Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04485169
542,NCT04869072,Convalescent Plasma Therapy - Zurich Protocol,CPT-ZHP,Completed,No Results Available,COVID-19,Drug: Convalescent plasma,"Safety of CPT applied to COVID-19 patients|Improvement of respiratory frequency|Improvement of O2-saturation|Improvement of Inflammatory markers (C Reactive Protein, CRP)|Improvement of Inflammatory markers (Ferritin)|Improvement of Inflammatory markers (IL-6)|Improvement of coagulation-markers (D-dimer)|Improvement of coagulation-markers (Fibrinogen)|Improvement of coagulation-markers (LDH)|Prevention of ICU-admission|Characterisation of virus reaction to plasma Therapy|Characterisation of the dynamic of humoral response after therapy|Better characterize the the in-vivo anti-virus humoral response against SARS-CoV-2.",University of Zurich,All,"Child, Adult, Older Adult",Phase 1,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-00787,30-Mar-21,29-Apr-20,335,30-Nov-20,3-May-21,,3-May-21,"University Hospital Zurich, ZÃ¼rich, Switzerland",,https://ClinicalTrials.gov/show/NCT04869072
543,NCT04645407,Effects of Fuzheng Huayu Tablets on COVID-19,,Completed,No Results Available,Novel Coronavirus Pneumonia,Drug: Fuzheng Huayu tablet,the percentage of patients showing improvement in chest CT|remission rate or progression rate of critical illness|clinical remission rate of respiratory symptoms|routine blood examination|C-reactive protein level|procalcitonin level|oxygen saturation,ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People's Hospital,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 4,66,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Fzhy-ncp-1,15-Apr-20,1-Feb-20,74,15-Apr-20,27-Nov-20,,27-Nov-20,"Shuguang Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04645407
544,NCT04352959,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,BBCovid,Completed,No Results Available,COVID19|Mouthwash|Saliva,Device: mouthrinse with bÃªta-cyclodextrin and citrox|Device: mouthrinse without bÃªta-cyclodextrin and citrox,Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days|Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days,Claude Bernard University|Hospices Civils de Lyon,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Not Applicable,176,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",BBCovid,11-Dec-20,27-Apr-20,228,11-Dec-20,20-Apr-20,,11-Feb-21,"Clinic of the Protestant Infirmary in Lyon, Caluire-et-Cuire, France|Hospital Center Emile Roux, Le Puy en Velay, France|Hospital Center Saint Luc Saint Joseph, Lyon, France|Intercommunal Hospital Center of Mont de Marsan, Mont de Marsan, France",,https://ClinicalTrials.gov/show/NCT04352959
545,NCT04405570,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",,Completed,No Results Available,SARS-CoV 2,Drug: EIDD-2801|Drug: Placebo (PBO),"Virologic Efficacy|Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach|Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach","Ridgeback Biotherapeutics, LP",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,204,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EIDD-2801-2003,21-Feb-21,16-Jun-20,250,21-Feb-21,28-May-20,,23-Feb-21,"Benchmark Research, Colton, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|NOLA Research, New Orleans, Louisiana, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Duke, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Fred Hutch, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04405570
546,NCT04336384,Impact of Covid-19 in Congenital Heart Disease,COVID-CHD,Completed,No Results Available,Congenital Heart Disease|Covid-19,,Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths,"University Hospital, Montpellier|Pr. Jean-BenoÃ®t THAMBO, Bordeaux (prÃ©sident)|Dr. CÃ©line GRUNENWALD GRONIER, Strasbourg|Dr. SÃ©bastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier",All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0155,30-Dec-20,1-Mar-20,304,1-Dec-20,7-Apr-20,,2-Feb-21,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04336384
547,NCT04832945,SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study,,Completed,No Results Available,Covid19,Drug: Ivermectin 6 Mg Oral Tablet,Number of participants RT-PCR positive for Covid-19|Number of sick participants who condition deteriorated|Number of sick participants who died,Grupo Rescue S.A.S RepÃºblica Dominicana,All,"18 Years and older Â  (Adult, Older Adult)",,713,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,8953,10-Apr-21,29-Jun-20,285,20-Sep-20,6-Apr-21,,13-Apr-21,"Centro Medico Bournigal, Puerto Plata, Dominican Republic|Centro MÃ©dico Punta Cana, Punta Cana, Dominican Republic",,https://ClinicalTrials.gov/show/NCT04832945
548,NCT04713111,Stress and Recovery in Frontline COVID-19 Workers,,Completed,No Results Available,Covid19|Stress|Wearables,Behavioral: Lifestyle (Meditation)|Behavioral: Lifestyle (Exercise),Study Retention|Daily survey/task adherence|Oura adherence|Garmin adherence,4YouandMe|Center for International Emergency Medical Services|Evidation Health|Vector Institute for Artificial Intelligence|Cambridge Cognition Ltd|Bill and Melinda Gates Foundation,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,383,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,4UCOVID1901,30-Nov-20,4-May-20,210,30-Nov-20,19-Jan-21,,12-Mar-21,"4YouandMe, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04713111
549,NCT04479644,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198",,Completed,No Results Available,COVID-19,Drug: BRII-198|Drug: Placebo,Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-198,Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD,All,18 Years to 49 Years Â  (Adult),Phase 1,17,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BRII-198-001,3-Feb-21,13-Jul-20,205,3-Feb-21,21-Jul-20,,12-Apr-21,"Investigative Site, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04479644
550,NCT04479631,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196",,Completed,No Results Available,COVID-19,Drug: BRII-196|Drug: Placebo,Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-196,Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD,All,18 Years to 49 Years Â  (Adult),Phase 1,16,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BRII-196-001,29-Jan-21,12-Jul-20,201,29-Jan-21,21-Jul-20,,12-Apr-21,"Investigative Site, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04479631
551,NCT04443140,Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,,Completed,No Results Available,Covid-19|Preeclampsia|Pregnancy Related,"Diagnostic Test: PCR, lung ultrasound",PCR positivity,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,Female,18 Years to 40 Years Â  (Adult),,131,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,70/2020,10-Jul-20,15-Mar-20,117,1-Jul-20,23-Jun-20,,28-Jul-20,"Zeynep Kamil Maternity and Childrens Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04443140
552,NCT04473157,COVID-19 in Patients With Anosmia in Egypt,,Completed,No Results Available,Anosmia|Covid19|Dysgeusia,,Recovery from Anosmia|Seroconversion|COVID 19,Ain Shams University,All,"18 Years and older Â  (Adult, Older Adult)",,58,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,FMASU P45a/2020,30-Dec-20,1-Jul-20,182,30-Nov-20,16-Jul-20,,15-Jan-21,"Ain Shams University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04473157
553,NCT04872764,Acute Kidney Injury in Patients With CoVID-19,AKI-COVID-19,Completed,No Results Available,Covid19|Acute Kidney Injury,"Other: duration of hospitalization, mortality rate",mortality rate|duration of hospitalisation,UÅŸak University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,600,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,UsakU3,20-Dec-20,20-Mar-20,275,20-Nov-20,4-May-21,,4-May-21,"Usak University, Usak, Turkey",,https://ClinicalTrials.gov/show/NCT04872764
554,NCT04690920,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,,Completed,No Results Available,Corona Virus Disease 2019 (COVID-19),Drug: Tocilizumab,Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen|Hospital stay|Oxygen demand|Viral load,University of Lahore,All,"Child, Adult, Older Adult",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,UOL/IMBB/2020/118,10-Dec-20,23-Jul-20,140,10-Dec-20,31-Dec-20,,31-Dec-20,"The University of Lahore, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04690920
555,NCT04771117,Defiances to Face COVID-19 Pandemic in Mexico,,Completed,No Results Available,Health Behavior|Risk-Taking|Covid19,Behavioral: Fear of Covid-19 Scale,Risk Factors|Fear of Covid-19,Instituto Mexicano del Seguro Social,All,"16 Years and older Â  (Child, Adult, Older Adult)",,4004,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,Fear5,1-Dec-20,1-May-20,214,1-Aug-20,25-Feb-21,,26-Feb-21,"Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT04771117
556,NCT04399980,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,,Completed,Has Results,COVID 19|SARS-CoV 2|Pneumonia,Drug: Mavrilimumab|Drug: Placebos,Subjects Alive and Off of Oxygen at Day 14|Number of Subjects Alive and Without Respiratory Failure at Day 28|Mortality at Day 28,"The Cleveland Clinic|Kiniksa Pharmaceuticals, Ltd.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IND 149324|IRB 20-523,23-Apr-21,20-May-20,338,23-Apr-21,22-May-20,13-May-21,13-May-21,"Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic Health System, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04399980/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04399980
557,NCT04789447,"Evaluation of Prognosis of COVID-19 Patients With Only CT Findings, Only RT-PCR Positivity and Both of Them Positive",,Completed,No Results Available,"Covid19|SARS-CoV Infection|Pneumonia, Viral",,mortality|need for intensive care|length stay,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",All,"18 Years and older Â  (Adult, Older Adult)",,909,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,COP-19,6-May-21,4-Mar-21,63,6-May-21,9-Mar-21,,11-May-21,"Sultan AbdÃ¼lhamid Han Training and Research Hospital, Istanbul, Turkey|Sultan AbdÃ¼lhamid Han Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04789447
558,NCT04341766,Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,,Completed,No Results Available,"Pneumonia, Viral|COVID-19",Other: No special intervention,Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients,Centre Hospitalier Intercommunal Creteil,All,"18 Years to 105 Years Â  (Adult, Older Adult)",,106,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-ECHO,30-Jun-20,31-Mar-20,91,27-May-20,10-Apr-20,,17-Jul-20,"CHU Amiens, Amiens, France|CH de la CÃ´te Basque, Bayonne, France|CHU Ambroise ParÃ©, Boulogne-Billancourt, France|CHU Caen, Caen, France|CHG de Chambery, ChambÃ©ry, France|Centre Hospitalier Intercommunal de CrÃ©teil, CrÃ©teil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|CHU NÃ®mes, NÃ®mes, France|CHR OrlÃ©ans, OrlÃ©ans, France|CHU Cochin, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen, Rouen, France|CH Saint-Quentin, Saint-Quentin, France|CHU Larrey - Toulouse, Toulouse, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04341766
559,NCT04729491,EAT-DUTA AndroCoV Trial,,Completed,No Results Available,Covid19,Drug: Dutasteride 0.5 mg|Drug: Azithromycin|Drug: Nitazoxanide|Drug: Placebo,"Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death]|Time-to-recovery|SARS-CoV-2 viral load|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of vasopressors use|Proportion of deaths|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to baseline (Day 0))|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to baseline (Day 0))|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Variation in oxygen saturation compared to baseline (Day 0)|Disease duration|Change in viral load from baseline to Day 5|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms",Corpometria Institute,Male,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,138,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CORPO-AB-DRUG-SARS-004B,7-Oct-20,30-Jun-20,99,15-Sep-20,28-Jan-21,,28-Jan-21,"Corpometria Institute, BrasÃ­lia, DF, Brazil",,https://ClinicalTrials.gov/show/NCT04729491
560,NCT04453501,Anti Infective Agents Impact in COVID-19 Pneumonia,AZITHROVID,Completed,No Results Available,"COVID|Pneumonia, Viral",Drug: favorable outcome,Favorable outcome|Risk factors 1|Risk factors 2|Interest of anti-infective agents,Centre d'Investigation Clinique et Technologique 805,All,"18 Years and older Â  (Adult, Older Adult)",,132,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,AZITHROVID|INDS,25-Apr-20,2-Mar-20,54,25-Apr-20,1-Jul-20,,1-Jul-20,"Benjamin Davido, Garches, France",,https://ClinicalTrials.gov/show/NCT04453501
561,NCT04701710,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Ivercar-Tuc,Completed,No Results Available,Covid19|SARS (Severe Acute Respiratory Syndrome),Drug: Ivermectin / Iota-Carrageenan,"Pearson's Chi-square and proportion test.|Odd Ratio, probabilistic test|Logistic regression test","Maria de los Angeles Peral de Bruno|Ministry of Public Health, Argentina",All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5076-410-CH2020,31-Dec-20,15-Oct-20,77,18-Dec-20,8-Jan-21,,23-Feb-21,"SI.PRO.SA, Ministerio de Salud PÃºblica, TucumÃ¡n, Argentina",,https://ClinicalTrials.gov/show/NCT04701710
562,NCT04412278,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,,Completed,No Results Available,"COVID|Isolation, Social",Other: Online Survey,Exercise Benefits and Barriers Scale|Sociodemographic information|International Physical Activity Questionairre,Okan University,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",,392,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,500600127,8-Jun-20,1-Jun-20,7,8-Jun-20,2-Jun-20,,11-Jun-20,"Istanbul Okan University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04412278
563,NCT04873141,Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia,,Completed,No Results Available,Cytokine Release Syndrome|Covid-19 Pneumonia,Drug: Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML),Mortality Rate|Time to discharge|Laboratory parameters|Oxygen Saturation,Shaheed Zulfiqar Ali Bhutto Medical University,All,"18 Years and older Â  (Adult, Older Adult)",,24,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Tocilizumab and CRS,22-Jun-20,28-Apr-20,55,22-Jun-20,5-May-21,,5-May-21,"Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan",,https://ClinicalTrials.gov/show/NCT04873141
564,NCT04525417,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,,Completed,No Results Available,Covid-19 Immune Status of Healthcare Workers,Diagnostic Test: AAZ Covid-19 rapid test,To assess the predictive value of Covid-19 rapid test|Compare the results of rapid tests on serum and capillary samples|A posteriori diagnosis of a covid-19 recent infection with suggestive symptomatology|Analysis of factors associated with negativity of PCR test on oropharyngeal swabs and positive serology,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GERES20200409|ID RCB 2020-A01031-38,25-Oct-20,25-Apr-20,183,25-Sep-20,25-Aug-20,,3-Feb-21,"Bichat University Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04525417
565,NCT04812496,Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV),TEDHICOV,Completed,No Results Available,Covid19|SARS-CoV Infection|Tenofovir,,Mortality within 30 days of hospital admission|Mechanical Ventilation|Hospital stay,Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,TEDHICOV,15-Jan-21,1-Mar-20,320,30-May-20,23-Mar-21,,25-Mar-21,"Hospital Nacional CASE - EsSalud, Arequipa, Peru",,https://ClinicalTrials.gov/show/NCT04812496
566,NCT04401085,COVID-19: Herd Immunity Study in the Czech Republic,SARSCoV2CZPrev,Completed,No Results Available,COVID|SARS-CoV 2,Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies,"Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.|Estimation of the proportion of people with a subclinical course of the disease|Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.|Estimation of the proportion of persons suitable for the donation of convalescent plasma","Institute of Health Information and Statistics of the Czech Republic|Ministry of Health, Czech Republic|Palacky University|Masaryk University|University of Ostrava|Faculty of Military Health Sciences, University of Defence in Brno|Faculty of Health Studies, J. E. PurkynÄ› University in ÃšstÃ­ nad Labem|First Faculty of Medicine, Charles University, Czech Republic|Institute for Clinical and Experimental Medicine|General University Hospital, Prague|University Hospital Olomouc|Brno University Hospital|KrajskÃ¡ zdravotnÃ­, a.s., ÃšstÃ­ nad Labem Region Hospitals|Military University Hospital, Prague|Masaryk Memorial Cancer Institute|Institute Of Sociology, Czech Academy of Sciences|Czech Statistical Office|Faculty of Medicine in Hradec KrÃ¡lovÃ©, Charles University",All,"8 Years to 89 Years Â  (Child, Adult, Older Adult)",,27000,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,UZIS 2020/1,1-May-20,23-Apr-20,8,1-May-20,26-May-20,,1-Jun-20,"Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT04401085
567,NCT04433039,COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,,Completed,No Results Available,COVID,,COVID19 versus H1N1; radiological comparative study,Alexandria University,All,"4 Years to 80 Years Â  (Child, Adult, Older Adult)",,130,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Retrospective,"IRB (00012098), SN (0304669)",14-Jun-20,22-May-20,23,12-Jun-20,16-Jun-20,,16-Jun-20,"Faculty of Medicine, University of Alexandria, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT04433039
568,NCT04893031,"Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study",,Completed,No Results Available,Tocilizumab|COVID-19|Critical Care|Mortality,Drug: Tocilizumab,Rates of intensive care mortality in the groups|Rates of needed of mechanical ventilation in the groups,Karadeniz Technical University,All,"18 Years and older Â  (Adult, Older Adult)",,213,Other,Observational,Observational Model: Cohort|Time Perspective: Other,2021/24|2021-01-24T17_19_44,1-Apr-21,1-Mar-20,396,1-Mar-21,19-May-21,,20-May-21,"Karadeniz Technical University, Trabzon, Turkey",,https://ClinicalTrials.gov/show/NCT04893031
569,NCT04561219,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,,Completed,No Results Available,"Covid19|Corona Virus Infection|Pneumonia, Viral",Drug: Nitazoxanide|Drug: Placebo,Orotracheal intubation rate|Mechanical ventilation free days|Hospitalisation days|ICU days|Intranasal oxygen support days|Mortality rate|Days with fever|Days with cough|Days with dyspnea|Radiologic findings|Cardiologic findings|C-reactive protein - absolute number|C-reactive protein serum levels|Lactate dehydrogenase (LDH) serum levels|Troponin serum levels|Electrolytes serum levels|Glucose serum levels|Renal function|Coagulogram|Liver function panel|Ferritin|D-dimer|Blood cell count|Inflammatory mediators,"Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|Financiadora de Estudos e Projetos|ATCGen|Hospital Central da AeronÃ¡utica, Rio de Janeiro|Hospital da ForÃ§a AÃ©rea do GaleÃ£o|Hospital Naval Marcilio Dias|Hospital Universitario Pedro Ernesto|Hospital de ForÃ§a AÃ©rea de SÃ£o Paulo|Hospital das ClÃ­nicas Luzia de Pinho Melo|Complexo Hospitalar Municipal de SÃ£o Caetano do Sul|Hospital Municipal de Barueri Dr Francisco Moran|Hospital Regional de Sorocaba Dr Adib Domingos Jatene|Hospital Geral de SÃ£o Mateus Dr Manoel Bifulco|Santa Casa de MisericÃ³rdia de Belo Horizonte|Mater Dei Hospital, Brazil|Hospital Eduardo de Menezes|Hospital das ClÃ­nicas da Universidade Federal de Pernambuco|Hospital das ForÃ§as Armadas, Brazil|Hospital Regional da Asa Norte, Brazil|Complexo Hospitalar do Trabalhador de Curitiba|Hospital Estadual de DoenÃ§as Tropicais Dr Anuar Auad|Hospital Geral de Fortaleza",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",SARITA-1|RBR-88bs9x|30662420.0.1001.0008,2-Oct-20,19-Apr-20,166,2-Oct-20,23-Sep-20,,28-Oct-20,"Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04561219
570,NCT04716088,Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19,,Completed,No Results Available,SARS-CoV-2 Rapid Antigen Test,Diagnostic Test: Rapid antigen test for SARS CoV2,SARS CoV2 infection,"The University Clinic of Pulmonary and Allergic Diseases Golnik|Insitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana",All,"18 Years to 65 Years Â  (Adult, Older Adult)",,36,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,RADT for COVID-19 Golnik,22-Dec-20,18-Nov-20,34,2-Dec-20,20-Jan-21,,22-Jan-21,"Universitiy Clinic for respiratory and allergic diseases, Golnik, Slovenia",,https://ClinicalTrials.gov/show/NCT04716088
571,NCT04370171,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,TeleCoviDiab,Completed,No Results Available,Diabetes|Covid-19,Other: care modalities|Other: Teleconsultation either by phone or by computer consultation,"Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.|HbA1C measured at 6 months post-telemedicine consultation for the TC group / post-cancellation of the face-to-face consultation for the P group.|Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.|Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.|Results of patient satisfaction questionnaire.|Results of doctor satisfaction questionnaire.|Number of patients infected with Covid-19 (positive smear by RT-PCR for SARS-CoV-2 virus).|Number of conventional hospitalizations, in intensive care and deaths.","University Hospital, Strasbourg, France",All,"18 Years and older Â  (Adult, Older Adult)",,610,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,7775,29-May-20,4-May-20,25,29-May-20,30-Apr-20,,10-Nov-20,"HÃ´pitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04370171
572,NCT04347382,Honey & Nigella Sativa Trial Against COVID-19,HNS-COVID-PK,Completed,No Results Available,Coronavirus Infection|Sars-CoV2,Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos,Days required to get a positive COVID-19 PCR to negative|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Clinical Grade Status|Fever|Oxygen Saturation at room air,Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,313,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SZMC/IRB/Internal/0026/2020|IRB/2020/658/SIMS,30-Aug-20,30-Apr-20,122,30-Aug-20,15-Apr-20,,12-Nov-20,"Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04347382
573,NCT04365153,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),,Completed,Has Results,COVID-19|SARS-CoV 2,Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos,Number of Participants With Clinical Improvement at Day 14|All-cause Mortality,The Cleveland Clinic|Novartis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,45,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IND 149328,1-Apr-21,24-Apr-20,342,2-Feb-21,28-Apr-20,15-Apr-21,15-Apr-21,"Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04365153/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04365153
574,NCT04389294,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,,Completed,No Results Available,COVID,Diagnostic Test: SARS-CoV2 serum antibody testing,Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation,"Hospital for Special Surgery, New York",All,"21 Years and older Â  (Adult, Older Adult)",Not Applicable,143,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2020-0850,4-Sep-20,5-May-20,122,16-Jun-20,15-May-20,,11-Feb-21,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04389294
575,NCT04609462,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,HiFlo-COVID,Completed,No Results Available,Covid19|Acute Hypoxemic Respiratory Failure,Procedure: Conventional oxygen therapy|Procedure: High flow nasal cannula,Intubation rate|Clinical recovery|Proportion of patients with requirement of early mechanical ventilation.|Mechanical ventilation-free days|Renal replacement therapy-free days|Length of ICU stay|Length of hospital stay|All-cause day-28 mortality|Proportion of serious adverse events|Proportion of bacterial - fungal infections,Fundacion Clinica Valle del Lili,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,199,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1635,10-Feb-21,11-Aug-20,183,13-Jan-21,30-Oct-20,,1-Apr-21,"Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia",,https://ClinicalTrials.gov/show/NCT04609462
576,NCT04780594,Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital,,Completed,No Results Available,Covid19|Surgery--Complications|Nosocomial Infection,"Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases",Register the post-surgical complications|Register the rate of surgical reintervention|Register the ICU admission|Register the Hospital stay|Register the Mortality,Hospital Universitari de Bellvitge,All,"18 Years and older Â  (Adult, Older Adult)",,2530,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Retrospective,COVID19 surgical impact,9-Dec-20,13-Feb-20,300,15-May-20,3-Mar-21,,3-Mar-21,"Marta Caballero, Hospitalet de Llobregat, Barcelona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04780594/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04780594
577,NCT04491240,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,COVID-19EXO,Completed,Has Results,Covid19|SARS-CoV-2 PNEUMONIA|COVID-19,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,Number of Participants With Non-serious and Serious Adverse Events During Trial|Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure|Time to Clinical Recovery (TTCR)|SpO2 Concentration|C-reactive Protein|Lactic Acid Dehydrogenase (LDH),"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other",COVID-19 EXO,20-Oct-20,20-Jul-20,92,1-Oct-20,29-Jul-20,4-Nov-20,4-Nov-20,"Medical Centre Dinasty, Samara, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04491240/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04491240
578,NCT04346342,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),,Completed,No Results Available,COVID|Mechanical Ventilation|Acute Respiratory Failure,,Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (P plateau) or peak pressure (P peak) (cm H2O);|Level of pressure support above positive end-expiratory pressure (PEEP)|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years and older Â  (Adult, Older Adult)",,1122,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PRoVENT-COVID,1-Sep-20,6-Mar-20,179,1-Sep-20,15-Apr-20,,22-Sep-20,"Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|St Anna Ziekenhuis, Geldrop, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Leeuwarden Medisch Centrum, Leeuwarden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|St Antonius Ziekenhuis, Nieuwegein, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard, Netherlands|Isala Ziekenhuis, Zwolle, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04346342/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04346342
579,NCT04415879,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,,Completed,No Results Available,COVID-19,Device: N-95 Respirator|Device: Cloth Face Mask|Diagnostic Test: Graded exercise test,Exercise Capacity,The Cleveland Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20-538,1-Aug-20,1-Jun-20,61,1-Aug-20,4-Jun-20,,13-Aug-20,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04415879
580,NCT04374422,COVID-19 Pandemic and Female Sexual Behavior,,Completed,No Results Available,Sexual Behavior|COVID,Behavioral: fsfi survey,FSFI (Female Sexual Function Index)SCORE difference,Acibadem University,Female,"18 Years and older Â  (Adult, Older Adult)",,58,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AcibademU cov,12-Apr-20,10-Apr-20,2,12-Apr-20,5-May-20,,5-May-20,"Haseki Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04374422
581,NCT04382040,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",,Completed,No Results Available,COVID-19|Corona Virus Infection|SARS-CoV 2|Coronavirus|Coronavirus Infection,Drug: ArtemiC|Drug: Placebo,"Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours in comparison to routine treatment|Percentage of participants with definite or probable drug related adverse events|Time to negative COVID-19 PCR|Proportion of participants with normalization of fever and oxygen saturation through day 14 since onset of symptoms|COVID-19 related survival|Incidence and duration of mechanical ventilation|Incidence of Intensive Care Init (ICU) stay|Duration of ICU stay|Duration of time on supplemental oxygen",MGC Pharmaceuticals d.o.o,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MGC-006,21-Dec-20,8-May-20,227,5-Nov-20,11-May-20,,3-Mar-21,"Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India|Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel|Rambam Health Care Campus, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT04382040
582,NCT04339712,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,ESCAPE,Completed,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,102,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,8-Jan-21,2-Apr-20,281,1-Dec-20,9-Apr-20,,11-Jan-21,"2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, IoÃ¡nnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, ElefsÃ­na, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT04339712
583,NCT04697030,Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan,,Completed,No Results Available,"Burnout, Psychological|Covid-19 Pandemic",,Burnout Rating Scale,Sialkott College of Physical Therapy,All,"13 Years to 19 Years Â  (Child, Adult)",,443,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,129,22-Dec-20,15-Sep-20,98,15-Oct-20,6-Jan-21,,6-Jan-21,"Sialkot College of Physical Therapy, Amin Welfare & Teaching Hospital, Sialkot, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04697030
584,NCT04609774,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,COVID-19,Completed,No Results Available,Coronavirus Disease (COVID-19),Other: Severe Acute Respiratory Syndrome CoronaVirus 2 detection,Airborne transmission of Severe Acute Respiratory Syndrome CoronaVirus 2,Hospital Italiano de Buenos Aires,All,"18 Years and older Â  (Adult, Older Adult)",,8,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,1345,1-Dec-20,8-Oct-20,54,20-Nov-20,30-Oct-20,,4-Feb-21,"Hospital Italiano de Buenos Aires, Ciudad autÃ³noma de Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04609774
585,NCT04472052,Frequency of Perforated Appendicitis in Times of COVID-19,,Completed,No Results Available,Perforated Appendicitis|Covid19,Other: appendectomy,rate of perforated appendicitis,University Hospital Tuebingen,All,"16 Years and older Â  (Child, Adult, Older Adult)",,143,Other,Observational,Observational Model: Cohort|Time Perspective: Other,AZ: 324/2020BO2,31-May-20,16-Mar-20,76,31-May-20,15-Jul-20,,15-Jul-20,"University Hospital of Tuebingen, Tuebingen, Germany",,https://ClinicalTrials.gov/show/NCT04472052
586,NCT04508556,Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study,COVID,Completed,No Results Available,Covid19,Device: Breath Biopsy face masks with removable filters and fitted PVA strip|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: oropharyngeal swabs,Positive control for technical validation|Evaluation of test performance,Owlstone Ltd|OLVG|Maastricht University,All,"18 Years and older Â  (Adult, Older Adult)",,40,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SARS-CoV-2 study,19-Dec-20,30-Sep-20,80,19-Dec-20,11-Aug-20,,1-Apr-21,"OLVG, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT04508556
587,NCT04830943,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,,Completed,No Results Available,Covid19 Related Anosmia and Aguesia,Drug: Cerebrolysin,The smell and taste questionnaire component of the National Health and Nutrition Examination Survey (NHNES). And the modified Arabic translated and validated sniffin' sticks odor identification test was used for objective olfactory evaluations.|The short modified version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS)|The Globas Rating for smell (GRS)|The Globas Rating for taste (GRT),Assiut University,All,20 Years to 60 Years Â  (Adult),Phase 4,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-NGF/AUH_SAH/2020,30-Mar-21,1-Aug-20,241,28-Feb-21,5-Apr-21,,5-Apr-21,"Assiut University Hospitals, Faculty of Medicine, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04830943
588,NCT04355702,Covid-19 in Lupus Patients,,Completed,No Results Available,Systemic Lupus Erythematosus|Covid-19,,prevalence and severity of Covid-19 infection in patients with SLE|prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine,"University Hospital, Montpellier",All,"18 Years to 90 Years Â  (Adult, Older Adult)",,130,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0219,30-Dec-20,1-Mar-20,304,1-Dec-20,21-Apr-20,,1-Mar-21,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04355702
589,NCT04601012,OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection,,Completed,No Results Available,Covid19,Diagnostic Test: Optical coherence tomography angiography,"The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography.",Federico II University,All,18 Years to 60 Years Â  (Adult),,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2020/03,22-Oct-20,20-Sep-20,32,20-Oct-20,23-Oct-20,,19-Jan-21,"University of Naples ""Federico II"", Naples, Italy",,https://ClinicalTrials.gov/show/NCT04601012
590,NCT04625985,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",DMMETCOV19-2,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Metformin Glycinate|Drug: Placebo oral tablet,Viral load|consciousness level|temperature|systolic blood pressure|Oxigen saturation|Heart rate|respiratory rate|Days of hospitalization|Days of supplementary oxygen if applies|Days of supplementary mechanical ventilation|Toxicity of study drug assessed by incidence of adverse events (grade 3 or 4)|Changes in laboratory test results,Laboratorios Silanes S.A. de C.V.,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SIL-30000-II-20(2),18-Mar-21,14-Jul-20,247,8-Mar-21,12-Nov-20,,8-Apr-21,"The American British Cowdray Medical Center, I.A.P, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT04625985
591,NCT04292964,Prognostic Factors of Patients With COVID-19,,Completed,No Results Available,"SARS-CoV-2|Outcome, Fatal",,all-cause mortality|Severe state,Chongqing Medical University,All,"18 Years and older Â  (Adult, Older Adult)",,201,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2/2/2020,13-Mar-20,1-Mar-20,12,13-Mar-20,3-Mar-20,,17-Mar-20,"The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,https://ClinicalTrials.gov/show/NCT04292964
592,NCT04337346,Evaluation of Covid 19 Anxiety in Endometriosis Patients,,Completed,No Results Available,Endometriosis|Covid19,,Covid 19 Anxiety levels in Endometriosis Patients,Kanuni Sultan Suleyman Training and Research Hospital,Female,18 Years to 45 Years Â  (Adult),,80,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,endocovid19,25-Apr-20,5-Apr-20,20,20-Apr-20,7-Apr-20,,20-May-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04337346
593,NCT04405999,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,,Completed,No Results Available,Increased Risk of SARS-CoV-2 Infection,Drug: Bromhexine Hydrochloride,Polymerase chain reaction (PCR)|Time to symptoms|Time to positive PCR|Number of cases|Case severity|Drug tolerance,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,05-20-02-Ð¡,31-Aug-20,14-May-20,109,9-Aug-20,28-May-20,,3-Sep-20,"Almazov National Medical Research Centre, Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT04405999
594,NCT04498442,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",,Completed,No Results Available,Covid19|Stress|Anxiety Depression,Behavioral: Simha Kriya|Behavioral: Reading a Book,Change in Perceived Stress Levels|Changes in Resilience Levels|Changes in Covid-19 Prevalence|Changes in self-reported duration of fever and respiratory symptoms in COVID-19 positive participants|Changes in self-reported readiness to return to work in COVID-19 positive participants,Beth Israel Deaconess Medical Center,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,8519,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020P000433,22-Oct-20,22-May-20,153,22-Oct-20,4-Aug-20,,1-Feb-21,"Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04498442
595,NCT04701489,UNITE Study (UMN-GE) for COVID-19,,Completed,No Results Available,Covid19|Cytokine Storm|Inflammation,Device: Splenic ultrasound,Between-arm change of IL-6 levels from baseline to end of treatment between groups|Between-arm change of IL-1Î² levels from baseline to end of treatment between groups|Between-arm change of CRP levels from baseline to end of treatment between groups|Change in time to recovery,University of Minnesota|General Electric Research|DARPA (Department of Defense),All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,STUDY00011290,7-Apr-21,14-Jan-21,83,15-Mar-21,8-Jan-21,,22-Apr-21,"M Health Fairview St. Joseph's Hospital, Saint Paul, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT04701489/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04701489
596,NCT04374071,Early Short Course Corticosteroids in COVID-19,,Completed,No Results Available,"COVID|Pneumonia, Viral",Drug: Methylprednisolone,Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).,Henry Ford Health System,All,"18 Years and older Â  (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HFH IRB # 13739,30-Apr-20,12-Mar-20,49,27-Mar-20,5-May-20,,5-May-20,"Henry Ford Hospital, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04374071
597,NCT04397900,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,,Completed,No Results Available,Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection|Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types,,Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection.|Determine which SARS-CoV-2 proteins are frequently recognized by T cells in patients with varying HLA types.,"TScan Therapeutics, Inc.",All,"Child, Adult, Older Adult",,80,Industry,Observational,Observational Model: Other|Time Perspective: Retrospective,1586788,12-Apr-21,9-Apr-20,368,12-Apr-21,21-May-20,,14-Apr-21,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04397900
598,NCT04874753,The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease,COVID19-CKD,Completed,No Results Available,Covid19|Chronic Kidney Diseases|Proteinuria,Other: change in kidney function and proteinuria,eGFR change|change in proteinuria|initiation of renal replacement therapies,UÅŸak University,All,"18 Years to 85 Years Â  (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,UsakU4,1-Jan-21,3-Nov-20,59,1-Dec-20,6-May-21,,6-May-21,"Usak University, Usak, Turkey",,https://ClinicalTrials.gov/show/NCT04874753
599,NCT04756479,Mortality Due to COVID-19 in the COVID-AGEBRU Study,COVID-AGEBRU,Completed,No Results Available,"Covid19|Old Age; Debility|Morbidity, Multiple",,All-cause mortality during hospital admission (admission up to discharge time)|Prevalence of medical diseases and geriatric syndromes,Brugmann University Hospital,All,70 Years and older Â  (Older Adult),,160,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,COVID-19 AGE-BRUGMANN 2022/111,30-Jun-20,1-Mar-20,121,30-Jun-20,16-Feb-21,,16-Feb-21,"CHU Brugmann, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT04756479
600,NCT04384406,COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Handicall,Completed,No Results Available,Chronic Disabling|COVID-19,,Proportion of patients necessitating the scheduling of a medical consultation|the reason for this urgent need of a medical consultation|the access to other medical services during the quarantine period|the interruption of home-based rehabilitation services,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,467,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0262,9-May-20,1-Apr-20,38,1-May-20,12-May-20,,21-May-20,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04384406
601,NCT04390165,Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study,,Completed,No Results Available,SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia,Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances,Presence or absence of olfactory and taste disturbances in COVID-19 patients|Prevalence of olfactory disturbances in COVID-19 patients|Prevalence of taste disturbances in COVID-19 patients|Clinical manifestations of study participants|Other pre-existing health conditions|Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey,"Hospital Sultanah Bahiyah|Hospital Tuanku Fauziah, Kangar, Perlis|Penang Hospital, Malaysia|Hospital Raja Permaisuri Bainun|Hospital Sungai Buloh, Selangor|Kuala Lumpur General Hospital|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan|Hospital Melaka, Melaka|Hospital Enche Besar Hajjah Khalsom, Kluang, Johor|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu|Hospital Tengku Ampuan Afzan, Kuantan, Pahang|Sarawak General Hospital|Hospital Queen Elizabeth, Malaysia",All,"18 Years and older Â  (Adult, Older Adult)",,498,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,MCO-001|NMRR-20-934-54803,30-Nov-20,6-Jun-20,177,30-Nov-20,15-May-20,,25-Feb-21,"Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia",,https://ClinicalTrials.gov/show/NCT04390165
602,NCT04719234,Lung Ultrasonography in COVID-19 Pneumonia,,Completed,No Results Available,Lung Ultrasound|Pneumonia|Covid19,Device: lung ultrasonography,Relationship between Thoracic CT imaging results and LUS results|Characteristics of lesions,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-KAEK-25 2020/5-21,1-Dec-20,15-Jun-20,169,1-Dec-20,22-Jan-21,,22-Jan-21,"University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey",,https://ClinicalTrials.gov/show/NCT04719234
603,NCT04806867,Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia,SePaRIC,Completed,No Results Available,Covid19|Inflammatory Rheumatism|Rheumatoid Arthritis|Spondyloarthritis|Inflammatory Arthritis,Other: SePaRIC-Covid19 cohort,Proportion of patients requiring an advice from the referring rheumatologist following the telephone survey.|Evaluate the association between rheumatologist advice asked by student and/or patient and the factors studied|COVID-19 infection evaluation in the monitored patient population|Proportion of patients informed about COVID-19|Evaluate the association between the increase in rheumatic activity perceived by patients and the factors studied|Evaluate the association between pain increase perceived by patients and the factors studied|Evaluate the association between rheumatologist advice asked by student and the factors studied|Evaluate the association between rheumatologist advice asked by patient and the factors studied|To evaluate the satisfaction of the telephone call with patients and students. Time Frame: phone call day,"University Hospital, Limoges",All,"18 Years and older Â  (Adult, Older Adult)",,918,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,87RI20_0044 (SePaRIC),31-Jul-20,1-May-20,91,1-Jul-20,19-Mar-21,,1-Apr-21,"Service de Rhumatologie, CHu de Limoges, Limoges, France",,https://ClinicalTrials.gov/show/NCT04806867
604,NCT04452682,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,,Completed,No Results Available,COVID|Critical Limb Ischemia,Other: COVID 19 impact,The ICU admission with associated Pneumonia|Impact of COVID-19 on the different presentation of vascular surgery at the emergency|Mortality rates,Mansoura University,,"Child, Adult, Older Adult",,998,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,R.20.06.898 - 2020/06/16,21-Jun-20,25-May-20,27,21-Jun-20,30-Jun-20,,30-Jun-20,"Mansoura university, Mansoura, Egypt",,https://ClinicalTrials.gov/show/NCT04452682
605,NCT04412031,Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,PredictCovid19,Completed,No Results Available,to Predict an Unfavorable Evolution of Covid-19 at the Hospital Admission of Patients,Other: non applicable,"Need of mechanical ventilation, transfer to an intensive care unit or death within 21 days of admission.",Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,802,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20_185,15-May-20,11-Nov-19,186,14-May-20,2-Jun-20,,2-Jun-20,"HÃ´pital E Herriot - Hospices Civils de LYON, Lyon, France",,https://ClinicalTrials.gov/show/NCT04412031
606,NCT04346420,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,,Completed,No Results Available,COVID|Hypoxemia,Other: Standard interface|Device: Double-Trunk Mask,Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DTM-001,1-May-20,9-Apr-20,22,1-May-20,15-Apr-20,,9-Jun-20,"Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",,https://ClinicalTrials.gov/show/NCT04346420
607,NCT04424017,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,,Completed,No Results Available,COVID|Corona Virus Infection,Biological: Specific anti-SARS-CoV-2 antibodies,Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies,"Egyptian Center for Research and Regenerative Medicine|Cairo University|National Research Centre, Egypt|Academy of Scientific Research and Technology, Egypt",All,18 Years to 60 Years Â  (Adult),,1546,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,COVID-19\004,30-Oct-20,7-Jun-20,145,30-Oct-20,9-Jun-20,,9-Mar-21,"ECRRM, Cairo, Egypt|Faculty of Medicine, Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04424017
608,NCT04668196,Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR),CATCOVID-AIR,Completed,No Results Available,Covid19|Acute Respiratory Failure|Corona Virus Infection,Device: High-flow nasal cannula treatment|Device: Continuous positive airway pressure (CPAP) treatment|Device: Noninvasive ventilation treatment,Treatment failure|28-day mortality|Hospital mortality|Endotracheal intubation|Duration of hospital stay,Hospital Universitari Vall d'Hebron Research Institute|Barcelona Institute for Global Health,All,"18 Years and older Â  (Adult, Older Adult)",,367,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PR(AG)265/2020,25-Jan-21,22-May-20,248,25-Jan-21,16-Dec-20,,13-Apr-21,"Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|FundaciÃ³ Althaia, Manresa, Barcelona, Spain|CorporaciÃ³ SanitÃ ria Parc TaulÃ­, Sabadell, Barcelona, Spain|Hospital Universitari MÃºtua Terrassa, Terrassa, Bardelona, Spain|Hospital del Mar, Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Dr.Josep Trueta, Girona, Spain",,https://ClinicalTrials.gov/show/NCT04668196
609,NCT04407286,Vitamin D Testing and Treatment for COVID 19,,Completed,No Results Available,Covid 19|Vitamin D Deficiency,Dietary Supplement: Vitamin D3,Vitamin D levels|severity of COVID 19 symptoms,Arizona State University|Southwest College of Naturopathic Medicine,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,41,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00011960,30-Nov-20,19-May-20,195,30-Aug-20,29-May-20,,2-Dec-20,"Arizona State University, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04407286
610,NCT04839094,Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19.,RESTART,Completed,No Results Available,SARS-CoV-2,Diagnostic Test: rapid antigen testing versus RT-PCR,Diagnostic assessment|Limit of detection determination.,Centre Hospitalier Universitaire Vaudois,All,"18 Years and older Â  (Adult, Older Adult)",,58,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Q2059,1-Feb-21,10-Dec-20,53,1-Feb-21,9-Apr-21,,9-Apr-21,"Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT04839094
611,NCT04628637,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,,Completed,No Results Available,Covid19|Endoplasmic Reticulum Stress,Other: Serum protein level analysis,"Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to control group|Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to Covid-19 negative pneumonia group.|Determination of the correlations between laboratory parameters, clinical parameters and radiological parameters",Kafkas University|Pamukkale University Faculty of Medicine|Acibadem Mehmet Ali Aydinlar University Faculty of Medicine,All,"18 Years and older Â  (Adult, Older Adult)",,144,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Clinical-2,10-Oct-20,16-Apr-20,177,1-Oct-20,13-Nov-20,,13-Nov-20,"Aylin Koseler, Denizli, Outside Of The US, Turkey",,https://ClinicalTrials.gov/show/NCT04628637
612,NCT04590352,Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients,MuCo,Completed,No Results Available,SARS-CoV-2 Infection,Procedure: nasopharyngeal and throat swab|Procedure: collection of mucosal lining fluid|Procedure: blood collection via fingerprick,Mucosal antibodies|Mucosal antibodies in all participants|SARS-CoV-2 infection|Serum antibodies|Functional antibody assays,Radboud University,All,"Child, Adult, Older Adult",,187,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-6342|NL73418.091.20,13-May-20,26-Mar-20,48,13-May-20,19-Oct-20,,29-Jan-21,"Radboudumc, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT04590352
613,NCT04420247,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,,Completed,No Results Available,COVID|COVID-19|SARS-CoV 2|Coronavirus|Corona Virus Infection,Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care,World Health Organization (WHO) 9-levels ordinal scale (from 0-8)|Mortality|Ventilation free days|ICU Lenght of Stay|Hospital Lenght of Stay|Acute Kidney Disease incidence|Percentage of patients needing dialysis|Coagulopathy incidence|Mean of C Reactive Protein Levels|Sequential Organ Failure Assessment (SOFA) scores|Neutrophils/lymphocytes ratio,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,142,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLOROTRIAL,3-Sep-20,16-Apr-20,140,20-Aug-20,9-Jun-20,,12-May-21,"Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil",,https://ClinicalTrials.gov/show/NCT04420247
614,NCT04412057,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,,Completed,No Results Available,COVID-19 Pneumonia|Acute Lung Injury|ARDS,Drug: CERC-002|Drug: Placebo,Proportion of patient alive and free of respiratory failure|Proportion of subjects who are alive,"Aevi Genomic Medicine, LLC, a Cerecor company|Cerecor Inc",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,83,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CERC-002-CVID-201,19-Jan-21,9-Jun-20,224,2-Dec-20,2-Jun-20,,2-Mar-21,"Hoag Memorial Hospital, Newport Beach, California, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Parkview Research Center, Fort Wayne, Indiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|LSUHSC - Shreveport, Shreveport, Louisiana, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|AnMed Health Medical Center, Anderson, South Carolina, United States|Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States|BRCR Global Texas, McAllen, Texas, United States",,https://ClinicalTrials.gov/show/NCT04412057
615,NCT04898166,Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).,,Completed,No Results Available,Androgenetic Alopecia|Coronavirus Disease 2019|Covid19|Male Pattern Baldness|Female Pattern Baldness|COVID-19 Pneumonia,,"Androgenetic alopecia prevalence in participants.|Severity of androgenetic alopecia in patients|Disease outcome as assessed by number of participants experiencing better or worst outcome.|Age of each participant.|Comorbidities including diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity in participants|Disease duration of COVID-19",Syeda Mahanum Ali|Jinnah Postgraduate Medical Centre,All,"20 Years to 100 Years Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NO.F.2-81/2021-GEN/56923/JPMC,31-Mar-21,1-Dec-20,120,31-Mar-21,24-May-21,,24-May-21,"Jinnah postgraduate medical center, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT04898166
616,NCT04405544,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,,Completed,No Results Available,Encephalopathy|COVID,Diagnostic Test: CT-scan|Diagnostic Test: EEG|Diagnostic Test: EP|Diagnostic Test: Pulse oximetry|Diagnostic Test: Blood tests,The percentage of patients who have developed encephalopathy,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",All,18 Years to 60 Years Â  (Adult),Not Applicable,51,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NMSC-01-20,29-Oct-20,22-May-20,160,22-Jul-20,28-May-20,,30-Oct-20,"N.I. Pirogov National Medical and Surgical Center, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04405544
617,NCT04579627,"Facial Hair, PPE and COVID-19",FACIAL HAIR,Completed,No Results Available,COVID|Safety Issues,Behavioral: Questionnaire,Change in facial hair between January 2020 and during April 2020.|Does facial hair change adhere to the PPE guidance from PHE,Royal Cornwall Hospitals Trust,All,"Child, Adult, Older Adult",,358,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,283609,8-Jun-20,14-May-20,25,8-Jun-20,8-Oct-20,,8-Oct-20,"Royal Cornwall Hospital, Truro, Cornwall, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04579627/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04579627/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04579627
618,NCT04699097,The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children,,Completed,No Results Available,Azithromycin Adverse Reaction|Covid19|Long QT Syndrome,Drug: Azithromycin,Effect of azitromycin on ventricle repolarization,Kayseri City Hospital,All,"1 Year to 18 Years Â  (Child, Adult)",,105,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,139,1-Nov-20,1-Jul-20,123,1-Sep-20,7-Jan-21,,7-Jan-21,"SÃ¼leyman Sunkak, Kayseri, In The USA Or Canada, Please Select..., Turkey",,https://ClinicalTrials.gov/show/NCT04699097
619,NCT04754633,Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines,,Completed,No Results Available,Covid19|Infection Viral|CT Scan,,Current study evaluating the success of the guidelines recommended by RSNA and BSTI in detecting COVID-19 disease,Seyhmus Kavak|Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,764,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,2020/588,20-Jul-20,1-Jul-20,19,20-Jul-20,15-Feb-21,,15-Feb-21,"SaÄŸlik Bilimleri Ãœniversitesi Training and Research Hospital, DiyarbakÄ±r, Turkey",,https://ClinicalTrials.gov/show/NCT04754633
620,NCT04896944,Is Precariousness a Risk Factor for COVID-19 Mortality in Intensive Care?,,Completed,No Results Available,Precariousness|Critically Ill|Covid19,Other: No intervention,Mortality|Mortality in ICU|ICU length of stay|Hospital length of stay,Centre Hospitalier de Saint-Denis,All,"18 Years and older Â  (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Centre Hospitalier Saint Denis,30-Apr-21,13-Mar-20,413,30-Apr-21,21-May-21,,21-May-21,"Centre Hospitalier de Saint Denis, Saint-Denis, France",,https://ClinicalTrials.gov/show/NCT04896944
621,NCT04629638,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,,Completed,No Results Available,"Covid19|Depression, Anxiety|Pregnancy Related","Other: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores",Maternal attachment in SARS- cov2 positive and negative pregnant women|Edinburgh depression scores in in SARS- cov2 positive and negative pregnant women|Postpartum anxiety scale scores in in SARS- cov2 positive and negative pregnant women,Kanuni Sultan Suleyman Training and Research Hospital,Female,18 Years to 45 Years Â  (Adult),,500,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,maternalattachmentcovid,20-Nov-20,1-Aug-20,111,15-Nov-20,16-Nov-20,,22-Dec-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04629638
622,NCT04432922,"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",,Completed,No Results Available,COVID19,Other: Hospitalized Patients for COVID-19 Infection,"To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients",Centre Hospitalier Intercommunal Creteil,All,"18 Years and older Â  (Adult, Older Adult)",,15,Other,Observational,Observational Model: Other|Time Perspective: Prospective,ISOCOV,15-Nov-20,1-Nov-20,14,15-Nov-20,16-Jun-20,,23-Feb-21,"Centre hospitalier intercommunal de Villeneuve St Georges, Villeneuve St Georges, France",,https://ClinicalTrials.gov/show/NCT04432922
623,NCT04641182,Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,,Completed,No Results Available,Covid19|Ards|Respiratory Failure,Other: Prone position,Therapeutic failure|Mortality|Length of hospital stay|Days requiring high flow nasal oxygen|Days requiring supplemental oxygen|Displacement of invasive devices during position changes|Occurrence of pressure ulcers on the anterior surface of the body|Respiratory superinfection|Delirium|Caloric intake|Proteic intake,Pontificia Universidad Catolica de Chile,All,"18 Years and older Â  (Adult, Older Adult)",,66,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1,16-Sep-20,6-Jul-20,72,16-Aug-20,23-Nov-20,,23-Nov-20,"Hospital Clinico Red de Salud UC - Christus, Santiago, Region Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT04641182
624,NCT04467931,ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,,Completed,No Results Available,Hypertension|COVID,Drug: ACEI/ARB|Drug: Non-ACEI/ARB|Drug: ACEI|Drug: ARB,All-Cause-Hospitalization or All-Cause Mortality|All-Cause Mortality|ICU admission|Mechanical ventilation|Dialysis,University of Utah|VA Salt Lake City Health Care System|University of Pennsylvania|Wake Forest University Health Sciences|University of Florida|Johns Hopkins Bloomberg School of Public Health|Boston University|Northwestern University|Edith Nourse Rogers Memorial Veterans Hospital|Columbia University|MedStar Georgetown University Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,22213,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Retrospective,132408,31-Dec-20,19-Jan-20,347,21-Oct-20,13-Jul-20,,28-Apr-21,"University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04467931/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04467931
625,NCT04581811,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),,Completed,No Results Available,ARDS|Covid19|Acute Hypoxemic Respiratory Failure,Other: Prolonged Proned Positioning|Other: Traditional Proning Arm,Duration in prone position|Change in P:F ratio|Change in Drive Pressure|Unplanned extubations|Pressure ulcers|Line displacement|Vent Free Days|Mortality|Rescue Interventions|Tracheostomy|ICU Free Days|S:F Ratio,University of Alabama at Birmingham,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-300005979,20-Mar-21,10-Nov-20,130,20-Mar-21,9-Oct-20,,25-May-21,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04581811
626,NCT04311697,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,COVID-AIV,Completed,No Results Available,Critical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection|Acute Lung Injury,Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care,Resolution of Respiratory Failure (Composite Endpoint)|Improvement on NIAID Scale (key secondary measure)|Survival through day 28 and day 60|Time to ICU discharge|Time on ventilation|Time to extubation|Time to discharge alive|Multi-organ failure free days,"NeuroRx, Inc.|Lavin Consulting, LLC",All,"18 Years to 100 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,196,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COVID-AIV,22-Feb-21,15-May-20,283,22-Feb-21,17-Mar-20,,26-Feb-21,"St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Heartland/Mosaic Health, Saint Joseph, Missouri, United States|Hendrick Health, Abilene, Texas, United States|Texas Health Harris Methodist Hospital, Fort Worth, Texas, United States|Texas Health Hospital Frisco, Frisco, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04311697
627,NCT04422873,The Impact of COVID-19 on Dialysis Users,,Completed,No Results Available,End Stage Renal Disease|Sars-CoV2,,"Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours|Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK",University of Portsmouth|Portsmouth Hospitals NHS Trust|University of Reading,All,"18 Years and older Â  (Adult, Older Adult)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,4,15-Mar-21,10-Jun-20,278,15-Jul-20,9-Jun-20,,28-Apr-21,"School of Sport, Health and Exercise Science, Portsmouth, Outside The United States Or Canada, United Kingdom",,https://ClinicalTrials.gov/show/NCT04422873
628,NCT04480398,Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,,Completed,No Results Available,Covid19|Asymptomatic Condition,Drug: Guduchi Ghan Vati,Virologic clearance|Change in the number of patients going from asymptomatic to moderately disease|Hospital Stay|Clinically relevant adverse effects,"Aarogyam UK|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University|Samta Ayurveda Prakoshtha, India",All,"18 Years to 75 Years Â  (Adult, Older Adult)",,91,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,AYU/DSSR/02,3-Jul-20,12-May-20,52,15-Jun-20,21-Jul-20,,22-Jul-20,"Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT04480398
629,NCT04813770,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,,Completed,No Results Available,Vaccination|Covid19,Behavioral: Theory-based messages|Behavioral: General messages,Covid-19 vaccination intention measured by a single item and aggregated as the proportion of intenders.|Mean COVID-19 illness coherence score as assessed by the IPQ-R|Mean perceived necessity score as assessed by the BMQ|Mean perceived concerns score as assessed by the BMQ,University of Glasgow,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,1113,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,200200052,26-Apr-21,6-Apr-21,20,26-Apr-21,24-Mar-21,,10-May-21,"University of Glasgow, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT04813770
630,NCT04385901,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,,Completed,No Results Available,SARS-CoV 2|SARS Pneumonia,Behavioral: Therapy Intervention,Change in 6 Minute Walk Test|Change in Short Form 35 (SF-36) Questionnaire|Change in Strength testing|Change in Peak Flow Meter Test,University of Missouri-Columbia,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COVID19Recovery,19-Sep-20,19-May-20,123,19-Sep-20,13-May-20,,8-Feb-21,"Missouri Orthopedic Institute, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04385901
631,NCT04454333,COVID-19 in Pain Perspective,,Completed,No Results Available,Infection|COVID|Pain,,Numeric Rating Scale for Pain|Hospital Anxiety and Depression Scale (HADS)|SF-12 Health assesment Questionaire,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years to 95 Years Â  (Adult, Older Adult)",,466,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2811,20-Jun-20,3-Jun-20,17,18-Jun-20,1-Jul-20,,1-Jul-20,"ÅžiÅŸli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04454333
632,NCT04565106,Automatic Oxygen Titration With O2maticÂ® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,O2matic-COVI,Completed,No Results Available,Covid19|Hypoxemic Respiratory Failure|Hypoxemia,Device: Closed-loop control of oxygen supplementation by O2matic,Time in SpO2 target|Time with SpO2 not more than 2 % outside target|Time with SpO2 more than 2 % outside target|Time with SpO2 < 85 %,Hvidovre University Hospital|Innovation Fund Denmark,All,"18 Years and older Â  (Adult, Older Adult)",,16,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,O2matic-COVID,31-May-20,15-Apr-20,46,31-May-20,25-Sep-20,,25-Sep-20,"Hvidovre University Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04565106
633,NCT04367545,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,MolCOVID,Completed,No Results Available,COVID|RT-ddPCR Multiplex,Diagnostic Test: Saliva collection,Number of positive patient using saliva method compared to number of positive patient using standard method|Number of negative patient using saliva method compared to number of negative patient using standard method,"University Hospital, Rouen",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2020/0094/OB,17-May-20,16-Apr-20,31,17-May-20,29-Apr-20,,5-Nov-20,"Rouen University Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT04367545
634,NCT04530357,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine",,Completed,No Results Available,Covid19|SARS-CoV Infection|Vaccine Adverse Reaction,Biological: QazCovid-inÂ® - COVID-19 inactivated vaccine|Other: Placebo,"Frequency of adverse events up to seven days after immunization|Frequency of adverse events up to 21 days after immunization|The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo|Changing of virus-neutralizing antibodies to SARS-CoV-2 virus in blood serum samples|Incidence of serious adverse events during the study|Cell-mediated immune profile",Research Institute for Biological Safety Problems|National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Phase 1|Phase 2,244,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,QAZCOV-I/II-01/2020,25-Apr-21,19-Sep-20,218,25-Nov-20,28-Aug-20,,4-May-21,"Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan",,https://ClinicalTrials.gov/show/NCT04530357
635,NCT04475588,Efficacy and Safety of Itolizumab in COVID-19 Complications,,Completed,Has Results,Acute Respiratory Distress Syndrome|Cytokine Release Syndrome|Covid19,Drug: Itolizumab IV infusion|Drug: Best supportive care (BSC),"One-month Mortality Rate Between the Two Arms|Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2|Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV)|Reduction in Proportion of Patients on Non-invasive Ventilation|Lung Function Assessment - Proportion of Patients With Stable PaO2 Without Increasing FiO2|Reduction in Proportion of Patients- Invasive Mechanical Ventilation|Reduction in Proportion of Patients-High Flow Nasal Oxygen|Mean Change From Baseline in Ferritin|Mean Change From Baseline in LDH|Mean Change From Baseline in CRP (C-reactive Protein)|Mean Change From Baseline D-Dimer|Mean Change From Baseline of Absolute Lymphocyte Count|Biomarkers (IL-6, TNF-a)|Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio)|Radiological Response",Biocon Limited,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 2,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITOLI-C19-02-I-00,7-Jul-20,1-May-20,67,7-Jul-20,17-Jul-20,20-May-21,20-May-21,"Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India|Seth GS Medical College and KEM Hospital, Mumbai, India|MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India|All India Institute Of Medical Sciences, New Delhi, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04475588/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04475588/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04475588
636,NCT04534569,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),,Completed,No Results Available,Covid19|Acute Respiratory Failure|Acute Respiratory Distress Syndrome,Other: Experts consensus,Consensus using participating experts opinions.,NMC Specialty Hospital,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C19ARFstudy,6-Oct-20,4-Sep-20,32,3-Oct-20,1-Sep-20,,8-Oct-20,"NMC Specialty Hospital, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT04534569
637,NCT04720794,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,,Completed,No Results Available,Covid19|SARS (Severe Acute Respiratory Syndrome)|Corona Virus Infection,Device: Lucira COVID-19 All-In-One test kit,COVID-19 Prevalence Rate / Expected Values counts|COVID-19 Prevalence Rate / Expected Values percentages|Collection Performance/ Incidence Rate counts|Collection Performance/ Incidence Rate percentages|Sensitivity and specificity,Lucira Health Inc,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,101,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,07A-CLI-006,20-Oct-20,25-Sep-20,25,20-Oct-20,22-Jan-21,,26-Jan-21,"Neeraj Kochhar Family Medicine, Los Gatos, California, United States",,https://ClinicalTrials.gov/show/NCT04720794
638,NCT04649931,Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease),,Completed,No Results Available,SARS (Severe Acute Respiratory Syndrome)|Covid19,Device: Ion Mobility Spectrometry (IMS),SARS-CoV-2 related volatile organic compounds (VOC)|To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 (Corona Virus Disease 2019),B. Braun Melsungen AG|CeGaT GmbH,All,"18 Years and older Â  (Adult, Older Adult)",,450,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HC-N-H-2006,25-Apr-21,14-Dec-20,132,25-Apr-21,2-Dec-20,,3-May-21,"University Hospital GieÃŸen and Marburg (UKGM), site Marburg, Marburg, Germany",,https://ClinicalTrials.gov/show/NCT04649931
639,NCT04407468,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,APRONOX,Completed,No Results Available,COVID|ARDS|Pneumonia,Procedure: Prone position,To analyze the relationship between the prone position and the need for orotracheal intubation.|The impact of the prone position on the partial oxygen saturation / inspired oxygen fraction index (SaO2 / FiO2).,Hospital General San Juan del Rio|Instituto Nacional de Cancerologia de Mexico,All,"18 Years and older Â  (Adult, Older Adult)",,827,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,1178/SESEQ-HSGJR/08-05-20/UTI,13-Jul-20,1-May-20,73,13-Jul-20,29-May-20,,15-Jul-20,"Hospital Materno Celaya, Celaya, Guanajuato, Mexico|Hospital Santo Tomas, QuerÃ©taro City, Queretaro, Mexico|Hospital General San Juan del Rio, QuerÃ©taro City, Queretaro, Mexico|ISSSTE Hospital Regional Merida, MÃ©rida, Yucatan, Mexico|Hospital General de Zona 48 San PEDRO Xalpa IMSS, Estado De MÃ©xico, Mexico|Hospital Fernando Quiroz Gutierrez, Mexico City, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04407468/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04407468
640,NCT04365595,SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),,Completed,No Results Available,SARS-CoV 2|COVID,"Other: Questionnaires, spirometry",Health-related quality-of-life|Anxiety and depression|Symptom burden|Spirometry,University of Zurich,All,"18 Years and older Â  (Adult, Older Adult)",,58,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2020-00745,17-Feb-21,3-Jun-20,259,17-Feb-21,28-Apr-20,,23-Feb-21,"University Hospital Zurich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT04365595
641,NCT04412304,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,,Completed,No Results Available,Covid-19|Thromboembolic Events|Bleeding,Drug: Dose of Tinzaparin or Dalteparin,28-days ICU mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission.,Karolinska Institutet,All,"Child, Adult, Older Adult",,166,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Anticoagulant therapy Covid-19,28-May-20,6-Mar-20,83,30-Apr-20,2-Jun-20,,22-Jun-20,"South General Hospital, Stockholm, Stockholms LÃ¤n, Sweden",,https://ClinicalTrials.gov/show/NCT04412304
642,NCT04382417,Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,,Completed,No Results Available,Covid-19|Critical Illness,Other: Observational study,All-cause mortality|Hospital length of stay|ICU length of stay|Number of days on mechanical ventilation|Number of patients receiving vasopressor support|Number of patients receiving renal replacement therapy|Patient characteristics,Region VÃ¤stmanland,All,"18 Years and older Â  (Adult, Older Adult)",,57,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RegionVastmanland,12-Nov-20,26-Mar-20,231,12-Nov-20,11-May-20,,15-Mar-21,"Intensive Care Unit, VÃ¤sterÃ¥s Hospital, VÃ¤sterÃ¥s, VÃ¤stmanland, Sweden",,https://ClinicalTrials.gov/show/NCT04382417
643,NCT04611269,Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,SATICOVID19,Completed,No Results Available,Respiratory Failure|Covid-19|Mechanical Ventilation,,ICU Mortality|Hospital mortality,Argentinian Intensive Care Society,All,"18 Years and older Â  (Adult, Older Adult)",,950,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SATI,31-Oct-20,20-Mar-20,225,31-Oct-20,2-Nov-20,,13-Nov-20,"Hospital Interzonal General de Agudos Gral. San MartÃ­n, La Plata, BA, Argentina|Sanatorio Las Lomas, san Isidro, BA, Argentina|Hospital General de Agudos Juan A. FernÃ¡ndez, Buenos Aires, Caba, Argentina|Sanatorio Anchorena Recoleta, Buenos Aires, Caba, Argentina|Sanatorio Otamendi, Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04611269
644,NCT04646642,"Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers",,Completed,No Results Available,Coping Skills|Healthcare Workers|Covid19,,Positive Patient Health Questionnaire-2 (PHQ-2)|Positive PHQ-2 + High risk COVID physical condition|Positive PHQ-2 + pre-existing mental health conditions|Positive Generalized Anxiety Disorder-2 (GAD-2)|Positive GAD-2 + High risk COVID physical condition|Positive GAD-2 + pre-existing mental health conditions|Positive Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI-A)|Positive PSQI-A + High risk COVID physical condition|Positive PSQI-A + pre-existing mental health conditions|Deployer Identified COVID-19 Stressors|Positive Brief Coping Orientation to Problems Experienced (Brief COPE)|Negative Brief Coping Orientation to Problems Experienced (Brief COPE)|COVID-19 Coping Strategy and Resource Inventory|Demographic questionnaire,David Grant U.S. Air Force Medical Center,All,"Child, Adult, Older Adult",,21,U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,FWH20200203E,1-Feb-21,14-Dec-20,49,1-Feb-21,30-Nov-20,,2-Apr-21,"David Grant Medical Center (DGMC), Travis Air Force Base, California, United States",,https://ClinicalTrials.gov/show/NCT04646642
645,NCT04391738,Association Between BMI and COVID-19,BMI-SARS-CoV-2,Completed,No Results Available,SARS-CoV 2,Other: Patients admitted to Intensive Care Unit with SARS-CoV2,Relationship between body mass index (BMI) and SARS-CoV-2|Associations between BMI and outcomes is independent of the known cardiometabolic risk factors|Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation|Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,1200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DEC20-095,1-Sep-20,1-Feb-20,213,15-May-20,18-May-20,,26-Mar-21,"Centre Hospitalier RÃ©gional & Universitaire de Lille (CHRU), Lille, France",,https://ClinicalTrials.gov/show/NCT04391738
646,NCT04700254,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece",,Completed,No Results Available,Diabetes Mellitus|SARS-CoV-2,Other: DASS questionnaire|Other: EAT-26 questionnaire,DASS (Depression)|DASS (Anxiety)|Eating Attitudes Test (EAT-26),"Chania General Hospital ""St. George""|AHEPA University Hospital of Thessaloniki Thessaloniki, Greece",All,"18 Years to 85 Years Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Diabetes and COVID-19,11-Jan-21,28-Dec-20,14,11-Jan-21,7-Jan-21,,25-Jan-21,"General Hospital of Chania, Chania, Crete, Greece",,https://ClinicalTrials.gov/show/NCT04700254
647,NCT04371692,Prevalence of COVID-19 Infection Among HCW in a French University Hospital,EXPOCOVIA,Completed,No Results Available,Sars-CoV2,Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing,the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care Worker,"University Hospital, Lille|Fondation SantÃ© Roquette",All,"18 Years and older Â  (Adult, Older Adult)",,900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_35|2020-A00951-38,9-Jul-20,15-Jun-20,24,9-Jul-20,1-May-20,,23-Apr-21,"Hop Claude Huriez Chu Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04371692
648,NCT04435522,Maraviroc in Patients With Moderate and Severe COVID-19,,Completed,No Results Available,COVID,Drug: Maraviroc,Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng/mL)|Change in Interleukin-6 (IL-6) (pg/mL)|Change in CCL5 (RANTES) (ng/mL)|Mortality|Time to Discharge|Days on mechanical ventilation,Rhode Island Hospital,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1611471-1,31-Dec-20,1-Oct-20,91,31-Dec-20,17-Jun-20,,4-Feb-21,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04435522
649,NCT04558645,Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,,Completed,No Results Available,Type 1 Diabetes Mellitus|Covid19,Other: Online Survey,Physical activity level|General Quality of life|Depression|Anxiety|Self-reported hypoglycemia|Loneliness|Hypoglisemia fear|Dyspnea,Gazi University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,118,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,91610558-604.01.02,26-Dec-20,18-Sep-20,99,18-Dec-20,22-Sep-20,,29-Dec-20,"Zeliha Ã‡ELÄ°K, Ankara, Ã‡ankaya, Turkey",,https://ClinicalTrials.gov/show/NCT04558645
650,NCT04359693,Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,COVAPID,Completed,No Results Available,SARS-CoV 2,,Cumulative incidence of ventilator-associated lower respiratory tract infection|Cumulative incidence of ventilator-associated tracheobronchitis|Cumulative incidence of ventilator-associated pneumonia|the cumulative incidence of ICU acquired bacteremia diagnosed|ICU mortality|Mortality|the duration of mechanical ventilation|Length of stay in Intensive Care Unit,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,1576,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_27|2020-A00995-34,1-Jul-20,22-Apr-20,70,1-Jul-20,24-Apr-20,,22-Jul-20,"HÃ´pital Roger Salengro, ICU, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04359693
651,NCT04373109,Stroke Rehabilitation Outcome During COVID-19 Lockdown,SROCL,Completed,No Results Available,Stroke|Rehabilitation|COVID-19|Cohort Studies,Behavioral: Observation,Rehabilitation data|Motor Activity Log - 14 Item Version|International Physical Activity Questionnaire|Patient-Reported Outcomes Measurement Information System - 29 Version|Global Rating of Perceived Changes (physical activity engagement and upper limb use)|Fatigue Severity Scale|Hospital Anxiety and Depression Scale|Montreal Cognitive Assessment|Functional Ambulation Categories|Ten-Meter Walk Test|Rivermead Mobility Index|Activities-specific Balance Confidence Scale|Fugl-Meyer Motor Assessment|Action Research Arm Test|modified Rankin Scale|National Institutes of Health Stroke Scale,Jeremia Held|University of Zurich,All,"18 Years and older Â  (Adult, Older Adult)",,36,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BASEC-Nr. 2020-00761,12-Oct-20,16-Apr-20,179,12-Oct-20,4-May-20,,20-Oct-20,"University Hospital Zurich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT04373109
652,NCT04414267,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,ACTIVATEII,Completed,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection|Coronary Heart Disease|Chronic Obstructive Pulmonary Disease,Biological: BCG vaccine|Biological: Placebo,"Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5|Prevalence of IgG/IgM against SARS-CoV-2|Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19.|The impact of new cardiovascular events between the two study groups|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 5|Differences in cardiac ultrasound at visit 5 between the two sub-study groups|Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups",Hellenic Institute for the Study of Sepsis,All,"50 Years and older Â  (Adult, Older Adult)",Phase 4,301,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Activate II|2020-002448-21,7-May-21,26-May-20,346,28-Apr-21,4-Jun-20,,11-May-21,"General Hospital of Argolida - Nafplion Unit, NÃ¡fplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Therapeutics, Alexandra General Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, IoÃ¡nnina, Greece|Department of Internal Medicine, General Hospital of Karditsa, KardÃ­tsa, Greece|General Hospital of Korinthos, KÃ³rinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolemaá¸¯da, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, ThessalonÃ­ki, Greece|General Hospital of Imathia - Veria Unit, VÃ©ria, Greece",,https://ClinicalTrials.gov/show/NCT04414267
653,NCT04402853,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,,Completed,No Results Available,Sars-CoV2|Tear,Diagnostic Test: Tears swab,Virus presence in COVID 19 patients tears|Concordance to Naso-Pharingeal Swab,UniversitÃ  degli Studi dell'Insubria,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,72/2020,20-May-20,1-Feb-20,109,1-Mar-20,27-May-20,,3-Dec-20,"ASST Sette Laghi, Varese, Italy",,https://ClinicalTrials.gov/show/NCT04402853
654,NCT04619407,"Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers",COKITS,Completed,No Results Available,SARS-CoV-2,Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Serum testing,"Share of participants with SARS-CoV-2 detectable in PCR|Seroprevalence of SARS-CoV-2 antibodies|SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life","University Medicine Greifswald|Ministry of Education, Science and Culture of the State of Mecklenburg-Vorpommern|Ministry of Social Affairs, Integration and Equality of the State of Mecklenburg-Vorpommern|State Office for Health and Social Affairs of the State of Mecklenburg-Vorpommern",All,"3 Years to 67 Years Â  (Child, Adult, Older Adult)",,142,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BB 179/20,26-Mar-21,4-Nov-20,142,26-Mar-21,6-Nov-20,,14-Apr-21,"Greifswald University Medicine, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT04619407
655,NCT04391179,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,DICER,Completed,No Results Available,COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection,Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet,Change in D-dimer|Global composite rank score,University of Michigan,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HUM00179783,22-Feb-21,31-May-20,267,22-Feb-21,18-May-20,,18-Mar-21,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04391179
656,NCT04437940,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,,Completed,No Results Available,COVID|Sars-CoV2,Diagnostic Test: Vaginal fluid Covid-19 PCR test,Vaginal fluid Covid-19 PCR test result|becoming negative from positive,Acibadem University,Female,"18 Years to 70 Years Â  (Adult, Older Adult)",,38,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Acibadem Maslak Ob&Gyn,30-Nov-20,15-Jun-20,168,10-Jul-20,18-Jun-20,,12-Jan-21,"Acibadem Maslak Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04437940
657,NCT04577105,Risk Factors and Computed Tomography Findings in COVID-19.,,Completed,No Results Available,"Covid19|ARDS|Pneumonia, Viral|Computed Tomography",Diagnostic Test: Simple chest tomography,Assessment of the level of suspicion of SARS-CoV2 infection|Evaluate the severity degree of pulmonary affection by chest computed tomography|Percentage of patients requiring endotracheal intubation|Death from any cause|Modified Sequential Organ Failure Assessment (mSOFA)|Sepsis-induced coagulopathy (SIC)|National Early Warning Scale (NEWS 2)|COVID-GRAM severe illness risk score|Rapid Severity Index for COVID-19 (qCSI)|Neutrophil-Lymphocyte Ratio (NLR)|Alveolar-arterial gradient of oxygen|Berlin Criteria for Acute Respiratory Distress Syndrome,Instituto Nacional de Cardiologia Ignacio Chavez,All,"Child, Adult, Older Adult",,233,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-1177,1-Oct-20,1-Apr-20,183,31-Aug-20,6-Oct-20,,8-Oct-20,"Instituto Nacional Ignacio Chavez, Ciudad de mexico, Mexico",,https://ClinicalTrials.gov/show/NCT04577105
658,NCT04466839,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,ERCO-Park,Completed,No Results Available,Parkinson Disease|COVID,Other: Questionnaire and interview,Impact of containment related to the Covid-19 pandemic.|Conditions of containment during the Covid-19 pandemic.|The number of patients infected or possibly infected with Covid-19|Symptoms modifications,"University Hospital, Toulouse",All,"Child, Adult, Older Adult",,411,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,RC31/20/0193,18-Dec-20,2-Jul-20,169,18-Dec-20,10-Jul-20,,23-Mar-21,"Centre Hospitalier RÃ©gionale Universitaire de BesanÃ§on, BesanÃ§on, France|Centre Hospitalier Universitaire Lille, Lille, France|Centre Hospitalier Universitaire de Marseille, Marseille, France|Centre Hospitalier Universitaire de NÃ®mes - Caremeau, Nimes, France|Centre Hospitalier Universitaire de la PitiÃ©-SalpÃªtriÃ¨re, Paris, France|Centre Hospitalier Universitaire de Reims, Reims, France|Centre Hospitalier Universitaire de Rouen, Rouen, France|CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04466839
659,NCT04357340,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,,Completed,No Results Available,Covid-19|Pneumonia|SARS Pneumonia,Other: Pulmonary Physiotherapy Techniques,Mixed venous O2 pressure (PVO2)|Mixed venous CO2 pressure (PVCO2)|PH|HCO3|Oxygen saturation (O2 Sat) from VBG|Three minute walk test|O2 Sat after one minute walking|O2 Sat after two minutes use of Partial Rebreather|O2 Sat after two minutes free air breathing|O2 sat/ Fio2|Mortality rate|Number of participants with Rehospitalization|The Health-Related Quality of Life (HRQOL)|breathlessness,Tehran University of Medical Sciences,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,99-1-103-47429,30-May-20,2-Apr-20,58,30-Apr-20,22-Apr-20,,2-Jun-20,"Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT04357340
660,NCT04449094,Emergence of the COVID 19 Epidemic in the City of Nice,,Completed,No Results Available,COVID,,Attack rate,Centre Hospitalier Universitaire de Nice,All,"Child, Adult, Older Adult",,200,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Retrospective,20dspcovid01,4-Apr-20,28-Feb-20,36,30-Mar-20,26-Jun-20,,26-Jun-20,"CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT04449094
661,NCT04435080,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,,Completed,No Results Available,COVID-19|Acute Respiratory Distress Syndrome|Rehabilitation|Intensive Care Unit Acquired Weakness|Critical Illness Polyneuromyopathy,,Hand grip strength|Short form - 36|Length of stay in intensive care unit|Length of stay in hospital|Duration of invasive mechanical ventilation|Manual muscle strength|Range of joint motion,KoÃ§ University,All,"18 Years and older Â  (Adult, Older Adult)",,35,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020.169.IRB1.037,11-Jun-20,15-Mar-20,88,11-Jun-20,17-Jun-20,,17-Jun-20,"Koc University School of Medicine, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04435080
662,NCT04396197,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,,Completed,No Results Available,COVID-19|Critical Illness|Ards|ICU Acquired Weakness,Other: Physiotherapy,Mobility level|Time taken to first mobilise|Discharge location,University Hospital Birmingham NHS Foundation Trust,All,"18 Years and older Â  (Adult, Older Adult)",,92,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PhysioCOVID-19,8-May-20,1-Mar-20,68,8-May-20,20-May-20,,20-May-20,"UHB NHS Foundation Trust, Birmingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT04396197
663,NCT04357418,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,ICOS,Completed,No Results Available,"Anxiety State|COVID-19|Isolation, Social|Health Personnel Attitude",Other: it is a survey,State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)|Visual numeric scales assessing anger and stress the ongoing week.|Beck Depression Inventory,"Centre hospitalier de Ville-Evrard, France",All,"18 Years and older Â  (Adult, Older Adult)",,187,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,10477M-ICOS,30-Jun-20,1-Apr-20,90,30-Jun-20,22-Apr-20,,3-Aug-20,"URC Ville Evrard, Neuilly-sur-Marne, France",,https://ClinicalTrials.gov/show/NCT04357418
664,NCT04880122,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,,Completed,No Results Available,SARS-CoV-2 Acute Respiratory Disease,Diagnostic Test: Dried blood spot and venous blood collection,Sensitivity and specificity of DBS for SARS-CoV-2 antibody detection|Optimization of the cut-off for seropositivity.,University Ghent,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,440,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,BC-07665,30-Sep-20,1-Aug-20,60,30-Sep-20,10-May-21,,10-May-21,"Ghent University, Ghent, Oost-Vlaanderen, Belgium",,https://ClinicalTrials.gov/show/NCT04880122
665,NCT04366778,Thrombosis and Covid-19,COVBIO,Completed,No Results Available,Thrombosis|Covid-19|SARS-CoV 2,Diagnostic Test: TEM-tPA,Coagulability|Venous thrombotic event (VTE) or arterial thrombosis,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,341,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,69HCL20_0401 - COVBIO|ID-RCB,1-Jan-21,1-May-20,245,1-Jan-21,29-Apr-20,,25-Jan-21,"HÃ´pital Louis Pradel, Bron, France",,https://ClinicalTrials.gov/show/NCT04366778
666,NCT04395755,Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,,Completed,No Results Available,"Infertility, Female|ART|IVF|COVID-19",Behavioral: Generalized Anxiety Disorder-7 (GAD-7)|Behavioral: Patient Health Questionnaire-9 (PHQ-9),Severity of anxiety|Severity of depression,Ospedale Policlinico San Martino,Female,"18 Years and older Â  (Adult, Older Adult)",,503,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19-NOIVF,15-May-20,1-Apr-20,44,15-May-20,20-May-20,,28-Jul-20,"IRCCS Ospedale Policlinico San Martino, Genoa, Italy",,https://ClinicalTrials.gov/show/NCT04395755
667,NCT04705753,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",COVID-19-IAMA,Completed,No Results Available,Covid19|Viral Infection|Respiratory Viral Infection,Dietary Supplement: Cretan IAMA,Number of patients with symptom resolution|Number of people cohabiting with a patient not developing VRI symptoms|Median time to full symptom resolution|Intensity of symptoms|Duration of symptoms|Number of patients whose symptoms never exceeded a score of 3-4 (mild)|Quality of life (QoL) of patients,University of Crete|Galenica SA|Olvos Science SA,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2|Phase 3,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,78/26.03.2020,15-Oct-20,1-Apr-20,197,15-Oct-20,12-Jan-21,,12-Jan-21,"Cretan Medicare, Heraklion, Crete, Greece",,https://ClinicalTrials.gov/show/NCT04705753
668,NCT04395833,National Survey on the Lockdown of Children With Disabilities,ECHO,Completed,No Results Available,Identify Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic,,Experience during lockdown|Health risk during lockdown|Impact on medical and rehabilitation follow up|Impact on daily living,"University Hospital, Brest",All,"up to 18 Years Â  (Child, Adult)",,2500,Other,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,CHRU de BREST ECHO,11-May-20,7-Apr-20,34,11-May-20,20-May-20,,20-May-20,"CHRU de Brest, Brest, France",,https://ClinicalTrials.gov/show/NCT04395833
669,NCT04551690,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),CONSCIENCE,Completed,No Results Available,Pregnancy|Covid19|Labor (Obstetrics)--Complications|Demography,,Prevalence of SARS-CoV-2 in pregnant patients on labor|Characterization of clinical features of patients who tested positive for COVID 19.|Characterization of living conditions of pregnant women with COVID 19|Neonatal hospitalization|Neonatal weight|Perinatal outcomes,"Hospital San Juan de Dios, Santiago",Female,18 Years to 45 Years Â  (Adult),,720,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,COVID 19 Pregnancy HSJD Chile,15-Jul-20,15-Apr-20,91,15-Jul-20,16-Sep-20,,16-Sep-20,"Hospital San Juan de Dios, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT04551690
670,NCT04379258,Analysis of Mortality of Critically Ill Patients With COVID-19,,Completed,No Results Available,"COVID-19|Critical Illness|Effectiveness|Outcome, Fatal",,ICU mortality|hospital mortality|28-day mortality|effectiveness of treatment|length of ICU stay|length of hospital stay|ventilator-associated pneumonia|bacteriemia|barotrauma|duration of mechanical ventilation,Hospital Universitario Getafe|Hospital Universitario del Tajo|Puerta de Hierro University Hospital|Hospital de Henares|Hospital Universitario Ramon y Cajal|Hospital Universitario de MÃ³stoles|Hospital Universitario Severo Ochoa|FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa|Hospital Universitario Madrid Sanchinarro|Hospital Universitario Santa Creu i Sant Pau|Hospital Universitario Infanta Cristina|Hospital General Universitario Gregorio MaraÃ±on|Hospital Universitario de TorrejÃ³n|Hospital Universitario La Paz|Hospital Universitario 12 de Octubre,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,868,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-UCI_Spain,8-Feb-21,8-Feb-21,0,8-Feb-21,7-May-20,,11-Feb-21,"Hospital Universitario de Getafe, Getafe, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04379258
671,NCT04542941,Assessment of Safety and Efficacy of CCP,COVIDIT,Completed,No Results Available,Covid19,Biological: COVID Convalescent Plasma,Time to viral clearance (RT-PCR negativity)|Time to symptom resolution|Time to severe/critical disease|Number of participants reporting an adverse event as evidenced by clinical manifestations,"Makerere University|Uganda Blood Transfusion Services|Joint Clinical Research Center|Uganda Peoples Defence Forces Medical Services|Mulago Hospital, Uganda",All,"18 Years to 100 Years Â  (Adult, Older Adult)",Not Applicable,136,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCP,31-Dec-20,16-Jun-20,198,31-Dec-20,9-Sep-20,,15-Jan-21,"Mulago Specialised Hospital, Kampala, Uganda",,https://ClinicalTrials.gov/show/NCT04542941
672,NCT04344210,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,,Completed,No Results Available,"COVID|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Behavioral: Tele-interventions related to diabetes management and mental well-being,Variation in HbA1c levels|COVID-19 infection|Variation in lipid profile|Variation in blood pressure levels|Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|Comparison of eating disorders between groups|Comparison of adherence to the proposed clinical treatment between groups|Comparison of minor psychiatric disorders between groups|Comparison of sleep pattern changes between groups,Federal University of Rio Grande do Sul,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,149,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2020241093,20-Sep-20,17-Apr-20,156,20-Sep-20,14-Apr-20,,14-Oct-20,"Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT04344210
673,NCT04376905,Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),PiCCOVID,Completed,No Results Available,COVID-19|Pneumonia|Acute Respiratory Distress Syndrome,,Changes of Extra Vascular Lung Water|Changes of Pulmonary Vascular Permeability Index|Changes of pulmonary compliance,"University Hospital, Montpellier",All,"18 Years to 99 Years Â  (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0193,30-Sep-20,1-Apr-20,182,1-Sep-20,6-May-20,,29-Dec-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04376905
674,NCT04472078,"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina",,Completed,No Results Available,SARS-CoV-2,Diagnostic Test: Serological Assay or IgG for SARS-CoV-2,to establish the seroprevalence of SARS-CoV-2,Hospital Italiano de Buenos Aires|Hospital de NiÃ±os R. Gutierrez de Buenos Aires|Salud Comunitaria Ministerio de Salud GCBA,All,"14 Years and older Â  (Child, Adult, Older Adult)",,873,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,1831,11-Dec-20,10-Jun-20,184,26-Jun-20,15-Jul-20,,17-Dec-20,"Hospital de NiÃ±os Ricardo Gutierrez, Buenos Aires, Caba, Argentina",,https://ClinicalTrials.gov/show/NCT04472078
675,NCT04394078,Impact of COVID-19 Pandemic on Depression and Quality of Life,,Completed,No Results Available,Depression|Quality of Life|Covid 19|Social Isolation,Other: Online survey,Sociodemographic information form|Zung Depression Scale|World Health Organization Quality of Life - Bref,Okan University|Yuksek Ihtisas University,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",,543,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,56665618-204.01.07,18-May-20,6-May-20,12,18-May-20,19-May-20,,11-Jun-20,"Okan University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04394078
676,NCT04351399,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,PRPsyCOVID,Completed,No Results Available,Sars-CoV2|Rheumatic Diseases|Rheumatoid Arthritis|Chronic Pain,Other: questionnaire assesment,Frequency of RA patients with emotional impact (feeling of isolation)|self-reported questionnaire for painful,"University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,318,Other,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,2020_29|2020-A00907-32,4-May-20,27-Apr-20,7,4-May-20,17-Apr-20,,11-Dec-20,"Hopital Roger Salengro, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04351399
677,NCT04453566,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",,Completed,No Results Available,COVID-19|Life Satisfaction|Anxiety|Mental Health Wellness 1|Athlete|Stress,Other: Online Survey,Sociodemographic information and training characteristics|The Beck Anxiety Inventory (BAI)|The Visual Analogue Scale (VAS)|Perceived Stress Scale (PSS)|Satisfaction with Life Scale|Brunel mood scale (BRUMS),Uskudar University|New York Medical College,All,18 Years to 35 Years Â  (Adult),,208,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,61351342/ 2020-286,24-Aug-20,27-May-20,89,15-Aug-20,1-Jul-20,,30-Apr-21,"Uskudar University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04453566
678,NCT04407169,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,CRITICoVid,Completed,No Results Available,COVID,Other: no intervention,"Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measured","Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,617,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020PI081,17-Nov-20,1-Jun-20,169,17-Nov-20,29-May-20,,20-Nov-20,"Valentin Simon, Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT04407169
679,NCT04479163,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,,Completed,No Results Available,COVID,Biological: Convalescent Plasma|Other: Placebo,"Development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93%|Life threatening respiratory disease|Critical systemic illness, defined as respiratory failure|Death|Combination of secondary outcomes #2 (Life threatening respiratory disease) and/or #3 (Critical systemic illness, defined as respiratory failure) and//or #4 (death)|Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%.",Fundacion Infant,All,65 Years and older Â  (Older Adult),Not Applicable,165,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",FundacionINFANT-Plasma,25-Oct-20,4-Jun-20,143,25-Oct-20,21-Jul-20,,22-Dec-20,"Hospital Militar Central, Caba, Buenos Aires, Argentina|CEMIC, Caba, Buenos Aires, Argentina|Centro de Investigacion Clinica OSECAC, Caba, Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Caba, Buenos Aires, Argentina|Sanatorio Anchorena, Caba, Buenos Aires, Argentina|Sanatorio de Los Arcos, Caba, Buenos Aires, Argentina|Hospital ""Simplemente Evita"", GonzÃ¡lez CatÃ¡n, Buenos Aires, Argentina|Hospital Especializado de Agudos y CrÃ³nicos ""San Juan de Dios"", La Plata, Buenos Aires, Argentina|Clinica Olivos, Buenos Aires, Argentina|Hospital Central de San Isidro, Buenos Aires, Argentina|Hospital General de Agudos ""Dr. Carlos Bocalandro"", Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04479163
680,NCT04456010,COVID-19 in ART: Perception and Experience,COVAPEX,Completed,No Results Available,COVID19|Fertility Issues|ART,Other: Questionnaire,Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation|Risk assessment|Patients'expectations regarding the management of an abrupt closure of the fertility center,"University Hospital, Montpellier",All,18 Years to 60 Years Â  (Adult),,600,Other,Observational,Observational Model: Other|Time Perspective: Prospective,RECHMPL20_0351,30-Jul-20,1-Jun-20,59,30-Jul-20,2-Jul-20,,29-Dec-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04456010
681,NCT04343261,Convalescent Plasma in the Treatment of COVID 19,,Completed,Has Results,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|COVID|Coronavirus,Biological: Convalescent Plasma,Mortality|Viral Load|Serum Antibody Titers,Saint Francis Care,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Phase 2,48,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SFH-20-23,13-Aug-20,10-Apr-20,125,23-Jul-20,13-Apr-20,17-Sep-20,24-Sep-20,"Trinity Health Of New England, Hartford, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/Prot_SAP_000.pdf|""Informed Consent Form: Donor Consent"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_001.pdf|""Informed Consent Form: Patient Consent"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04343261
682,NCT04816656,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,COVID-ONCO,Completed,No Results Available,Covid19|Oncology|PROMs|Chemotherapeutic Toxicity,Other: ePROMs assessment,Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)|5-level EQ-5D version (EQ5D5L)|Covid-19 triage questionnaire|COVID-19 questionnaire|COVID-19 Peritraumatic Distress Index (CPDI)|Patient satisfaction,Jessa Hospital|Hasselt University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,43,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20.60-onco20.07,22-Mar-21,3-Aug-20,231,1-Feb-21,25-Mar-21,,26-Mar-21,"Hasselt University, Hasselt, Limburg, Belgium|Jessa Ziekenhuis, Hasselt, Limburg, Belgium",,https://ClinicalTrials.gov/show/NCT04816656
683,NCT04319445,Mindfulness During COVID-19,,Completed,No Results Available,Migraine Disorders|Stress|Anxiety,Behavioral: Mindfulness session(s),Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference,Wake Forest University Health Sciences,All,"Child, Adult, Older Adult",Not Applicable,233,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB00064587,30-Mar-21,22-Mar-20,373,31-Aug-20,24-Mar-20,,6-May-21,"Wake Forest Health Sciences, Winston-Salem, North Carolina, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04319445/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04319445
684,NCT04883801,Clinical Outcomes of Newborns Born to Pregnant Women With and Without COVID-19,,Completed,No Results Available,Covid19|Vertical Transmission of Infectious Disease|Neonatal Infection|Pregnancy Related,Diagnostic Test: Reviewed clinical records and laboratory results,Vertical transmission|Neonatal birth outcomes|Neonatal postnatal outcomes,Kahramanmaras Sutcu Imam University,All,19 Years to 45 Years Â  (Adult),,202,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,Newborns outcomes,5-May-21,11-Mar-20,420,11-Mar-21,12-May-21,,12-May-21,"Denizli State Hospital, Denizli, Turkey",,https://ClinicalTrials.gov/show/NCT04883801
685,NCT04381273,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,,Completed,No Results Available,Covid-19|Periodontal Diseases|COVID,Other: No intervention,How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?|Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?|Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life?|Have people changed their oral hygiene practices in times of the Covid-19 pandemic?,Heidelberg University,All,"18 Years and older Â  (Adult, Older Adult)",,1178,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,S-303/2020,8-Aug-20,15-May-20,85,8-Aug-20,8-May-20,,28-Apr-21,"University Hospital Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, Germany",,https://ClinicalTrials.gov/show/NCT04381273
686,NCT04407273,Statin Therapy and COVID-19 Infection,STACOV,Completed,No Results Available,COVID|Statin|Cardiovascular Diseases,Drug: observational,SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy,Institut Investigacio Sanitaria Pere Virgili,All,"18 Years and older Â  (Adult, Older Adult)",,2159,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,106/2020,30-Dec-20,14-May-20,230,20-Aug-20,29-May-20,,11-Mar-21,"Facultat de Medicina i CiÃ¨ncies de la Salut de Reus, Reus, Tarragona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04407273/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04407273
687,NCT04492501,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,,Completed,No Results Available,Covid19|Cytokine Release Syndrome|Critical Illness|ARDS,Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy,survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications,UNICEF|Pak Emirates Military Hospital Rawalpindi,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sultan Mehmood Kamran 3,20-Jul-20,1-Apr-20,110,20-Jul-20,30-Jul-20,,30-Jul-20,"Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04492501
688,NCT04382469,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,,Completed,No Results Available,COVID,,"Radiological pattern of initial presentation, disease progress, healing and recovery|Survey of co-morbid lung diseases",Alexandria University,All,"Child, Adult, Older Adult",,48,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Retrospective,"IRB (00012098), FWA (00018699)",1-May-20,1-Feb-20,90,30-Apr-20,11-May-20,,12-May-20,"Faculty of Medicine, University of Alexandria, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT04382469
689,NCT04570254,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,ANTIOX-COVID,Completed,No Results Available,"Pneumonia, Viral|Covid19|ARDS|Oxidative Stress",Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline,Death from any cause|Percentage of patients who required orotracheal intubation|Assisted mechanical ventilation|Stay in an intensive care unit|Measure lipoperoxidation in basal and post-therapy samples|Evaluation of the total antioxidant capacity|Oxidative and antioxidant stress|Effect of antioxidant therapy at the level on organ failure secondary to SARS-COV2,Unidad Temporal COVID-19 en Centro Citibanamex|Instituto Nacional de Cardiologia Ignacio Chavez|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"Child, Adult, Older Adult",Not Applicable,110,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-CEI-011-20160627,1-Dec-20,19-Aug-20,104,1-Dec-20,30-Sep-20,,21-May-21,"Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT04570254
690,NCT04366934,Study of the Pathogenesis of Olfactory Disorders in COVID-19,COVIDSMELL,Completed,No Results Available,Coronavirus Infection|Severe Acute Respiratory Syndrome|Sars-CoV2,Other: Nasal swab|Other: Taste and olfactory function evaluation,Molecular and cellular defects in olfactory epithelium|Biological mechanisms involved in the pathogenesis of the disease|Epidemiological characteristics|Olfactory and taste dysfunction,"Institut Pasteur|HÃ´pital LariboisiÃ¨re, AP-HP",All,"18 Years and older Â  (Adult, Older Adult)",,26,Industry|Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2020-021,29-Oct-20,4-May-20,178,29-Oct-20,29-Apr-20,,29-Jan-21,"HÃ´pital LariboisiÃ¨re, Policlinique, Paris, France|HÃ´pital LariboisiÃ¨re, Service ORL, Paris, France",,https://ClinicalTrials.gov/show/NCT04366934
691,NCT04334148,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,HERO-HCQ,Completed,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events,Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,1363,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",Pro00105274,9-Jan-21,22-Apr-20,262,10-Dec-20,6-Apr-20,,25-Mar-21,"Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04334148
692,NCT04355442,Evolution of Facial Trauma During COVID Containment Measures,Traumax,Completed,No Results Available,Maxillofacial Injuries|Skull Fractures|COVID-19,Procedure: Facial fractures reduction or osteosynthesis,evolution of number of maxillofacial trauma|variability in terms of type of trauma|Comparative assessment of types of trauma by the inter-regional variability,"University Hospital, Montpellier|UnitÃ©s de CMF des CHU de Paris (Dr Davrou - PitiÃ© salpetriÃ¨re)|Amiens (Dr Dapke)|Nantes (Pr Corre)|Toulouse (Pr Lauwers - Purpan)|Marseille (Dr Foletti - La conception)|Nice (Dr Savoldelli)|Clermont Ferrand (Dr Sesque)|Perpignan (Dr Llobet)|Lyon (Dr Bourlet - Croix Rousse)",All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL20_0228,30-May-20,1-Apr-20,59,1-May-20,21-Apr-20,,29-Jul-20,"Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04355442
693,NCT04618861,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,,Completed,No Results Available,Covid19|Pneumonia|Surfactant Protein Deficiency,,"Meassuring the serum surfactant protein D levels in patient who have Covid-19 infection or pneumonia.|Analyzing the correlations between serum surfactant protein D levels and demographic,laboratory, clinical and radiological datas.",Kafkas University,,"18 Years and older Â  (Adult, Older Adult)",,127,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Clinical-1,2-Nov-20,13-Oct-20,20,2-Nov-20,6-Nov-20,,6-Nov-20,"Aylin Koseler, Denizli, Outside Of The US, Turkey",,https://ClinicalTrials.gov/show/NCT04618861
694,NCT04725084,Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,SONIC-19,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Other: Use of High Flow Nasal Cannula alone|Other: Use of Non-invasive Ventilation|Other: Use of Continuous Positive Airway Pressure,Refractory hypoxemia|Mechanical Ventilation free days|Survival at ICU discharge|ICU length of stay|Complications during ICU stay|Delay between admission and intubation,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,All,"18 Years and older Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2021-CHITS-001,15-Dec-20,1-Jul-20,167,15-Dec-20,26-Jan-21,,26-Jan-21,"Centre Hospitalier de Bethune, BÃ©thune, Nord-Pas-de-Calais, France|Grand HÃ´pital de l'Est Francilien, Jossigny, Seine-et-Marne, France|Groupe Hospitalier Sud Ile de France, Melun, Seine-et-Marne, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, Var, France",,https://ClinicalTrials.gov/show/NCT04725084
695,NCT04342728,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,COVIDAtoZ,Completed,No Results Available,COVID|Corona Virus Infection,Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care,Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Symptom Resolution: Muscle/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects,The Cleveland Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,214,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB 20-361,11-Feb-21,8-Apr-20,309,30-Dec-20,13-Apr-20,,16-Feb-21,"Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04342728
696,NCT04628195,Cardiac Performance in Mechanically Ventilated COVID-19 Patients,,Completed,No Results Available,Covid19|Acute Cor Pulmonale|Cardiac Failure,,Percentage of patients with left ventricle dysfunction (hypokinetic)|Percentage of patients with acute cor pulmonale|Differences in respiratory system compliance between patients with and without acute cor pulmonale|Differences in partial arterial pressure of carbon dioxide (PCO2) between patients with and without acute cor pulmonale|Differences in PaO2/FiO2 ratio between patients with and without acute cor pulmonale,Pontificia Universidad Catolica de Chile|Clinica Alemana de Santiago|Hospital Barros Luco Trudeau|University of Chile,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,200422002,1-Aug-20,1-Apr-20,122,30-Jun-20,13-Nov-20,,13-Nov-20,"Pontificia Universidad CatÃ³lica de Chile, Santiago, RegiÃ³n Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT04628195
697,NCT04669509,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit,,Completed,No Results Available,Covid19; Liver Injury; Mortality,Diagnostic Test: Liver function tests,7 and 28 day mortality,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,532,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CKKacar,14-Dec-20,1-Apr-20,257,1-Oct-20,16-Dec-20,,16-Dec-20,"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital, DiyarbakÄ±r, Turkey",,https://ClinicalTrials.gov/show/NCT04669509
698,NCT04385147,Advanced Endoscopy During COVID-19,,Completed,No Results Available,"Cholangitis, Secondary Biliary|Cholangiocarcinoma|Obstructive Jaundice|Pancreas Cancer|COVID-19|SARS-CoV-2",Other: Endoscopic management according to standard of care,"Age, gender, nationality|Indication for procedure, status of SARS-CoV-2 infection|Complete blood count and liver functions tests|procedure related complications|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on staff number","Al-Azhar University|Helwan University|National Liver Institute, Egypt",All,"Child, Adult, Older Adult",,670,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Global-Endo-COVID,5-Jul-20,18-May-20,48,1-Jul-20,12-May-20,,8-Jul-20,"Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Al-Azhar Univerisity, Cairo, Egypt|University Medicine Greifswald, Greifswald, Germany|2- Hospital Guillermo Kaelin De la Fuente - EsSalud, Lima, Peru|Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04385147
699,NCT04401033,Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),DECORE,Completed,No Results Available,SARS-CoV 2|COVID,Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound,SARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCW,Hospital del RÃ­o Hortega,All,"18 Years and older Â  (Adult, Older Adult)",,450,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,3,30-Jun-20,11-May-20,50,30-Jun-20,26-May-20,,28-Jul-20,"Hospital Rio Hortega, Valladolid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04401033/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04401033
700,NCT04749121,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,,Completed,No Results Available,Covid19,Device: UVC Irradiation|Drug: UVC Irradiation|Device: Fit test|Device: Tensile strength,Fit test|Colony count of microorganisms|Load of Tensile strength,Bangkok Metropolitan Administration Medical College and Vajira Hospital,All,18 Years to 60 Years Â  (Adult),Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,059/63,5-Feb-21,1-Apr-20,310,5-Feb-21,11-Feb-21,,11-Feb-21,"Faculty of Medicine ,Vajira hospital,Navamindradhiraj University, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT04749121
701,NCT04386512,Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),LymphoCov1,Completed,No Results Available,COVID|Lymphoma,,mortality|transfer to ICU,Versailles Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,89,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,P20/12_LymphoCov,15-Jul-20,15-May-20,61,1-Jun-20,13-May-20,,7-Aug-20,"CH de Versailles, Le Chesnay, France",,https://ClinicalTrials.gov/show/NCT04386512
702,NCT04357769,COVID-19 Pandemic Burden in Severe Mental Disease Patients,PsyCOVID,Completed,No Results Available,Psychological Distress|COVID|Severe Mental Disorder,Other: PSS (Perceived Stress Scale)|Other: GAD-7 (7-item Generalized Anxiety Disorder)|Other: PHQ-9 (9-item Patient Health Questionnaire)|Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Other: Zaritt Burden Interview,Perceived Stress Scale (PSS) outcome|Generalized Anxiety Disorder (GAD-7) scale outcome|Patient Health Questionnaire (PHQ-9) scale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome|Caregiver Burden,Federico II University,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,152/20,25-Apr-20,10-Apr-20,15,20-Apr-20,22-Apr-20,,3-Feb-21,"University of Naples ""Federico II"", Napoli, Italy",,https://ClinicalTrials.gov/show/NCT04357769
703,NCT04397848,Mental Health Outcomes in Healthcare Workers During COVID-19,,Completed,No Results Available,Mental Health Wellness 1|PTSD|Anxiety|Stress|Depression|COVID-19|Healthcare Workers,,Impact of Event Scale - Revised (IES-R)|General Anxiety Disorder (GAD-7)|Patient Health Questionnaire (PHQ-9)|Qualitative Data,"University Health Network, Toronto|William Osler Health System|University of Toronto|Sunnybrook Health Sciences Centre",All,"18 Years and older Â  (Adult, Older Adult)",,3852,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,3189,3-Jul-20,14-May-20,50,3-Jul-20,21-May-20,,3-Nov-20,"University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04397848
704,NCT04400877,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,,Completed,No Results Available,COVID-19|Venous Thromboembolism|Pulmonary Embolism|Deep Vein Thrombosis|SARS-CoV 2,Diagnostic Test: Diagnostic examination for venous thromboembolism,Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?|Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?|Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?|Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?|How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?|Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?,"University Hospital, Linkoeping",All,"18 Years and older Â  (Adult, Older Adult)",,7795,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,SE2020-02701,30-Sep-20,8-Jun-20,114,30-Jul-20,26-May-20,,27-Nov-20,"University Hospital LinkÃ¶ping, LinkÃ¶ping, Ã–stergÃ¶tland, Sweden",,https://ClinicalTrials.gov/show/NCT04400877
705,NCT04524234,Cardiac Dysfunction in Critically Ill Patients With COVID-19,CARDYCOVID,Completed,No Results Available,Covid19|Left Ventricular Dysfunction|Right Ventricular Dysfunction|Pulmonary Hypertension,Diagnostic Test: Echocardiography,Mortality|Left ventricular dysfunction|Right ventricular dysfunction|Risk-factors|Cardiac biomarkers,"Sahlgrenska University Hospital, Sweden",All,"18 Years to 99 Years Â  (Adult, Older Adult)",,132,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CARDY CRIT COVID,30-Sep-20,20-Apr-20,163,31-Aug-20,24-Aug-20,,24-Dec-20,"SÃ¶dersjukhuset, Stockholm, Region Stockholm, Sweden|North Ã„lvsborg County Hospital, TrollhÃ¤ttan, VÃ¤stra GÃ¶talandsregionen, Sweden|Sahlgrenska University Hospital/MÃ¶lndal, Gothenburg, VÃ¤stra GÃ¶taland, Sweden|Sahlgrenska University Hospital/Ã–stra, Gothenburg, VÃ¤stra GÃ¶taland, Sweden|Sahlgrenska University Hospital, Gothenburg, VÃ¤stra GÃ¶taland, Sweden",,https://ClinicalTrials.gov/show/NCT04524234
706,NCT04491214,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),,Completed,No Results Available,Covid19|Follow up|Rehabilitation,Other: quality of live assessment,assess quality of life after severe COVID infection|Quality of life and Clinical status,"University Hospital, Strasbourg, France",All,"18 Years and older Â  (Adult, Older Adult)",,112,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,7890,21-Jan-21,24-Jul-20,181,21-Jan-21,29-Jul-20,,12-Feb-21,"HÃ´pitaux Universitaires de Strasbourg (Nouvel HÃ´pital Civil), Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04491214
707,NCT04384887,"""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",,Completed,No Results Available,"COVID|Anxiety|Depression, Postpartum",Behavioral: covid-19 positive pregnant women,Evaluation of depression and anxiety score changes of covid-19 positive pregnants,Kanuni Sultan Suleyman Training and Research Hospital|AyÅŸegÃ¼l Bestel|Ä°brahim Polat|Merve AldÄ±kaÃ§tÄ±oÄŸlu TalmaÃ§,Female,18 Years to 45 Years Â  (Adult),,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,beckcovid,26-Aug-20,25-Apr-20,123,25-Aug-20,12-May-20,,2-Sep-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04384887
708,NCT04448418,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,,Completed,No Results Available,Transgender Persons|Coronavirus|Coronavirus Infection|COVID|COVID-19,Other: web based survey,Assessment of the specific health need of the transpopulation during the COVID-19 pandemic in Italy|Assessment of risk factors for COVID-19 infection in the traspopulation|Evaluation of the satisfaction of this population with telemedicine for hormonal treatment monitoring|Evaluation of the psychological wellbeing of the trans-population during COVID-19 outbreak in Italy|Evaluation of the psychological and physical wellbeing of the trans-population during COVID-19 outbreak in Italy,Unita Complessa di Ostetricia e Ginecologia,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,111,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,TRANSCOVID-19,20-Jun-20,20-May-20,31,20-Jun-20,25-Jun-20,,29-Apr-21,"1Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT04448418
709,NCT04402229,Psychological Impact of the Covid-19 Pandemic on Student Nurses,StudentCov,Completed,No Results Available,Nurse|Student|Post Traumatic Stress Disorder|COVID-19,,Prevalence of PTSD-related symptoms assessed by the IES-R|PTSD-related symptoms assessed by the IES-R in the total population of students nurses|PTSD-related symptoms assessed by the IES-R according to student's years of school,Versailles Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Other|Time Perspective: Prospective,P17/04_StudentCov,31-Jul-20,12-May-20,80,31-Jul-20,26-May-20,,19-Nov-20,"Versailles hospital, Le Chesnay, France|Toulouse University Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04402229
710,NCT04386551,Detection of COVID-19 in Saliva Collection,SALICOV,Completed,No Results Available,Sars-CoV2|RT-PCR|Saliva Collection|Nasopharyngeal Sample,,Detection of SARS-CoV-2 RNA in the saliva sample|Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results,"Centre Hospitalier Universitaire, Amiens",All,"18 Years and older Â  (Adult, Older Adult)",,501,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PI2020_843_0045,5-Aug-20,6-May-20,91,5-Aug-20,13-May-20,,11-Dec-20,"CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT04386551
711,NCT04378452,Assessment of the Psycho-social Impact of COVID-19 Outbreak,COM-COVID,Completed,No Results Available,SARS-CoV 2|COVID-19|Quality of Life|Mental Health Wellness 1|Social Distance|SARS (Disease)|Psychological,Behavioral: COM-COVID anonimous survey,"Psychological impact of the outbreak, total score|Psychological impact of the outbreak: depression questions score|Psychological impact of the outbreak: anxiety questions score|Psychological impact of the outbreak: stress questions score|Psychological impact of the outbreak: PSTD questions score|Descriptive statistics for the non-psychological questions","FundaciÃ³ Institut Germans Trias i Pujol|Anaxomics SL|FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia|FundaciÃ³ Sant Joan de DÃ©u",All,"16 Years and older Â  (Child, Adult, Older Adult)",,56656,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COM-COVID,7-Apr-21,31-Mar-20,372,22-Mar-21,7-May-20,,8-Apr-21,"FundaciÃ³ Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|FundaciÃ³ Lluita contra la Sida (FLS, Fight AIDS Foundation), Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain|FundaciÃ³ Privada per a la Recerca i la DocÃ¨ncia Sant Joan de DÃ©u, Esplugues De Llobregat, Spain",,https://ClinicalTrials.gov/show/NCT04378452
712,NCT04411459,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,,Completed,No Results Available,COVID-19|Mechanical Ventilation|Quality of Life|Radiologic Increased Density of Lung|Sedation|Complication of Treatment,Other: Invasive mechanical ventilation,Duration of mechanical ventilation and 28 days ventilator free days|ICU Mortality|30 days survival after ICU discharge|90 days survival after ICU discharge|Quality of life at 90 days after ICU discharge measured with 15D instrument|Radiologic aspects - structured description of CT and RX data,Azienda Usl di Bologna|Lorenzo Gamberini,All,"18 Years and older Â  (Adult, Older Adult)",,470,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,273/2020/OSS/AUSLBO,16-Oct-20,1-Feb-20,258,30-Jun-20,2-Jun-20,,19-Oct-20,"Ospedale Santa Maria Annunziata - Anestesia e Rianimazione, Bagno A Ripoli, FI, Italy|A.O. SS. Antonio, Biagio e Cesare Arrigo - Anestesia e Rianimazione, Alessandria, Italy|Anestesia e Rianimazione - Ospedale Civile di Baggiovara, Baggiovara, Italy|Anestesia e Rianimazione - Ospedale di Bentivoglio, Bentivoglio, Italy|Azienda UnitÃ  Sanitaria Locale, Bologna, Italy|Anestesia e Rianimazione - Ospedale Bellaria, Bologna, Italy|Anestesia e Rianimazione - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia intensiva dei trapianti addominali e chirurgia epatobiliare - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia Intensiva Polivalente - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Ospedale SS. TrinitÃ  - Anestesia e Rianimazione, Borgomanero, Italy|Anestesia e Rianimazione - Ospedale M. Bufalini, Cesena, Italy|Anestesia e Rianimazione - Ospedale degli Infermi, Faenza, Italy|Anestesia e Rianimazione Universitaria - Arcispedale Sant'Anna Ferrara, Ferrara, Italy|Anestesia e Rianimazione - Ospedale Morgagni - Pierantoni, ForlÃ¬, Italy|Anestesia e Rianimazione - Ospedale di Imola S.Maria della Scaletta, Imola, Italy|Ospedale Santo Stefano - Anestesia e Rianimazione, Prato, Italy|Anestesia e Rianimazione - Ospedale S. Maria delle Croci, Ravenna, Italy|Anestesia e Rianimazione - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Anestesia e Rianimazione - Ospedale di Riccione, Riccione, Italy|Anestesia e Rianimazione - Ospedale Infermi, Rimini, Italy",,https://ClinicalTrials.gov/show/NCT04411459
713,NCT04434144,A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,,Completed,No Results Available,Ivermectin|Hydroxychloroquine|COVID19,Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin,"Number of participants with ""treatment success"" determine by a negative RT PCR for COVID19.|Number of participants with ""adverse effects"" determined by the existence of the pharmacological side effects of the particular drug during treatment.","Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar",All,"16 Years to 80 Years Â  (Child, Adult, Older Adult)",,116,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,10000918,5-Jun-20,2-May-20,34,5-Jun-20,16-Jun-20,,16-Jun-20,"Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh",,https://ClinicalTrials.gov/show/NCT04434144
714,NCT04779944,Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers,,Completed,No Results Available,SARS-CoV-2,Other: other,Questionnaire to assess the psychological impacts of SARS-CoV-2 on health care workers,Assiut University,All,"25 Years to 70 Years Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AssiutU1235,15-Aug-20,7-Apr-20,130,30-Jul-20,3-Mar-21,,3-Mar-21,"heba Yassa, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04779944
715,NCT04390516,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,READY,Completed,No Results Available,COVID-19|Coronavirus|Mortality|Mechanical Ventilation,Device: COViage,Mechanically ventilated patient outcome|Mortality or mechanically ventilated patient outcome,Dascena,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,197,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,51420,30-May-20,24-Mar-20,67,4-May-20,15-May-20,,12-Jun-20,"Dascena, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT04390516
716,NCT04769284,Psychological State of Students of Health Sciences During COVID-19,,Completed,No Results Available,"Stress, Psychological|Anxiety|Depression|Covid19",Other: Mental health student,Modified version of EPP-10 related to COVID-19 (EPP-10-C)|Abbreviated Goldberg Anxiety Scale EADG|Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).|Short International Physical Activity Questionnaire (IPAQ),Yolanda Marcen Roman|Universidad de Zaragoza|Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,All,"Child, Adult, Older Adult",,332,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Mental health student,21-Feb-21,12-Feb-21,9,20-Feb-21,24-Feb-21,,24-Feb-21,"Faculty of Health Sciences. Zaragoza's University, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT04769284
717,NCT04598581,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",COVID-RT-01,Completed,No Results Available,Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Radiation: Low Dose Radiation Therapy (LD-RT)|Other: Sham irradiation,"Ventilator free days (VFD)|Change in pulmonary function, measured as relative change (%) from baseline in oxygenation index (PaO2 / FiO2)|Overall mortality|Change in levels of ferritin (ng/ml)|Change in levels of c-reactive protein (mg/l)|Change in levels of white blood cell counts (number of white blood cells per volume of blood)","University Hospital, Basel, Switzerland",All,"40 Years and older Â  (Adult, Older Adult)",Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2020-02047qu20Papachristofilou,9-Apr-21,2-Nov-20,158,9-Apr-21,22-Oct-20,,19-Apr-21,"Department of Radiooncology, University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT04598581
718,NCT04498507,Psychosocial Outcomes in Families of COVID-19 ICU Patients,,Completed,No Results Available,Critical Illness|Family|Psychological Stress|Covid19,Diagnostic Test: HADS questionnaire,occurence of anxiety and depression|occurence of acute stress|occurence of post-traumatic stress disorder|quality of life,University of Liege,All,"18 Years and older Â  (Adult, Older Adult)",,39,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Family COVID,30-Oct-20,16-Apr-20,197,30-Oct-20,4-Aug-20,,3-Nov-20,"University Hospital of LiÃ¨ge, LiÃ¨ge, Belgium",,https://ClinicalTrials.gov/show/NCT04498507
719,NCT04446429,Anti-Androgen Treatment for COVID-19,,Completed,Has Results,COVID-19|SARS-CoV2|Androgenetic Alopecia|Prostate Cancer|Benign Prostatic Hyperplasia|SARS (Severe Acute Respiratory Syndrome),Drug: Proxalutamide|Other: Standard of Care,COVID-19 Hospitalization,"Applied Biology, Inc.",Male,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,262,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB-DRUG-SARS-004,21-Jan-21,15-Sep-20,128,24-Dec-20,24-Jun-20,3-Feb-21,3-Feb-21,"Corpometria Institute, Brasilia, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04446429/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04446429
720,NCT04344327,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,CCF,Completed,No Results Available,"Infection Viral|Infection, Hospital|COVID",,Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form,"French Cardiology Society|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",All,"18 Years and older Â  (Adult, Older Adult)",,2878,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-02,21-Apr-20,10-Apr-20,11,21-Apr-20,14-Apr-20,,28-Apr-20,"CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de FrÃ©jus / Saint-Raphael, FrÃ©jus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'OrlÃ©ans, OrlÃ©ans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Ã‰tienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, VandÅ“uvre-lÃ¨s-Nancy, France",,https://ClinicalTrials.gov/show/NCT04344327
721,NCT04459364,The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,,Completed,No Results Available,"Hypertension, Pulmonary|Right Ventricular Overload|COVID",,Prevalence,Attgeno AB,All,"18 Years and older Â  (Adult, Older Adult)",,67,Industry,Observational,Observational Model: Cohort|Time Perspective: Other,20200422PA,15-Jul-20,1-Jun-20,44,7-Jul-20,7-Jul-20,,11-Jan-21,"Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT04459364
722,NCT04645563,Using Whatsapp for the Consultation,,Completed,No Results Available,Covid-19,Other: Sending thorax ct video images via smartphone applications,Analyzing the effect of consultation via whatsapp to lenght of stay the patients in emergency medicine department.|Comparing the effect of bedside consultation and consultation via whatsapp on patient discharge or hospitalisation and readmission.,Kafkas University,All,"18 Years and older Â  (Adult, Older Adult)",,144,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,Clinical-3,31-May-20,11-Mar-20,81,30-May-20,27-Nov-20,,27-Nov-20,"Ramazan Sabirli, Kars, Outside Of The US, Turkey",,https://ClinicalTrials.gov/show/NCT04645563
723,NCT04332991,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,ORCHID,Completed,Has Results,Coronavirus|Acute Respiratory Infection|SARS-CoV Infection,Drug: Hydroxychloroquine|Drug: Placebo,"COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)|Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28|Oxygen-free Days Through Day 28|Ventilator-free Days Through Day 28|Vasopressor-free Days Through Day 28|ICU-free Days to Day 28|Hospital-free Days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,479,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PETAL 05 Orchid,23-Jul-20,2-Apr-20,112,19-Jun-20,3-Apr-20,17-Mar-21,17-Mar-21,"University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04332991
724,NCT04706299,"Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing",,Completed,No Results Available,Prevention of COVID-19,Other: Resistance Exercise,Evaluate the effects of wearing a surgical face mask while performing resistance exercise on average peak force and total work performed.|Identify changes in the level of discomfort experienced while wearing a surgical mask during resistance exercise.,The Cleveland Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20-1303,21-May-21,12-Jan-21,129,21-May-21,12-Jan-21,,24-May-21,"Cleveland Clinic Sports Health, Garfield Heights, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04706299
725,NCT04396353,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,WHO,Completed,No Results Available,COVID-19|SARS-CoV 2|Corona Virus Infection|Sedentary Behavior,Other: Electronic questionnaire,Number of hospitalizations|Percentage of symptoms of the disease|Length of hospital stay|Percentage of mechanical ventilation,University of Sao Paulo General Hospital,All,"Child, Adult, Older Adult",,1574,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COVID-19,1-Oct-20,4-Jun-20,119,1-Oct-20,20-May-20,,22-Oct-20,"Marcelo Rodrigues dos Santos, SÃ£o Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04396353
726,NCT04352517,Influence Physical Activity Psychological Responses COVID-19 Pandemic,,Completed,No Results Available,Sedentary Behavior|Mental Health Wellness 1,Other: Online Survey,"Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21|IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21",University of Extremadura,All,"18 Years and older Â  (Adult, Older Adult)",,3500,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,3.954.038,30-Sep-20,16-Mar-20,198,31-Aug-20,20-Apr-20,,21-Feb-21,"Universidade da Sao Paulo, RibeirÃ£o Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, RegiÃ³n Metropolitana, Chile|Universidad de la RepÃºblica, Rivera, Uruguay","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04352517/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04352517
727,NCT04340050,COVID-19 Convalescent Plasma,,Completed,No Results Available,Coronavirus,Biological: anti-SARS-CoV-2 convalescent plasma,"Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)",University of Chicago,All,"18 Years and older Â  (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0523,23-Dec-20,10-Apr-20,257,23-Dec-20,9-Apr-20,,28-Dec-20,"University of Chicago Medicine, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04340050
728,NCT04452695,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,,Completed,No Results Available,COVID-19|Telemedicine|Robotics|Emergencies|Emerging Infectious Disease,Device: Doctor Spot,Acceptance of robotic telehealth system|Willingness to interact with robotic telehealth system|Satisfaction of interacting with a robotic telehealth system|Use of robotic system versus in-person triage,Brigham and Women's Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020P000957,10-Aug-20,10-Mar-20,153,3-Aug-20,30-Jun-20,,26-Jan-21,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04452695
729,NCT04507230,COVID-19 Associated Coagulopathy in Egypt,,Completed,No Results Available,Coagulopathy,,"Coagulation screen|Thrombophilia screen|VWF, FVIII",Assiut University,All,"Child, Adult, Older Adult",,106,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,17300413,31-Oct-20,7-Aug-20,85,31-Oct-20,11-Aug-20,,11-Mar-21,"Assiut University Hospitals, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04507230
730,NCT04350281,Double Therapy With IFN-beta 1b and Hydroxychloroquine,,Completed,No Results Available,COVID,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes,The University of Hong Kong,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UW 20-211,7-Jul-20,9-Apr-20,89,1-Jul-20,17-Apr-20,,28-Jul-20,"The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04350281
731,NCT04352699,Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,,Completed,No Results Available,Surgery|Complication of Surgical Procedure|COVID,,Rate of UCI admission for surgery-related complication|Rate of surgery-specific death|Rate of coronaviruse positive serologies,Centre Hospitalier Universitaire de Nice,All,"18 Years and older Â  (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20urocovid01,1-May-20,15-Mar-20,47,17-Apr-20,20-Apr-20,,15-May-20,"CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT04352699
732,NCT04890600,COVID-19 and Psycological Well-being in Healthcare Workers,BE-STRONG,Completed,No Results Available,"Distress, Emotional|Coping Behavior",Behavioral: well-being assessment,Levels of anxiety and depression|Coping strategies|Levels of resilience|Levels of fear of COVID-19,IRCCS San Raffaele,All,"18 Years and older Â  (Adult, Older Adult)",,350,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Other,RP 20/14,1-Apr-21,1-Sep-20,212,1-Apr-21,18-May-21,,18-May-21,"IRCCS San Raffaele Roma, Rome, Italy",,https://ClinicalTrials.gov/show/NCT04890600
733,NCT04453852,Monovalent Recombinant COVID19 Vaccine,COVAX19,Completed,No Results Available,Coronavirus Infection|COVID,Biological: COVID19 vaccine|Biological: Saline,Incidence of Adverse Events|COVID19 antibody titers|COVID19 T cell immunogenicity,Vaxine Pty Ltd|Central Adelaide Local Health Network Incorporated,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",13110,14-Apr-21,30-Jun-20,288,1-Feb-21,1-Jul-20,,6-May-21,"PARC,, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT04453852
734,NCT04808921,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,,Completed,No Results Available,SARS-CoV-2|Covid-19|Coronavirus,"Diagnostic Test: Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test",Percent Positive Agreement and Negative Percent Agreement,"Sky Medical Supplies & Equipments, LLC",All,"Child, Adult, Older Adult",Not Applicable,151,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SKYCOV001,28-Jan-21,9-Jan-21,19,18-Jan-21,22-Mar-21,,8-Apr-21,"D&H National Research Centers INC, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04808921
735,NCT04384380,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,,Completed,No Results Available,Coronavirus Infection,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil],Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,"Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, Taiwan",All,"20 Years to 79 Years Â  (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TYGH109014,31-May-20,1-Apr-20,60,31-May-20,12-May-20,,4-Aug-20,"Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04384380
736,NCT04324528,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,CYCOV,Completed,No Results Available,Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm,Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption),interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate,Dr. Alexander Supady|University Hospital Freiburg,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CYCOV,27-Jan-21,27-Mar-20,306,27-Jan-21,27-Mar-20,,15-Mar-21,"University Clinic Freiburg, Freiburg, Germany",,https://ClinicalTrials.gov/show/NCT04324528
737,NCT04332380,Convalescent Plasma for Patients With COVID-19: A Pilot Study,CP-COVID-19,Completed,No Results Available,Coronavirus|Coronavirus Infection,Drug: Plasma,Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality,Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|FundaciÃ³n Universitaria de Ciencias de la Salud,All,18 Years to 60 Years Â  (Adult),Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ABN011-1,28-Jul-20,1-May-20,88,28-Jul-20,2-Apr-20,,17-Aug-20,"Universidad del Rosario, Bogota, Cundinamarca, Colombia",,https://ClinicalTrials.gov/show/NCT04332380
738,NCT04698044,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period,,Completed,No Results Available,Anxiety|Depression|Covid19|Cancer|Chronic Disease,Diagnostic Test: Hospital Anxiety Depression Scale,HADS,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",All,"18 Years and older Â  (Adult, Older Adult)",,1107,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COVFAIROFALL,25-Jun-20,8-May-20,48,25-Jun-20,6-Jan-21,,7-Jan-21,"Sultan AbdÃ¼lhamid Han Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04698044
739,NCT04362956,Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,,Completed,No Results Available,Covid19|Pregnancy Related|Neonatal Infection,,Vertical transmission|Neonatal protection due to maternal antibodies|Increase risk of neonatal morbidity|Increase risk of obstetric complications,Fundacion Infant,Female,"Child, Adult, Older Adult",,114,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Perinatal COVID-19,1-Oct-20,10-Jul-20,83,1-Oct-20,27-Apr-20,,9-Feb-21,"Hospital Italiano, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04362956
740,NCT04425213,Obesity and Mortality of Critically Ill Patients With COVID-19,COV-OB-ICU,Completed,No Results Available,COVID|Severe Acute Respiratory Syndrome|Obesity|Comorbidities and Coexisting Conditions,,ICU mortality|Invasive mechanical ventilation|In-hospital mortality,"Central Hospital, Nancy, France",All,"18 Years and older Â  (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020PI082,26-May-20,12-May-20,14,25-May-20,11-Jun-20,,16-Jun-20,"Centre hospitalo-universitaire rÃ©gional de Nancy, VandÅ“uvre-lÃ¨s-Nancy, France",,https://ClinicalTrials.gov/show/NCT04425213
741,NCT04805684,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,,Completed,No Results Available,Lung Ultrasound|Pneumonia|Covid19,Device: LUS Twelve area|Device: LUS Fourteen area,Correlation between Thoracic CT imaging results and LUS results|Characteristics of lesions,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,2011-KAEK-25 2021,5-Mar-21,1-Jan-21,63,5-Mar-21,18-Mar-21,,18-Mar-21,"University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey",,https://ClinicalTrials.gov/show/NCT04805684
742,NCT04468802,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,,Completed,No Results Available,Covid19|Measles Vaccine|Mortality,Other: Case fatality rate,Case Fatality Rate,Kanuni Sultan Suleyman Training and Research Hospital,All,"Child, Adult, Older Adult",,32,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,KSSEAH--0965,1-Jul-20,1-Feb-20,151,30-Jun-20,13-Jul-20,,14-Jul-20,"Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey",,https://ClinicalTrials.gov/show/NCT04468802
743,NCT04745416,Clinical Characteristics of Patients With Leukemia and COVID-19,,Completed,No Results Available,"Leukemia, Acute|Covid19|Leukemia, Lymphoblastic",,Overall survival|Progression free survival|Number of relapses|Complete Remission|COVID-19 confirmed,Hospital General de Mexico,All,"18 Years and older Â  (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DECS/JPO-CT-400-2020,25-Jan-21,1-Jan-20,390,31-Dec-20,9-Feb-21,,9-Feb-21,"Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico|Hospital General de MÃ©xico ""Dr. Eduardo Liceaga"", Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT04745416
744,NCT04733625,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,,Completed,No Results Available,Covid19|SARS-CoV Infection,Drug: Cholecalciferol|Drug: Placebo,Death or need for intubation,Kasr El Aini Hospital,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",KA-2020/151,17-Dec-20,15-Sep-20,93,17-Dec-20,2-Feb-21,,2-Feb-21,"Cairo university hospitals, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04733625
745,NCT04376814,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,,Completed,No Results Available,COVID-19|Favipiravir|Kaletra|Hydroxychloroquine|Lopinavir/Ritonavir,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir,Mortality|long of hospitalization|Laboratory Treatment Response (Blood cell count)|Laboratory Treatment Response (CRP )|Dyspnea|Oxygen saturation without supplemental oxygen.|Oxygen therapy,Baqiyatallah Medical Sciences University,All,"16 Years to 100 Years Â  (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IR.BMSU.REC.1399.017,25-May-20,29-Mar-20,57,5-Apr-20,6-May-20,,16-Jun-20,"Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT04376814
746,NCT04407156,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,,Completed,No Results Available,COVID|AKI,Other: acute kidney injury,Incidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patients,University Hospitals of Derby and Burton NHS Foundation Trust,All,"18 Years to 110 Years Â  (Adult, Older Adult)",,724,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,UHDB/2020/050,20-Jul-20,1-Jun-20,49,7-Jun-20,29-May-20,,9-Sep-20,"Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04407156
747,NCT04845984,Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Four Hospital of the Alpine Region,PACAAP,Completed,No Results Available,Covid19|Health Care Worker,,SARS-CoV-2 prevalency among hospital health care professionals,Centre Hospitalier Annecy Genevois,All,"18 Years and older Â  (Adult, Older Adult)",,3500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-12,15-Jan-21,1-Sep-20,136,15-Jan-21,15-Apr-21,,15-Apr-21,"Ch Annecy Genevois, Pringy, France",,https://ClinicalTrials.gov/show/NCT04845984
748,NCT04604119,Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,,Completed,No Results Available,Sars-CoV2|Anxiety|Burnout,,Anxiety|Burnout,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,104,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,1577,1-Jun-20,1-May-20,31,30-May-20,27-Oct-20,,28-Oct-20,"Sisli Hamidiye Etfal Education and Training Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04604119
749,NCT04402983,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,,Completed,No Results Available,Covid19|Telerehabilitation|Physical Therapy,Other: Physiotherapy,Modified Medical Research Council Dyspnea Score|Timed up and go test|Visual analog scale to assess the pain severity|The Short Physical Performance Battery (SPPB)|Visual analog scale to assess the fatigue severity|BECK depression inventory|Saint George Respiratory Questionnaire,Istanbul Medipol University Hospital,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Telerehab_Covid19,1-Dec-20,27-May-20,188,1-Dec-20,27-May-20,,14-Dec-20,"University of Health Sciences Turkey, Ä°stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04402983
750,NCT04431856,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Co-PARENT,Completed,No Results Available,Anxiety|Depression|Traumatic Stress Disorder,Behavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHG,Measure of Anxiety as assessed by the OASIS|Measure of Depression as assessed by the ODSIS|Measure of PTSD as assessed by the PCL-5|Measure of Parenting Overprotection/Overcontrol as assessed by the S-EMBU|Measure of Parenting Rejection as assessed by the S-EMBU|Measure of Parenting Emotional Warmth as assessed by the S-EMBU|Measure of Parent Accommodation for Child Anxiety as assessed by the FASA,University of Miami,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20200484,17-Nov-20,15-May-20,186,17-Nov-20,16-Jun-20,,1-Dec-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04431856
751,NCT04332835,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",CP-COVID-19,Completed,No Results Available,Coronavirus|Coronavirus Infection,Drug: Plasma|Drug: Standard Therapy,Change in Viral Load|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality,Universidad del Rosario|FundaciÃ³n Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia BiotecnologÃ­a e Innovacion en Salud,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Phase 2|Phase 3,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ABN011-2,15-Nov-20,8-Aug-20,99,31-Oct-20,3-Apr-20,,27-Nov-20,"Universidad del Rosario, Bogota, Cundinamarca, Colombia",,https://ClinicalTrials.gov/show/NCT04332835
752,NCT04351139,Impact of the COVID-19 Pandemic in Gynecological Oncology,COVID-GYN,Completed,No Results Available,Gynecologic Cancer|Breast Neoplasm Female|Uterine Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms,Other: modification of the planned therapeutic management,"percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)",Hospices Civils de Lyon,Female,"18 Years and older Â  (Adult, Older Adult)",,205,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,69HCL20_0346|2020-A01036-33,30-Nov-20,6-May-20,208,30-Nov-20,17-Apr-20,,19-Jan-21,"Service de GynÃ©cologie, HFME, Hospices Civils de Lyon, Bron, France|Service de GynÃ©cologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service GynÃ©cologie, CHLS, Hospices Civils de Lyon, Pierre-BÃ©nite, France",,https://ClinicalTrials.gov/show/NCT04351139
753,NCT04615728,MANAGEMENT OF APPENDICITIS DURING THE COVID-19 PANDEMIC,observational,Completed,No Results Available,Acute Appendicitis,Procedure: laparoscopic or open appendicectomy,Mortality|Failure of primary proposed treatment|length of stay|Re-attendance|Imaging|Intra-operative findings during surgery,"Cambridge University Hospitals NHS Foundation Trust|R Antakia, A Xanthis, F Georgiades, V Hudson, J Ashcroft, S Rooney, AA Singh, JR O'Neill, N Fearnhead, RH Hardwick, RJ Davies, John M Bennett",All,"16 Years and older Â  (Child, Adult, Older Adult)",,207,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRN8996,6-Oct-20,1-Nov-19,340,5-Jul-20,4-Nov-20,,4-Nov-20,"Addenbrooke's University Hospital, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04615728
754,NCT04784403,SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY,UB-GTMS-COVID,Completed,No Results Available,SARS-CoV-2 Infection,Diagnostic Test: SARS-CoV-2 PCR and serology tests,Number of people with a positive SARS-CoV-2 PCR.|Incidence of people with a positive SARS-CoV-2 PCR.|Number of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Prevalence of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Number of people with a positive SARS-CoV-2 Ig total titer and a negative IgG.,Dr. Francisco Ciruela AlfÃ©rez|Gerencia Territorial del Ãrea Metropolitana Sur - Instituto CatalÃ¡n de la Salud|Hospital Universitario de Bellvitge|FundaciÃ³ IDIBELL|University of Barcelona,All,"18 Years and older Â  (Adult, Older Adult)",,3356,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,UB-EPI-2020-01,24-Feb-21,14-Dec-20,72,24-Feb-21,5-Mar-21,,5-Mar-21,"Francisco Ciruela AlfÃ©rez, L'Hospitalet De Llobregat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04784403
755,NCT04349098,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Coronavirus,Completed,No Results Available,Coronavirus Infection,Drug: Selinexor|Other: Placebo,Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants â‰¤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE),Karyopharm Therapeutics Inc,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,202,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,XPORT-CoV-1001|2020-001411-25,5-Oct-20,17-Apr-20,171,5-Oct-20,16-Apr-20,,24-Dec-20,"UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT04349098
756,NCT04407182,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,,Completed,No Results Available,Covid-19|Sars-CoV2|Diabete Mellitus|Cardiopathy|Pulmonary Disease|Renal Disease|Liver Diseases,Dietary Supplement: Viusid and Asbrip,Symptom resolution|Cumulative incidence of disease severity|Complementary drugs required|Side effects of supplementation|Duration of SARS-CoV-2 PCR positivity|Concentration of reactive protein c in peripheral blood|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity,Catalysis SL,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",IESS-HTMC-JUTD-2020-0305-M,1-Oct-20,4-May-20,150,1-Aug-20,29-May-20,,8-Jan-21,"Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil, Ecuador",,https://ClinicalTrials.gov/show/NCT04407182
757,NCT04514016,Cross Sectional CFAR HIV/COVID-19 Study,,Completed,No Results Available,SARS-CoV Infection|Covid19,,Number of participants who tested positive with SARS COV-2 Infection|Number of participants who tested positive with SARS COV-2 antibody,University of Miami|Miami Center for AIDS Research (CFAR),All,"3 Years to 25 Years Â  (Child, Adult)",,64,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,20200802,17-Mar-21,12-Aug-20,217,17-Mar-21,14-Aug-20,,23-Mar-21,"Batchelor's Children's Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04514016
758,NCT04847687,Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study,,Completed,No Results Available,COVID-19|Methylprednisolone|Pneumonia,Drug: methylprednisolone,prognosis|hospitalization time,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,300,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,2011-KAEK-25 2021/03-02,1-Apr-21,1-Mar-21,31,1-Apr-21,19-Apr-21,,19-Apr-21,"Bursa YÃ¼ksek Ä°htisas EAH, Bursa, Eyalet/YerleÅŸke, Turkey",,https://ClinicalTrials.gov/show/NCT04847687
759,NCT04407260,"Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic COVID-19 Patients. Prospective Cohort Study.",,Completed,No Results Available,COVID -19|Respiratory Failure|Hypoxia,Device: Oxygen Hood,Oxygen saturation|In-hospital Intubation/Mechanical Ventilation Status|In-hospital Mortality|Length of Hospitalization,Northwell Health,All,"Child, Adult, Older Adult",,136,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HoodStudy701,1-May-20,6-Mar-20,56,1-May-20,29-May-20,,16-Feb-21,"Phelps Hospital, Sleepy Hollow, New York, United States",,https://ClinicalTrials.gov/show/NCT04407260
760,NCT04378582,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,EpiCoV-Brazil,Completed,No Results Available,"SARS-CoV 2|Respiratory Distress Syndrome, Adult|Corona Virus Infection|Critical Illness",Other: risk factors,ICU survival at 28 days|Hospital survival at 60 days|Duration of mechanical ventilation|Need for renal replacement therapy|Complications during the ICU stay,University of Sao Paulo General Hospital,All,"14 Years to 100 Years Â  (Child, Adult, Older Adult)",,1589,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,31382620.0.0000.0068,5-Aug-20,7-May-20,90,28-Jul-20,7-May-20,,26-Aug-20,"Hospital das ClÃ­nicas -HCFMUSP, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT04378582
761,NCT04365881,Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology,,Completed,No Results Available,"Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety",Other: Cross-sectional observational study,UCLA Loneliness Scale-8 (ULS-8)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7),Modum Bad|University of Oslo,All,"18 Years and older Â  (Adult, Older Adult)",,10084,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,REK12345,7-Apr-20,31-Mar-20,7,7-Apr-20,28-Apr-20,,28-Apr-20,"University of Oslo, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT04365881
762,NCT04339881,NOsocomial Dissemination Risk of SARS-Cov2,NODS-Cov2,Completed,No Results Available,Sars-CoV2,,Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2,Assistance Publique - HÃ´pitaux de Paris,All,"Child, Adult, Older Adult",,2523,Other,Observational,Observational Model: Other|Time Perspective: Prospective,APHP200417,12-Jul-20,17-Apr-20,86,10-Jul-20,9-Apr-20,,23-Nov-20,"Didier Guillemot, Garches, France",,https://ClinicalTrials.gov/show/NCT04339881
763,NCT04329533,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,,Completed,No Results Available,Perceived Stress|Anxiety|Sleep Disturbance,"Other: ""Calm"" is a mindfulness meditation mobile app",Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire,University of Arizona,Female,"18 Years to 99 Years Â  (Adult, Older Adult)",Not Applicable,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2003524869,1-Nov-20,13-Apr-20,202,1-Nov-20,1-Apr-20,,13-Nov-20,"Banner University Medicine Women's Institute, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04329533
764,NCT04621461,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,,Completed,No Results Available,Corona Virus Infection,Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo,Number of participants hospitalized and/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms,"St. Francis Hospital, New York",All,"30 Years and older Â  (Adult, Older Adult)",Phase 4,3,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-19,8-Feb-21,20-Dec-20,50,8-Feb-21,9-Nov-20,,11-Feb-21,"St. Francis Hospital - The Heart Center, Roslyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04621461
765,NCT04375410,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,,Completed,No Results Available,Hand Eczema|Hand Dermatitis|Covid19,,Dermal reaction to frequent hand wash and disinfection in children,Vendsyssel Hospital|Aalborg University Hospital,All,up to 13 Years Â  (Child),,6273,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SH042020,10-May-20,22-Apr-20,18,30-Apr-20,5-May-20,,1-Apr-21,"Tine Caroc Warner, HjÃ¸rring, Nordjylland, Denmark",,https://ClinicalTrials.gov/show/NCT04375410
766,NCT04413968,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",COVIDOCRECHE,Completed,No Results Available,Coronavirus|Coronavirus Infection|Covid19|Sars-CoV2,Diagnostic Test: Rapid detection test|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Stool collection,Assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period,Assistance Publique - HÃ´pitaux de Paris,All,"1 Month and older Â  (Child, Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP200587|2020-A01540-39,2-Oct-20,2-Jun-20,122,2-Jul-20,4-Jun-20,,26-Oct-20,"Hopital Avicenne, Bobigny, France|HÃ´pital Jean Verdier - Service de PÃ©diatrie, Bondy, France|HÃ´pital Jean Verdier, Bondy, France|HÃ´pital Antoine bÃ©clÃ¨re, Clamart, France|HÃ´pital Louis Mourier, Colombes, France|CH intercommunal de CrÃ©teil, CrÃ©teil, France|HÃ´pital AndÃ© Mignot, Le Chesnay, France|HÃ´pital Trousseau, Paris, France|HÃ´pital Robert debrÃ©, Paris, France|CHU de Rouen, Rouen, France|HÃ´pital Annecy Genevois, Ã‰pagny, France",,https://ClinicalTrials.gov/show/NCT04413968
767,NCT04419623,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,,Completed,No Results Available,COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood Cancer,Drug: TL-895,Recommended dose of TL-895,"Telios Pharma, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,7,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TL-895-202,15-Dec-20,9-Jul-20,159,22-Sep-20,5-Jun-20,,12-May-21,"Georgia Cancer Center, Augusta, Georgia, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04419623
768,NCT04354779,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV 2|Coronavirus Infection|Covid19,Diagnostic Test: a specifically designed self-administered questionnaire,Antibody status in HCW|Active virus carriers in HCW|Incubation time|Background incidence rate|Occupation associated infection risk,AUVA|Paracelsus Medical University,All,"15 Years to 90 Years Â  (Child, Adult, Older Adult)",,3301,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,AUVA SARS-CoV-2 Studie,28-Sep-20,11-May-20,140,23-Aug-20,21-Apr-20,,30-Sep-20,"Allgemeine Unfallversicherungsanstalt, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04354779
769,NCT04532411,COVID-19 Testing Sample Acquisition Throughput and Efficiency,HexapodBooth,Completed,No Results Available,SARS-CoV Infection|Respiratory Viral Infection|Personal Protective Equipment|Covid19,Other: Personal Protective Testing Booth,Change in Testing Throughput After Hexapod Implementation|Change in Isolation Gowns Utilized After Hexapod Utilization|Change in Cost per Test After Hexapod Implementation|Return on Investment|Change in Testing Personnel Cost Per Test|Change in Cost of Isolation Gowns Utilized,Massachusetts General Hospital,All,"Child, Adult, Older Adult",,28948,Other,Observational,Observational Model: Other|Time Perspective: Other,QI Initiative,30-Sep-20,1-Mar-20,213,30-Sep-20,31-Aug-20,,24-Feb-21,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04532411
770,NCT04396210,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,,Completed,No Results Available,Coronavirus|COVID|ART|Fertility Issues,Other: Questionnaire,Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire|Patients reproductive behaviour by using a questionnaire|Patients views on resuming fertility treatment by using a questionnaire,"University Hospital, Ghent",All,18 Years to 47 Years Â  (Adult),,389,Other,Observational,Observational Model: Other|Time Perspective: Prospective,B6702020000247,18-Jun-20,14-May-20,35,18-Jun-20,20-May-20,,18-Nov-20,"Ghent University Hospital, Ghent, Belgium",,https://ClinicalTrials.gov/show/NCT04396210
771,NCT04816942,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,,Completed,No Results Available,Convalescent Plasma|Covid19|Immunoglobulins|Plasma|Egypt,Biological: Convalescent Plasma,COVID-19 Cure rate,"Ministry of Health and Population, Egypt",All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,102,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-2020/13,12-Oct-20,23-Apr-20,172,21-Jul-20,25-Mar-21,,25-Mar-21,"Ministry of Health, Cairo, Giza, Egypt",,https://ClinicalTrials.gov/show/NCT04816942
772,NCT04506515,Psychological Impact of COVID-19 Pandemic in Healthcare Workers,PSIMCOV,Completed,No Results Available,"Covid19|Stress, Psychological|Work Related Stress|Epidemic Disease|SARS-CoV Infection",Diagnostic Test: Psychological stress and adaptation at work score (PSAS),PSAS (Psychological Stress and Adaptation at work Score) during the crisis|PSAS (Psychological Stress and Adaptation at work Score) in basal conditions,Hospital General Universitario de Valencia,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,3000,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,COV2-2020,30-Apr-20,9-Apr-20,21,19-Apr-20,10-Aug-20,,10-Aug-20,"CHGUV, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04506515
773,NCT04438954,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",,Completed,No Results Available,Multiple Sclerosis|Covid-19,,Fatigue|Physical activity|Sleep quality|Anxiety,Ankara Yildirim BeyazÄ±t University,All,21 Years to 58 Years Â  (Adult),,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2020,18-Jun-20,5-May-20,44,5-Jun-20,19-Jun-20,,22-Jun-20,"Ankara YÄ±ldÄ±rÄ±m BeyazÄ±t University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04438954
774,NCT04337424,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,EasyCoV,Completed,No Results Available,SARS-CoV-2,Diagnostic Test: Sampling salivary,Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples,"University Hospital, Montpellier|societe SkillCell - 97198 Jarry|CNRS Alcediag UMR9005 - societe Sys2Diag - 34184 Montpellier",All,"18 Years to 90 Years Â  (Adult, Older Adult)",,627,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RECHMPL20_0170,7-Oct-20,13-Apr-20,177,7-Oct-20,7-Apr-20,,4-Nov-20,"UCH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04337424
775,NCT04374617,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,,Completed,No Results Available,"COVID-19|Critical Illness|Venous Thromboembolism|Venous Thromboses|Venous Thromboses, Deep|Venous Thrombosis Pulmonary|Pulmonary Embolism|Pulmonary Embolism and Thrombosis|Sars-CoV2|SARS-CoV Infection",Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography,Venous thromboembolisms|Deaths,Hospital Universitari Vall d'Hebron Research Institute,All,"18 Years and older Â  (Adult, Older Adult)",,230,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PR(AG)213/2020,1-May-20,1-Apr-20,30,25-Apr-20,5-May-20,,6-May-20,"Vall dÂ´Hebron Research Institute VHIR, Barcelona, Catalunya, Spain|Hospital Germans Trias i Pujol. Universitat AutÃ²noma de Barcelona, Badalona, Spain|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04374617
776,NCT04367363,Social Media and COVID-19,,Completed,No Results Available,Coronavirus|Depression|Anxiety|Stress,Behavioral: Social media & news consumption,WhatsApp usage|Changes in fear with regards the COVID-19 situation across 1 week|Changes in amount of thinking about the COVID-19 situation across 1 week,Jean Liu|Yale-NUS College,All,"21 Years and older Â  (Adult, Older Adult)",,151,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-CERC-001B,31-May-20,17-Mar-20,75,7-May-20,29-Apr-20,,29-Dec-20,"Yale-NUS College, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04367363
777,NCT04312009,Losartan for Patients With COVID-19 Requiring Hospitalization,,Completed,No Results Available,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection,Drug: Losartan|Other: Placebo,Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (S/F)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15,University of Minnesota|Bill and Melinda Gates Foundation,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURG-2020-28675|INV-017069,1-Feb-21,13-Apr-20,294,1-Feb-21,17-Mar-20,,13-Apr-21,"University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States|M Health Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper University Hospital, Camden, New Jersey, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04312009
778,NCT04311177,Losartan for Patients With COVID-19 Not Requiring Hospitalization,,Completed,No Results Available,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection,Drug: Losartan|Other: Placebo,Hospital Admission|Change in PROMIS Dyspnea scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days,University of Minnesota|The Minnesota Foundation,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,580,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURG-2020-28683,1-Feb-21,9-Apr-20,298,1-Feb-21,17-Mar-20,,15-Feb-21,"Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04311177
779,NCT04513561,Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19,CONFIMID,Completed,No Results Available,Inflammatory Disease|Covid19,,"The answer will be considered positive if the patient answers ""totally agree"", or ""agree"", or ""slightly agree"", or ""neither agree nor disagree"".|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""Slightly agree"", ""Agree"" or ""Totally agree"" to question 9 of the lock down questionnaire|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""yes"" to question 34 of the lock down questionnaire|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""Slightly agree"" or ""Agree"" or ""Strongly agree"" to question 38 of the lock down questionnaire|Proportion of patients (in percentages and numbers) whose response will be considered positive to questions 13 and 14 of the lock down questionnaire and comparison between the different specialities filled in in question 3.|Proportion of patients (in percent and numbers) whose response will be considered positive to questions 9, 13, 14, 38 or ""Yes"" to question 34 of the end of lock down and lock down Evaluation Questionnaire.","University Hospital, Lille",All,"18 Years and older Â  (Adult, Older Adult)",,921,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_51|2020_A01596_33,27-Aug-20,21-Jul-20,37,27-Aug-20,14-Aug-20,,15-Mar-21,"Hop Claude Huriez Chu Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04513561
780,NCT04459403,Psychiatric Disturbances and COVID-19 Infection,,Completed,No Results Available,Corona Virus Infection,,"Psychiatric well-being, level of anxiety, symptoms of depression and coping strategies questionnaire|Prevalence and types of Psychiatric disturbances in patients with COVID-19 infection","Cairo University|Ministry of Health and Population, Egypt|National Hepatology & Tropical Medicine Research Institute",All,"18 Years and older Â  (Adult, Older Adult)",,400,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,15-2020/1,30-Dec-20,8-Jun-20,205,30-Dec-20,7-Jul-20,,28-Jan-21,"15 Mayo Smart Hospital, Cairo, Egypt|National hepatology and tropical medicine research institute, Cairo, Egypt|Students hospital, Giza, Egypt",,https://ClinicalTrials.gov/show/NCT04459403
781,NCT04377581,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",,Completed,No Results Available,Public Health|Demography|Pandemics|Corona Virus Infection|News|Global Health|Perception,,"Knowledge and Confidence in Knowledge of COVID-19|Beliefs about the effectiveness of public health recommendations|Intent to comply with public health recommendations|Perception of Risk of COVID-19 and other health threats|Perceptions of trust in common health information sources|Single most trusted news source|Intention to change consumption of news because of COVID-19 (yes/no)|For participants who will change their news consumption, in what way will they change?|Secondary information sources|Concerns about COVID-19","Milton S. Hershey Medical Center|The Huck Institutes of the Life Sciences|The Social Science Research Institute|The Department of Family and Community Medicine, Penn State College of Medicine|The College of Healthcare Information Management Executives (CHIME)",All,"18 Years and older Â  (Adult, Older Adult)",,18251,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,STUDY00014798,10-Jul-20,9-Apr-20,92,10-Jul-20,6-May-20,,16-Jul-20,"Penn State College of Medicine, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04377581
782,NCT04652648,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,,Completed,No Results Available,Covid19|Hydroxychloroquine|Coronavirus Infection|Transmission|Prophylaxis,Drug: Hydroxychloroquine,COVID-19 symptom development with positive PCR test|Positive coronavirus PCR test without symptoms|Hospital admission for COVID-19|Death by Day 14|HCQ discontinuation or study withdrawal|Symptom severity at specified time points|COVID -19 rate at study entry|EKG changes during study,Bryn Mawr Hospital|Sharpe-Strumia Research Foundation|Bryn Mawr Hospital Foundation|Cotswold Foundation,All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,BM02332,15-Nov-20,27-May-20,172,31-Oct-20,3-Dec-20,,3-Dec-20,"Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04652648
783,NCT04340466,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,FRENCH CORONA,Completed,No Results Available,"Pneumonia, Viral|Critically Ill|Corona Virus Infection",Other: No intervention,Mortality at day 28|severe complications|Imaging|Delay in Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status,Centre Hospitalier Universitaire de NÄ«mes,All,"18 Years and older Â  (Adult, Older Adult)",,1003,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A00797-32,3-Jul-20,3-Apr-20,91,3-Jul-20,9-Apr-20,,19-Dec-20,"CHU Nimes, NÃ®mes, France",,https://ClinicalTrials.gov/show/NCT04340466
784,NCT04689399,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,,Completed,No Results Available,Covid19|Rapid Antigen Test|SARS-CoV-2,"Diagnostic Test: Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.",Sensitivity and specificity of the rapid antigen test of COVID-19|Economic analyses|PCR analysis on nasopharyngeal swabs,"Rigshospitalet, Denmark|Testcenter Danmark, Statens Serum Institut|Copenhagen Emergency Medical Services",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,4697,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,COVID-19,25-Mar-21,26-Dec-20,89,25-Mar-21,30-Dec-20,,30-Mar-21,"Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04689399
785,NCT04621214,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,,Completed,No Results Available,Audio-Visual Triage System|Anxiety Levels|COVID-19 Spread|GAD-7 Score|Healthcare Professionals|Screening Strategy,Device: Audio-Visual Triage System (AVT),Polymerase chain reaction (PCR) to detect SARS-CoV-2 virus|General Anxiety Disorder-7 (GAD-7) scoring system,University of Lahore,All,20 Years to 38 Years Â  (Adult),,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,IRBEC/BIH/013-2020,28-Apr-20,21-Mar-20,38,28-Apr-20,9-Nov-20,,9-Nov-20,"The University of Lahore, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04621214
786,NCT04363632,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,ONCOVID-19,Completed,No Results Available,Sars-CoV2|Cancer,,Mortality of cancer patients under active anticancer treatment|Overall survival|Hospitalizations|Death|Complications|Patients' characteristics,Centre Leon Berard,All,"Child, Adult, Older Adult",,1231,Other,Observational,Observational Model: Cohort|Time Perspective: Other,ET20-069,30-Jun-20,2-Apr-20,89,30-Jun-20,27-Apr-20,,1-Jul-20,"Institut BergoniÃ©, Bordeaux, France|Centre FranÃ§ois Baclesse, Caen, France|Centre Hospitalier MÃ©tropole Savoie, ChambÃ©ry, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges FranÃ§ois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|CH Annecy-Genevois, Metz-Tessy, France|Institut de CancÃ©rologie de Montpellier, Montpellier, France|Groupement Hospitalier Porte de Provence, MontÃ©limar, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier Lyon-Sud, Pierre-BÃ©nite, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut de CancÃ©rologie de l'Ouest, Saint-Herblain, France|Institut de cancÃ©rologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse, France|CH Valence, Valence, France",,https://ClinicalTrials.gov/show/NCT04363632
787,NCT04422587,Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea,EPRICOD,Completed,No Results Available,Emergencies,Other: RECOP unit patient,Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea|Describe the characteristics of patients admitted to reCOP units according to their virological status|Virological status|Mortality status,"University Hospital, Toulouse",All,"15 Years and older Â  (Child, Adult, Older Adult)",,1860,Other,Observational,Observational Model: Cohort|Time Perspective: Other,RC31/20/0149,7-Jun-20,13-Mar-20,86,5-Jun-20,9-Jun-20,,5-Nov-20,"University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04422587
788,NCT04659200,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,,Completed,No Results Available,COVID-19 Infection|Thyroid Function Tests|Inflammation; Thyroid|Inflammatory Markers,Diagnostic Test: Venous blood was collected for biochemistry testing.,Comparison of thyroid stimulating hormone (TSH) between groups|Comparison of free triiodothyronine (fT3) between groups|Comparison of free thyroxine (fT4) between groups|Comparison of anti-thyroid peroxidase (Anti-TPO) between groups|Comparison of anti-thyroglobulin (Anti-Tg) between groups|White blood cells (WBC) results of Covid 19 patient group|Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group|C-reactive protein (CRP) results of Covid 19 patient group|Fibrinogen results of Covid 19 patient group|Procalcitonin results of Covid 19 patient group|Ferritin results of Covid 19 patient group|D-dimer results of Covid 19 patient group,Bezmialem Vakif University,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,20,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,6122020,7-Dec-20,1-Sep-20,97,5-Dec-20,9-Dec-20,,26-Jan-21,"Sabahattin Destek, Fatih, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04659200
789,NCT04645433,Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit,,Completed,No Results Available,Mortality|Intensive Care Unit,,Mortality for ICU|hospital stay,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2854,15-May-20,15-Mar-20,61,15-May-20,27-Nov-20,,27-Nov-20,"SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04645433
790,NCT04413058,Menstrual Cycle Characteristics of Healthcare Professionals,,Completed,No Results Available,Menstrual Irregularity|Covid 19,,Rate of irregular menstrual cycle|Length of cycle|Rate of prolonged bleeding|Amount of flow|Rate of dysmenorrhea|The number of difference in menstrual cycle length|The number of difference in bleeding days|The number of difference in amount of flow,Haydarpasa Numune Training and Research Hospital,Female,18 Years to 47 Years Â  (Adult),,260,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,HNEAH KAEK 2020/KK/|Ministry of Health,10-Sep-20,10-Apr-20,153,10-Sep-20,2-Jun-20,,19-Nov-20,"University of Health Sciences Turkey, Istanbul, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04413058/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04413058
791,NCT04385238,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,,Completed,Has Results,COVID-19|Pregnancy Complications|Mental Health Wellness 1|Anxiety|Depression|Ptsd|Coronavirus,Other: This is an online survey with no intervention.,Number of Participants With Symptoms of Post-traumatic Stress Disorder|Number of Participants With Symptoms of Anxiety and Depression,Pregistry|Harvard School of Public Health,Female,"18 Years and older Â  (Adult, Older Adult)",,6894,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2,20-Jun-20,15-May-20,36,20-Jun-20,12-May-20,7-Jan-21,7-Jan-21,"Pregistry, Los Angeles, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04385238/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04385238/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04385238
792,NCT04426266,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,,Completed,No Results Available,Questionnaire Designs|COVID-19 Pandemic|Psychological Stress|Coping Skills|Two-Item Generalised Anxiety Disorder Scale|Patient Health Questionnaire Anxiety and Depression Scale|Health Status Index|Subjective Health Complaint|Mood,,sociodemopraphic factors|perceived stress|level of anxiety|self-reported health state|number of complaints|strategies in coping with stressful situations|psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic|level of depression,Szeged University,All,"18 Years and older Â  (Adult, Older Adult)",,441,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,PSZ-002,28-Sep-20,1-May-20,150,28-Sep-20,11-Jun-20,,29-Sep-20,"University of Szeged Department of Dermatology and Allergology, Szeged, Hungary",,https://ClinicalTrials.gov/show/NCT04426266
794,NCT04686708,COVID-19 Pandemic and General Surgery Emergencies,,Completed,No Results Available,Emergencies,Other: Emergency general surgical admissions,Incidence of general surgical emergencies|Complication rate,Gulhane Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,750,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Gulhane2020-258,11-Sep-20,11-Mar-19,550,11-Sep-20,29-Dec-20,,29-Dec-20,"Gulhane Training and Research Hospital, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04686708
795,NCT04522986,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,COVID-19,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2,Biological: Mesenchymal stem cell,Safety: Adverse Event,"Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older Â  (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADR-001-1919,2-Feb-21,21-Aug-20,165,2-Feb-21,21-Aug-20,,18-Mar-21,"Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT04522986
796,NCT04492384,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,ACTIV,Completed,No Results Available,Covid19|SARS-CoV-2 Infection|Pneumonia|Copd|CKD|Cardiac Event|Overweight and Obesity|Cardiovascular Diseases|Diabetes|Hypertension|Coronary Heart Disease,Other: non-interventional,rate of non-infectious diseases|severity of COVID-19 depending on pre-existing diseases|disability registration / change of disability status|rate of letal outcomes|rate of letal outcomes depending on pre-existing disease,Eurasian Association of Therapists,All,"18 Years and older Â  (Adult, Older Adult)",,5800,Other,Observational,Observational Model: Cohort|Time Perspective: Other,ACTIV11062020,14-Jan-21,11-Jun-20,217,14-Jan-21,30-Jul-20,,20-Apr-21,"Eurasian Association of Therapists, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04492384
797,NCT04605692,Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic,MBI,Completed,No Results Available,Burnout|COVID-19|Dentistry|Filiation|Pandemic,,706 of participants' burnout (MBI) and stress levels during the Covid 19 pandemic process assessed with survey.,Akdeniz University,All,"Child, Adult, Older Adult",,706,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,KAEK- 590,20-May-20,9-Mar-20,72,20-May-20,28-Oct-20,,28-Oct-20,"Akdeniz Ãœniversitesi, Antalya, KonyaaltÄ±, Turkey",,https://ClinicalTrials.gov/show/NCT04605692
798,NCT04701502,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,,Completed,No Results Available,Covid19|Respiratory Disease|Immune System|Immunomodulator|Antiseptic|Supportive Care,Dietary Supplement: Viusid|Dietary Supplement: Asbrip|Drug: Standard Care,Clinical Improvement|Time to semirecover|Symptom resolution|Time to recovery|Cumulative assessment of disease severity|Duration of SARS-CoV-2 PCR positivity|Concentration of C-reactive protein in peripheral blood|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate,Catalysis SL,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,COVID_BULG_2020,15-Feb-21,9-Nov-20,98,15-Feb-21,8-Jan-21,,26-Feb-21,"MBAL, Sv. Mina, Plovdiv, Bulgaria|MTB Plovdiv, Plovdiv, Bulgaria",,https://ClinicalTrials.gov/show/NCT04701502
799,NCT04454606,The New Silicone N99 Half-Piece Respirator,,Completed,No Results Available,COVID|Personal Protective Equipment,Device: Fit test|Device: Filtration Test,Fit test,Bangkok Metropolitan Administration Medical College and Vajira Hospital,All,18 Years to 60 Years Â  (Adult),Not Applicable,43,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,053/2563,31-May-20,1-May-20,30,15-May-20,1-Jul-20,,1-Jul-20,"Bangkok Metroplitan Administration and Vajira Hospital, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT04454606
800,NCT04547218,Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population,,Completed,No Results Available,"Age Problem|Surgery|Depression, Anxiety",,Incidence of elective surgeries has postponed during COVID-19 pandemic in geriatric population|Incidence of cancer surgeries postponed during COVID-19 pandemic in geriatric population|Physical and psychological impact of postponed elective surgery in geriatric population during COVID-19 pandemic,University of Malaya,All,65 Years and older Â  (Older Adult),,150,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2020623-8801,31-Dec-20,22-Jun-20,192,31-Dec-20,14-Sep-20,,19-Jan-21,"Department of Anesthesiology & Intensive Care, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT04547218
801,NCT04631172,Covid-19 Anxiety and Phobia Levels of the Parents,,Completed,No Results Available,SARS-CoV-2|Anxiety and Fear|Parents,"Other: Coronavirus Anxiety Scale , COVID-19 Phobia Scale",Coronavirus Anxiety Scale (CAS)|COVID 19 phobia scale (C19P-S),Selcuk University,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,farukcicekci,15-Oct-20,1-May-20,167,30-Sep-20,17-Nov-20,,18-Nov-20,"Selcuk University, School of Medicine, Konya, Turkey",,https://ClinicalTrials.gov/show/NCT04631172
802,NCT04392778,Clinical Use of Stem Cells for the Treatment of Covid-19,,Completed,No Results Available,Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection,Biological: MSC Treatment|Biological: Saline Control,Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus),All,40 Years to 60 Years Â  (Adult),Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Bak. Sadi Konuk-Istinye Uni.,30-Nov-20,1-Apr-20,243,1-Nov-20,19-May-20,,25-May-21,"Istinye University, Istanbul, Turkey|SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04392778
803,NCT04473898,Telerehabilitation After Coronavirus,,Completed,No Results Available,COVID,Other: Aerobic Exercise Training|Behavioral: Patient Education|Other: Respiratory Exercise Training,Dyspnoea|Anxiety and Depression|Sleep Quality|Health Related Quality of Life|Kinesiophobia|Patient Satisfaction|Fatigue,KTO Karatay University,All,"25 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,KaratayU2,17-Feb-21,19-Jun-20,243,19-Oct-20,16-Jul-20,,18-Feb-21,"KTO Karatay University, Konya, Karatay, Turkey",,https://ClinicalTrials.gov/show/NCT04473898
804,NCT04358640,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,PSY_CO_CHU,Completed,No Results Available,"Critical Illness|Sars-CoV2|SARS Pneumonia|Coronavirus Infection|Stress Disorders, Post-Traumatic",,Anxiety|Insomnia|Catastrophism,Centre Hospitalier Universitaire de NÄ«mes,All,"18 Years and older Â  (Adult, Older Adult)",,1784,Other,Observational,Observational Model: Other|Time Perspective: Prospective,LOCAL COVID 2019/JYL-01),27-Apr-20,9-Apr-20,18,27-Apr-20,24-Apr-20,,19-Dec-20,"Intensive care unit CHU Nimes, NÃ®mes, France",,https://ClinicalTrials.gov/show/NCT04358640
805,NCT04407208,Convalescent Plasma Therapy in Patients With COVID-19,,Completed,No Results Available,Convalescence|Corona Virus Infection|Plaque,Biological: Convalescent plasma,Plaque reduction neutralization test (PNRT)|D-dimer|C-Reactive Protein (CRP)|International Normalized Ratio (INR)|Oxygenation Index|Chest X-ray|severe adverse event,Biofarma|Rumah Sakit Pusat Angkatan Darat Gatot Soebroto|Eijkman Institute for Molecular Biology,All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3471041S322342020040800002,22-Jun-20,1-May-20,52,22-Jun-20,29-May-20,,30-Jun-20,"Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04407208/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04407208
806,NCT04843878,COVID-19 Testing Pilot Study,,Completed,No Results Available,"Diagnostic Test, Routine|Coronavirus|Diagnoses Disease|Rapid Coronavirus Test",Diagnostic Test: COVID Detect,Device Accuracy - Positive and Negative Percentage|Device Accuracy - False positive and False negative percentage,"University of Pennsylvania|Benjamin S. Abella, MD, MPhil|Marcelo Der Torossian Torres, Ph.D.|Cesar De La Fuente, Ph.D.",All,"18 Years and older Â  (Adult, Older Adult)",,326,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,844488,12-Mar-21,5-Jan-21,66,12-Mar-21,14-Apr-21,,14-Apr-21,"Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04843878
807,NCT04339387,COVID-19 Risk Stratification,,Completed,No Results Available,Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere,,Suitable for discharge,Brigham and Women's Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,1326,Other,Observational,Observational Model: Cohort|Time Perspective: Other,2020P000944,26-Apr-20,1-Mar-20,56,26-Apr-20,9-Apr-20,,30-Nov-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04339387
808,NCT04256395,Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19,COVID-19,Completed,No Results Available,Susceptibility to Viral and Mycobacterial Infection,Other: mobile internet survey on self-test,positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient,Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University,All,"Child, Adult, Older Adult",,102456,Other,Observational,Observational Model: Other|Time Perspective: Prospective,RWS-BTCH-002,1-Jul-20,1-Feb-20,151,1-Jul-20,5-Feb-20,,7-Jul-20,"Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04256395
809,NCT04797936,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,,Completed,No Results Available,Covid19|Nasopharyngitis|Anosmia|Fever|Myalgia|Cough|Nasal Congestion,Drug: BNO 1030|Other: Standard care,"Day of response to treatment from baseline to end of treatment (up to two weeks) - decrease in the average score of the symptom assessed by the patient (VAS, 0-10 points for each symptom) by 50% compared to baseline.|Symptom Dynamics (assessed by patients)",Ivano-Frankivsk National Medical University,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 4,133,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BERI_UA_IMU_2020_000003751,8-Jan-21,1-May-20,252,19-Dec-20,15-Mar-21,,15-Mar-21,"Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine",,https://ClinicalTrials.gov/show/NCT04797936
810,NCT04336761,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,INCOVPED,Completed,No Results Available,Coronavirus|COVID|Infection Viral,Diagnostic Test: nasopharyngeal swab,Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR,"University Hospital, Lille",All,"up to 18 Years Â  (Child, Adult)",,901,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_21|2020-A00811-38,1-Jan-21,15-Apr-20,261,1-Jan-21,7-Apr-20,,11-Mar-21,"CH Louis MOURIER, Colombes, France|HÃ´pital Jeanne de Flandres, CHU, Lille, France|HÃ´pital MÃ¨re Enfant CHU, Nantes, France|HÃ´pitaux PÃ©diatriques de Nice CHU-Lenval, Nice, France|HÃ´pital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04336761
811,NCT04456556,Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19),,Completed,No Results Available,Endophthalmitis and Orbital Cellulitis,,Combined Endophthalmitis and Orbital Cellulitis in patients with Novel Coronavirus Disease (COVID-19),Minia University,All,"Child, Adult, Older Adult",,5,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,ocular infection in covid19,30-Jun-20,27-Apr-20,64,20-Jun-20,2-Jul-20,,2-Jul-20,"Minia university Hospital, Minya, Minia, Egypt",,https://ClinicalTrials.gov/show/NCT04456556
812,NCT04407572,Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,,Completed,No Results Available,COVID|Zinc Deficiency|Vitamin D Deficiency,"Other: Serum zinc, vitamin d vitamin b12 levels .","Serum zinc, vitamin d vitamin b12 deficiency levels",Kanuni Sultan Suleyman Training and Research Hospital|AyÅŸegÃ¼l Bestel|Ä°brahim Polat|Merve AldÄ±kaÃ§tÄ±oÄŸlu TalmaÃ§,Female,18 Years to 45 Years Â  (Adult),,44,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,zinc-dvit-covid19,14-Jun-20,20-Apr-20,55,1-Jun-20,29-May-20,,23-Jun-20,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04407572
813,NCT04357886,Awareness of COVID-19 in Turkey,,Completed,No Results Available,Healthy,,COVID-19 Awareness Survey,Istanbul University-Cerrahpasa,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",,2605,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,60350273-605.99-,1-Jun-20,15-May-20,17,1-Jun-20,22-Apr-20,,26-Mar-21,"Istanbul University-Cerrahpasa, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04357886
814,NCT04345159,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,COVCALL,Completed,No Results Available,SARS-CoV-2|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sjogren's Syndrome|Psoriatic Arthritis,Other: Questionnaire by phone call,Adjusted Odds Ratio,Fondation Ophtalmologique Adolphe de Rothschild,All,"18 Years and older Â  (Adult, Older Adult)",,572,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,GDE_2020_11,30-Nov-20,17-Apr-20,227,30-Nov-20,14-Apr-20,,7-Jan-21,"Fondation Adolphe de Rothschild, Paris, France",,https://ClinicalTrials.gov/show/NCT04345159
815,NCT04393142,Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,,Completed,No Results Available,Coronavirus Infection,,Identify antibodies|Determine antibody sensitivity|IgM determination|IgG determination,Hospital Universitario Dr. Jose E. Gonzalez,All,"1 Year and older Â  (Child, Adult, Older Adult)",,96,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,IF20-00004,16-Feb-21,5-May-20,287,16-Feb-21,19-May-20,,18-Feb-21,"Hospital Universitario JosÃ© E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,https://ClinicalTrials.gov/show/NCT04393142
816,NCT04775966,CPAP Observance During the COVID-19 (SARS-CoV-2) Pandemic,COVADENE,Completed,No Results Available,Sleep Apnea Syndromes,,Change in positive airway pressure(PAP)-adherence during the first lockdown versus corresponding 2019 weeks (h/days)|Change in positive airway pressure(PAP)-adherence during the second lockdown versus corresponding 2019 weeks (h/days)|Change in PAP-adherence 2020 versus 2019 (h/days/weeks)|Change in the percentage of adherent patients (adherence > 4h/day/week) during the first lockdown versus corresponding 2019 weeks (h/days)|Change in the percentage of adherent patients (adherence > 4h/day/week) during the second lockdown versus corresponding 2019 weeks (h/days)|Change in patient adherence 2020 versus 2019 (%).,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,8477,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL21_0067,15-Feb-21,15-Jan-21,31,15-Feb-21,1-Mar-21,,3-Mar-21,"Adene Group, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04775966
817,NCT04872673,The Professional Values and Ethical Sensitivities During the COVID-19 Pandemic,,Completed,No Results Available,Professional Values|Ethical Sensitivities,,The first evaluation- Pre-test|The second evaluation- Post-test,Ankara Yildirim BeyazÄ±t University,All,"18 Years and older Â  (Adult, Older Adult)",,302,Other,Observational,Observational Model: Other|Time Perspective: Prospective,42/2020,15-Sep-20,15-Feb-20,213,13-Jul-20,4-May-21,,6-May-21,"Ankara YÄ±ldÄ±rÄ±m BeyazÄ±t University, Ankara, Ã‡ubuk, Turkey",,https://ClinicalTrials.gov/show/NCT04872673
818,NCT04884321,Complementary And Alternative Medicine During The COVID-19 Pandemic,,Completed,No Results Available,Complementary Therapies,Other: Complementary And Alternative Medicine,Participant adults' responses to the questions raised about the use of complementary and alternative methods during the COVID-19 pandemic|Means of scores obtained by participant adults from the holistic complementary and alternative medicine questionnaire (HCAMQ) and its sub-scales|Complementary and alternative treatment methods used during the COVID-19 pandemic|Plants consumed during the COVID-19 pandemic|Symptoms against which complementary and alternative methods are used during the COVID-19 pandemic,Hasan Kalyoncu University|Filiz Polat|Aynur Ekren Ã‡akÄ±cÄ±,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,3242,Other,Observational,Observational Model: Other|Time Perspective: Other,HasanKUMYO,30-Mar-21,27-Feb-21,31,30-Mar-21,12-May-21,,12-May-21,"Hasan Kalyoncu Ãœnivrsitesi, Gaziantep, LÃ¼tfen SeÃ§, Turkey",,https://ClinicalTrials.gov/show/NCT04884321
819,NCT04751227,Modafinil for Wakefulness in the Critical Care Units,,Completed,No Results Available,Critical Illness|COVID-19|Cognitive Dysfunction,Drug: Modafinil,Median change in of Glasgow Coma Scale (GCS)|adverse drug reactions (ADRs)|Duration of Mechanical Ventilation|ICU Length of stay (LOS)|Hospital Length of Stay (LOS)|Mortality rate,King Faisal Specialist Hospital & Research Center,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,8,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RAC # 2201230,30-Jan-21,22-Nov-20,69,30-Jan-21,12-Feb-21,,12-Feb-21,"King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT04751227
820,NCT04669912,COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management,COVIDIABADO,Completed,No Results Available,Type 1 Diabetes,Other: glucose control and sensor usage,Changes in percentage of time spent in range 70-180 mg/dL after lockdown compared to before lockdown|Changes in percentage of time spent in range 70-180 mg/dL during first month of lockdown compared to before lockdown|Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown|Evolution of glucose management indicator (GMI) compared to before lockdown.|Evolution of glucose time spent below range <54 mg/dL|Evolution of glucose time spent below range 54 - 70 mg/dL|Evolution of glucose time spent below range 180-250 mg/dL|Evolution of glucose time spent below range > 250 mg/dL|Evolution of average glucose in mg/dL compared to before lockdown.|Evolution of hypoglycaemia frequency compared to before lockdown.|Evolution of glucose sensor use compared to before lockdown.,Centre Hospitalier Sud Francilien,All,"13 Years to 25 Years Â  (Child, Adult)",,77,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IDRCB 2020-A02760-39,22-Jan-21,15-Jan-21,7,22-Jan-21,17-Dec-20,,2-Feb-21,"Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France",,https://ClinicalTrials.gov/show/NCT04669912
821,NCT04608097,Understanding Reactions to Emotional Material in the Media During COVID-19,,Completed,No Results Available,Healthy Participants|Intrusive Memories,Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo,Number of intrusive memories related to the trauma film|Characteristics of intrusive trauma memories related to the trauma film|Intrusion questionnaire|Impact of Event Scale - Revised (IES-R): Degree of subjective distress of post-film intrusions|Self-rated functioning associated with intrusive memories|Self-rated concentration disruption associated with intrusive memories|Self-rated sleep ratings|Behavior Change Questionnaire|Intrusion provocation task (IPT)|Verbal recognition memory test|Visual recognition memory test|Time perspective questionnaire|Future self questionnaire|Future Expectancy Scale,Uppsala University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",2020-03991,12-Mar-21,28-Oct-20,135,12-Mar-21,29-Oct-20,,30-Apr-21,"Uppsala University, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT04608097
822,NCT04413071,Cardiac COVID-19 Health Care Workers,CCC,Completed,No Results Available,SARS-CoV 2|COVID-19|Coronavirus|Cardiac Magnetic Resonance|Myocarditis|Cardiac Anomaly,Other: Passed infection of SARS-CoV-2,Myocarditis|Pericarditis|Atrial fibrillation|Ischemic heart disease|Dilatation of right heart chambers|Valvular hear disease|Rhythm disorders,AORTICA Group|Salamanca University Hospital|Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca,All,"18 Years to 71 Years Â  (Adult, Older Adult)",,142,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CCC_2020,12-Jun-20,25-May-20,18,12-Jun-20,2-Jun-20,,16-Jun-20,"University Hospital of Salamanca, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT04413071
823,NCT04449081,"Knowledge, Attitude and Practice of Dental Students About COVID-19",,Completed,No Results Available,Acute Respiratory Distress Syndrome|Corona Virus Infection|Acute Lung Injury|Fever|Myalgia|Cough|Dyspnea|Septic Shock|Bleeding,"Behavioral: Knowledge, Attitude, Practice, Awareness, Preference","Knowledge, Attitude, Practice of dental students towards COVID-19|Awareness level about Infection control to prevent COVID-19 transmission in clinics|Preference towards online learning.",Melaka Manipal Medical College,All,18 Years to 30 Years Â  (Adult),,215,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,MelakaMMC,20-Jun-20,25-Apr-20,56,10-Jun-20,26-Jun-20,,2-Sep-20,"Faculty of Dentistry, Melaka-Manipal Medical College, Melaka Tengah, Melaka, Malaysia",,https://ClinicalTrials.gov/show/NCT04449081
824,NCT04900233,Effect of Covid-19 Pandemic in Non Covid-19 Patients at the Emergency Surgical Department,,Completed,No Results Available,"Covid19|Emergencies|Appendicitis|Surgical Procedure, Unspecified",Other: surgery,Number of patients admitted to the emergency department|Clinical presentation of the patients at the time of admission|Has the COVID-19 pandemic made a significant change in the hospital admissions?,Hospital Italiano de Buenos Aires,All,"Child, Adult, Older Adult",,651,Other,Observational,Observational Model: Cohort|Time Perspective: Other,5684,6-May-21,6-May-21,0,6-May-21,25-May-21,,25-May-21,"Hospital Italiano de Buenos Aires, Ciudad autÃ³noma de Buenos Aires, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04900233
825,NCT04342650,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,CloroCOVID19II,Completed,No Results Available,COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial,Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet,Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,152,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAAE: 30504220.5.0000.0005,8-Jun-20,8-Apr-20,61,14-May-20,13-Apr-20,,7-Jul-20,"Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,https://ClinicalTrials.gov/show/NCT04342650
826,NCT04560413,"Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients",,Completed,No Results Available,SARS-CoV-2|Post-stroke Depression|Anxiety and Fear,,Hospital Anxiety and Depression Scale|Covid 19 Phobia Scale,Fatih Sultan Mehmet Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,77,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,FSMEAH-KAEK 2020/41,10-Aug-20,1-Jun-20,70,25-Jul-20,23-Sep-20,,30-Sep-20,"Fatih Sultan Mehmet Training and Research Hospital, Ä°stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04560413
827,NCT04536441,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,,Completed,No Results Available,Mental Health Wellness|Psychological Security|Psychological Distress,Behavioral: Ultra Brief Online Mindfulness-based Intervention|Behavioral: Control,Changes of Subjective Unit of Distress|Changes of Anxiety Scores|Changes of Psychological Insecurity|Changes of General Well-being|Fear of COVID-19,Universiti Tunku Abdul Rahman|Sunway University,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Not Applicable,161,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",U/SERC/62/2020,30-Jun-20,1-Apr-20,90,30-May-20,2-Sep-20,,2-Sep-20,"Universiti Tunku Abdul Rahman, Kampar, Perak, Malaysia",,https://ClinicalTrials.gov/show/NCT04536441
828,NCT04501991,Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes|Metabolic Control,Other: antidiabetic treatment,Glucose|HbA1c|Lipid profile,University of Pisa,All,"18 Years to 85 Years Â  (Adult, Older Adult)",,114,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,AS0007,30-Jun-20,11-Mar-20,111,4-May-20,6-Aug-20,,6-Aug-20,"University of Pisa, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT04501991
829,NCT04284046,CT Scores Predict Mortality in 2019-nCoV Pneumonia,,Completed,No Results Available,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Other: CT score,7-day mortality,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",All,"Child, Adult, Older Adult",,39,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CT2019-nCoV,18-Feb-20,31-Jan-20,18,18-Feb-20,25-Feb-20,,25-Feb-20,"Wuhan third hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04284046
830,NCT04516824,Experience of Orthopaedic and Spine Center Pakistan During COVID-19,,Completed,No Results Available,Orthopaedic Disorders,Procedure: Orthopaedic Surgical Procedures,Clinical and functional characteristics|Patient's journey,Ghurki Trust and Teaching Hospital,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,2160,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,30,15-Aug-20,19-Mar-20,149,13-Jul-20,18-Aug-20,,18-Aug-20,"Ghurki trust hospital, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04516824
831,NCT04361877,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),,Completed,No Results Available,Cardiovascular Prevention Behaviour,,Change of physical activity|change of nutrition behaviour|semiquantitative change of alcohol intake|change of smoking behaviour|change of stress level|step count,Klinikum der Universitaet Muenchen,All,"18 Years and older Â  (Adult, Older Adult)",,1900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-268 KB,20-Apr-20,30-Mar-20,21,20-Apr-20,24-Apr-20,,5-May-21,"University Hospital Munich (LMU Klinikum), Munich, Germany",,https://ClinicalTrials.gov/show/NCT04361877
832,NCT04344197,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",,Completed,No Results Available,Surgery|COVID|Asymptomatic Patient|Covid-19|Preventive Measures,Other: global survey,"overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.",University of Rome Tor Vergata,All,"Child, Adult, Older Adult",,1200,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,s-covid survey,15-Apr-20,2-Apr-20,13,8-Apr-20,14-Apr-20,,29-Dec-20,"Tor Vergata Hospital, Rome, Italy",,https://ClinicalTrials.gov/show/NCT04344197
833,NCT04362319,Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,,Completed,No Results Available,"Burnout, Professional|Depression|Medical Errors|Covid-19",Diagnostic Test: Questionnaire forms,"Prevalence of burnout among anaesthesiology clinicians during Covid-19|Prevalence of depression risk among anaesthesiology clinicians during Covid-19|Prevalence of self-perceived medical errors among anaesthesiology clinicians during Covid-19|Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19","University of Malaya|Ministry of Health, Malaysia",All,"18 Years and older Â  (Adult, Older Adult)",,85,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,54753,31-May-20,15-May-20,16,31-May-20,24-Apr-20,,16-Jun-20,"Sungai Buloh Hospital, Sungai Buloh, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04362319
834,NCT04366297,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,,Completed,No Results Available,Cardiac Arrest|Emergencies,Device: Intravenous access|Device: Intraosseous access,successful rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ease of use|Preferred intravascular access method,Lazarski University|Poznan University of Medical Sciences|Medical University of Bialystok|Wroclaw Medical University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IO_PPE_MS_1,25-Feb-20,12-Jan-20,44,25-Feb-20,28-Apr-20,,28-Apr-20,"Lazarski Univeristy, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT04366297
835,NCT04375501,A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,,Completed,No Results Available,Femoral Neck Fractures|SARS-CoV 2,"Other: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail",Mortality|Morbidity|Discharge,"Barts & The London NHS Trust|University College London Hospitals|Barking, Havering and Redbridge University Hospitals NHS Trust|Mid and South Essex NHS Foundation Trust|Frimley Park Hospital NHS Trust|The Hillingdon Hospitals NHS Foundation Trust",All,"18 Years and older Â  (Adult, Older Adult)",,442,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,284104,15-Apr-20,1-Feb-20,74,15-Apr-20,5-May-20,,20-May-20,"Barts Health NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04375501
836,NCT04347408,Seroprevalence of SARS-Cov-2 Antibodies in Children,,Completed,No Results Available,COVID|Corona Virus Infection,Diagnostic Test: Covid-19 Antibody testing (IgG and IgM),Immunoglobulins (G and M) to SARS-Cov2 in plasma,"Queen's University, Belfast|Belfast Health and Social Care Trust",All,2 Years to 15 Years Â  (Child),,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,282617,13-Dec-20,6-May-20,221,13-Dec-20,15-Apr-20,,10-Mar-21,"Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04347408
837,NCT04817280,COVID-19 in Polish Ice Swimmers.,ICE,Completed,No Results Available,"Covid19|SARS-CoV Infection|Resistance, Disease|Hypothermia|Hypothermia Due to Cold Environment",Other: Ice Swimming,"Assessment of the incidence of COVID-19 among ice swimmers compared to the general population.|Assessment of the frequency of asymptomatic SARS-CoV-2 infection among ice swimmers compared to the general population.|Assessment of the frequency of occurrence of particular symptoms of SARS-CoV-2 infection among ice swimmers compared to the general population.|Assessment of the frequency of COVID-19 treatment in an outpatient, inpatient and intensive care unit among ice swimmers compared to the general population.|Assessment of the impact of parameters and ice swimming strategies on the likelihood of developing COVID-19, the occurrence of individual symptoms of the disease and the severity of its course.|Assessment of the influence of blood group on susceptibility to SARS-CoV-2 infection among ice swimmers.|Assessment of the immunity of the ice swimmer's immune system compared to the general population.",Wroclaw Medical University,All,"Child, Adult, Older Adult",,2534,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,KB-03/139/2021,1-Mar-21,1-Dec-20,90,17-Jan-21,26-Mar-21,,9-Apr-21,"Department of Public Health at Wroclaw Medical University, WrocÅ‚aw, Dolny Slask, Poland|Department of Radiotherapy of Multidisciplinary Provincial Hospital, GorzÃ³w Wielkopolski, Lubuskie, Poland|Treasury Medical Company, Zielona GÃ³ra, Lubuskie, Poland",,https://ClinicalTrials.gov/show/NCT04817280
838,NCT04532632,Taste and Smell Impairment in Critically Ill COVID-19 Patients,,Completed,No Results Available,Smell Disorder|Taste Disorders|Coronavirus Infection,,taste and smell impairment,Pinar Ay Sayin|Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Other|Time Perspective: Prospective,3334-02,9-Oct-20,1-Sep-20,38,1-Oct-20,31-Aug-20,,10-Nov-20,"Sisli Etfal Research and Training Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04532632
839,NCT04275414,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,BEST-CP,Completed,No Results Available,Coronavirus Infections,Drug: Bevacizumab Injection,Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Rate of improvement of oxygen-support status|The change of areas of pulmonary lesions shown on chest radiological imaging (chest CT or X-ray)|Blood lymphocyte counts|Level of CRP|Level of hs-CRP|All-cause mortality|Discharge rate,Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QLEmer20200214,2-May-20,15-Feb-20,77,5-Apr-20,19-Feb-20,,14-Sep-20,"Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy",,https://ClinicalTrials.gov/show/NCT04275414
840,NCT04894331,Telemedicine for SNAS Patients in COVID-19 Pandemic,DISTANCE,Completed,No Results Available,Systemic Nickel Allergic Syndrome,Other: Dietary intervention|Other: Video call,Dietary assessment|Change of body mass index (BMI)|Change of circumference of wrist|Change of circumference of arm|Change of circumference of waist|Change of circumference of hip|State of well-being|Adherence to dietary therapy,Catholic University of the Sacred Heart,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ID 3448,30-Nov-20,8-Oct-20,53,23-Nov-20,20-May-21,,20-May-21,"Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04894331
841,NCT04395144,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,COVAYDE,Completed,No Results Available,Coronavirus Infection|COVID|Severe Acute Respiratory Syndrome|Respiratory Failure|Respiratory Insufficiency|Respiratory Distress Syndrome|ARDS|Lung Diseases,Procedure: Awake Prone Positioning|Procedure: Standard care,"Rate of Therapeutic failure, defined as a combined outcome of rate of intubation or death|Intubation rate|Mortality|Days spent on mechanical ventilation|Days spent in the ICU|Hospital stay (in days)",HÃ´pital de Verdun,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,13,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2021-01,15-Mar-21,15-May-20,304,15-Mar-21,20-May-20,,23-Mar-21,"HÃ´tel-Dieu de GaspÃ©, GaspÃ©, Quebec, Canada|HÃ´pital de la CitÃ©-de-la-SantÃ©, Laval, Quebec, Canada|Montreal General Hospital, McGill University Healthcare Center, MontrÃ©al, Quebec, Canada|Royal Victoria Hospital, McGill University Healthcare Center, MontrÃ©al, Quebec, Canada|HÃ´pital de Verdun, MontrÃ©al, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04395144
842,NCT04453579,"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",,Completed,No Results Available,Obese|Morbid Obesity,Behavioral: Telephonic interview during the Italian lockdown.,Psychological conditions,University of Rome Tor Vergata,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,116,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UNRomeB,30-May-20,9-Mar-20,82,4-May-20,1-Jul-20,,1-Jul-20,"Michela Campanelli, Rome, RM, Italy",,https://ClinicalTrials.gov/show/NCT04453579
843,NCT04359875,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,COVIQuest,Completed,No Results Available,Cardiovascular Diseases|Mental Disorder,Behavioral: Phone-call screening and management by a medical student/general practitioner tandem,Hospitalization(s) at 1 month|Phone-call from the general practitioner (in the experimental group only)|Mortality at 1 month|Use of primary care|Use of secondary care|Number of prescriptions related to the chronic disease dispensed by the pharmacy|Number of hospitalization(s)|Time to hospitalization(s)|Hospitalization(s)' durations|Reasons for hospitalization(s)|Mortality at 6 months|Cardiovascular events (MACE)|Psychotropic drugs,"University Hospital, Tours|INSERM CIC-P 1415",All,"18 Years to 110 Years Â  (Adult, Older Adult)",Not Applicable,22000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2020-CD-COVIQuest (COVID-19)|2020-A01061-38,31-Dec-20,30-Apr-20,245,30-Jun-20,24-Apr-20,,12-Apr-21,"Dibao-Dina, Tours, France",,https://ClinicalTrials.gov/show/NCT04359875
844,NCT04445506,Short Term Corticosteroids in SARS-CoV2 Patients,,Completed,No Results Available,Corticosteroids|Covid19|SARS-CoV 2|Steroids|Dexamethasone,Drug: Dexamethasone,Effect on transfers to ICU and escalation of care needing mechanical ventilation|Effect on length of stay|Change in CRP levels,The Miriam Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,50,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,20-027,31-May-20,1-Apr-20,60,31-May-20,24-Jun-20,,24-Jun-20,"The Miriam Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04445506
845,NCT04797624,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,,Completed,No Results Available,Stomach Cancer|Corona Virus Infection,Procedure: Gastric cancer surgery,Comparison of the mean monthly numbers of newly diagnosed gastric cancer patients between the groups|Comparison of the clinical staging and pathologic TNM staging of the patients|Comparison of the demographic data,Adana City Training and Research Hospital,All,"18 Years to 95 Years Â  (Adult, Older Adult)",,146,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,1248,15-Feb-21,15-Jan-21,31,15-Feb-21,15-Mar-21,,15-Mar-21,"Adana City Training and Research Hospital, Adana, Yuregir, Turkey",,https://ClinicalTrials.gov/show/NCT04797624
846,NCT04513847,PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,,Completed,No Results Available,Psoriasis|Covid19,,"Percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey.",Dermatrials Research,All,"Child, Adult, Older Adult",,661,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,Pso-Vac,6-Oct-20,13-Aug-20,54,13-Sep-20,14-Aug-20,,8-Oct-20,"Dermatrials Research, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04513847
847,NCT04487197,"SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)",,Completed,No Results Available,Kidney Transplant|Pancreatic Transplat|Pancreatic Islets Langerhans,Procedure: blood sample for seroepidemiological investigation,"Serum-prevalence of COVID-19 TX|Serum-prevalence of COVID-19 / Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients|Asymptomatic or subclinical infections in transplanted patients|Risk factors for infection COVID-19 transplanted patients|Hospitalization rate COVID-19 transplanted patients|Mortality rate COVID-19 transplanted patients",Antonio Secchi|IRCCS San Raffaele,All,"18 Years and older Â  (Adult, Older Adult)",,282,Other,Observational,Observational Model: Cohort|Time Perspective: Other,COVID-SIERO TRAPIANTI,15-Jan-21,15-Jul-20,184,15-Jan-21,27-Jul-20,,10-Feb-21,"IRCCS San Raffaele, Milan, Italy",,https://ClinicalTrials.gov/show/NCT04487197
848,NCT04445961,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,COVID-VENT,Completed,No Results Available,SARS Pneumonia,Diagnostic Test: Respiratory mechanics measurement|Diagnostic Test: Gas exchange measurement,Optimum positive end-expiratory pressure (PEEP) level|Number of patients with recruitable lung|Change in alveolar dead space|Change in plethysmogram variability during recruitment maneuver|Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio|Change in driving pressure with different positive end-expiratory pressure (PEEP) levels,I.M. Sechenov First Moscow State Medical University,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,117,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,COVID-VENT,14-Aug-20,1-May-20,105,14-Aug-20,24-Jun-20,,27-Aug-20,"Sechenov University Clinic #1, Moscow, Russian Federation|Sechenov University Clinic #3, Moscow, Russian Federation|Sechenov University Clinic #4, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04445961
849,NCT04323592,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,MP-C19,Completed,Has Results,"Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human",Drug: Methylprednisolone|Other: standard care,"Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28|In-hospital Death Within 28 Days|Admission to Intensive Care Unit (ICU)|Endotracheal Intubation (Invasive Mechanical Ventilation)|Change in C-reactive Protein (CRP)|Number of Days Free From Mechanical Ventilation",University of Trieste,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,173,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MP-19 023_2020,10-May-20,23-Mar-20,48,10-May-20,26-Mar-20,4-Jun-20,24-Jun-20,"Marco Confalonieri, Trieste, TS, Italy","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/SAP_004.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_006.pdf",https://ClinicalTrials.gov/show/NCT04323592
850,NCT04371419,COVID-19 Health Messaging to Underserved Communities,,Completed,No Results Available,Coronavirus,Behavioral: Messaging,Knowledge Beliefs and Practices related to COVID-19|Video Ratings,"National Bureau of Economic Research, Inc.|Massachusetts General Hospital|Stanford University|Yale University|Massachusetts Institute of Technology|Harvard University",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,15475,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2003000118,24-May-20,13-May-20,11,24-May-20,1-May-20,,19-Jun-20,"JPAL North America, Cambridge, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04371419/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04371419
851,NCT04377776,"Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",,Completed,No Results Available,Kidney Transplant|Pancreas Tranplant|Pancreatic Islet Transplantation,Other: Practice details,Global Prevalence of COVID-19 TX|Hospitalization rate in COVID-19 TX|Correlation COVID-19 TX and type of transplantation|Prevalence of COVID-19 TX in italian provinces|Symptoms in COVID-19 TX|Correlation COVID-19 TX and comorbidities|COVID-19 TX Therapies|COVID-19 TX in family settings,IRCCS San Raffaele,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,644,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COVID-19 MITRA,18-May-20,4-May-20,14,18-May-20,6-May-20,,22-Jun-20,"IRCCS San Raffaele, Milano, Italy",,https://ClinicalTrials.gov/show/NCT04377776
852,NCT04761874,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,TELECAST-CSC,Completed,No Results Available,"Stroke, Acute",Other: Telestroke,Guideline-Based Inpatient Stroke Care|Stroke Recurrence|Readmission Rate,University of Minnesota,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,296,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TC0002,29-Sep-20,1-Dec-19,303,29-Jun-20,21-Feb-21,,22-Apr-21,"M Health Fairview Southdale Hospital, Edina, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04761874
853,NCT04426318,COVID-19 and the Healthy Minds Program for Educators,CAHMP-ED,Completed,No Results Available,Anxiety|Depression|Psychological Stress|Psychological Distress|Well-being,Behavioral: Healthy Minds Program Foundations Training,Change from baseline on an aggregate measure of Psychological distress that averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depressive Measures and the NIH Perceived Stress Scale|Change from baseline on the Five Facet Mindfulness Questionnaire Act with Awareness subscale|Change from baseline on the Drexel Defusion Scale (DDS)|Change from baseline on the Meaning in Life Questionnaire|Change from baseline on the NIH Toolbox Loneliness scale|Change from baseline on the Conway COVID Questionnaire|Change from baseline on the Self-Compassion Scale Short Form|Change from baseline on the Perseverative Thought Questionnaire|Change from baseline on the World Health Organization 5-item (WHO-5) well-being scale|Change from baseline on the Neutral Face Rating task|Change from baseline on the Growth Mindset Scale for Well-Being,"University of Wisconsin, Madison|Chan Zuckerberg Initiative|Healthy Minds Innovations|Center for Healthy Minds",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,733,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2020-0533|A171600|EDUC/COUNSELING PSYCH|Protocol Approval 10/15/2020,12-Jan-21,14-Jun-20,212,12-Jan-21,11-Jun-20,,26-Jan-21,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04426318
854,NCT04460027,W-SUDs for COVID-19,,Completed,No Results Available,Substance Use Disorders|Alcohol Use Disorder,Other: Woebot Substance Use Disorder,Change of number of days drinking|Change of number of days drug use|Short Inventory of Problems - Alcohol and Drugs (SIP-AD)|Drug Abuse Screening Test (DAST-10)|Brief Situational Confidence Questionnaire (BSCQ)|Craving rating|Pain rating|Patient Health Questionnaire-9 (PHQ-9)|General Anxiety Disorder-7 (GAD-7)|CAIR Pandemic Impact Questionnaire (CAIR-PIQ)|Client Satisfaction Questionnaire (CSQ)|Usage Rating Profile Intervention (URPI),"Athena Robinson|Stanford University|Woebot Labs, Inc.",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1,180,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",56439,30-Nov-20,22-Jun-20,161,30-Nov-20,7-Jul-20,,28-Apr-21,"Stanford University, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT04460027
855,NCT04839913,"Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study",COVID-19,Completed,No Results Available,SARS-CoV Infection|Seroprevalence|Covid19,Diagnostic Test: Antibodies testing,SARS-COV-2 seroprevalence,University of Cagliari,All,"18 Years and older Â  (Adult, Older Adult)",,121,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,COVID-SER,10-Jan-21,1-Sep-20,131,10-Dec-20,9-Apr-21,,9-Apr-21,"University of Cagliari, Cagliari, Italy",,https://ClinicalTrials.gov/show/NCT04839913
856,NCT04402970,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),DORNASESARS2,Completed,Has Results,SARS-CoV 2|ARDS,Drug: Dornase Alfa Inhalation Solution,Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2)|Change in Static Lung Compliance|Duration of Mechanical Ventilation|Length of ICU Stay|Length of Hospitalization|Secondary Bacterial Infections|Mortality,University of Missouri-Columbia,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2022206,31-Dec-20,19-Jun-20,195,31-Dec-20,27-May-20,14-Apr-21,14-Apr-21,"University of Missouri Hospital and Clinics, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04402970/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04402970/ICF_004.pdf",https://ClinicalTrials.gov/show/NCT04402970
857,NCT04501432,Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19,CODIS,Completed,No Results Available,Cardiac Rehabilitation,Other: No intervention,Work load (W)|Work load % of predicted value|Heart rate (bpm)|Framingham Recurrent Coronary Heart Disease risk score|Metabolic Equivalent (MET) minutes / week|Patient Experience,"Ludwig Boltzmann Institute for Digital Health and Prevention|Institute of Sports Medicine, Prevention and Rehabilitation, Salzburg, Austria",All,"18 Years and older Â  (Adult, Older Adult)",,27,Other,Observational,Observational Model: Cohort|Time Perspective: Other,23_CODIS,24-Oct-20,14-Jul-20,102,24-Oct-20,6-Aug-20,,3-Dec-20,"Institute of Sports Medicine, Prevention and Rehabilitation, Salzburg, Austria",,https://ClinicalTrials.gov/show/NCT04501432
858,NCT04365608,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,,Completed,No Results Available,Intubation Complication|Intubation; Difficult or Failed|Cardiac Arrest|Influenza|Safety Issues,Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy,Intubation success rate during at the first laryngoscopy|Intubation difficulty Scale score|Complications related to tracheal intubation|Time to completion of tracheal intubation (TI) procedure|Duration of the interruption of chest compression during ETI procedure|Laryngeal View during intubation|POGO score,Lazarski University|Poznan University of Medical Sciences|Wroclaw Medical University|Medical University of Bialystok,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,INT_EMS_PPE_1,10-Dec-20,20-Mar-20,265,30-Nov-20,28-Apr-20,,19-Dec-20,"Emergency Medical Service, Poznan, Poland|Emergency Medical Service, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT04365608
859,NCT04415359,Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period,AMPCOVID-19,Completed,No Results Available,Covid-19,,Study of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period,"University Hospital, Strasbourg, France",Female,18 Years to 43 Years Â  (Adult),,700,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,7789,31-Dec-20,1-Aug-20,152,31-Oct-20,4-Jun-20,,1-Apr-21,"Service Clinico biologique d'Assistance MÃ©dicale Ã  La ProcrÃ©ation, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04415359
860,NCT04363593,Serology COVID-19 From the Cornwall Hospital Union,ROCOCO,Completed,No Results Available,Corona Virus Infection,Biological: Serological test|Biological: Serum test,Serological test evaluation|Population seroprevalence,Centre Hospitalier de Cornouaille|Centre Hospitalier RÃ©gional et Universitaire de Brest,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,2587,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,29BRC20.0122,16-Nov-20,4-May-20,196,16-Nov-20,27-Apr-20,,10-Dec-20,"CH de Cornouaille, Quimper, France",,https://ClinicalTrials.gov/show/NCT04363593
861,NCT04451993,Physical Activity Level in Patients With OSAS During Covid-19 Pandemic,,Completed,No Results Available,Obstructive Sleep Apnea-hypopnea Syndrome,,Physical Activity|Sleep Quality|Daytime Sleepiness|Fear of movement|Health literacy,Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital,All,"19 Years to 70 Years Â  (Adult, Older Adult)",,63,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,GO 20/540,30-Sep-20,25-Jun-20,97,1-Sep-20,30-Jun-20,,5-Feb-21,"Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital, Trabzon, Turkey",,https://ClinicalTrials.gov/show/NCT04451993
862,NCT04758039,Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort,,Completed,No Results Available,Corona Virus Infection,,"In hospital Mortality|Admission to an intensive care unit (ICU)|Use of invasive mechanical ventilation (IMV)|Presence of thromboembolic disease (deep vein thrombosis, pulmonary embolism or both)|Acute kidney injury (AKI)|Renal replacement therapy (RRT).",University of Chile,All,"18 Years and older Â  (Adult, Older Adult)",,395,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,OAIC NÂ° 1119/20,10-Jul-20,13-Mar-20,119,10-Jul-20,17-Feb-21,,18-Feb-21,"Hospital Clinico de la Universidad de Chile, Santiago, RegiÃ³n Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT04758039
863,NCT04604769,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,ICUcovid,Completed,No Results Available,Coronavirus|Nurse's Role|Professional Stress,,stress at work|stress in a medical unit|hobby activities,University of Liege,All,"18 Years and older Â  (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,stressICUcovid,1-Sep-20,26-Jun-19,433,1-Sep-20,27-Oct-20,,27-Oct-20,"University of LiÃ¨ge, LiÃ¨ge, Province De LiÃ¨ge, Belgium",,https://ClinicalTrials.gov/show/NCT04604769
864,NCT04370210,Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry,CONFIDODO,Completed,No Results Available,Sleep Disturbance,Behavioral: Questionnaires,Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up|Assessment of child depression in both groups|Assessment of child anxiety in both groups|Assessment of the influence of socio-demographic factors on sleep in both groups|Measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups|Assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry,Centre Hospitalier RenÃ© Dubos,All,7 Years to 12 Years Â  (Child),,247,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHRD 0520,4-Jun-20,4-May-20,31,4-Jun-20,30-Apr-20,,2-Jul-20,"Centre Hospitalier RenÃ© Dubos, Pontoise, France",,https://ClinicalTrials.gov/show/NCT04370210
865,NCT04371848,Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuÃ©bec Sub-study,,Completed,No Results Available,Eating Habits,,Change in diet quality|Change in food insecurity|Change in intake of sodium|Change in intake of sugar|Change in intake of saturated fat|Change in intake of vegetables and fruits|Change in intake of dairy products|Change in physical activity|Change in sleep quality|Change in health-related quality of life,Laval University,All,"18 Years and older Â  (Adult, Older Adult)",,2465,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2018-042Phase IIA6/09-04-2020,7-May-20,16-Apr-20,21,7-May-20,1-May-20,,5-Mar-21,"UniversitÃ© Laval, QuÃ©bec, Canada",,https://ClinicalTrials.gov/show/NCT04371848
866,NCT04374097,Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak,,Completed,No Results Available,Post Traumatic Stress Disorder|Anxiety|Depression,,PTSD Checklist for DSM-5 (PCL-5)|Patient Health Questionnaire 9 (PHQ-9)|The Generalized Anxiety Disorder 7 (GAD-7)|Health anxiety,University of Oslo|Modum Bad,All,"18 Years and older Â  (Adult, Older Adult)",,1778,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,REK125510(2),7-Apr-20,31-Mar-20,7,7-Apr-20,5-May-20,,6-May-20,"University of Oslo, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT04374097
867,NCT04377074,Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety,,Completed,No Results Available,Parental Stress|Depression|Anxiety,,Measure of parental stress|Patient Health Questionnaire 9|Generalized Anxiety Disorder 7,University of Oslo|Modum Bad|Oslo Metropolitan University|University of Bergen,All,"18 Years and older Â  (Adult, Older Adult)",,2880,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,REK125510(3),7-Apr-20,31-Mar-20,7,7-Apr-20,6-May-20,,6-May-20,"University of Oslo, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT04377074
868,NCT04381000,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,,Completed,No Results Available,Chronic Pain,Other: Exercise Group,Anxiety and Depression|Quality of Life and overall health|Pain Intensity|Quality and patterns of sleep|Patients' illness perceptions|Disability,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory|University of Thessaly,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3,10-Jun-20,1-Apr-20,70,29-May-20,8-May-20,,1-Jul-20,"Clinical Exercise Physiology and Rehabilitation Laboratory, Lamia, Sterea Ellada, Greece",,https://ClinicalTrials.gov/show/NCT04381000
869,NCT04340219,"Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic",ONCOVID,Completed,No Results Available,Cancer,Other: Survey administration,"Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs â‰¥ 29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression); in terms of proportions (0-4 vs â‰¥ 5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21-Anxiety); in terms of proportions (0-3 vs â‰¥ 4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21-Stress); in terms of proportions (0-7 vs â‰¥ 8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21-Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21-Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21-Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF-Physical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Psychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Social relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Environment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire-in terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21-Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21-Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21-Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Physical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Psychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Social relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Environment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics","University Hospital, Ghent",All,"18 Years and older Â  (Adult, Older Adult)",,394,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BC-07505-LGE,18-Sep-20,30-Mar-20,172,10-Apr-20,9-Apr-20,,25-Sep-20,"University Hospital Gent, Gent, Belgium",,https://ClinicalTrials.gov/show/NCT04340219
870,NCT04387799,Determinants of COVID-19 Pneumonia (MC-19),MC-19,Completed,No Results Available,"Pneumonia, Viral|Pneumonia, Bacterial|Coronavirus Infection|Obstructive Lung Disease",Diagnostic Test: Serology for Covid-19,Serology|Efficacy of CT scan and Serology|Efficacy of different pharmaceutical treatments,Catholic University of the Sacred Heart,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,520,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20200505,17-Jun-20,13-May-20,35,12-Jun-20,14-May-20,,19-Jun-20,"Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04387799
871,NCT04859023,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,AutoCoV,Completed,No Results Available,SARS-CoV Infection,Diagnostic Test: saliva sample combined to an anterior nare self-swabbing (Self-samples)|Diagnostic Test: saliva sample (Self-sample)|Other: Survey of SARS-COV-19 knowledge|Other: Survey of acceptability of the different self-samples.,"Positivity of self-samples combining saliva and anterior nare specimens tested by rapid antigenic test compared to saliva tested by RT-PCR (gold-standard).|Number and percentage of SARS-CoV-2 infection in the selected population tested by reference RT-PCR on saliva|Number and percentage of the circulation of different variants of interest of SARS-CoV-2 viruses in the tested population|Evaluate the acceptability (pain, discomfort, speed of execution) of self-samples according to age and socio-professional categories|Evaluate the cost-effectiveness ratio of the new strategy by comparison to the gold standard (RT-PCR on saliva)|Number of people who have benefited from sensitization and support specifically set up as part of the screening campaign|Number of persons cared for by the territorial isolation support cell (CTAI)|Health literacy questionnaire",Centre Hospitalier Universitaire de Saint Etienne,All,"10 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,10000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,21CH037|2021-A00390-41,28-Feb-21,22-Feb-21,6,28-Feb-21,26-Apr-21,,6-May-21,"CHU Saint-Etienne, Saint-Ã‰tienne, France",,https://ClinicalTrials.gov/show/NCT04859023
872,NCT04511949,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,FAMICOV,Completed,No Results Available,Coronavirus Infection,"Diagnostic Test: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)",Measure of the proportion of contact persons who have developed anti-SARS-CoV-2 antibodies (secondary transmission rate) within the same household of a subject who had a COVID-19 disease assessed by a rapid diagnostic-oriented test,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,All,"3 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CREPATS 012,30-Nov-20,12-Jul-20,141,30-Sep-20,13-Aug-20,,3-Feb-21,"Christine KATLAMA, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT04511949
873,NCT04845880,SARS Cov_2 Incidence of Healthy Health Workers,,Completed,No Results Available,SARS COV-2 IgG Levels on Health Workers,Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2,Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital,Baskent University|Hikmet Eda Aliskan|Hatice Hale Gumus|Ilker Odemis|Zuhal Ekici Unsal,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,182,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,KA20/449,1-Apr-21,1-Oct-20,182,1-Mar-21,15-Apr-21,,15-Apr-21,"Adana Dr. Turgut Noyan Application and Research Center, Adana, Turkey",,https://ClinicalTrials.gov/show/NCT04845880
874,NCT04604080,Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan,,Completed,No Results Available,"Depression, Anxiety",Other: service of questionnaire,Prevalence estimation of depression in adults,Islamia University of Bahawalpur,All,"Child, Adult, Older Adult",,390,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,U1111-1260-1614,18-Nov-20,1-Nov-20,17,18-Nov-20,27-Oct-20,,19-Nov-20,"The Islamia University of Bahawalpur, BahÄwalpur, Punjab, Pakistan|GC University Faisalabad, Faisalabad, Punjab, Pakistan|University of Veterinary and Animal Sciences, Lahore, Lahore, Punjab, Pakistan|Bahauddin Zakriya University Multan, Multan, Punjab, Pakistan|Quaid-i-Azam University Islamabad, Islamabad, Pakistan",,https://ClinicalTrials.gov/show/NCT04604080
875,NCT04356885,COVID-19 and Psychotic Symptoms in France,SCHIZOVID-19,Completed,No Results Available,Mental Disorder,,Total score of the Cardiff Anomalous Perceptions Scale (CAPS)|Paranoia Scale,"University Hospital, Montpellier|Epsylon Laboratory, EA 4556, University Paul ValÃ©ry Montpellier 3, France|Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France|Centre rÃ©fÃ©rent de rÃ©habilitation psychosociale de Grenoble, Grenoble, France",All,"18 Years to 65 Years Â  (Adult, Older Adult)",,600,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0225,1-Aug-20,1-Apr-20,122,30-Jul-20,22-Apr-20,,29-Dec-20,"UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04356885
876,NCT04694664,COVID-19 Vaccine Confidence Among Pregnant Women and Mothers,VCCOVID,Completed,No Results Available,Pregnancy Related|Mothers,Other: This is an online survey with no intervention.,Percentage of acceptance of a COVID-19 vaccine,Pregistry|Harvard School of Public Health,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",,18000,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,3,1-Dec-20,1-Oct-20,61,1-Dec-20,5-Jan-21,,5-Jan-21,"Pregistry, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04694664
877,NCT04447638,Percutaneous Tracheostomy With COVID-19,,Completed,No Results Available,Tracheostomy,Procedure: Tracheostomy with aerosol box in COVID-19 positive patients,Complications observed in the cases in which we applied percutaneous tracheostomy with aerosol box,Ã‡anakkale Onsekiz Mart University,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,24,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,TT17,1-Jun-20,20-Mar-20,73,1-Jun-20,25-Jun-20,,24-Sep-20,"Canakkale Onsekiz Mart University, Canakkale, Turkey",,https://ClinicalTrials.gov/show/NCT04447638
878,NCT04556604,Surgical Consent During the COVID-19 Pandemic,,Completed,No Results Available,Consent,Behavioral: Educational meetings and visual prompts,Compliance to consenting practice,Medway Primary Care Trust,All,"18 Years and older Â  (Adult, Older Adult)",,45,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,2021.016N,14-Aug-20,10-Apr-20,126,14-Aug-20,21-Sep-20,,21-Sep-20,"Medway NHS Foundation Trust, Gillingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT04556604
879,NCT04417374,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19",HoCoPsy,Completed,No Results Available,COVID 19|Disease Outbreak|Mental Disorders,Other: Description of groups caracteristics,Number of hospitalized patients|Cause of hospitalization,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,94,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0320,30-Jun-20,1-May-20,60,30-May-20,4-Jun-20,,29-Jul-20,"University hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04417374
880,NCT04429477,Cerebral Compliance Impairment in COVID-19,,Completed,No Results Available,Intracranial Hypertension|Cerebral Circulatory Failure,Device: Cerebral compliance and hemodynamics monitoring,Detection of cerebral compliance impairment by the B4C sensor|Detection of cerebral hemodynamics impairment by transcranial Doppler|Calculate mortality in this population,University of Sao Paulo,All,"1 Year and older Â  (Child, Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,31750820.1.0000.0068,31-Jul-20,1-May-20,91,15-Jul-20,12-Jun-20,,22-Sep-20,"Hospital das ClÃ­nicas da Faculdade de Medicina da USP., SÃ£o Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04429477
881,NCT04424836,HFNC Treatment in COVID-19 Pneumonia,,Completed,No Results Available,"Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Failure",Device: high flow nasal cannula device,short term mortality|icu stay|blood gases,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,43,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,5569,5-Jun-20,15-May-20,21,4-Jun-20,11-Jun-20,,16-Jul-20,"Sisli Etfal Research and Training Hospital, Istanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04424836/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04424836/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04424836
882,NCT04356365,The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's),,Completed,No Results Available,Depression|Generalized Anxiety|Adherence to Non-pharmacological Epidemiological Interventions (NPIs),Other: Cross-sectional study investigating the association of NPIs with mental health,Patient Health Questionnaire 9|Generalized Anxiety Disorder 7|Measures of adherence,University of Oslo|Modum Bad,All,"18 Years and older Â  (Adult, Older Adult)",,10084,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,REK125510,7-Apr-20,31-Mar-20,7,7-Apr-20,22-Apr-20,,24-Apr-20,"University of Oslo, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT04356365
883,NCT04431284,Impact of COVID-19 Lockdown on Obesity and Eating Behaviors,CIO,Completed,No Results Available,Feeding and Eating Disorders,Other: Questionnaires,Comparison of the BMI (kg/mÂ²) evolution between the two groups|Score comparison of the Dutch Eating Behavior Questionnaire,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,37,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,69HCL20_0516|2020-A01616-33,16-Dec-20,16-Jun-20,183,16-Dec-20,16-Jun-20,,1-Feb-21,"Centre IntÃ©grÃ© de l'obÃ©sitÃ© de Lyon / HCL, Pierre-BÃ©nite, France",,https://ClinicalTrials.gov/show/NCT04431284
884,NCT04727372,Social Acceptability of COVID-19 Vaccines in Pakistan,,Completed,No Results Available,"Social Acceptance, Social Anxiety",Other: Questionnaire,"Demographics (Age)|Demographics (Weight)|Demographics (Gender)|Demographics (Education)|Demographics (Family set up)|Demographics (Residence)|Attitude, knowledge and behavior about COVID-19 Vaccine and its acceptance or rejection|Correlation of Age with a particular behavior|Correlation of Weight with a particular behavior|Correlation of Gender with a particular behavior|Correlation of Education level with a particular behavior|Correlation of Family set up with a particular behavior|Correlation of Residence with a particular behavior|Respondents Attitude, knowledge and behavior about COVID-19 Vaccine and its acceptance or rejection",Islamia University of Bahawalpur,All,"16 Years and older Â  (Child, Adult, Older Adult)",,986,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Living amongst the fear,23-Feb-21,23-Jan-21,31,23-Feb-21,27-Jan-21,,24-Feb-21,"Islamabad City, Islamabad, Capital Territory, Pakistan|Bahawalpur Rural and Urban Areas, Bahawalpur, Punjab, Pakistan|Faisalabad city, FaisalÄbad, Punjab, Pakistan|Lahore City, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04727372
885,NCT04335279,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,SPIN-CHAT,Completed,No Results Available,"Scleroderma|Scleroderma, Systemic|Systemic Sclerosis",Other: SPIN-CHAT Program,"Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Adverse Effects|Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions",Lady Davis Institute,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,172,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2021-2286,24-Jul-20,9-Apr-20,106,3-Jun-20,6-Apr-20,,30-Nov-20,"Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04335279
886,NCT04678778,Virtual Reality Study - COVID-19 Protocol,NRVR,Completed,No Results Available,Healthy Aging,Behavioral: Physical and Cognitive Activity,Magnetic Resonance Image (MRI) brain scan of hippocampal volume (cubic mm)|Mnemonic Similarity Task for visual memory performance - discrimination index,University of Southern California,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,HS17-00354,19-Feb-21,19-Mar-19,703,19-Feb-21,22-Dec-20,,29-Apr-21,"Mark and Mary Stevens Neuroimaging and Informatics Institute of the University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04678778
887,NCT04379531,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,LDCTiP,Completed,No Results Available,Pneumonia|Coronavirus Infection,Diagnostic Test: Low-dose Chest CT,Evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia.|Threshold value of the infiltration zone size detected by low-dose CT scan compared to standard CT scan.|Number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose CT scan in comparison with standard CT scan.,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2020-1,22-May-20,25-Apr-20,27,22-May-20,7-May-20,,12-Jun-20,"Victor Gombolevskiy, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04379531
888,NCT04874779,Acute Kidney Injury Risk in COVID-19,,Completed,No Results Available,Sever Acute Respiratory Syndrome and Acute Kidney Injury,Other: non,The development of acute kidney injury or not following COVID-19,Zagazig University,All,"18 Years and older Â  (Adult, Older Adult)",,83,Other,Observational,Observational Model: Cohort|Time Perspective: Other,COVID-1927,1-May-21,8-Jun-20,327,18-Nov-20,6-May-21,,6-May-21,"Faculty of Medicine -Zagazig University, Zagazig, Egypt",,https://ClinicalTrials.gov/show/NCT04874779
889,NCT04337502,Clinical and Radiomic Model of COVID-19,,Completed,No Results Available,Coronavirus|Machine Learning,Diagnostic Test: Machine learning model,Predictive performance,Maastricht University|Wuhan Central Hospital,All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,UM_2020_GY_COVID-19,3-Mar-20,23-Dec-19,71,20-Jan-20,7-Apr-20,,7-Apr-20,"The central hospital of Wuhan, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04337502
890,NCT04337047,Distress in Crisis Situations During COVID-19,,Completed,No Results Available,"Stress, Psychological",Other: questionnaire assesment,quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.,Wefight,All,"18 Years and older Â  (Adult, Older Adult)",,2000,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,WefightDistress20,3-May-20,31-Mar-20,33,30-Apr-20,7-Apr-20,,5-May-20,"Wefight, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04337047
891,NCT04891276,Impact of COVID-19 Infection and Confinement on Diabetic Ulcer Management and Amputation Risk,COROPIEDIAB,Completed,No Results Available,Diabetic Subjects With Hospital Stays,Other: Data collection,Frequency of lower limb amputations,Centre Hospitalier Universitaire Dijon,All,"Child, Adult, Older Adult",,3300000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PETIT SERI 2020,14-Apr-21,16-Oct-20,180,14-Apr-21,18-May-21,,18-May-21,"Chu Dijon Bourogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT04891276
892,NCT04728594,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,,Completed,No Results Available,Vaccination Refusal|Communication,Behavioral: Social Proof|Behavioral: Reframing|Behavioral: Scarcity Message,Number of employees who scheduled vaccination appointments after 2 days|Number of emails opened after 2 days|Number of scheduling links clicked after 2 days,Geisinger Clinic,All,"Child, Adult, Older Adult",Not Applicable,9656,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",2021-0128,20-Jan-21,15-Jan-21,5,17-Jan-21,28-Jan-21,,1-Feb-21,"Geisinger, Danville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04728594
893,NCT04368377,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,PIC-19,Completed,No Results Available,"Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis",Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux,P/F ratio|PaO2 difference|A-a O2 difference|CPAP duration|In-hospital change in intensity of the respiratory support|PaCO2 difference|HCO3- difference|Lactate difference|Hb difference|Plt difference|Adverse effects,"University of Milan|Fondazione ""Un Cuore per Milano"" - a no profit foundation",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18275/2020,23-Apr-20,6-Apr-20,17,23-Apr-20,29-Apr-20,,29-Apr-20,"L. Sacco Hospital, Milano, Lombardia, Italy",,https://ClinicalTrials.gov/show/NCT04368377
894,NCT04572399,UVA Light Device to Treat COVID-19,,Completed,No Results Available,Coronavirus,Device: UV Light Treatment,Change in viral load|Change in bacterial load|Ventilated associated pneumonia|Days to extubation|Days to discharge|Change in C-reactive protein|7-point clinical outcome|Catheter tip assessment,"Cedars-Sinai Medical Center|Aytu BioPharma, Inc.",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,5,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,883,28-Dec-20,30-Oct-20,59,28-Dec-20,1-Oct-20,,30-Dec-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04572399
895,NCT04668937,ConsÃ©quences of the COVID-19 Lockdown Measures on the CHRU Nancy Pediatric Emergency Services,,Completed,No Results Available,Number of Patients During the Studying Period|Reason for Consultation,,Number of patient who came to Nancy's pediatric emergencies during the study period|Reason of consultation during the study period|Number of children who was send by a General practician|Medical reason to be sending by a General practician,"Central Hospital, Nancy, France",All,up to 17 Years Â  (Child),,11000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020PI235,30-Jun-20,18-Mar-20,104,18-Mar-20,16-Dec-20,,16-Dec-20,"CHRU Nancy's Pediatric Emergencies, VandÅ“uvre-lÃ¨s-Nancy, Lorraine, France",,https://ClinicalTrials.gov/show/NCT04668937
896,NCT04324684,Prognostic Factors Keeping Track for COVID-19 Pneumonia,NIKE_C19,Completed,No Results Available,"Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease",,rate of recovery|time to improvement|efficacy of treatments|organ failure,Catholic University of the Sacred Heart,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,198,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20202503,7-May-20,31-Mar-20,37,7-May-20,27-Mar-20,,14-May-20,"Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04324684
897,NCT04410692,Can the Prediction Market Improve Predictions of COVID-19?,,Completed,No Results Available,"Health Knowledge, Attitudes, Practice",Other: Prediction Market,Predictions of COVID-19 Cases and Deaths|Fear,"National University, Singapore",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,560,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,SG-COVID,17-May-20,15-May-20,2,16-May-20,1-Jun-20,,2-Jun-20,"National University of Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04410692
898,NCT04730934,Effects of the COVID-19 Pandemic on Fibromyalgia Patients,,Completed,No Results Available,Fibromyalgia|Chronic Low-back Pain,"Other: Perceived stress scale|Other: Fibromyalgia impact questionnaire|Other: The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status",Physical activity|Occupation conditions|General health condition|General pain condition|Perceived stress scale|Fibromyalgia impact questionnaire,Kars State Hospital,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,1360,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020/43-01,25-Feb-21,1-Jan-21,55,25-Feb-21,29-Jan-21,,1-Mar-21,"Ã‡am and Sakura City Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04730934
899,NCT04379245,COVID-19 Infection in Patients Infected With HIV and/or on PrEP,COVIDHIVPrEP,Completed,No Results Available,HIV|Pre-exposure Prophylaxis,"Other: Data research, database analysis",Covid attack rate,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,4200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CRC_GHN_2020_002,4-May-20,30-Apr-20,4,30-Apr-20,7-May-20,,7-May-20,"Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT04379245
900,NCT04306055,Blood Donor Recruitment During Epidemic of COVID-19,,Completed,No Results Available,Blood Donation,Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information,Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks,Guangzhou Blood Center,All,18 Years to 60 Years Â  (Adult),Not Applicable,19491,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Blood donor recruitment,3-Apr-20,13-Mar-20,21,13-Mar-20,12-Mar-20,,13-Apr-20,"Guangzhou Blood Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04306055
901,NCT04400006,Ozone Therapy in the Prevention of COVID-19 Infection,,Completed,No Results Available,Corona Virus Infection,,The survey that was taken by telephone calls,Marmara University,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,71,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2761,17-May-20,6-May-20,11,16-May-20,22-May-20,,22-May-20,"Kardelen Gencer Atalay, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04400006
902,NCT04370886,Recruit Blood Donors Via SMS During Epidemic of COVID-19,,Completed,No Results Available,Blood Donation,Behavioral: blood donation SMS,Blood donation rate,Guangzhou Blood Center,All,18 Years to 60 Years Â  (Adult),Not Applicable,456517,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Recruit Blood Donors via SMS,10-May-20,30-Apr-20,10,30-Apr-20,1-May-20,,1-Jun-20,"Guangzhou Blood Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04370886
903,NCT04665193,An Approach to Screening for COVID-19 at Vancouver Airport,,Completed,No Results Available,Asymptomatic Condition|Healthy,Diagnostic Test: Rapid Antigen Test,COVID-19 status,University of British Columbia|Vancouver Airport Authority|WestJet Airlines|Providence Health & Services|KLM Royal Dutch Airlines,All,"13 Years to 90 Years Â  (Child, Adult, Older Adult)",Not Applicable,592,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,H20-03225,28-Apr-21,23-Nov-20,156,28-Feb-21,11-Dec-20,,4-May-21,"Vancouver International Airport, WestJet Domestic Terminal, Level 3, Richmond, British Columbia, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/Prot_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT04665193
904,NCT04440098,Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology,,Completed,No Results Available,Loneliness|Depression|Anxiety|Alcohol Abuse|Drug Abuse,,Loneliness as evaluated by the UCLA loneliness scale|Alcohol Use as evaluated by the AUDIT|Drug Use as evaluated by the DAST-10|Anxiety as evaluated by GAD-7|Depression as assessed by CES-D-10,University of Miami,All,18 Years to 35 Years Â  (Adult),,1008,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,20200446,11-May-20,22-Apr-20,19,11-May-20,19-Jun-20,,19-Jun-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04440098
905,NCT04718519,Migrant Workers' Responses to the COVID-19 Pandemic,,Completed,No Results Available,Coronavirus|Trust|Misinformation,,Confidence in government|Fear for health|Fear for job|Degree of exposure to rumours|Online habits,Yale-NUS College,Male,21 Years to 60 Years Â  (Adult),,1011,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,510d2,11-Oct-20,22-Jun-20,111,11-Oct-20,22-Jan-21,,6-May-21,"Yale NUS, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04718519
906,NCT04425863,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",IDEA,Completed,Has Results,Severe Acute Respiratory Syndrome|Ventilation Pneumonitis,"Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.",Patients Who Improved Their Condition or Did Not Worsen it|ICU-treated Patients After 2-week Treatment|Mortality|Patients Needing Drug Dose Adjustment|Adverse Events,Eurnekian Public Hospital,All,"5 Years and older Â  (Child, Adult, Older Adult)",,167,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IDEA,30-Aug-20,1-May-20,121,30-Aug-20,11-Jun-20,19-Oct-20,19-Oct-20,"Hospital Eurnekian, Buenos Aires, Argentina","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04425863/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04425863
907,NCT04416308,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),AntiCoV-HB,Completed,No Results Available,Coronavirus,Diagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnary,"rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.|a) Validation of the Biotech NG test:|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.|b) Risk of presence of anti SARS-CoV-2 antibodies in function:|c) Risk of presence of anti SARS-CoV-2 antibodies in function:|d) Description of the experience and behavioral changes related to the epidemic,|e) Evolution of seroprevalence over time:",Rennes University Hospital|Fonds NOMINOE,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,9453,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,35RC20_9716,12-Oct-20,29-May-20,136,10-Jul-20,4-Jun-20,,14-Apr-21,"CENTRE HOSPITALIER de VITRE_ Saint Jean (La Guerche), La Guerche de Bretagne, La Guerche-de-Bretagne, France|Centre Hospitalier de Fougeres, FougÃ¨res, France|Centre Hospitalier Grand Fougeray, Grand-Fougeray, France|Centre Hospitalier de La Roche Aux Fees, JanzÃ©, France|Centre Hospitalier Montfort-Sur-Meu, Montfort sur Meu, France|Centre Hospitalier de Redon Carentoir, Redon, France|Chu Rennes, Rennes, France|Centre Hospitalier St Meen Le Grand, Saint-MÃ©en-le-Grand, France|CENTRE HOSPITALIER VITRE_Simone Veil, VitrÃ©, France",,https://ClinicalTrials.gov/show/NCT04416308
908,NCT04435106,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),,Completed,No Results Available,Coronavirus Infections,Drug: Opaganib|Drug: Standard of Care,Measure the time to weaning from high-flow nasal cannula|Measure the time to breathing ambient (room) air|Measure change in lymphocyte count|Measure change in C-reactive protein,Shaare Zedek Medical Center,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,23,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,0123-20- SZMC,15-May-20,3-Apr-20,42,1-May-20,17-Jun-20,,17-Jun-20,"Shaare-Zedek Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT04435106
909,NCT04444661,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,,Completed,No Results Available,Osteoporosis|Sarcopenia,,SMI|BMD-LS|BMD-hip|Sarcopenia-Z-Score|Fat infiltration thigh muscles|Fat infiltration para-vertebral muscles|Maximum hip-/leg extensor strength|Metabolic Syndrome Z-Score|Self rated physical performance,University of Erlangen-NÃ¼rnberg Medical School|Friedrich-Alexander-UniversitÃ¤t Erlangen-NÃ¼rnberg,Male,74 Years to 95 Years Â  (Older Adult),,21,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,FrOST-FU,31-Dec-20,10-Jun-20,204,11-Nov-20,23-Jun-20,,28-Apr-21,"Institute of Medical Physics, Friedrich Alexander University Erlangen-NÃ¼rnberg, Erlangen, Bavaria, Germany",,https://ClinicalTrials.gov/show/NCT04444661
910,NCT04420806,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,,Completed,No Results Available,Exercise|Detraining|Muscle Weakness|Muscle Atrophy,Other: HIT-exercise|Other: Sham intervention,Body composition|Hip-/Leg extension strength|Metabolic Syndrome|Bone Mineral Density (BMD)|Menopausal symptoms|Back and joint pain,University of Erlangen-NÃ¼rnberg Medical School,Female,48 Years to 60 Years Â  (Adult),Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ER_ACTLIFE_FU,30-Oct-20,14-Mar-20,230,30-Jul-20,9-Jun-20,,13-Nov-20,"Institute of Medical Physics, Friedrich-Alexanden University Erlangen-NÃ¼rnberg, Erlangen, Germany",,https://ClinicalTrials.gov/show/NCT04420806
911,NCT04635813,The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study,,Completed,No Results Available,Thyroid Disease,Procedure: Thyroidectomy,Quantify the overall reduction of surgical activity for thyroid disease|Quantify if the number of thyroid cancers operated during COVID-19 pandemic was significant different from the number of patients operated during the same period of the previous year|Quantify the number of aggressive tumors operated during COVID-19 pandemic and the same period of the previous year,University of Cagliari,All,"Child, Adult, Older Adult",,3800,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,THYCOVIT,12-Nov-20,10-Mar-20,247,30-Sep-20,19-Nov-20,,19-Nov-20,"AOU Cagliari, Cagliari, CA, Italy",,https://ClinicalTrials.gov/show/NCT04635813
912,NCT04302688,Accurate Classification System for Patients With COVID-19 Pneumonitis,,Completed,No Results Available,Pneumonitis,,survival status,Renmin Hospital of Wuhan University,All,"Child, Adult, Older Adult",,669,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,COVID-19 WU1,4-Mar-20,10-Dec-19,85,10-Feb-20,10-Mar-20,,10-Mar-20,"Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04302688
913,NCT04448704,Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak,,Completed,No Results Available,Mental Health Issue,,DASS-21 Scores,Yale-NUS College,All,"21 Years and older Â  (Adult, Older Adult)",,1011,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CCF@EXPO/R001/2020,11-Oct-20,22-Jun-20,111,11-Oct-20,26-Jun-20,,23-Feb-21,"EXPO, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04448704
914,NCT04406246,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,,Completed,No Results Available,Coronavirus Infection,Drug: Nitazoxanide 500Mg Oral Tablet,Health workers that require hospitalization,Materno-Perinatal Hospital of the State of Mexico|Laboratorios Liomont,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 4,150,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-04-682,31-Dec-20,21-May-20,224,31-Dec-20,28-May-20,,30-Mar-21,"Materno-Perinatal Hospital ""MÃ³nica Pretelini"", Toluca, Mexico",,https://ClinicalTrials.gov/show/NCT04406246
915,NCT04819282,Mask Usage and Physical Performance During COVID-19 Pandemic in Geriatrics,,Completed,No Results Available,Exercise Capacity|Geriatric|Mask,Diagnostic Test: Senior Fitness Test,Senior Fitness Test-Arm Curl|Senior Fitness Test-Chair Stand Up and Sitting|Senior Fitness Test-Chair Sit and Reach|Senior Fitness Test-Back Scratch|Senior Fitness Test-Eight Foot Up and Go|Senior Fitness Test-Two-Minute Step Test,KTO Karatay University,All,65 Years to 85 Years Â  (Older Adult),,46,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,KaratayU4,17-Feb-21,10-Sep-20,160,30-Dec-20,26-Mar-21,,1-Apr-21,"KTO Karatay University, Konya, Karatay, Turkey",,https://ClinicalTrials.gov/show/NCT04819282
916,NCT04357314,Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,MODIF,Completed,No Results Available,Myocardial Infarction,,The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI)|Rates of patients presenting with acute myocardial infarction|Patient profile during admission for acute myocardial infarction|Medical care times analysis|Clinical evolution of patients|STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates|Proportion of patients who underwent systemic thrombolysis|Proportion of patients infected with COVID-19,"French Cardiology Society|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",All,"18 Years and older Â  (Adult, Older Adult)",,6332,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-03,31-May-20,1-Mar-20,91,31-May-20,22-Apr-20,,19-Aug-20,"HÃ´pital Universitaire CarÃ©meau, NÃ®mes, France",,https://ClinicalTrials.gov/show/NCT04357314
917,NCT04757285,Copeptin and Psychological Stress of Medic During COVID-19 Pandemic,COVID-19,Completed,No Results Available,Psychological Stress|Hemostatic Disorder,,evaluation of psychological stress|determine stress hormones in serum cortisol and copeptin|correlation of psychological stress with stress hormone copeptin,Alexandria University,All,24 Years to 37 Years Â  (Adult),,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,304842,30-Oct-20,10-May-20,173,30-Oct-20,17-Feb-21,,17-Feb-21,"Alexandria University Faculty of Medicine, Alexandria, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04757285
918,NCT04394195,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,COVIDsFlt1,Completed,No Results Available,CORONAVIRUS INFECTIONS,Other: measurement of circulating sFlt1 concentration,Association between concentration of circulating sFlt1 and use of vasopressor,CHU de Reims,All,"18 Years and older Â  (Adult, Older Adult)",,72,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PO20043*,1-Sep-20,3-Apr-20,151,1-May-20,19-May-20,,1-Apr-21,"Chu Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT04394195
919,NCT04333849,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,TOVID-49,Completed,No Results Available,Coronavirus,,"Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.","University Hospital, Angers",All,70 Years and older Â  (Older Adult),,132,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020/29,11-May-20,25-Mar-20,47,11-May-20,3-Apr-20,,20-Jul-20,"Angers University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT04333849
920,NCT04366947,Intravascular Access in Suspected/Confirmed COVID-19 Patient,,Completed,No Results Available,Emergency Medicine|Cardiopulmonary Arrest|Shock,Device: NIOÂ® (Intraosseous access)|Device: Standard of Care (Intravenous access),Success rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ROSC,Lazarski University|Poznan University of Medical Sciences|Medical University of Bialystok|Wroclaw Medical University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IO_PPE_1,30-Oct-20,14-Apr-20,199,20-Sep-20,29-Apr-20,,19-Dec-20,"Lazarsku University, Warsaw, Masovian, Poland",,https://ClinicalTrials.gov/show/NCT04366947
921,NCT04535297,Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke,,Completed,No Results Available,Parkinson Disease|Stroke,Other: exposure,Patient Activation Measure (PAMÂ®)|Answers to multiple-choice questions,University of Haifa,All,"18 Years and older Â  (Adult, Older Adult)",,198,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,203/20,30-Jun-20,10-May-20,51,30-May-20,1-Sep-20,,1-Sep-20,"Galit Yogev-Seligmann, Haifa, Please Select..., Israel",,https://ClinicalTrials.gov/show/NCT04535297
922,NCT04738721,Physical Activity and Physical Fitness Parameters in COVID-19 Lockdown,,Completed,No Results Available,"Assessment, Self",Behavioral: Evaluation,Physical activity|Physical fitness|Flexibility|Body composition,Medipol University,All,18 Years to 22 Years Â  (Adult),,79,Other,Observational,Observational Model: Other|Time Perspective: Prospective,E-10840098-772.02-2685,4-May-21,5-Feb-21,88,4-Apr-21,4-Feb-21,,5-May-21,"Istanbul Medipol University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04738721
923,NCT04459455,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",,Completed,No Results Available,Anxiety,Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI,Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention|Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up|Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention|COVID-19 Related Questions|Inventory of Depression and Anxiety Symptoms (IDAS)|Self Hate Scale (SHS)|Comprehension Questions|Everyday Discrimination Scale-Short version|Perceived Changes in generalized anxiety symptoms|Activity Hand Washing Intentions - 3 item version (WASH-I),Stony Brook University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB2020-00204,15-Oct-20,19-Aug-20,57,15-Oct-20,7-Jul-20,,20-Oct-20,"Stony Brook University, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT04459455
924,NCT04488549,Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19),DECOR-19,Completed,No Results Available,Colo-rectal Cancer|Colon Cancer|Rectal Cancer|Oncology|Surgery,Other: Survey,Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,Treviso Regional Hospital|Gaetano Gallo|Gian Luca Di Tanna,All,"Child, Adult, Older Adult",,1051,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Treviso,10-Jun-20,20-May-20,21,10-Jun-20,28-Jul-20,,28-Jul-20,"Treviso Regional Hospital, Treviso, Italy",,https://ClinicalTrials.gov/show/NCT04488549
925,NCT04413435,Clinical Characteristics of Critically Ill Patients With COVID-19,,Completed,No Results Available,Coronavirus Infection|Critical Illness|Characteristics Disease,Other: File Scanning,Polymerase Chain Reaction (PCR) test|A scoring system for patients to be admitted to the intensive care unit,Nevsehir Public Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,105,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,2020-245,25-Dec-20,30-Oct-20,56,15-Dec-20,4-Jun-20,,5-Jan-21,"Konya Trainig and Research Hospital, Konya, Turkey",,https://ClinicalTrials.gov/show/NCT04413435
926,NCT04417270,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,,Completed,No Results Available,Diabetes Mellitus,Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform,Comparison of values between two devices,Northwell Health,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,20-0455,30-Nov-20,12-Jun-20,171,30-Nov-20,4-Jun-20,,2-Mar-21,"Lenox Hill Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04417270
927,NCT04840082,Optimal Length for Nasal Mid-turbinate and Nasopharyngeal Swabs,,Completed,No Results Available,Covid19,Diagnostic Test: Nasopharyngeal swab for COVID-19 testing,Length from the vestibulum nasi to the posterior wall of the nasopharynx.|Length from the vestibulum nasi to the mid-turbinate.,"Rigshospitalet, Denmark",All,"16 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,109,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,21015626,8-Mar-21,7-Mar-21,1,8-Mar-21,9-Apr-21,,9-Apr-21,"Rigshospitalet, Copenhagen, Copenhagen East, Denmark",,https://ClinicalTrials.gov/show/NCT04840082
928,NCT04812184,Adhesive Tape Placement on Patients' Masks in the ED Increases Compliance of Proper Face Mask Use,,Completed,No Results Available,Covid19,Device: Tape Face Mask,Proper face mask use up to 60 minutes|Descriptive analysis by demographics,Indiana University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,123,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IUMASKstudy,30-Oct-20,1-Apr-20,212,30-Oct-20,23-Mar-21,,23-Mar-21,"Eskenazi Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT04812184
929,NCT04876560,Implementation of a CDSS in Oncology Patients During COVID-19,CDSS,Completed,No Results Available,Breast Cancer|Obesity|Cardiovascular Disease Other,Other: Application of CDSS to provide nutritional care in breast cancer patients from home|Other: General lifestyle advice to breast cancer patients by phone,"change in the Mediterranean diet adherence|change in ""Global health, quality of life"" score|alterations in the amount of daily intake of nutrients|changes in levels of blood lipids|change in body weight (kg)|change in body fat mass (%)","Iaso Maternity Hospital, Athens, Greece|Harokopio University",Female,"37 Years to 68 Years Â  (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,31052019,15-Apr-21,11-Mar-20,400,10-Oct-20,6-May-21,,6-May-21,"Panos Papandreou, Athens, Greece|Panos Papandreou, Athens, Greece",,https://ClinicalTrials.gov/show/NCT04876560
930,NCT04773756,Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt,,Completed,No Results Available,Covid19,Drug: Sofosbuvir 400 MG/ Daclatasvir 60mg,evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19.,Alexandria University,All,"12 Years to 90 Years Â  (Child, Adult, Older Adult)",Phase 4,54,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,305032,12-Dec-20,1-Nov-20,41,30-Nov-20,26-Feb-21,,26-Feb-21,"Amr Aly Abd elmoety, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT04773756
931,NCT04423289,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,,Completed,No Results Available,Face-to-face Reconsultation to Emergency Room,Other: Farmalarm,Re-consultation|Telephone calls,Hospital Universitari Vall d'Hebron Research Institute,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PR(AG)182-2020,18-May-20,31-Mar-20,48,4-May-20,9-Jun-20,,9-Jun-20,"Vall d'Hebron Hospital Universitari, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04423289
932,NCT04681261,"Occupational Balance, Fear and Agoraphobia",OB,Completed,No Results Available,Covid19,Other: this study is not an intervention study,Occupational Balance Questionnaire,Hacettepe University,All,"19 Years to 65 Years Â  (Adult, Older Adult)",,699,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020/185,4-Jun-20,4-May-20,31,4-Jun-20,23-Dec-20,,23-Dec-20,"Ã–zgÃ¼ Ä°nal, Edirne, Merkez, Turkey",,https://ClinicalTrials.gov/show/NCT04681261
933,NCT04542226,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,,Completed,Has Results,"Infections, Coronavirus",Drug: Polyoxidonium,Clinical Status of the Patient (According to 7-point Ordinal Scale)|Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score|Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale))|Number of Patients Requiring Supplementary Oxygen|Hospitalisation Duration|Mortality|The Number of Participants With Serious Adverse Events|The Number of Participants With Adverse Events|Number of Participants With Discontinuation of Drug Administration,NPO Petrovax,All,"18 Years and older Â  (Adult, Older Adult)",,81,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Covid_v_1.0,30-Oct-20,31-Mar-20,213,15-Jul-20,9-Sep-20,3-Dec-20,9-Dec-20,"Healthcare Institution ""Grodno Regional Infectious Clinical Hospital"", Grodno, Belarus|State-Funded Healthcare Institution ""Emergency Hospital"" of Ministry of Health of Chuvash Republic, Cheboksary, Chuvashia, Russian Federation|State-Funded Healthcare Institution ""Infectious Disease Hospital No.3"" of Ministry of Health of Krasnodar Krai, Novorossiysk, Krasnodar Krai, Russian Federation|State-Funded Institution of Mari El Republic ""Yoshkar-Ola City Hospital"", Yoshkar-Ola, Mari El Republic, Russian Federation|State-Funded Healthcare Institution of Voronezh Region ""Novaya Usman District Hospital"", Novaya Usman, Voronezh Region, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04542226/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04542226
934,NCT04573361,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,,Completed,No Results Available,Musculoskeletal Pain|Disability Physical|Psychological Distress,Other: Chiropractic care (one visit)|Other: Chiropractic care (more than one visit),Pain intensity|Pain frequency|Pain evolution|Pain interference|Pain Catastrophizing Scale|Tampa Scale Kinesiophobia|General Anxiety Disorder scale|Intolerance of Uncertainty Scale|General Self-Efficacy scale|Fear of Illness and Virus Evaluation,Real Centro Universitario Maria Cristina|UniversitÃ© du QuÃ©bec Ã  Trois-RiviÃ¨res|University of Birmingham,All,"14 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,723,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ChiroCOVID19,27-May-20,2-May-20,25,27-May-20,5-Oct-20,,5-Oct-20,"Real Centro Universitario MarÃ­a Cristina, San Lorenzo De El Escorial, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04573361
935,NCT04533048,A Clinical Study to Evaluate MW33 Injection,,Completed,No Results Available,Covid19,Combination Product: MW33 injection|Combination Product: MW33 injection placebo,Adverse Event|Serious Adverse Event,"Mabwell (Shanghai) Bioscience Co., Ltd.|Shanghai Public Health Clinical Center",All,18 Years to 45 Years Â  (Adult),Phase 1,42,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MW33-2020-CP101,2-Dec-20,7-Aug-20,117,16-Nov-20,31-Aug-20,,26-Feb-21,"Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04533048
936,NCT04501172,Impact of Spectacles on Compliance to Mask-wearing Directives,,Completed,No Results Available,Covid19,Behavioral: Questionnaire completion,Demographic characteristics|Compliance to mask-wearing directives|Questionnaire subscale: Near vision|Questionnaire subscale: Distance vision|Questionnaire subscale: Ocular discomfort|Questionnaire subscale: Driving|Questionnaire subscale: Limitation|Questionnaire subscale: Collaboration|Questionnaire subscale: Need for help|Questionnaire subscale: Emotional impact|Assessment of the relationship between the compliance to mask-wearing directives and the use of spectacles|Assessment of the relationship between the compliance to mask-wearing directives and the other demographic characteristics|Assessment of the relationship between the compliance to mask-wearing directives and the questionnaire items|Assessment of the relationship between demographic characteristics and the 20 questionnaire items,Democritus University of Thrace,All,"18 Years to 85 Years Â  (Adult, Older Adult)",,1214,Other,Observational,Observational Model: Other|Time Perspective: Prospective,ES8/Th5/25-06-2020,14-Aug-20,25-Jun-20,50,24-Jul-20,6-Aug-20,,16-Sep-20,"University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece",,https://ClinicalTrials.gov/show/NCT04501172
937,NCT04497519,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,,Completed,No Results Available,Covid19,Drug: inhaled hydroxychloroquine,Local tolerability|Pharmacokinetic parameter,University Medical Center Groningen,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CARRIED-01,1-Nov-20,15-Sep-20,47,15-Oct-20,4-Aug-20,,10-Nov-20,"University Medical Center Groningen, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT04497519
938,NCT04490239,Intranasal Heparin Tolerability Study,,Completed,Has Results,Covid19,Drug: Intranasal heparin sodium (porcine),"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15|Percent Change in Platelet Count From Pre-dose Baseline|Number of Incidents of Epistaxis, Acute Phase|Number of Incidents of Epistaxis, Chronic Phase|Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14|Other Adverse Effects, Acute Phase|Other Adverse Effects, Chronic Phase","Joshua Sharp|University of Mississippi, Oxford",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Early Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Intranasal Heparin,18-Nov-20,9-Oct-20,40,18-Nov-20,29-Jul-20,28-Apr-21,30-Apr-21,"The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04490239/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04490239
939,NCT04325906,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,,Completed,No Results Available,Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection,Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP),Treatment failure (intubation or death)|Intubation rate|mortality|Efficacy of PP|the incidence of adverse events,Rush University Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,222,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19-HFNC+PP,21-Feb-21,2-Apr-20,325,26-Jan-21,30-Mar-20,,23-Apr-21,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04325906
940,NCT04548934,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,,Completed,No Results Available,Cardiopulmonary Resuscitation|Personal Protective Equipment,Device: Personal protective equipment (PPE)|Device: No Personal protective equipment (PPE),Depth of chest compression|Chest compression rate|Relaxation,Institute of Mountain Emergency Medicine,All,18 Years to 60 Years Â  (Adult),Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPR PPE,31-Jan-21,13-Sep-20,140,31-Oct-20,16-Sep-20,,2-Feb-21,"Headquarter of ""Croce Bianca"" EMS organization, Bolzano, Italy",,https://ClinicalTrials.gov/show/NCT04548934
941,NCT04344964,Endoscopy-related Phone Consultation During the COVID-19 Outbreak,,Completed,No Results Available,"Colon Polyp|Colon Disease|Reflux, Gastroesophageal|Varices, Esophageal",Other: None - NA,Failed to attend patients|Patient satisfaction with the phone consult|Consultant satisfaction with the phone consult,Austin Health,All,"18 Years and older Â  (Adult, Older Adult)",,186,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,38839,3-Jul-20,15-Apr-20,79,29-May-20,14-Apr-20,,9-Jul-20,"Austin Health, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT04344964
942,NCT04448769,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),COVAL-NANCY,Completed,No Results Available,Coronavirus Infection|Prevalence,Biological: Anti-SARS-CoV-2 IgT seropositivity,"Anti-SARS-CoV-2 IgT (IgM/IgA/IgG) seropositivity|Proportion of asymptomatic, symptomatic cases among seropositive people|Proportion of asymptomatic cases among seropositive people|Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status.|Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score|Proportion of infected households|Anti-SARS-CoV-2 IgT seropositivity in the household|Clinical expression patterns of infection by symptom/antibody association|Serological Response to Infection|Anti-SARS-CoV-2 IgT seropositivity|â€¢ Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum.","Central Hospital, Nancy, France|University of Lorraine|MÃ©tropole du Grand Nancy",All,"5 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,2006,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2020PI128,24-Jul-20,26-Jun-20,28,24-Jul-20,26-Jun-20,,19-Aug-20,"Chru Nancy, VandÅ“uvre-lÃ¨s-Nancy, France",,https://ClinicalTrials.gov/show/NCT04448769
943,NCT04738032,Stories for Change: Digital Storytelling Intervention for Diabetes Self-Management in the COVID-19 Pandemic,S4C - COVID-19,Completed,No Results Available,Type2 Diabetes,Other: Digital Storytelling Intervention,Diabetes self-management behaviors,Mayo Clinic|Hennepin Healthcare Research Institute|Mountain Park Health Center,All,"18 Years to 70 Years Â  (Adult, Older Adult)",,76,Other,Observational,Observational Model: Other|Time Perspective: Other,20-006354,7-Jan-21,26-Aug-20,134,7-Jan-21,4-Feb-21,,4-Feb-21,"Mountain Park Health Center, Phoenix, Arizona, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04738032
944,NCT04391166,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,,Completed,No Results Available,Visual Impairment,Other: Non invasive visual acuity testing,Best Corrected Visual Acuity (BCVA) Per Eye,Vanderbilt University Medical Center,All,"18 Years to 90 Years Â  (Adult, Older Adult)",,108,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,200826,1-Dec-20,20-May-20,195,10-Jul-20,18-May-20,,23-Mar-21,"Vanderbilt Eye Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04391166
945,NCT04505761,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",COVRehab,Completed,No Results Available,Coronavirus|Post Intensive Care Unit Syndrome,Device: Virtual Reality,Semi-structured interview with 15 patients on their experiences of VR for rehabilitation from COVID-19.|Use of VR|Semi-structured interviews with physiotherapists on their experiences of VR for rehabilitation from COVID-19.|Change in baseline performance test (guidelines KNGF) - Patient specific complaints.|Change in baseline performance test (guidelines KNGF) - 6 minute walk test|Change in baseline performance test (guidelines KNGF) - one-repetition maximum test|Change in baseline performance test (guidelines KNGF) - 30 sec sit to stand|Change in baseline performance test (guidelines KNGF) - Borgscale for fatigue|Change in activities of daily life.|Change in HADS.|Change in CFQ.|Change in SF12.|Change in positive health.,Radboud University,All,"16 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVRehab,31-Mar-21,1-Aug-20,242,1-Feb-21,10-Aug-20,,6-Apr-21,"Radboud university medical center, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT04505761
946,NCT04665960,Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2,IC-COVID-19,Completed,No Results Available,Covid19|SARS-CoV Infection|SARS Pneumonia|Coronavirus Infection|Infection,,Consensus using participating experts opinions.,NMC Specialty Hospital,All,"25 Years to 70 Years Â  (Adult, Older Adult)",,35,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NMCSpecialtyH,1-May-21,29-Mar-21,33,25-Apr-21,14-Dec-20,,11-May-21,"NMC Specialty Hospital, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT04665960
947,NCT04662437,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,,Completed,No Results Available,COVID-19 Infection|Parathyroid Gland|Parathyroid Hormone|Calcium|Phosphorus|Alkaline Phosphatase,Diagnostic Test: Venous blood was collected for biochemistry testing,Comparison of parathyroid hormone between groups|Comparison of calcium between groups|Comparison of phosphorus between groups|Comparison of alkaline phosphatase between groups|White blood cells (WBC) results of Covid 19 patient group|Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group|C-reactive protein (CRP) results of Covid 19 patient group|Fibrinogen results of Covid 19 patient group|Procalcitonin results of Covid 19 patient group|Ferritin results of Covid 19 patient group|D-dimer results of Covid 19 patient group,Bezmialem Vakif University|Didem Ertorul,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,8122020,9-Dec-20,10-Sep-20,90,1-Dec-20,10-Dec-20,,10-Dec-20,"Bezmialem VU, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04662437
948,NCT04818164,Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome,,Completed,No Results Available,Acute Respiratory Distress Syndrome|Coronavirus|Mechanical Ventilation Complication|Ventilation Perfusion Mismatch,,Partial Pressure of Oxygen/ Fraction of Inspired Oxygen|End Expiratory Lung Volume,Istanbul University-Cerrahpasa,All,"18 Years and older Â  (Adult, Older Adult)",,22,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-19-16163,20-Mar-21,1-Sep-20,200,31-Dec-20,26-Mar-21,,8-Apr-21,"Istanbul University-CerrahpaÅŸa, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04818164
949,NCT04550390,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19,SAMILCOV,Completed,No Results Available,SARS-CoV Infection,Diagnostic Test: Saliva collection,Qualitative result of molecular tests for the SARS-CoV-2 virus.,Direction Centrale du Service de SantÃ© des ArmÃ©es,All,"18 Years and older Â  (Adult, Older Adult)",,329,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-COVID19-36|2020-A02536-33,19-Oct-20,15-Sep-20,34,19-Oct-20,16-Sep-20,,10-Mar-21,"HÃ´pital d'Instruction des ArmÃ©es Percy, Clamart, France|HÃ´pital d'Instruction des ArmÃ©es Laveran, Marseille, France|HÃ´pital d'Instruction des ArmÃ©es BÃ©gin, Saint-MandÃ©, France|HÃ´pital d'Instruction des ArmÃ©es Sainte-Anne, Toulon, France",,https://ClinicalTrials.gov/show/NCT04550390
950,NCT04327388,Sarilumab COVID-19,,Completed,Has Results,Corona Virus Infection,Drug: Sarilumab SAR153191|Drug: Placebo,"Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points|Percentage of Participants Who Were Alive at Day 29|Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29|Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score|Time to Resolution of Fever|Time to Resolution of Fever and Improvement in Oxygenation|Number of Days With Fever|Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29|Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours|Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2|Time-to-improvement in Oxygenation|Percentage of Participants Alive Off Supplemental Oxygen at Day 29|Percentage of Days With Hypoxemia|Percentage of Days With Supplemental Oxygen Use|Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute|Time to Oxygen Saturation >= 94% on Room Air|Mean Number of Ventilator Free Days|Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula|Percentage of Participants Who Required Rescue Medication|Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study|Number of Days of Hospitalization Among Survivors (Alive Participants)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Major or Opportunistic Bacterial or Fungal Infections|Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection|Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters",Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC16844|2020-001162-12|U1111-1249-6021,2-Sep-20,28-Mar-20,158,31-Jul-20,31-Mar-20,13-May-21,13-May-21,"Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, SÃ£o JosÃ© Do Rio Preto, Brazil|Investigational Site Number 0760005, SÃ£o Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, KÃ¶ln, Germany|Investigational Site Number 2760001, MÃ¼nster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04327388
951,NCT04321369,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,,Completed,No Results Available,"Infections, Respiratory|Fever|Cough",Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals,Accuracy of patient administered tests,Dr. Deneen Vojta|Quest Diagnostics-Nichols Insitute|Bill and Melinda Gates Foundation|UnitedHealth Group,All,"Child, Adult, Older Adult",,533,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,20-001,23-Mar-20,9-Mar-20,14,23-Mar-20,25-Mar-20,,13-Apr-20,"Everett Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04321369
952,NCT04677270,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,COVIDPROBLEM,Completed,No Results Available,Problem Solving,Behavioral: Digital problem solving tool,System Usability Scale|Treatment Credibility Scale|Use of intervention,"Karolinska Institutet|Stockholm County Council, Sweden",All,"16 Years and older Â  (Child, Adult, Older Adult)",Not Applicable,397,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,COVIDPROBLEM,30-Nov-20,31-Aug-20,91,30-Nov-20,21-Dec-20,,21-Dec-20,"Centrum fÃ¶r Psykiatriforskning, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT04677270
953,NCT04388579,Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19,PRAISE@COVID,Completed,No Results Available,Respiratory Disease,Other: Pulmonary Rehabilitation,Patient's self-efficacy|Respiratory exercises|Physical activity,"University of Lisbon|Centro Hospitalar Lisboa Norte|FundaÃ§Ã£o para a CiÃªncia e a Tecnologia|Nippon Gases Portugal, Unipessoal, Lda.",All,"18 Years to 88 Years Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,046i/17,27-Mar-20,20-Mar-20,7,27-Mar-20,14-May-20,,14-May-20,"Nippon Gases Portugal Unipessoal Lda, Maia, Porto, Portugal|Universidade de Lisboa, Faculdade de Medicina, Instituto de SaÃºde Ambiental (ISAMB), Lisboa, Portugal|Centro Hospitalar UniversitÃ¡rio Lisboa Norte, Hospital Pulido Valente, Unidade de ReabilitaÃ§Ã£o RespiratÃ³ria, Lisboa, Portugal",,https://ClinicalTrials.gov/show/NCT04388579
954,NCT04441424,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,,Completed,No Results Available,IMMUNOTHERAPY,Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin,Death versus survival of treated patients|The length of stay in hospitals,Alkarkh Health Directorate-Baghdad,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPT-COVID-19,1-Jun-20,3-Apr-20,59,1-Jun-20,22-Jun-20,,23-Jun-20,"Akarkh Healt hdirectorate, Baghdad, Iraq","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04441424/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04441424
955,NCT04389333,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,,Completed,No Results Available,Gastrointestinal Disease|Infectious Disease|Capsule Endoscopy,Device: non-contact magnetically-controlled capsule endoscopy,Maneuverability score|Gastric examination time(GET)|the comfort and acceptability of patients|diagnostic yield,Changhai Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,nc-MCE pilotRCT,20-May-20,26-Mar-20,55,26-Apr-20,15-May-20,,21-Jul-20,"Changhai Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04389333
956,NCT04394013,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,,Completed,No Results Available,Mental Health Issue,Behavioral: Mindfulness intervention|Behavioral: Non-Mindfulness intervention,Loneliness (UCLA-8 Loneliness Scale)|Mindfulness (FFMQ)|Quality of life (EQ-5D-5L Questionnaire),Monash University Malaysia,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",180320201,31-Dec-20,26-Aug-20,127,31-Dec-20,19-May-20,,24-Feb-21,"Monash University Malaysia, Subang Jaya, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04394013
957,NCT04448782,Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation,,Completed,No Results Available,Mechanical Ventilation Complication,Diagnostic Test: Asynchronies detection,Incidence and pattern of presentation of Reverse triggering in COVID-19 patients under invasive mechanical ventilation|Incidence of Reverse Triggering related to the level of sedation in COVID-19 patients under invasive mechanical ventilation|Reverse triggering and secondary asynchronies in COVID-19 patients under invasive mechanical ventilation|Incidence and pattern of presentation of asynchronies in COVID-19 patients under invasive mechanical ventilation|Influence of asynchronies in different outcomes in in COVID-19 patients under invasive mechanical ventilation,Corporacion Parc Tauli,All,"18 Years and older Â  (Adult, Older Adult)",,32,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RT COVID-19,30-Jun-20,9-Mar-20,113,30-Jun-20,26-Jun-20,,14-Jul-20,"Candelaria de Haro, Sabadell, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04448782
958,NCT04380766,Covid-19 Pandemic and Pancreatic Surgery in Italy,PanCOVID,Completed,No Results Available,Pancreatic Cancer,Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer,Changes in pancreatic cancer management during the COVID-19 pandemic,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,All,"18 Years and older Â  (Adult, Older Adult)",,730,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,FPGemelliIRCCS,31-Jul-20,1-Jan-19,577,31-Jul-20,8-May-20,,3-Aug-20,"Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italy",,https://ClinicalTrials.gov/show/NCT04380766
959,NCT04633941,Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Obesity, Morbid|Bariatric Surgery Candidate",Other: Standard Care,Weight|Blood Sugar Control|Medical Adherence|Stress level|Physical Activity Level,Singapore General Hospital,All,"18 Years to 65 Years Â  (Adult, Older Adult)",,272,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,HenryLew,30-Jul-20,1-Jun-20,59,30-Jul-20,18-Nov-20,,20-Nov-20,"Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04633941
960,NCT04460196,Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments,,Completed,No Results Available,Emergency Medicine,Other: survey,rate of patients who gave up consulting in the emergency department,"University Hospital, Angers",All,"18 Years and older Â  (Adult, Older Adult)",,900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,49RC20_0155,18-Sep-20,8-Jul-20,72,18-Sep-20,7-Jul-20,,23-Sep-20,"CHU Angers, Angers, France|CH Le Mans, Le Mans, France",,https://ClinicalTrials.gov/show/NCT04460196
961,NCT04469621,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,,Completed,No Results Available,Corona Virus Infection,Drug: SAR443122|Drug: Placebo,"Relative change from baseline in CRP level|Time to 50% decrease from baseline in CRP level|Time to improvement of oxygenation|Change from baseline in SPO2/FiO2 ratio|Number of Days without need for oxygen support and alive|Numbers of Ventilator-free days and alive|Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes|Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio|Change from baseline in marker of inflammation: interleukin 6 (IL-6)|Change from baseline in D-Dimer|Incidence of Deaths|Percentage of participants receiving thrombolytic treatment|Percentage of participants receiving vasopressor treatment|Incidence of serious adverse events (SAEs), adverse events of special interest (AESI) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation|Incidence of TEAEs leading to study discontinuation (primary reason)|Numbers of Respiratory Failure-Free Days (RFFD) and alive",Sanofi,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 1,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDY16879|2020-002104-39|U1111-1250-1185,23-Oct-20,17-Jul-20,98,23-Oct-20,14-Jul-20,,13-Nov-20,"Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, SÃ£o JosÃ© Do Rio Preto, Brazil|Investigational Site Number 0760002, SÃ£o Paulo, Brazil|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Talca, Chile|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04469621
962,NCT04488796,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,,Completed,No Results Available,Health Behaviour Change,Behavioral: Assigned Strategies: Opt-in|Behavioral: Assigned Strategies: Active Choice|Behavioral: Assigned Strategies: Enhanced Active Choice|Behavioral: Choice of Assignment: Opt-in|Behavioral: Choice of Assignment: Active Choice|Behavioral: Choice of Assignment: Enhanced Active Choice,Change in sedentary behaviour break frequency|Change in sedentary behaviour break duration|Change in work-related quality of life|Change in Health outcomes|Change in sitting time|Change in standing time|Change in moving time|Change in prolonged sitting bouts|Change in percentage of time spent sitting|Change in percentage of time spent standing|Change in percentage of time spent moving|Change in sedentary break frequency|Change in sedentary break duration,"Western University, Canada|Duke University",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,148,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,116127,16-Dec-20,7-Sep-20,100,16-Dec-20,28-Jul-20,,8-Apr-21,"University of Western Ontario, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04488796
963,NCT04365335,Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic,AUTONOMIC,Completed,No Results Available,Occupational Stress,Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Other: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation,Professional burnout|Mindfulness level|Perceived stress level following the emotional stimulation|Parasympathetic flexibility evolution during emotional recall|Sympathetic tone at rest|Corticotropic activation at rest|Mood disorders (anxiety / depression)|Post-traumatic stress disorder|Sleep quality,Direction Centrale du Service de SantÃ© des ArmÃ©es|Institut de Recherche Biomedicale des Armees,All,18 Years to 60 Years Â  (Adult),,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-COVID19-11|2020-A01058-31,12-Jun-20,25-Apr-20,48,12-Jun-20,28-Apr-20,,9-Mar-21,"ElÃ©ment Militaire de RÃ©animation (EMR), Mulhouse, France",,https://ClinicalTrials.gov/show/NCT04365335
964,NCT04548544,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,,Completed,No Results Available,Healthy,"Behavioral: Training for Awareness, Resilience, and Action (TARA)",Change in Emotional Problems,"University of California, San Francisco",All,"14 Years to 18 Years Â  (Child, Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,19-29083 (b),20-May-20,18-Oct-19,215,20-May-20,14-Sep-20,,14-Sep-20,"UCSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04548544
965,NCT04321278,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),,Completed,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,14-Jun-20,28-Mar-20,78,14-Jun-20,25-Mar-20,,20-Jan-21,"Hospital de UrgÃªncia e EmergÃªncia de Rio Branco, Rio Branco, AC, Brazil|Hospital e ClÃ­nica SÃ£o Roque, IpiaÃº, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade SÃ£o Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital EvangÃ©lico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de SaÃºde de Goias, GoiÃ¢nia, GO, Brazil|Santa Casa de MisericÃ³rdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (SÃ£o JoÃ£o Del Rey), SÃ£o JoÃ£o Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, PoÃ§os De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, ParanÃ¡, Brazil|Hospital Adventista de BelÃ©m, BelÃ©m, ParÃ¡, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao CÃ¢ncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval MarcÃ­lio Dias, Rio de Janeiro, RJ, Brazil|Hospital SÃ£o Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|AssociaÃ§Ã£o Dr. Bartholomeu Tacchini, Bento GonÃ§alves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital SÃ£o Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, CriciÃºma, Santa Catarina, Brazil|Hospital Nereu Ramos, FlorianÃ³polis, SC, Brazil|Hospital UniversitÃ¡rio Polydoro Ernani de SÃ£o Thiago/HU - UFSC, FlorianÃ³polis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa ClÃ­nica de Campinas, Campinas, SP, Brazil|FundaÃ§Ã£o do ABC (Hospital Estadual MÃ¡rio Covas), Santo AndrÃ©, SP, Brazil|AC Camargo Cancer Center - FundaÃ§Ã£o Antonio Prudente, SÃ£o Paulo, SP, Brazil|Casa de Saude Santa Marcelina, SÃ£o Paulo, SP, Brazil|Hospital AlemÃ£o Oswaldo Cruz, SÃ£o Paulo, SP, Brazil|Hospital Moriah, SÃ£o Paulo, SP, Brazil|Hospital Nove de Julho, SÃ£o Paulo, SP, Brazil|Hospital Santa Paula, SÃ£o Paulo, SP, Brazil|Hospital SÃ£o Camilo Pompeia, SÃ£o Paulo, SP, Brazil|FundaÃ§Ã£o Pio XII, Barretos, SÃ£o Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, SÃ£o Paulo, Brazil|Hospital Israelita Albert Einstein, SÃ£o Paulo, Brazil|A BeneficÃªncia Portuguesa de SÃ£o Paulo - BP, SÃ£o Paulo, Brazil|Associacao Beneficente Siria, SÃ£o Paulo, Brazil|Hospital Vila Santa Catarina, SÃ£o Paulo, Brazil|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP - 1, SÃ£o Paulo, Brazil|Secretaria de SaÃºde do Estado de SÃ£o Paulo, SÃ£o Paulo, Brazil|Serv Social da Industria do papel, papelÃ£o e cortiÃ§a do estado de SP, SÃ£o Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs, SÃ£o Paulo, Brazil|Universidade Federal de SÃ£o Paulo, SÃ£o Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04321278
966,NCT04337918,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,NOCOVID,Completed,No Results Available,Corona Virus Infection,Drug: NORS (Nitric Oxide Releasing Solution),Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2,"Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life Science",All,"19 Years and older Â  (Adult, Older Adult)",Phase 2,143,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,COVID-CTP-01,2-Feb-21,8-May-20,270,31-Jan-21,8-Apr-20,,10-Feb-21,"BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche QuÃ©bec, QuÃ©bec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-BorromÃ©e, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04337918
967,NCT04564040,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,,Completed,No Results Available,Mantle Cell Lymphoma|COVID-19,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D,Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)|Part 1 and 2: Half-life associated with terminal slope (Î»z) of a semi-logarithmic concentrationtime curve (t1/2)|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)|Part 1 and 2: Terminal elimination rate constant (Î»z)|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL/F)|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)|Part 1 and 2: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])|Number of subjects with serious and non-serious adverse events,AstraZeneca|Parexel,All,18 Years to 55 Years Â  (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8223C00005,11-Dec-20,12-Oct-20,60,11-Dec-20,25-Sep-20,,29-Dec-20,"Research Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT04564040
968,NCT04818697,"Effect of Social Isolation on Physical Activity Level, and Kinesophobia in Heart Rhythm Disorders During Pandemic",,Completed,No Results Available,Heart Rhythm Disorder|Covid19|Social Isolation,,Physical Activity Level|Fear of Movement|Health Literacy|Weekly Average of Steps|Weekly Average of Going Outside|The Comorbid Conditions,Hacettepe University,All,"18 Years and older Â  (Adult, Older Adult)",,105,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,GO 20/633,19-Mar-21,24-Jun-20,268,19-Mar-21,26-Mar-21,,30-Mar-21,"Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04818697
969,NCT04346693,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,,Completed,No Results Available,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study,Burnasyan Federal Medical Biophysical Center,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAL-05-04-2020,20-Nov-20,8-Apr-20,226,1-Nov-20,15-Apr-20,,27-Jan-21,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04346693
970,NCT04322396,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,ProPAC-COVID,Completed,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,117,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,2-Feb-21,6-Apr-20,302,2-Feb-21,26-Mar-20,,15-Feb-21,"Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|NordsjÃ¦llands Hospital, HillerÃ¸d, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark",,https://ClinicalTrials.gov/show/NCT04322396
971,NCT04849546,Staff Physical and Mental Health Assessment in the Aftermath of the First Peak of the Covid-19 Outbreak,SAMAF,Completed,No Results Available,Occupational Stress,,global health|psychosocial factors,"University Hospital, Brest",All,"18 Years to 70 Years Â  (Adult, Older Adult)",,1491,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Retrospective,SAMAF - 29BRC21.0125,1-Sep-20,1-Jul-20,62,31-Aug-20,19-Apr-21,,19-Apr-21,"Chu Brest, Brest, Bretagne, France",,https://ClinicalTrials.gov/show/NCT04849546
972,NCT04344041,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),,Completed,No Results Available,Coronavirus,"Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHDâ‰¥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHDâ‰¥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHDâ‰¥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHDâ‰¥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or â‰¥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or â‰¥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or â‰¥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or â‰¥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology","University Hospital, Angers|Mylan Laboratories",All,65 Years and older Â  (Older Adult),Phase 3,260,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001602-34,14-Jan-21,15-Apr-20,274,14-Jan-21,14-Apr-20,,30-Apr-21,"CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04344041
973,NCT04747132,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,,Completed,No Results Available,Effectiveness,Other: Telegeriatric intervention,Visual analog scale of the European quality of life questionnaire|Physical performance.|Depressive symptoms|Symptoms of anxiety.|Body composition|Anthropometric measures|Dietary intake,"Universidad Iberoamericana A.C., Mexico",All,"60 Years and older Â  (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,SALUD-2021-Telegeria,16-Nov-20,20-Jul-20,119,20-Oct-20,10-Feb-21,,10-Feb-21,"Universidad Iberoamericana, Ciudad de Mexico, Ciudad De MÃ©xico, Mexico",,https://ClinicalTrials.gov/show/NCT04747132
974,NCT04459533,Sparing in Neuromuscular Blockade in COVID 19 ICU,TOF-COVID,Completed,No Results Available,Neuromuscular Blockade|Human Characteristics|Complication of Medical Care|Intensive Care Unit Acquired Weakness,Device: TOF protocol,NMB agents consumption,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,250,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,2020_TOF-COVID,1-Jun-20,1-Jun-20,0,1-Jun-20,7-Jul-20,,7-Jul-20,"Department of Anesthesiology and Intensive Care Medicine, HÃ´pital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT04459533
975,NCT04542954,Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,OMC-KTR,Completed,No Results Available,"Covid19|Kidney Transplant Infection|Risk Factor, Cardiovascular|Immunosuppression|Outcome, Fatal|Graft Failure",Other: Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East,patient outcome|Kidney graft outcome|risk factors for getting COVID19 infection,"Hamid Al-Essa Organ Transplant Center|Ministry of Health, Kuwait",,"Child, Adult, Older Adult",,104,Other,Observational,Observational Model: Cohort|Time Perspective: Other,2020/1481,31-Aug-20,1-Mar-20,183,31-Aug-20,9-Sep-20,,9-Sep-20,"OTC, MOH , Kuwait, Kuwait, Kuwait",,https://ClinicalTrials.gov/show/NCT04542954
976,NCT04343404,Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19,ECMO-COVID-19,Completed,No Results Available,Respiratory Distress Syndrome,,Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them,"University Hospital, Strasbourg, France",All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,7772,15-Apr-20,1-Apr-20,14,15-Apr-20,13-Apr-20,,29-Jun-20,"Service de Chirurgie Thoracique Nouvel HÃ´pital Civil HÃ´pitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04343404
977,NCT04407663,"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near",,Completed,No Results Available,Bariatric Surgery Candidate|Patient Underwent Bariatric Surgery,Other: Telemedicine to remote outpatient visit in bariatric patient,Evaluation of feasibility of telemedicine in outpatient visit in bariatric patients,"University of Campania ""Luigi Vanvitelli""",All,"18 Years and older Â  (Adult, Older Adult)",,138,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Telemedicine,4-May-20,3-Mar-20,62,4-May-20,29-May-20,,29-May-20,"University of Campania ""Luigi Vanvitelli"", Naples, Italy",,https://ClinicalTrials.gov/show/NCT04407663
978,NCT04405310,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,CPC-SARS,Completed,No Results Available,SARS Pneumonia,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment),"Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DI/20/201/04/19,10-Dec-20,20-May-20,204,20-Nov-20,28-May-20,,21-Dec-20,"Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT04405310
979,NCT04519385,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,,Completed,No Results Available,"Pneumonia, Viral",Drug: Tocilizumab|Drug: Dexamethasone,Proportion of participants with Overall Survival at 14 days|Fio2/Pao2,South Valley University,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",SouthVU,5-Aug-20,1-Mar-20,157,1-Jul-20,19-Aug-20,,25-Aug-20,"Qena faculty medicine, QinÄ, Egypt",,https://ClinicalTrials.gov/show/NCT04519385
980,NCT04400279,The COVID-19 Pandemic and Exercise Study,COPE,Completed,No Results Available,Depressive Symptomatology|Psychological Distress|Health Behavior,Behavioral: Yoga group|Behavioral: High Intensity Interval Training group|Behavioral: Combination,"Changes in depressive symptomology over the course of the exercise intervention|Changes in psychological stress as measured by the SCSQ over the course of the exercise intervention.|Changes in psychological distress as measured by the K10 over the course of the exercise intervention.|Changes in flourishing over the course of the exercise intervention|Changes in resilience over the course of the exercise intervention|Changes in life satisfaction over the course of the exercise intervention|Changes in weekly strain as a result of health problems, financial/work issues, and relationship trouble using the Chronic Burden Scale over the course of the exercise intervention.|Changes in general affect over the course of the exercise intervention|Changes in leisure time physical activity over the course of the exercise intervention|Changes in physical health symptomology over the course of the exercise intervention|Changes in alcohol habits over the course of the exercise intervention|Tracking the amount of exercise variety participants feel they engage in",University of British Columbia,All,18 Years to 64 Years Â  (Adult),Not Applicable,334,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",H20-01497,28-Nov-20,1-Jun-20,180,28-Nov-20,22-May-20,,11-Jan-21,"University of British Columbia, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT04400279
981,NCT04437342,Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia,,Completed,No Results Available,Postpartum Depression|Psychological Stress|Maternal Distress,Other: PHQ-9 (Patient Health Questionnaire) Depression Scale|Other: GAD-7 (General Anxiety Disorder) scale|Other: 38 questions questionnaire|Other: EPDS (Edinburgh Postnatal Depression Scale),"Correlation between the Covid-19 pandemic and postpartum depression with EPDS scale (Edinburgh postnatal depression scale)|Correlation between the Covid-19 pandemic, postpartum depression and type of anaesthesia (general, epidural, spinal, combined, epidural analgesia for vaginal delivery)|Correlation between the Covid-19 pandemic, postpartum depression and postpartum pain","General and Maternity Hospital of Athens Elena Venizelou|National and Kapodistrian University of Athens|Alexandra Hospital, Athens, Greece|University of Ioannina|Larissa University Hospital",Female,"18 Years and older Â  (Adult, Older Adult)",,330,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Covid-19 Postpartum depression,27-Oct-20,30-Jun-20,119,30-Aug-20,18-Jun-20,,6-Jan-21,"""Elena Venizelou"" General and Maternity Hospital of Athens, Athens, Attica, Greece|Aretaieio University Hospital, Athens, Attica, Greece|Alexandra Genaral Hospital Athens, Athens, Greece|University of Ioannina Health Science, Ioannina, Greece|University of Ioannina, Medical School, Ioannina, Greece|University of Thessaly Medical School, Larisa, Greece",,https://ClinicalTrials.gov/show/NCT04437342
982,NCT04368208,Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression,DEPRECOVID,Completed,No Results Available,Postnatal Depression,Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery,Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Describe the experience and the satisfaction about delivery during the covid 19 pandemia,Poitiers University Hospital,Female,18 Years to 50 Years Â  (Adult),,501,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A01065-34,27-Nov-20,29-Apr-20,212,21-Oct-20,29-Apr-20,,26-Jan-21,"Bertrand GACHON, Poitiers, France",,https://ClinicalTrials.gov/show/NCT04368208
983,NCT04368026,SARS-CoV-2 (COVID-19) and Surgery,,Completed,No Results Available,"Surgical Procedure, Unspecified",Other: No intervention (survey study for medical doctors).,Descriptive data on perceptions of current status of surgical wards during the pandemic and impact of the pandemic on conducting surgery.,Jagiellonian University,All,"25 Years and older Â  (Adult, Older Adult)",,70,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,1072.6120.103.2020,1-Dec-20,30-Mar-20,246,1-Dec-20,29-Apr-20,,10-Feb-21,"2nd Department of General Surgery, Jagiellonian University Medical College, Cracovia, MaÅ‚opolska, Poland",,https://ClinicalTrials.gov/show/NCT04368026
984,NCT04423315,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Covid-19,Completed,No Results Available,Corona Virus Infection|Thromboembolic Disease,,length of hospital stay,Nisantasi University,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,70,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20200504443,20-Jul-20,8-Jun-20,42,15-Jul-20,9-Jun-20,,23-Sep-20,"Vital Hospital, Bahcelievler, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04423315
985,NCT04517422,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,,Completed,No Results Available,SARS-CoV Infection,Dietary Supplement: Probiotics|Other: Placebo,"Severity progression of COVID-19|Stay at ICU|Mortality ratio|Viral load|Lung abnormalities|Levels of immunoglobulins|Gastrointestinal manifestations, where 0 means good health status and 5 worse status|Fecal microbiome|Adverse events|Change on Serum Biomarkers|Duration of Individual Symptoms","AB Biotics, SA|Innovacion y Desarrollo de Estrategias en Salud|Hospital General Dr. Manuel Gea GonzÃ¡lez|Hospital Angeles del Pedregal",All,18 Years to 60 Years Â  (Adult),Not Applicable,300,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",ABB-COVID19,2-Feb-21,19-Aug-20,167,2-Feb-21,18-Aug-20,,6-May-21,"Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Mexico",,https://ClinicalTrials.gov/show/NCT04517422
986,NCT04334434,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),,Completed,No Results Available,Telerehabilitation,Other: Telerehabilitation,Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly,"Kubra Koce, MSc PT|Istanbul University-Cerrahpasa",All,65 Years and older Â  (Older Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2,15-Dec-20,30-Jul-20,138,15-Sep-20,6-Apr-20,,3-Feb-21,"Istanbul university Cerrahpasa, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04334434
987,NCT04430062,Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital,,Completed,No Results Available,General Surgery|Disease Outbreaks,Procedure: Surgical procedures performed under general anesthesia,Mortality,Azienda Socio Sanitaria Territoriale di Lodi,All,"Child, Adult, Older Adult",,14,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,Covid19nr1,30-May-20,1-May-20,29,20-May-20,12-Jun-20,,16-Jun-20,"Ospedale di Lodi - ASST Lodi, Lodi, Lombardia, Italy",,https://ClinicalTrials.gov/show/NCT04430062
988,NCT04402905,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)",COVID-PSL,Completed,No Results Available,Coronavirus Infection,,COVID-PSL Cohort,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,All,"18 Years and older Â  (Adult, Older Adult)",,450,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CREPATS 011,15-Aug-20,15-Jun-20,61,15-Jul-20,27-May-20,,3-Feb-21,"Yasmine Dudoit, Paris, France",,https://ClinicalTrials.gov/show/NCT04402905
989,NCT04685681,The Get Outside Study,GO,Completed,No Results Available,Covid19|Risk Reduction|Stress|Sleep,Behavioral: Hiking challenge|Other: Activity list,Frequency of lower-risk activities|Frequency of higher-risk activities|Frequency of social activities|Frequency of physical activities|Frequency of hiking/nature walks|Frequency of restaurant dining|Stress|Sleep,State University of New York at Buffalo,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00005101,6-Apr-21,7-Jan-21,89,6-Apr-21,28-Dec-20,,4-May-21,"State University of New York at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04685681
990,NCT04479280,Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.,,Completed,No Results Available,Coagulation Disorder,"Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA",clot rate formation,Assiut University,All,"Child, Adult, Older Adult",,70,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,17300446,16-Aug-20,20-Jul-20,27,16-Aug-20,21-Jul-20,,9-Sep-20,"Assiut university, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04479280
991,NCT04276688,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",,Completed,No Results Available,Novel Coronavirus Infection,Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B,Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens,"The University of Hong Kong|Hospital Authority, Hong Kong",All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,127,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UW-20-074,31-Mar-20,10-Feb-20,50,30-Mar-20,19-Feb-20,,15-Apr-20,"University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04276688
992,NCT04412551,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,,Completed,No Results Available,Corona Virus Infection|Virus Diseases|Coronaviridae Infections,,Identification of requirement of mechanical ventilation|Prediction of requirement of mechanical ventilation|Association of LUS to clinical parameters|Description of findings on LUS,"Dalarna County Council, Sweden",All,"18 Years to 80 Years Â  (Adult, Older Adult)",,72,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LUS-Covid001,31-Dec-20,20-May-20,225,31-Dec-20,2-Jun-20,,18-May-21,"Falun Hospital, Falun, Sweden",,https://ClinicalTrials.gov/show/NCT04412551
993,NCT04345549,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,,Completed,No Results Available,Flu Like Symptom|Flu Like Illness,Other: Individualised Ayurveda,Time to achieve afebrile|Severity of influenza symptom score,Aarogyam UK,All,18 Years to 60 Years Â  (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AU08,30-Mar-20,26-Feb-20,33,30-Mar-20,14-Apr-20,,14-Apr-20,"Aarogyam, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04345549
994,NCT04427176,Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).,Masq-Aute,Completed,No Results Available,Nurse,Device: ARFC mask,"Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of tolerance|Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of compatibility with technical gestures.|Assess the acceptability of the wearing of an ARFC mask by nursing staff|To assess the minor complications of wearing the ARFC mask .",Centre Hospitalier Universitaire de Saint Etienne,All,"18 Years and older Â  (Adult, Older Adult)",,15,Other,Observational,Observational Model: Other|Time Perspective: Prospective,20CH073|2020-A00817-32,28-May-20,29-Apr-20,29,28-May-20,11-Jun-20,,29-Jun-20,"CHU Saint-Etienne, Saint-Ã‰tienne, France",,https://ClinicalTrials.gov/show/NCT04427176
995,NCT04393818,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,PsyCovid_App,Completed,No Results Available,Mental Health Disorder|Depression|Posttraumatic Stress Disorder|Burnout|Anxiety Disorders,Behavioral: Intervention App,"Depression, anxiety and stress|Post-traumatic stress syndrome|Insomnia|Self Efficacy",FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears|Universidad de las Islas Baleares|Hospital Miguel Servet|FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Andalusian School of Public Health|Hospital Son Espases,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,560,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",COVID-19/06,24-Aug-20,5-May-20,111,24-Aug-20,19-May-20,,10-Sep-20,"Ignacio Ricci-Cabello, Palma De Mallorca, Balearic Islands, Spain",,https://ClinicalTrials.gov/show/NCT04393818
996,NCT04324736,"""COVID-19 and Diabetes Outcomes""",CORONADO,Completed,No Results Available,Coronavirus|Diabetes,Other: no interventional study,Assess the prevalence of severe forms among hospitalized patients with diabÃ¨tes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19,Nantes University Hospital,All,"Child, Adult, Older Adult",,5309,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RC20_0148,31-Dec-20,10-Mar-20,296,10-Apr-20,27-Mar-20,,23-Feb-21,"CHU Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT04324736
997,NCT04435119,Covid-19 and Vitamin D in Nursing-home,COVIT-EHPAD,Completed,No Results Available,Coronavirus,,"Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19|Clinical severity score of COVID19 in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19","University Hospital, Angers",All,70 Years and older Â  (Older Adult),,96,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020/67,15-May-20,15-Mar-20,61,15-May-20,17-Jun-20,,17-Jun-20,"Angers University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT04435119
998,NCT04383457,Covid-19 Triage Using Camera-based AI,,Completed,No Results Available,Coronavirus Infections,Device: RIA-device (Remote Investigation and Assessment),Agreement between the new camera based method and reference standard to estimate body temperature|Agreement between the new camera based method and reference standard to estimate heart rate|Agreement between the new camera based method and reference standard to estimate blood oxygen saturation|Agreement between the new camera based method and reference standard to estimate systolic blood pressure|Agreement between the new camera based method and reference standard to estimate diastolic blood pressure|Agreement between the new camera based method and reference standard to estimate respiratory rate|Prediction of hospital admission using vital signs estimated using reference standard methods|Prediction of death using vital signs estimated using reference standard methods|Prediction of hospital admission using vital signs estimated using the new camera based method|Prediction of death using vital signs estimated using the new camera based method|Prediction of hospital admission using raw camera data|Prediction of death using raw camera data,Vastra Gotaland Region|Detectivio AB,All,"18 Years and older Â  (Adult, Older Adult)",,214,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,U1111-1251-4114,8-Oct-20,15-Jun-20,115,8-Oct-20,12-May-20,,1-Dec-20,"Ã–stra Sjukhuset, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT04383457
999,NCT04615741,Finding Wellness in the Pandemic,,Completed,No Results Available,"Mental Health Wellness 1|Addiction|Stress, Psychological|Covid19",Behavioral: Trauma Informed Yoga|Behavioral: Trauma Informed Psychotherapy,Changes in Tobacco Use|Changes in Alcohol Use|Changes in Drug Use|Changes in Gambling|Changes in Post-Traumatic Stress Symptoms|Changes in Depression Symptoms|Changes in Anxiety Symptoms|Changes in Eating Behaviour|Changes in Sleeping Behaviour|Changes in Physical Activity|Changes in Resilience|Changes in Self-Esteem|Changes in Loneliness|Changes in Dissociative Experiences,University of Lethbridge,Female,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,187,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-096,20-Apr-21,9-Nov-20,162,22-Jan-21,4-Nov-20,,29-Apr-21,"University of Lethbridge, Lethbridge, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT04615741
1000,NCT04354792,Asymptomatic COVID-19 Infection Among Healthcare Workers,,Completed,No Results Available,Immunologic Activity Alteration,Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers,Number of IGg seropositive health care workers|Differentiation between low risk and high risk HCWs,Kasr El Aini Hospital,All,25 Years to 60 Years Â  (Adult),,500,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,N-31-2020,10-Jun-20,1-May-20,40,10-Jun-20,21-Apr-20,,17-Jun-20,"Cairo University Hospital, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04354792
1001,NCT04389320,Antimalarial and Covid 19 in Rheumatoid Arthritis,,Completed,No Results Available,Rheumatoid Arthritis,Drug: Hydroxychloroquine,immunoglobulin mesurement,Assiut University,All,"20 Years to 70 Years Â  (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,covid 19 in RA,1-May-20,15-Mar-20,47,1-May-20,15-May-20,,15-May-20,"Manal Hassanien, Assiut, Yes, Egypt",,https://ClinicalTrials.gov/show/NCT04389320
1002,NCT04482205,Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures,,Completed,No Results Available,Economic Burden,,the effect of Covid -19 on the total costs of inpatient care|drop in the collective revenue generated in covid era,Aga Khan University,All,"Child, Adult, Older Adult",,840,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,akupde,31-May-20,16-Mar-20,76,31-May-20,22-Jul-20,,22-Jul-20,"Aga Khan University Hospital, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT04482205
1003,NCT04448405,Covid-19 Lockdown and Deviant Sexual Fantasies,,Completed,No Results Available,Deviant Sexual Fantasies,Behavioral: Questionnaire for evaluation of confinement on deviant sexual fantasies,Impact of confinement on deviant fantasies|Intensity of deviant fantasies|Frequency of deviant fantasies|Paraphilic type impacted|Occurrence of sexual act|Access mode for deviant fantasies|Use of support during confinement|Evaluating anxiety/depression level,"University Hospital, Montpellier",All,"18 Years and older Â  (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0341,30-Oct-20,18-Jun-20,134,1-Oct-20,25-Jun-20,,29-Dec-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04448405
1004,NCT04320953,Non-contact Endoscopy at Covid-19 Outbreak,,Completed,No Results Available,Gastrointestinal Disease|Infectious Disease,Device: Non-contact MCE system,Technical success|Clinical success|Adverse events,Changhai Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ncMCE1,9-Apr-20,16-Mar-20,24,26-Mar-20,25-Mar-20,,17-Apr-20,"Changhai Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04320953
1005,NCT04368312,Psychological Impairment Due to Covid-19,,Completed,No Results Available,Psychological Distress|Quality of Life,Other: No intervention,PCL5 Questionnaire|BSI - Brief symptom inventory|PHQD|WHO - QoL BREF|STAXI|AUDIT questionnaire,"University Hospital, Essen",All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TEMP553914-BO,30-Dec-20,6-May-20,238,30-Sep-20,29-Apr-20,,6-May-21,"University Hospital Essen, Essen, NRW, Germany",,https://ClinicalTrials.gov/show/NCT04368312
1006,NCT04412343,The Seniors COvid-19 Pandemic and Exercise Study,SCOPE,Completed,No Results Available,Well-Being (Psychological Flourishing)|Depression|Quality of Life|Loneliness|Physical Activity|Social Identification|Physical Health,Behavioral: Virtual Group Intervention|Behavioral: Personal Exercise Intervention,Well-Being (Psychological Flourishing)|Life Satisfaction|Stress|Depression|Resilience|Social Identification|Social and Emotional Lonliness|Chronic Illness (Physical Health)|Weekly Somatic Symptoms (Physical Health)|Leisure-time physical activity|Alcohol Habits|Physical Adherence|Affective Attitudes|Demographics,University of British Columbia|University of Victoria,All,65 Years and older Â  (Older Adult),Not Applicable,241,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,H20-01515,5-Oct-20,23-May-20,135,5-Oct-20,2-Jun-20,,3-Nov-20,"University of British Columbia, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT04412343
1007,NCT04854408,Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,,Completed,No Results Available,Covid19|Vaccine Reaction|Coronavirus|Menstrual Problem|Endometrium,Other: healthcare workers with the coronavac vaccine,Possible effects of Coronavac vaccine (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 vaccine) on menstrual cycle,Kanuni Sultan Suleyman Training and Research Hospital,Female,18 Years to 45 Years Â  (Adult),,300,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Coronavacendometrium,9-May-21,18-Mar-21,52,7-May-21,22-Apr-21,,11-May-21,"Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04854408
1008,NCT04395885,Sexual Function During COVID 19 Pandemic,,Completed,No Results Available,Sexual Dysfunction,Other: Electronic questionnaire,The percentage of study participants diagnosed with sexual dysfunction,Assiut University,All,18 Years to 40 Years Â  (Adult),,306,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,SFCOV,15-Sep-20,1-Jun-20,106,31-Aug-20,20-May-20,,6-Oct-20,"Ahmed Abbas, Assiut, Cairo, Egypt|Assiut Faculty of Medicine, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT04395885
1009,NCT04385212,Outcomes in Hospitalized Older Patients With COVID-19,,Completed,No Results Available,Coronavirus Infection|Sars-CoV2|Elderly Infection|Old Age; Debility,,To evaluate the relative contributions of comorbidities on intra-hospitalized death|To evaluate the relative contributions of functional characteristics on intra-hospitalized death|To explore specific clinical profiles that may influence COVID-19 disease outcomes in the elderly based on geriatrics syndromes,"University Hospital, Geneva",All,65 Years and older Â  (Older Adult),,230,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-00819,14-Apr-20,13-Mar-20,32,14-Apr-20,12-May-20,,12-May-20,"Department of Rehabilitation and Geriatrics, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT04385212
1010,NCT04567927,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,,Completed,No Results Available,SARS Virus,Other: Ultrasonography,Period prevalence of deep vein thrombosis (DVT),"Chiesa Alessandro Felice|Ente Ospedaliero Cantonale, Bellinzona",All,"18 Years and older Â  (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-01266,28-May-20,3-Mar-20,86,28-May-20,29-Sep-20,,29-Sep-20,"Ospedale Regionale di Bellinzona e Valli, Bellinzona, Ticino, Switzerland",,https://ClinicalTrials.gov/show/NCT04567927
1011,NCT04444557,Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study,COST-HD,Completed,No Results Available,Depression|Hemodialysis,Other: Beck Depression Inventory (BDI),Score of Beck Depression Inventory,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,97,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,200620,1-May-20,17-Apr-20,14,1-May-20,23-Jun-20,,23-Jun-20,"Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04444557
1012,NCT04836039,Rehabilitation Experiences of Physiotherapists in Covid-19 Outbreak,,Completed,No Results Available,Physical Therapy,Other: A questionnaire and scales.,A questionnaire created by research physiotherapists based on researches and examples in the literature.|Assessment of depression level with Center for Epidemiologic Studies Depression Scale|Assessment of anxiety level with Generalized Anxiety Disorder 7 Test|Assessment of stress level with Perceived Stress Scale,Medipol University,All,"22 Years to 65 Years Â  (Adult, Older Adult)",,400,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,E-10840098-772.02-2682,27-Feb-21,27-Jan-21,31,27-Feb-21,8-Apr-21,,8-Apr-21,"Medipol University, Istanbul, Beykoz, Turkey",,https://ClinicalTrials.gov/show/NCT04836039
1013,NCT04354272,Evaluation of Dental Emergency Treatments During COVID19 Crisis,URGDENTCOVID,Completed,No Results Available,Orofacial Pain|Orofacial Edema|Dental Trauma|Oral Infection,Other: Questionnaire,Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable|Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable|welcoming quality from hospital staff|anxiety score|perception of the technical quality of the emergency treatment,Assistance Publique - HÃ´pitaux de Paris,All,"18 Years and older Â  (Adult, Older Adult)",,503,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP200464,29-Jun-20,21-Apr-20,69,29-Apr-20,21-Apr-20,,2-Mar-21,"Service d'odontologie, HÃ´pital PitiÃ©-SalpÃªtriÃ¨re, Paris, France",,https://ClinicalTrials.gov/show/NCT04354272
1014,NCT04351542,Ayurveda for Flu Like Illness During Covid-19 Outbreak,,Completed,No Results Available,Flu Like Illness,Dietary Supplement: Ayurveda|Other: Usual Care,Time to achieve afebrile|Severity of symptom score|Patient reported improvement,Aarogyam UK,All,18 Years to 60 Years Â  (Adult),Not Applicable,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,AU09,12-Apr-20,6-Mar-20,37,6-Apr-20,17-Apr-20,,17-Apr-20,"Aarogyam, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04351542
1015,NCT04433754,The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,,Completed,No Results Available,Pancreatitis,Other: biochemical analysis,to compare presence of fever in patients with and without pancreatic injury|to compare presence of dyspnea in patients with and without pancreatic injury|To compare cRP levels in patients with and without pancreatic injury|To compare d-dimer levels in patients with and without pancreatic injury,UÅŸak University,All,"18 Years and older Â  (Adult, Older Adult)",,500,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,UsakU-Cevdet2,12-Jun-20,1-Mar-20,103,11-Jun-20,16-Jun-20,,16-Jun-20,"Usak University Training and Research Hospital, Usak, Turkey",,https://ClinicalTrials.gov/show/NCT04433754
1016,NCT04461353,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo,Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0|Change from baseline in clinical laboratory test results for CBC with differential|Incidence of abnormal laboratory test results for CBC with differential at Screening|Incidence of abnormal laboratory test results for CBC with differential - Day 8|Changes from baseline for blood glucose|Incidence of abnormal laboratory test results for chemistry -Screening|Incidence of abnormal laboratory tests results for chemistry - Day 8|Incidence of abnormal laboratory tests results for urinalysis - Screening|Incidence of abnormal laboratory tests results for urinalysis- Day 8|Changes in vital signs from baseline (pre-dose) - respiratory rate|Changes in vital signs from baseline (pre-dose)- temperature|Changes in vital signs from baseline (pre-dose) - seated blood pressure|Changes in vital signs from baseline (pre-dose) - pulse|Changes in vital signs from baseline (pre-dose) - O2 saturation|Incidence of abnormal and physical examinations findings during Screening- general appearance|Incidence of abnormal and physical examinations findings on Day 1 - general appearance|Incidence of abnormal and physical examinations findings on Day 2- general appearance|Incidence of abnormal and physical examinations findings on Day 8- general appearance|Incidence of abnormal and physical examinations findings during Screening- neurological|Incidence of abnormal and physical examinations findings on Day 1- neurological|Incidence of abnormal and physical examinations findings on Day 2- neurological|Incidence of abnormal and physical examinations findings on Day 8- neurological|Incidence of abnormal and physical examinations findings during Screening - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 1 - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 2 - heart/cardiovascular|Incidence of abnormal and physical examinations findings on Day 8 - heart/cardiovascular|Incidence of abnormal and physical examinations findings during Screening - lungs|Incidence of abnormal and physical examinations findings on Day 1 - lungs|Incidence of abnormal and physical examinations findings on Day 2 - lungs|Incidence of abnormal and physical examinations findings on Day 8 - lungs|Incidence of abnormal and physical examinations findings during Screening- abdomen|Incidence of abnormal and physical examinations findings on Day 1 - abdomen|Incidence of abnormal and physical examinations findings on Day 2- abdomen|Incidence of abnormal and physical examinations findings on Day 8- abdomen|Incidence of abnormal and physical examinations findings during screening- endocrine|Incidence of abnormal and physical examinations findings on Day 1 - endocrine|Incidence of abnormal and physical examinations findings on Day 2- endocrine|Incidence of abnormal and physical examinations findings on Day 8- endocrine|Incidence of abnormal and physical examinations findings during Screening- extremities|Incidence of abnormal and physical examinations findings on Day 1- extremities|Incidence of abnormal and physical examinations findings on Day 2- extremities|Incidence of abnormal and physical examinations findings on Day 8- extremities|Incidence of abnormal and physical examinations findings during Screening- lymphatic|Incidence of abnormal and physical examinations findings on Day 1- lymphatic|Incidence of abnormal and physical examinations findings on Day 2 - lymphatic|Incidence of abnormal and physical examinations findings on Day 8- lymphatic|Incidence of abnormal and physical examinations findings during screening - skin|Incidence of abnormal and physical examinations findings on Day 1 - skin|Incidence of abnormal and physical examinations findings on Day 2 - skin|Incidence of abnormal and physical examinations findings on Day 8 - skin|Changes from baseline for pulmonary function tests (PFTs) - FEV1|Changes from baseline for pulmonary function tests (PFTs) - FVC|Changes from baseline for pulmonary function tests (PFTs) - FEV1/FVC|Changes from baseline for ECG readings - QT interval|Changes from baseline for ECG readings - QTcB Interval|Changes from baseline for ECG readings - QRS duration|Changes from baseline for ECG readings - PR interval|Changes from baseline for ECG readings - heart rate|Incidence of abnormal ECG - Screening|Incidence of abnormal ECG- Day 1|Incidence of abnormal ECG - Day 2|Incidence of abnormal ECG - Day 8|HCQ concentration in whole blood versus time profiles,"Pulmoquine Therapeutics, Inc|Rockefeller University",All,"18 Years and older Â  (Adult, Older Adult)",Phase 1,12,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PUL-01,17-Aug-20,25-Jun-20,53,17-Aug-20,8-Jul-20,,8-Oct-20,"The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04461353
1017,NCT04815135,Effect of Covid-19 Pandemic on Emergency Surgery Practice,,Completed,No Results Available,Emergencies,Other: Observational study,Average duration of sx prior to admission in hours|Type of management (surgical vs conservative)|Length of stays in Days|Level of care (ICU vs floor),Ibrahim Khrais|University of Jordan,All,"Child, Adult, Older Adult",,344,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,10-2021-5926,18-Jan-21,1-Mar-19,689,31-May-20,24-Mar-21,,24-Mar-21,"Ibrahim Khrais, Amman, Please Select, Jordan",,https://ClinicalTrials.gov/show/NCT04815135
1018,NCT04425005,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,,Completed,No Results Available,Bariatric Surgery|Obesity,Other: Home-based exercise,Change from baseline on waist circumference at 3 months of follow-up.|Change from baseline on cardiometabolic risk factor at 3 months of follow-up.|Change from baseline on cardiopulmonary fitness at 3 months of follow-up.|Change from baseline on quality of life at 3 months of follow up.|Change from baseline on Physical activity levels at 3 months of follow up.|Change from baseline on dietary intake at 3 months of follow up.,University of Sao Paulo,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,21056813.3.0000.0068,7-Dec-20,10-May-20,211,7-Dec-20,11-Jun-20,,22-Jan-21,"Univsersity of Sao Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04425005
1019,NCT04568005,Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,,Completed,No Results Available,Lymphedema,,Coronavirus Phobia Scale|Lymphedema Quality of Life Arm|Lymphedema Quality of Life Leg|Hospital Anxiety and Depression Scale,Fatih Sultan Mehmet Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,60,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,feyzaakanbegoglu,1-Aug-20,1-Jun-20,61,1-Aug-20,29-Sep-20,,8-Oct-20,"Fatih Sultan Mehmet Training and Research Hospital, Istanbul, AtaÅŸehir, Turkey",,https://ClinicalTrials.gov/show/NCT04568005
1020,NCT04740125,SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS IN NORTH AFRICA COUNTRY,COVID-STRESS,Completed,No Results Available,HEALTH CARE WORKERS,,STRESS-COVID,"General Administration of Military Health, Tunisia",All,"18 Years to 70 Years Â  (Adult, Older Adult)",,368,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,UR17DN05SURVEY,30-Nov-20,1-May-20,213,31-Jul-20,5-Feb-21,,5-Feb-21,"Military Hospital of Tunis, Tunis, Montfleury, Tunisia",,https://ClinicalTrials.gov/show/NCT04740125
1021,NCT04379232,Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center,SurgiCovid,Completed,No Results Available,Digestive Cancer|Gynaecological Cancer|Head and Neck Cancer,Biological: Screening test for covid ( RT PCR and CT Chest),Symptoms of Covid after surgery,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Older Adult)",,112,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CRC_GHN_2020_001,25-Apr-20,19-Mar-20,37,20-Apr-20,7-May-20,,7-May-20,"Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT04379232
1022,NCT04466605,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,,Completed,No Results Available,Chronic Musculoskeletal Pain,Other: Tele-yoga therapy|Other: Primary care,Severity of pain|Interference of pain|Global rating of change in pain|Intervention specific satisfaction,Aarogyam UK|NMP Medical Research Institute|Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University,All,18 Years to 60 Years Â  (Adult),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AU/NMP/0921,6-Jul-20,30-Mar-20,98,30-Jun-20,10-Jul-20,,10-Jul-20,"NMP Medical Research Institute, Jaipur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT04466605
1023,NCT04815057,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,,Completed,No Results Available,Health Behavior,Behavioral: Wellness Education,Turkish child physical activity questionnaire|quality of life scale for children,Sumeyra YÄ±lmaz|Saglik Bilimleri Universitesi,All,"Child, Adult, Older Adult",Not Applicable,176,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SaÄŸlÄ±k Bilimleri Univesity,8-Mar-21,2-Nov-20,126,23-Nov-20,24-Mar-21,,14-Apr-21,"Second School, KÄ±rÅŸehir, Turkey",,https://ClinicalTrials.gov/show/NCT04815057
1024,NCT04305574,Social Media Use During COVID-19,,Completed,No Results Available,Coronavirus|Depression|Anxiety|Stress,Behavioral: Use of social media during COVID-19,"Depression, Anxiety and Stress Scale",Jean Liu|Yale-NUS College,All,"21 Years and older Â  (Adult, Older Adult)",,1145,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020-CERC-001,21-Apr-20,7-Mar-20,45,21-Apr-20,12-Mar-20,,7-Jul-20,"Yale-NUS College, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04305574
1025,NCT04796064,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,,Completed,No Results Available,Sarcopenia,Other: low-intensity aerobic training,Handgrip strength,Cairo University,Male,"60 Years to 80 Years Â  (Adult, Older Adult)",Not Applicable,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Sarcopenia,15-Dec-20,30-Mar-20,260,5-Nov-20,12-Mar-21,,12-Mar-21,"Marwa Eid, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04796064
1026,NCT04385823,Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure,,Completed,No Results Available,"Respiratory Syndrome, Acute, Severe|Hypoxic Respiratory Failure|Viral Pneumonia",Device: patients receiving nasal high flow,Changes in ROX index|NHF failure|NHF flow|NHF inspired fraction in oxygen|oxygenation|respiratory status|prediction of intubation|prediction of NHF success,HÃ´pital Louis Mourier,All,"18 Years and older Â  (Adult, Older Adult)",,62,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HLM_JDR9,4-May-20,1-Mar-20,64,4-May-20,13-May-20,,13-May-20,"HÃ´pital Louis Mourier, Assistance Publique - HÃ´pitaux de Paris, Colombes, France",,https://ClinicalTrials.gov/show/NCT04385823
1027,NCT04414618,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,COVID-19,Completed,No Results Available,Coronavirus Infections,Drug: Opaganib|Drug: Placebo,"Measurement of the oxygen requirement|Measurement of the reduction in oxygen requirement.|Eliminating supplemental oxygen|Elimination of fever|Time to negative swabs for SARS-CoV-2 by PCR post treatment|Time to negative swabs for SARS-CoV-2 by PCR at Day 14|Intubation and mechanical ventilation requirements|Evaluation of the time to mechanical ventilation|Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14|Evaluation of mortality 30 days post-baseline",RedHill Biopharma Limited,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 2,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ABC-110,23-Dec-20,2-Jul-20,174,26-Nov-20,4-Jun-20,,10-Mar-21,"HonorHealth Research Institute, Scottsdale, Arizona, United States|Miami Cancer Institute, Miami, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Albany Medical Center, Albany, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Memorial Herman Southeast Hospital, Houston, Texas, United States|Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States|Ziv Medical Center, Safed, Israel",,https://ClinicalTrials.gov/show/NCT04414618
1028,NCT04409197,"Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network",CO-RNPC,Completed,No Results Available,Comorbidities|Confinement|Obesity,,"Analyse the variation in weight loss kinetics before, during and after confinement in patients enrolled in a weight reduction programme (RNPC) in France|Define the effects of containment on the variation in the kinetics of anthropometric parameters other than weight|Evolution of blood pressure before versus after confinement|Characterize clusters (homogeneous groups of patients) associated with particular dynamics of weight kinetics during confinement|Evaluate the impact of teleconsultation monitoring during containment on weight loss","University Hospital, Grenoble",All,"18 Years and older Â  (Adult, Older Adult)",,4789,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC20.150,11-Jul-20,8-May-20,64,8-Jun-20,1-Jun-20,,28-Aug-20,"CHU Grenoble Alpes, Grenoble, France",,https://ClinicalTrials.gov/show/NCT04409197
1029,NCT04347031,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,,Completed,No Results Available,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,Burnasyan Federal Medical Biophysical Center,All,18 Years to 60 Years Â  (Adult),Phase 2|Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL-01/20,20-Nov-20,8-Apr-20,226,1-Nov-20,15-Apr-20,,27-Jan-21,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04347031
1030,NCT04696679,Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic,GPE-QolVID,Completed,No Results Available,Very Preterm Children With Dysexecutive Disorders,Other: Patient Quality of life assessment|Other: Control group Quality of life assessment,Assessment of the quality of life using the questionnaire Kidscreen 10 Index|Assessment of the quality of life using The VSP-A questionnaire (Life and Perceived Health of the Adolescent and the Child)|Specific data concerning the period of confinement-deconfinement|Data on children behavioral disorders:|Data concerning the anxiety symptoms of the parent completing the survey questionnaire:,Assistance Publique Hopitaux De Marseille,All,7 Years to 9 Years Â  (Child),,170,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,2020-38|2020-A01631-38,31-Dec-20,19-Jun-20,195,30-Nov-20,6-Jan-21,,29-Jan-21,"Assistance Publique des Hopitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT04696679
1031,NCT04441476,Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis,PsyCOVID,Completed,No Results Available,Psychological Strain,Other: Questionnaires|Other: psychological and sociological interviews,PS-ICU Scale Score,Centre Hospitalier Universitaire Dijon,All,"18 Years and older Â  (Adult, Older Adult)",,3080,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,QUENOT SERI 2020,21-Dec-20,21-Apr-20,244,21-Dec-20,22-Jun-20,,30-Mar-21,"Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT04441476
1032,NCT04874363,The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,,Completed,No Results Available,Covid19|Smoking,Other: no intervention,Mortality,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,2810,30-May-20,15-Mar-20,76,15-May-20,5-May-21,,5-May-21,"Sisli Hamidiye Etfal Research and Training Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04874363
1033,NCT04799704,Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.,Eye-Covid,Completed,No Results Available,Covid19|Eye Diseases,Diagnostic Test: swabbing of conjunctiva,The presence of SARS-nCoV-2 in the tear film of symptomatic and pauci-symptomatic SARS-nCoV-2 positive patients.|Correlations between SARS-nCoV-2 in the tear film,Universitaire Ziekenhuizen Leuven,All,"18 Years and older Â  (Adult, Older Adult)",,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,S64002,13-Dec-20,11-Sep-20,93,13-Dec-20,16-Mar-21,,16-Mar-21,"UZ Leuven, Leuven, Vlaams Brabant, Belgium",,https://ClinicalTrials.gov/show/NCT04799704
1034,NCT04343729,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,MetCOVID,Completed,No Results Available,SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia,Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution,"Mortality rate at day 28|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index",FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,416,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAEE: 30615920.2.0000.0005,20-Oct-20,18-Apr-20,185,16-Jun-20,13-Apr-20,,9-Mar-21,"Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,https://ClinicalTrials.gov/show/NCT04343729
1035,NCT04393077,Emotional Freedom Technique (EFT) Effect on Nurses,,Completed,No Results Available,"Stress|Anxiety|Burnout, Caregiver",Behavioral: Emotional Freedom Technique,The subjective units of distress scale|The State Anxiety|Burnout,Istanbul Saglik Bilimleri University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,2020\0192,20-May-20,10-May-20,10,15-May-20,19-May-20,,24-Nov-20,"Medeniyet University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04393077
1036,NCT04308668,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,COVID-19 PEP,Completed,Has Results,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections,Drug: Hydroxychloroquine|Other: Placebo,Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline|Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline|Rate of Hospitalization|Rate of Death|Rate of Confirmed SARS-CoV-2 Detection|Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)|Rate of All-Cause Study Medicine Discontinuation or Withdrawal|Overall Symptom Severity at 5 and 14 Days|Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry,University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,1312,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MED-2020-28673,20-May-20,17-Mar-20,64,20-May-20,16-Mar-20,13-May-21,13-May-21,"Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, MontrÃ©al, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04308668
1037,NCT04757207,Pandemia And Exercise in Turkey in University Students of Turkey,,Completed,No Results Available,Sedentary Behavior|Covid19,Other: survey,International Physical Activity Score (short form) MEt-min/week|Energy expenditure while stepping|Energy expenditure while exercising,GULIN FINDIKOGLU|Pamukkale University,All,"17 Years to 40 Years Â  (Child, Adult)",,5474,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,60116787-020/76132,3-May-21,22-Feb-21,70,3-May-21,17-Feb-21,,5-May-21,"Pamukkale University, Denizli, Turkey",,https://ClinicalTrials.gov/show/NCT04757207
1038,NCT04486144,Impact Nerium Oleander on Immune Function,,Completed,No Results Available,Covid19 Positive Patient|Covid19 Close Contact|Immune Function,Other: Proprietary extract of Nerium oleander,COVID19 symptoms|Mortality|COVID19 Live Virus|RT-PCR COVID19 Test,HealthQuilt,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,52020,23-Jul-20,20-May-20,64,23-Jul-20,24-Jul-20,,22-Apr-21,"KDunn and Associates, PA, dba Healthquilt, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04486144
1039,NCT04492189,Containment Measures and Eating Disorders,COVITA,Completed,No Results Available,Eating Disorders|COVID 19,,Variation in eating disorders|Vision of the bodily aspect|Variation in physical activity|Identify the clinical factors modulating the psychological state during confinement,"University Hospital, Montpellier|INSERM U1061 (Statistics)",All,"18 Years and older Â  (Adult, Older Adult)",,40,Other,Observational,Observational Model: Other|Time Perspective: Prospective,RECHMPL20_0220,30-Jun-20,1-Apr-20,90,30-May-20,30-Jul-20,,30-Jul-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04492189
1040,NCT04788355,Prevention of Complications (SARS-CoV-2): Clinical Study,,Completed,No Results Available,Complication,Drug: Control group (standard hospital treatment)|Drug: Group Hydroxychloroquine|Drug: Group Hydroxychloroquine and apixaban|Drug: Group Apixaban,"Patients in home isolation will be followed for (telemedicine) 14 days. The Beck scale will assess anxiety. Questions will be asked to patients about their health conditions. The answers will be tabulated in a spreadsheet composed of the following result|Assessment of the presence or absence of secondary complications for patients in home isolation or hospitalized, after using the drugs.",Universidade do Vale do Sapucai|Pfizer|Apsen Farmaceutica S.A.|Dermadia|Methodos Laboratory|Biofarma,All,"18 Years and older Â  (Adult, Older Adult)",Phase 3,176,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",HA and A COVID 19,23-Dec-20,1-Jul-20,175,15-Nov-20,9-Mar-21,,9-Mar-21,"UnivÃ¡s, Pouso Alegre, Minas Gerais, Brazil",,https://ClinicalTrials.gov/show/NCT04788355
1041,NCT04427969,Early Prone Position on Coronavirus Disease 2019 Pneumonia,Prone Position,Completed,No Results Available,Coronavirus Infection|Acute Respiratory Failure,Behavioral: prone position,intensive care unit stay|short term mortality|blood gases,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,33,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,pp34,30-Jun-20,15-Jun-20,15,25-Jun-20,11-Jun-20,,10-Nov-20,"Sisli Etfal Research and Training Hospital, Istanbul, Marmara, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04427969/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04427969/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04427969
1042,NCT04341584,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,CORIMUNO-ANA,Completed,No Results Available,Corona Virus Infection,Drug: Anakinra,"Survival without needs of ventilator utilization at day 14|WHO progression scale â‰¤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge",Assistance Publique - HÃ´pitaux de Paris,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,161,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-5,25-Jul-20,8-Apr-20,108,10-May-20,10-Apr-20,,1-Feb-21,"HÃ´pital BicÃªtre, Assistance Publique-HÃ´pitaux de Paris, Le Kremlin-BicÃªtre, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT04341584/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04341584
1043,NCT04799132,Association Between Body Mass Index and HFNC Therapy Success,,Completed,No Results Available,"Covid19|Obesity|Overweight|Pneumonia, Viral",,Primary outcome|Demographic and laboratory characteristics|Body mass index as a predictor|Body mass index and HFNC success|Mortality|Hospital stay.,ClÃ­nica del country,All,"18 Years and older Â  (Adult, Older Adult)",,303,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,BMI AND HFNC,1-Mar-21,11-Mar-20,355,1-Mar-21,16-Mar-21,,16-Mar-21,"ClÃ­nica del Country., BogotÃ¡, Colombia",,https://ClinicalTrials.gov/show/NCT04799132
1044,NCT04430023,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,,Completed,No Results Available,Corona Virus Infection|Pneumonia|Acute Respiratory Failure,Other: epidemiological and demographic characteristics,mortality|demographic characteristics,Sisli Hamidiye Etfal Training and Research Hospital,All,"18 Years and older Â  (Adult, Older Adult)",,150,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,DM3334,5-Jun-20,15-May-20,21,3-Jun-20,12-Jun-20,,16-Jun-20,"Sisli Etfal Research and Training Hospital, Istanbul, Marmara, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04430023/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04430023/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04430023
1045,NCT04517097,Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic,canSEROcov,Completed,No Results Available,Cancer,Biological: blood sample,seroprevalence of SARS-CoV-2,Centre Georges Francois Leclerc,All,"18 Years and older Â  (Adult, Older Adult)",,1680,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A00877-32,30-Jun-20,12-May-20,49,30-Jun-20,18-Aug-20,,18-Aug-20,"Centre Georges-FranÃ§ois LECLERC, Dijon, France",,https://ClinicalTrials.gov/show/NCT04517097
1046,NCT04467112,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,,Completed,No Results Available,COVID,Device: Breath Biopsy face masks with removable filters and fitted PVA strip,Detection of nCOVID-19 using a face mask|Independent Patient use of face mask,Owlstone Ltd|Cambridge University Hospitals NHS Foundation Trust,All,"16 Years and older Â  (Child, Adult, Older Adult)",,8,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COVID-Breath,19-Dec-20,30-Jul-20,142,19-Dec-20,10-Jul-20,,30-Mar-21,"Cambridge University Hospital NHS, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT04467112
1047,NCT04737486,A First-in-Human Study of AV-001 in Healthy Subjects,,Completed,No Results Available,Covid19-associated ARDS|Covid19|ARDS,Drug: AV-001|Other: Placebo,"Participants experiencing drug-related adverse events|Cmax: Maximum plasma AV-001 concentration|Tmax: Time of maximum plasma AV-001 concentration|AUClast: AUC from predose (time 0) to the time of the last quantifiable concentration|AUCinf: AUC from predose (time 0) extrapolated to infinite time|AUCtau: AUC over the dose interval time|Î»z: The terminal elimination rate|TÂ½: Terminal elimination half-life|CL: Total body clearance|Vz: Apparent volume of distribution|Ctau: Trough plasma concentration|Rac(AUCtau), Rac(Cmax), Rac(Ctau): Accumulation ratios assessment|LM: Time-invariance ratio calculation","Vasomune Therapeutics, Inc.",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AV001-PK-001,10-Mar-21,16-Dec-20,84,10-Mar-21,3-Feb-21,,24-Mar-21,"Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04737486
1048,NCT04403061,Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome,Resistir,Completed,No Results Available,"Disease, Viral|Cytokine Release Syndrome|TLRs",Diagnostic Test: Cytokines measurement|Diagnostic Test: Cellular response|Diagnostic Test: TLRs activation measurement|Diagnostic Test: KIR phenotype evaluation,Changes in cytokines associated with SARS CoV-2 infection|Evaluation of cellular response|TLRs activation|KIR phenotype determination,Asociacion para el Estudio de las Enfermedades Infecciosas|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,All,"18 Years to 100 Years Â  (Adult, Older Adult)",,106,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EC128/20,10-Jan-21,22-May-20,233,22-Dec-20,27-May-20,,12-Jan-21,"Hospital Ramon y Cajal, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04403061
1049,NCT04338841,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV,Completed,No Results Available,Coronavirus Infection,Other: HOME-CoV rule implementation,the composite rate of adverse outcomes|The rate of hospitalization,"University Hospital, Angers",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,3133,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-A00831-38,17-Jun-20,9-Apr-20,69,17-Jun-20,8-Apr-20,,23-Sep-20,"Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de LiÃ¨ge, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|HÃ´pital Bichat, Paris, France|HÃ´pital LariboisiÃ¨re, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco",,https://ClinicalTrials.gov/show/NCT04338841
1050,NCT04323527,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,CloroCOVID19,Completed,No Results Available,SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia,Drug: Chloroquine diphosphate,Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable),FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus VinÃ­cius GuimarÃ£es de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes MourÃ£o|Ludmila AbrahÃ£o Hajjar|Jorge Souza MendonÃ§a,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,278,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAAE: 30152620.1.0000.0005,7-Jun-20,23-Mar-20,76,7-May-20,26-Mar-20,,7-Jul-20,"Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,https://ClinicalTrials.gov/show/NCT04323527
1051,NCT04349163,Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.,Resi-CoV,Completed,No Results Available,Psychological,Other: Questionnaire,compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.,"University Hospital, Angers",All,"Child, Adult, Older Adult",,280,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A00831-39,25-Jun-20,10-May-20,46,15-Jun-20,16-Apr-20,,23-Sep-20,"CHU, Angers, France",,https://ClinicalTrials.gov/show/NCT04349163
1052,NCT04276987,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,,Completed,No Results Available,Coronavirus,Biological: MSCs-derived exosomes,Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality,"Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Phase 1,24,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEXCOVID,31-Jul-20,15-Feb-20,167,31-May-20,19-Feb-20,,7-Sep-20,"Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04276987
1053,NCT04822285,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Triaging,Completed,No Results Available,Psychological Distress|Resilience,Behavioral: Psychological Triaging Intervention|Behavioral: Routine psychological support,severity of psychological distress,Alexandria University,All,"Child, Adult, Older Adult",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,1522112020,21-Mar-21,22-Jan-20,424,22-Apr-20,30-Mar-21,,30-Mar-21,"Faculty of Nursing, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT04822285
1054,NCT04556149,"imPulseâ„¢ Una Full-spectrum, Over Clothing E-stethoscope",,Completed,No Results Available,Corona Virus Infection|Coronavirus,Device: imPulseâ„¢ Una e-stethoscope|Device: Philips Lumify Ultrasound System,Diagnostic performance characteristics,"Level 42 AI, Inc.|Schmidt Futures|Johns Hopkins University",All,"18 Years to 90 Years Â  (Adult, Older Adult)",,34,Industry|Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,110011,2-Dec-20,1-Oct-20,62,2-Dec-20,21-Sep-20,,21-Dec-20,"Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04556149
1055,NCT04322682,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),COVID-19,Completed,No Results Available,Corona Virus Infection,Drug: Colchicine|Drug: Placebo oral tablet,Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation,"Montreal Heart Institute|National Heart, Lung, and Blood Institute (NHLBI)|Bill and Melinda Gates Foundation|The Government of Quebec|DACIMA Software",All,"40 Years and older Â  (Adult, Older Adult)",Phase 3,4506,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MHIPS-2020-001|3R01HL146206-02S1,21-Jan-21,23-Mar-20,304,21-Jan-21,26-Mar-20,,25-Jan-21,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|University of Arkansas for medical Sciences, Little Rock, Arkansas, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Prisma Health, Greenville, South Carolina, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, SÃ£o Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04322682
1056,NCT04854941,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,,Completed,No Results Available,Coronavirus Infection,Other: Probiotics,Mortality|Duration of hospitalization|Total duration of the disease|Incidence of admission to intensive care unit|Need for non-invasive ventilation|Days of non-invasive ventilation|Need for invasive ventilation|Changes in the values of C-reactive protein level in serum|Changes in the counts of white blood cells in blood test|Changes in the counts of neutrophils in blood test|Changes in the counts of lymphocytes|Changes in the counts of platelets|Changes in the values of erythrocyte sedimentation rate in in blood test|Changes in the values of creatinine level in serum|Changes in the values of alanine aminotransferase (ALT) level in serum|Changes in the values of aspartate aminotransferase level in serum|Changes in the values of albumen level in serum|Changes in the values of total bilirubin level in serum|Changes in the values of lactate dehydrogenase level in serum|Changes in the values of ferritin level in serum|Changes in the values of fibrinogen level in serum|Changes in the values of potassium level in serum|Incidence of diarrhoea|The duration of diarrhoea|The maximum volume of the affected lungs,I.M. Sechenov First Moscow State Medical University,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PROCOV-19-2020,10-Apr-21,10-Dec-20,121,10-Mar-21,22-Apr-21,,22-Apr-21,"I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04854941
1057,NCT04282135,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,,Completed,No Results Available,Influenza,Diagnostic Test: MCC IMS,Cluster Analysis of MCC IMS spectra.,Klinikum Bayreuth GmbH,All,"18 Years and older Â  (Adult, Older Adult)",,76,Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,IMS 1,30-Jun-20,15-Feb-20,136,8-May-20,24-Feb-20,,14-Jul-20,"Klinikum Bayreuth, Bayreuth, Germany",,https://ClinicalTrials.gov/show/NCT04282135
1058,NCT04363788,Needle Stick Injuries in Emergency Medical Service Practice,,Completed,No Results Available,Cardiac Arrest|Needle Stick|Injuries|Glowe,Procedure: double gloves,Number of visible puncture|WLT,Lazarski University|Medical University of Bialystok|Poznan University of Medical Sciences,,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,OH_PPE_1,24-Apr-20,28-Feb-20,56,24-Apr-20,27-Apr-20,,28-Apr-20,"Lazarski Univeristy, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT04363788
1059,NCT04664296,COVID-19 - SARS-CoV-2 Community Contamination in Children and Adults (Dyn3CEA_Nosocor),,Completed,No Results Available,Infection Viral,Other: Review of medical patient file|Other: Phone call interview,"Percentage of possible contaminants, adults, adolescents and children with Covid-19",Hospices Civils de Lyon,All,"Child, Adult, Older Adult",,72,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,69HCL20_1100,23-Mar-21,21-Dec-20,92,23-Mar-21,11-Dec-20,,26-Apr-21,"Service de Reanimation Pediatrique, Lyon, Rhone, France",,https://ClinicalTrials.gov/show/NCT04664296
1060,NCT04252885,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,ELACOI,Completed,No Results Available,Coronavirus Infections,Drug: Lopinavir and Ritonavir Tablets|Drug: Arbidol,The rate of virus inhibition|The disease prorogation-temperature|The disease prorogation-respiratory function 1|The disease prorogation-respiratory function 2|The disease prorogation-respiratory function 3,Guangzhou 8th People's Hospital,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Phase 4,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GZ8H-V1.0 20200122,31-May-20,28-Jan-20,124,30-Apr-20,5-Feb-20,,1-Jul-20,"Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04252885
1061,NCT04392219,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",,Completed,No Results Available,Coronavirus,Drug: EIDD-2801|Drug: Placebo,Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events|Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events|Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Single Ascending Dose (SAD) (Part 1): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Multiple Ascending Dose (MAD) (Part 3): Maximum observed concentration Cmax|Safety and Tolerability of Single Doses of EIDD-2801 (Part 2): Adverse Events,"Ridgeback Biotherapeutics, LP",All,18 Years to 60 Years Â  (Adult),Phase 1,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EIDD-2801-1001|2020-001407-17,11-Aug-20,10-Apr-20,123,11-Aug-20,18-May-20,,17-Aug-20,"Covance Leeds Clinical Research Unit, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT04392219
1062,NCT04666233,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,,Completed,No Results Available,Neonates Needing Resuscitation at Birth,Procedure: Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|Procedure: Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection,Initiation of positive pressure ventilation|Duration of intubation procedure|Correct use of personal protective equipment|Participant's opinion on discomfort using personal protective equipment|Time of initiation of chest compressions,University Hospital Padova,All,"Child, Adult, Older Adult",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SARS-CoV-2-NEO-Res-01,23-Mar-21,16-Mar-21,7,23-Mar-21,14-Dec-20,,1-Apr-21,"Central Teaching Hospital of Bolzano/Bozen, Bolzano, Italy|Daniele Trevisanuto, Padova, Italy",,https://ClinicalTrials.gov/show/NCT04666233
1063,NCT04649996,Variation in Acute Appendicitis During COVID-19 Pandemic in Italy,,Completed,No Results Available,Acute Appendicitis,Procedure: Appendectomy,complicated appendicitis,University of Milano Bicocca,All,"Child, Adult, Older Adult",,532,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Appendicitis-pandemic,30-Nov-20,1-Sep-20,90,31-Oct-20,2-Dec-20,,4-Dec-20,"Policlinico San Pietro, Ponte San Pietro, BG, Italy|Ospedale Manzoni, Lecco, LC, Italy|ASST Monza, Monza, MB, Italy|Ospedale San Raffaele, Milano, Mi, Italy|ASST Lodi, Lodi, Italy|Azienda ospedaliero-universitaria Pisana,Ospedale Cisanello, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT04649996
1064,NCT04441632,Effect of Positive Attitudes on Behavior and Wellness,TEAM-ICU,Completed,No Results Available,"Burnout|Stress, Emotional",Behavioral: Positive feedback,"Teamwork climate, as measured by selected items from the validated Safety Attitude Questionnaire (SAQ)|Resiliency, as measured by the validated Brief Resilience Scale (BRS)|Burnout, as validated by the single-item burnout scale inventory",Cedars-Sinai Medical Center,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000786,30-Jul-20,15-Jun-20,45,26-Jul-20,22-Jun-20,,12-Aug-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04441632
1065,NCT04445441,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,CHLORAZ,Completed,No Results Available,Coronavirus Infection,,Clearance of viral load|Safety of the treatment,Centre Muraz,All,"18 Years to 99 Years Â  (Adult, Older Adult)",,153,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRSS-URCN-CM 001,30-Nov-20,24-Apr-20,220,3-Sep-20,24-Jun-20,,22-Jan-21,"Sourou Sanon University Hospital, Bobo-Dioulasso, Burkina Faso|Tingadogo University Hospital, Ouagadougou, Burkina Faso",,https://ClinicalTrials.gov/show/NCT04445441
1066,NCT04382560,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,,Completed,No Results Available,"Behavior, Social|Autonomic Imbalance",Other: Deep Breathing training|Other: Compassion focused intervention,Dispositional questionnaire 1|Dispositional questionnaire 2|Dispositional questionnaire 3|Dispositional questionnaire 4|Heart rate|Cardiac vagal modulation,University of Parma|University of Roma La Sapienza|King's College London,All,20 Years to 50 Years Â  (Adult),Not Applicable,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",ESPCOV1,31-May-20,2-May-20,29,31-May-20,11-May-20,,1-Apr-21,"Sapienza University of Rome, Rome, Italy",,https://ClinicalTrials.gov/show/NCT04382560
1067,NCT04408196,QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine,,Completed,No Results Available,Rehabilitation,,Short Form-36 Health Survey (SF36)|Short Form (36) Health Survey (SF36)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory-II (BDI-II)|modified Barthel Index (mBI),Fondazione Don Carlo Gnocchi Onlus,All,"18 Years and older Â  (Adult, Older Adult)",,121,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,FDG_socialdistancing_COVID-19,22-Feb-21,26-May-20,272,15-Feb-21,29-May-20,,26-Feb-21,"Don Gnocchi Foundation, Rome, Italy",,https://ClinicalTrials.gov/show/NCT04408196
1068,NCT04634903,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",,Completed,Has Results,Depression,Behavioral: Supportive Therapy SSI|Behavioral: Behavioral Activation SSI|Behavioral: Growth Mindset SSI,Change in Adolescent Depressive Symptom Severity|Change in State Hope Scale - Pathways Subscale|Change in Beck Hopelessness Scale - 4 Item Version|Program Feedback Scale,Stony Brook University|University of Denver,All,13 Years to 16 Years Â  (Child),Not Applicable,2452,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1505797-3,15-Mar-21,19-Nov-20,116,15-Mar-21,18-Nov-20,25-May-21,25-May-21,"Stony Brook University, Stony Brook, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04634903/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04634903
1069,NCT04420273,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,TMD,Completed,No Results Available,Melanoma,Behavioral: SSE educational intervention|Other: Home sample collection of concerning mole with physician supervision|Behavioral: Active control:Healthy Living,Change in SSE performance|Identification of concerning mole|Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma|Change in skin self-examination anxiety|Change in confidence performing mole checks|Number of physician visits for concerning moles|Number of biopsies of concerning moles,Northwestern University,Female,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",STU00212165,1-Mar-21,2-Jul-20,242,1-Mar-21,9-Jun-20,,3-Mar-21,"Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04420273
1070,NCT04370678,Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures,,Completed,No Results Available,Arthroscopy,Behavioral: Change in preference to surgery under COVID-19 pandemic.,Change in preference|Change in preference between groups,Region Zealand,All,"18 Years and older Â  (Adult, Older Adult)",,79,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ArthrocancellationSUH2020,24-Apr-20,17-Apr-20,7,24-Apr-20,1-May-20,,7-May-20,"Zealand University Hospital, KÃ¸ge, Zealand Region, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04370678/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04370678
1071,NCT04160975,Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects,,Completed,No Results Available,"Flu, Human|Influenza, Human|Covid19",Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination|Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy,Posterior beliefs about the risk/benefits of the flu shot|Demand for information about a COVID-19 vaccine|Willingness-to-pay (WTP) for a free flu shot coupon|Level of attention and recall from the infomercial video during Baseline survey|Level of attention and recall from the infomercial video during Endline survey|Redemption of said coupon,Harvard University|Stanford University|Massachusetts Institute of Technology,Male,18 Years to 51 Years Â  (Adult),Not Applicable,2902,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research",IRB19-1424,19-Feb-21,20-Dec-19,427,19-Feb-21,13-Nov-19,,24-Feb-21,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04160975
1072,NCT04378803,Mindfulness Training for Seniors,,Completed,No Results Available,Well Aging,Behavioral: Mindfulness training (MT) Connect,Change in mindfulness skills as measured by Five-Facet Mindfulness Questionnaire (5FMQ)|Change in mindfulness skills as measured by decentering - Experiences Questionnaire (EQ).|Change in psychological health as measured by Patient Health Questionnaire 4 items (PHQ4).|Change in positive affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in negative affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in loneliness measured by the loneliness questions from the social isolation battery.|Change in loneliness measured by a loneliness question.|Change in attention|Change in well-being as measured by the Perseverative Thought Questionnaire (PTQ)|Change in well-being as measured by the Experience of Intrusions Scale (EIS)|Change in well-being as measured by the short version of the perceived stress scale (PSS).|Change in well-being as measured by the PERMA-Profiler,University of Miami,All,"60 Years to 95 Years Â  (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20200443,4-Aug-20,13-May-20,83,4-Aug-20,7-May-20,,17-Aug-20,"University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT04378803
1073,NCT04727762,Use of the Mask and Current Pandemic,Mask,Completed,No Results Available,Face Mask Squeeze,,Generic health|Global well-be-ing|Headache Impact|Oral health|Dyspnea disability|Quantification of dyspnea|Level of Physical activity|Insomnia Symptom,University of Valencia,All,"18 Years and older Â  (Adult, Older Adult)",,629,Other,Observational,Observational Model: Cohort|Time Perspective: Other,ID0031,30-Mar-21,4-Feb-21,54,1-Mar-21,27-Jan-21,,1-Apr-21,"Gemma Victoria EspÃ­-LÃ³pez, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04727762
1074,NCT04549350,Sleep Quality Among HCWs,,Completed,No Results Available,Sleep Quality,Other: PSQI,Presence of poor sleep quality or not|reported medical errors,"Zagazig University|Ministry of Health, Kuwait",All,25 Years to 60 Years Â  (Adult),,217,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,2020/1464,5-Sep-20,19-May-20,109,18-Aug-20,16-Sep-20,,21-Sep-20,"Zagazig University, Zagazig, Egypt",,https://ClinicalTrials.gov/show/NCT04549350
1075,NCT04618341,A Clinical Study of Online Active Play Program With Adolescents,,Completed,No Results Available,Anxiety|Depression,,Anxiety|Depression,Revival Active|L.E.A.D|Aarogyam UK,All,11 Years to 17 Years Â  (Child),,32,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,RAP/003,28-Jul-20,30-Mar-20,120,30-Jun-20,5-Nov-20,,5-Nov-20,"Revival Active, Leicester, Leicestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04618341
1077,NCT04557605,Effects of a Face Mask on Oxygenation During Exercise,,Completed,No Results Available,Hypoxemia,Other: Progressive cycling exercise test to exhaustion,Time to exhaustion during exercise|Change from baseline in peak power output|Change from baseline in blood oxygen saturation|Change from baseline in quadriceps tissue oxygenation index|Change from baseline in rating of perceived exertion|Change from baseline in heart rate,University of Saskatchewan,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2201,15-Oct-20,14-Sep-20,31,15-Oct-20,21-Sep-20,,20-Oct-20,"University of Saskatchewan, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT04557605
1078,NCT04688840,Smartphone Application: A Possible Solution for Follow up of Patients With Hip Arthroplasty,,Completed,No Results Available,Telemedicine,Procedure: hip arthropalsty,Western Ontario McMaster Universities Osteoarthritis Index (WOMAC)|Short Form Health Survey Clinical care (SF12)|Self-Administered Patient Satisfaction Scale (SAPS),Tanta University,All,"Child, Adult, Older Adult",,167,Other,Observational,Observational Model: Other|Time Perspective: Prospective,TantaH,1-Dec-20,1-Jan-20,335,1-Sep-20,30-Dec-20,,30-Dec-20,"Ahmed Samy, Tanta, Egypt",,https://ClinicalTrials.gov/show/NCT04688840
1079,NCT04335851,Video-Based Exercises and Well-Being During Social Isolation,,Completed,No Results Available,Social Isolation|Physical Inactivity|Well-Being,Other: Video based aerobic exercise,World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale,Biruni University|Istanbul University-Cerrahpasa,All,18 Years to 35 Years Â  (Adult),Not Applicable,68,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Physical Activity Project,3-Jun-20,6-Apr-20,58,15-May-20,6-Apr-20,,9-Jun-20,"Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04335851
1080,NCT04399005,The Efficacy Comparing Daily and After-each-case Room Disinfection.,,Completed,No Results Available,Daily Room Disinfection|After-each-case Room Disinfection,Other: after-each-case room disinfection|Other: daily room disinfection,Qualified rate of room disinfection|The number of colony-forming units (CFU),The First Affiliated Hospital of Zhejiang Chinese Medical University,All,"Child, Adult, Older Adult",Not Applicable,240,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,DACD-HuY-2005,10-Jun-20,25-May-20,16,5-Jun-20,22-May-20,,25-Jun-20,"First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04399005/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04399005
1081,NCT04442958,Effectiveness of Convalescent Immune Plasma Therapy,,Completed,No Results Available,Acute Respiratory Distress Syndrome,Other: Convalescent Immune Plasma,Plasma ferritin level|Lymphocyte count|D-Dimer level|C-Reactive protein level|Plasma procalcitonin level|Plasma fibrinogen level|Fractional Inspired Oxygen Level|Partial Oxygen Saturation level|Arterial Oxygen level,Bagcilar Training and Research Hospital,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2020.05.2.14.070,17-Jun-20,15-May-20,33,15-Jun-20,23-Jun-20,,1-Jul-20,"Istanbul BagcÄ±lar Training and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04442958
1083,NCT04346927,Telerehabilitation for Patients Diagnosed With Coronavirus,COVID-19,Completed,No Results Available,Telerehabilitation|Coronavirus,Other: Telerehabilitation|Other: exercise brochure,Visual Analogue Scale|Modified Borg Scale|Leicester Cough Questionnaire|Timed Up and Go|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory,Yasemin Ã‡Ä±rak|Istinye University,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,9,30-Nov-20,10-Aug-20,112,10-Oct-20,15-Apr-20,,26-Mar-21,"Istinye University, Ä°stanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04346927
1084,NCT04409496,Chat-based Support for Preventing Smoking Relapse,,Completed,No Results Available,Smoking Cessation,Behavioral: Chat-based instant messaging support|Behavioral: SMS message support|Behavioral: Self-help booklet,Biochemically-validated tobacco abstinence|Self-reported 6-month prolonged tobacco abstinence|Self-reported 7-day point-prevalence tobacco abstinence|Self-reported relapse rate,The University of Hong Kong,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,108,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UW 20-356,22-Jan-21,2-Jun-20,234,22-Jan-21,1-Jun-20,,4-Mar-21,"Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04409496
1085,NCT04687488,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,,Completed,No Results Available,Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations,Other: Fluorescein|Other: Particle measurement,"Number of droplets spread on the investigator and their location on gown or goggles, by the end of the procedure of naso-gastric intubation for gastrointestinal motility investigations.|Generation of aerosol particles by insertion and by removal of the naso-gastric motility or pH monitoring probe.",Universitaire Ziekenhuizen Leuven,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,S64237,9-Nov-20,23-Jul-20,109,9-Nov-20,29-Dec-20,,29-Dec-20,"TARGID, Leuven, Vlaams-Brabant, Belgium",,https://ClinicalTrials.gov/show/NCT04687488
1086,NCT04769999,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,CALM-ED,Completed,No Results Available,Post Traumatic Stress Disorder,Behavioral: Simple cognitive task,"Change in the number of intrusive memories of traumatic event|Changes in ratings of intrusive memory characteristics|Impact of Events Scale-Revised score (IES-R; Weiss & Marmar, 1997)|The Patient Health Questionnaire Depression scale (PHQ-9; Kroenke, Spitzer, & Williams, 2001)|The Generalised Anxiety Disorder scale (GAD-7; Spitzer, Kroenke, Williams & LÃ¶we, 2006)|The Pittsburgh Sleep Quality Index (PSQI; Buysse, 1989)|Change in retrospective ratings of intrusive memory characteristics over the last week",University of Oxford|Oxford University Hospitals NHS Trust|Royal Berkshire NHS Foundation Trust|South Central Ambulance Service NHS Foundation Trust,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R64738/RE001,30-Oct-20,4-Jun-20,148,16-Oct-20,25-Feb-21,,25-Feb-21,"South Central Ambulance Service NHS Foundation Trust, Bicester, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Royal Berkshire NHS Foundation Trust, Reading, United Kingdom",,https://ClinicalTrials.gov/show/NCT04769999
1087,NCT04555954,Determining the Physical Activity Level of Healthy Adults During Pandemic,,Completed,No Results Available,"Health, Subjective|Healthy",Other: surveys and questionnaires,physical activity level,Pamukkale University,All,"Child, Adult, Older Adult",,205,Other,Observational,Observational Model: Other|Time Perspective: Prospective,2020/8/318,20-Aug-20,11-Apr-20,131,31-Jul-20,21-Sep-20,,21-Sep-20,"Afyonkarahisar Health Science University, Afyonkarahisar, Turkey",,https://ClinicalTrials.gov/show/NCT04555954
1088,NCT04751474,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction",,Completed,No Results Available,Motivation|Optimism|Hopelessness|Life Satisfaction,Other: Motivational messages,Optimistic level assessed by the Life Orientation Test|Hopelessness level assessed by the Beck Hopelessness Scale|Life satisfaction assessed by the Satisfaction with Life Scale,Saglik Bilimleri Universitesi,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,93,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2021/47-31,31-Mar-21,1-Feb-21,58,1-Mar-21,12-Feb-21,,20-Apr-21,"Elif Gezginci, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04751474
1089,NCT04418947,Project Resurgence Communication Trial,,Completed,No Results Available,Communication Research,Other: Communication type,Percent with visit or procedure with provider|Percent with scheduled visit or procedure with provider|Percent with completed telemedicine visit with provider,University of Pennsylvania,All,"Child, Adult, Older Adult",Not Applicable,11120,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",843220,17-Jul-20,15-Jun-20,32,17-Jul-20,5-Jun-20,,31-Jul-20,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04418947
1090,NCT04789525,Physical Training and Diet for Childhood Obesity,,Completed,No Results Available,"Obesity, Childhood",Other: High-intensity aerobic training with high protein diet,Body mass index,Cairo University,Male,5 Years to 12 Years Â  (Child),Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Obesity,25-Dec-20,10-Mar-20,290,1-Oct-20,9-Mar-21,,11-Mar-21,"Marwa Eid, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04789525
1091,NCT04435028,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,,Completed,No Results Available,Breast Cancer|Iron Chelation,Drug: Ketotifen 1 MG,prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines,Horus University,Female,30 Years to 60 Years Â  (Adult),,111,Other,Observational,Observational Model: Other|Time Perspective: Prospective,1890-1-2019,13-Aug-19,14-Jan-19,211,13-Aug-19,17-Jun-20,,17-Jun-20,"Horus University, Damietta, Damiete Governonate, Egypt",,https://ClinicalTrials.gov/show/NCT04435028
1092,NCT04748536,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,,Completed,No Results Available,Healthy Volunteer,Drug: IRL201104|Drug: Placebo,Number of subjects with TEAEs and number of events will be summarised by treatment|Number of subjects with potentially clinically important (PCI) abnormal haematology variables will be summarised by treatment|Number of subjects with PCI abnormal clinical chemistry variables will be summarised by treatment|Number of subjects with PCI and/or abnormal electrocardiogram variables will be summarised by treatment|Number of subjects with PCI abnormal vital sign variables will be summarised by treatment|Pharmacokinetics of IRL201104: Trough blood concentration (Ctrough)|PK of IRL201104: Maximum (peak) blood concentration (Cmax)|PK of IRL201104: Terminal half life (t1/2)|PK of IRL201104: Area under the curve from time zero to last quantifiable concentration of IRL201104 (AUCt)|PK of IRL201104: Apparent total body clearance from blood (CLss)|PK of IRL201104: steady state volume of distribution (Vz),Revolo Biotherapeutics,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C1104-003,5-Apr-21,29-Jan-21,66,5-Apr-21,10-Feb-21,,26-Apr-21,"Hammersmith Medicines Research, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04748536
1094,NCT04457388,Tele-Yoga Therapy for Chronic Pain,,Completed,No Results Available,Chronic Pain,Other: Tele-Yoga Therapy,Pain Intensity|Pain Disability|Anxiety|Depression,Aarogyam UK,All,18 Years to 60 Years Â  (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AU/018,15-Jun-20,25-Mar-20,82,15-Jun-20,7-Jul-20,,8-Jul-20,"Aarogyam UK, Leicester, Leicestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04457388
1095,NCT04514900,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,iREACH,Completed,No Results Available,Obesity,Behavioral: Video Chat +Personalized Feedback|Behavioral: Video Chat + Basic Feedback|Behavioral: Discussion Board for Social Support +Basic Feedback|Behavioral: Discussion Board for Social Support+Personalized Feedback,Weight loss|Change in body weight from baseline calculated as % of body weight lost|Treatment Engagement: daily weighing|Treatment Engagement: weekly food journal submissions|Treatment Engagement: completion of the 16 weekly interactive online modules|Treatment Engagement: Attendance at Video Chat condition,University of South Carolina|University of Vermont|University of Tennessee,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,73,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00101006,8-Mar-21,23-Sep-20,166,8-Mar-21,17-Aug-20,,30-Apr-21,"University of South Carolina, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04514900
1096,NCT04656626,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,,Completed,No Results Available,"Stress, Psychological",Behavioral: brief mindfulness based intervention|Behavioral: Progressive muscle relaxation,reduction of anxiety symptom severity|change in the level of psychological resilience|mental wellbeing|and functional status,Imam Abdulrahman Bin Faisal University,All,"22 Years and older Â  (Adult, Older Adult)",Not Applicable,146,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",Mindfullness during a pandemic,5-Sep-20,7-Jul-20,60,21-Jul-20,7-Dec-20,,10-Dec-20,"Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04656626/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04656626/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04656626
1097,NCT04595695,The Effect of Clear Masks in Improving Patient Relationships,,Completed,No Results Available,Communication|Trust|Covid19|Surgery,Behavioral: Transparent mask|Behavioral: Typical surgical covered mask,Patient Mask Preference Quantitative|Patient Mask Preference Qualitative|Patient Survey Scores Evaluating Surgeon Communication Skills|Patient Survey Scores Describing Trust in the Surgeon,"University of North Carolina, Chapel Hill",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,20-2229,14-Dec-20,3-Sep-20,102,12-Nov-20,20-Oct-20,,14-Jan-21,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04595695
1098,NCT04629755,A Smartphone Intervention for Relational and Mental Well Being,,Completed,No Results Available,"Depression|Loneliness|Relation, Interpersonal|Covid19",Behavioral: Intervention,Change in depressed mood|Change in loneliness|Change in relationship quality,University of Washington,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,1765,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00009897,3-Aug-20,4-Apr-20,121,3-Aug-20,16-Nov-20,,19-Nov-20,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04629755
1099,NCT04424953,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,,Completed,No Results Available,Coronavirus Infection|Ventilatory Failure|Anesthesia Intubation Complication,Device: McGrath videolaryngoscope|Device: Direct laryngoscope,Time to intubation for McGrath videolaryngoscope versus direct laryngoscope|Incidence of success at first intubation attempt with McGrath videolaryngoscope versus direct laryngoscope|Incidence of the use of adjuncts at first attempt with McGrath videolaryngoscope versus direct laryngoscope|Incidence of the use of adjuncts at subsequent attempts with McGrath videolaryngoscope versus direct laryngoscope|Incidence of success and failure at intubation using initial laryngoscope|Intubation Difficulty Scale with McGrath videolaryngoscope versus direct laryngoscope|Incidence of oxygen desaturation to less than 88% and oro-dental injuries with McGrath videolaryngoscope versus direct laryngoscope.|Incidence of inability to intubate despite all efforts by the anesthetist with McGrath videolaryngoscope versus direct laryngoscope|Closest distance from the patient's mouth to the anaesthetist's mouth during intubation,Singapore General Hospital|Duke-NUS Graduate Medical School,All,"21 Years to 99 Years Â  (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2020/2329,25-Sep-20,1-Jun-20,116,25-Sep-20,11-Jun-20,,17-Mar-21,"Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04424953
1100,NCT03852537,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,,Completed,No Results Available,Pneumonia,Drug: Methylprednisolone|Other: Usual Care,Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection|Need for Vasopressors and Inotropes|Duration of Vasopressors and Inotropes|New onset and worsening cardiac arrhythmias|Re-hospitalization for a primary cardiovascular diagnosis|Myocardial Injury|Oxygen Use|Need for Non Invasive and Invasive Mechanical Ventilation|Duration of Non Invasive and Invasive Mechanical Ventilation|Discharge Disposition,Mayo Clinic,All,"18 Years and older Â  (Adult, Older Adult)",Phase 2,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,18-010925,15-Mar-21,2-Dec-19,469,17-Nov-20,25-Feb-19,,28-Apr-21,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03852537
1101,NCT04356144,Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections,,Completed,No Results Available,"Disseminated Intravascular Coagulation|Critical Illness|Sars-CoV2|Viral Infection|Coagulation Disorder, Blood|Covid19",Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM),ETP (AUC) without rhThrombomodulin (rhTM)|ETP (AUC) with rhThrombomodulin (rhTM)|ETP-ratio|ETP-Normalisation,Medical University of Vienna|Medical Scientific Fund of the Mayor of Vienna,All,"18 Years and older Â  (Adult, Older Adult)",,58,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TGA-TM-Critical-2019,1-Feb-21,15-Apr-20,292,1-Feb-21,22-Apr-20,,23-Mar-21,"Medical University Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04356144
1102,NCT04443075,Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress,AGMFMSS,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Device: faecal sample collector,Gut microbiome composition of exposed group|Gut microbiome composition of non-exposed group|The Impact of Event Scale-Revised (IES-R) of exposed group|The Impact of Event Scale-Revised (IES-R) of non-exposed group|The 15-item Patient Health Questionnaire (PHQ-15) of exposed group|The 15-item Patient Health Questionnaire-15 (PHQ-15) of non-exposed group|The 9-item Patient Health Questionnaire (PHQ-9) of exposed group|The 9-item Patient Health Questionnaire (PHQ-9) of non-exposed group|The 7-item Generalized Anxiety Disorder Scale (GAD-7) of exposed group|The 7-item Generalized Anxiety Disorder Scale (GAD-7) of non-exposed group|The Pittsburgh Sleep Quality Index (PSQI) of exposed group|The Pittsburgh Sleep Quality Index (PSQI) of non-exposed group|The Symptom Check List 90 (SCL-90) of exposed group|The Symptom Check List 90 (SCL-90) of non-exposed group,First Affiliated Hospital Xi'an Jiaotong University,All,18 Years to 50 Years Â  (Adult),,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,XJTU1AF2020LSK-022,24-Dec-20,24-Jun-20,183,4-Dec-20,23-Jun-20,,3-Mar-21,"First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China",,https://ClinicalTrials.gov/show/NCT04443075
1103,NCT04439825,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,,Completed,No Results Available,Mood,Drug: Botulinum Neurotoxin|Drug: Placebo,Self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the PI.|Happiness levels before treatment and after achieving an optimal cosmetic result as determined by the PI.|Measurement of the Glabellar Wrinkle Severity Scores before treatment. The onset of effect and maximum efficacy compared to previous BOTOX Cosmetic injections will also be assessed by questionnaires.,DeNova Research,All,"10 Years to 75 Years Â  (Child, Adult, Older Adult)",Phase 1,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BTX-PST-COVID,1-Dec-20,20-Jul-20,134,3-Sep-20,19-Jun-20,,15-Mar-21,"DeNova Research, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04439825
1104,NCT04468581,Characteristics of TraceTogether Users,,Completed,No Results Available,Coronavirus,Behavioral: Use of mobile application,Demographic information,Yale-NUS College,All,"21 Years and older Â  (Adult, Older Adult)",,505,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,510d,17-Jul-20,3-Apr-20,105,17-Jul-20,13-Jul-20,,19-Dec-20,"Yale NUS, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04468581
1105,NCT04473274,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",GOTCHA,Completed,No Results Available,Coronavirus Infection|Diabetes,Drug: Pioglitazone,Adverse events outcomes without attribution|Adverse events attributable|Clinical improvement|Levels of treatment|d-Dimer|C Reactive Protein|Ferritin|Lactate dehydrogenase|A1c,Samaritan Health Services,All,"18 Years and older Â  (Adult, Older Adult)",Phase 4,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-042,1-Dec-20,21-May-20,194,1-Nov-20,16-Jul-20,,4-Dec-20,"Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States",,https://ClinicalTrials.gov/show/NCT04473274
1106,NCT04346121,Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis,PSI-RECORd-GP,Completed,No Results Available,Patient Safety,"Other: GPs reports of potential patient safety incidents, non-COVID-19 related","Describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 PSI required|Describe patient safety incidents (types, severity, contributing and correcting factors) - 100 PSI required",Nantes University Hospital,All,"Child, Adult, Older Adult",,132,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC20_0182,29-Jun-20,28-Apr-20,62,29-Jun-20,15-Apr-20,,19-Oct-20,"University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT04346121
1107,NCT04703400,Analysis of the Impact on Surgical Residency Programs in Times of Pandemic in Argentina,,Completed,No Results Available,Surgical Education,Other: anonymous survey,Demographic variables|type of hospital|type and year of training program|attendance at your institution and surgical practices,"Clinica Universitaria Reina Fabiola, Universidad Catolica de Cordoba",All,20 Years to 30 Years Â  (Adult),,195,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,817040,3-Jan-21,15-Aug-20,141,1-Oct-20,11-Jan-21,,11-Jan-21,"RenÃ© M. Palacios Huatuco, CÃ³rdoba, Argentina",,https://ClinicalTrials.gov/show/NCT04703400
1108,NCT04329897,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,,Completed,No Results Available,Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus,Behavioral: Software Messaging,Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.,University of Iowa,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,201412701-1,1-Jun-20,5-Apr-20,57,15-May-20,1-Apr-20,,16-Jul-20,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT04329897
1109,NCT04657471,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,,Completed,No Results Available,Coronavirus Infection,Other: revised HOME-CoV score,The safety of the revised HOME-CoV score strategy for home treatment|The efficacy of the revised HOME-CoV score strategy for home treatment|The applicability of the revised HOME-CoV score strategy for home treatment|The reliability of the revised HOME-CoV score strategy for home treatment|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCIâ‰¥5.|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCIâ‰¥6|The predictive performances of the revised HOME-CoV score of evolution towards a fatal COVID-19|Subgroup analysis in patients with confirmed COVID-19 (positive SARS-CoV2 RT-PCR) of the predictive performances of the revised HOME-CoV score|The predictive performances of the revised HOME-CoV score as compared to those of other prognostic scores for COVID-19|Venous thrombo-embolism in COVID-19 patients (ancillary study),"University Hospital, Angers",All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,1300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-A03067-32,8-Mar-21,8-Dec-20,90,8-Mar-21,8-Dec-20,,15-Mar-21,"CHU Angers, Angers, France",,https://ClinicalTrials.gov/show/NCT04657471
1110,NCT04444986,Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions,,Completed,No Results Available,Bioequivalence,Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT,AUC0-tlast of favipiravir|Cmax of favipiravir|AUC0-inf of favipiravir|tmax of favipiravir,Kocak Farma|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Male,18 Years to 40 Years Â  (Adult),Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,NOV2020/01919,13-Jun-20,5-Jun-20,8,11-Jun-20,24-Jun-20,,30-Nov-20,"Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04444986/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04444986
1111,NCT04363775,Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions,,Completed,No Results Available,Tracheal Intubation|Infection|Projection,Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope,time to intubation|success of intubation|Number of optimalization maneuvers|Procedure Ease of use|the degree of visibility of the glottis|Cormack - Lehane grade,Lazarski University|Poznan University of Medical Sciences|Wroclaw Medical University|Medical University of Bialystok,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,INT_PPE_2020_1,25-Feb-20,20-Jan-20,36,23-Feb-20,27-Apr-20,,28-Apr-20,"Lazarski Univeristy, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT04363775
1112,NCT04387708,Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID),QUALICOVID,Completed,No Results Available,Anorexia Nervosa,,Content analysis concerning the reorganization of care for children or adolescent and thier parents,Centre PsychothÃ©rapique de Nancy,All,"Child, Adult, Older Adult",,18,Other,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,RIPH 2020-01,20-May-20,12-May-20,8,20-May-20,14-May-20,,21-May-21,"Centre PsychothÃ©rapique de Nancy, Laxou, France",,https://ClinicalTrials.gov/show/NCT04387708
1113,NCT04885777,Topical Lidocaine Anesthesia for Nasopharyngeal Sampling,,Completed,No Results Available,Nasopharyngeal Sampling|Local Anesthesia,Drug: Lidocaine|Other: Placebo,Changes in the severity of pain during the sampling procedure.|Changes in the severity of discomfort during the sampling procedure.|Changing the frequency of undesirable reactions|Judgment of the practitioner staff about the sampling procedure,Ataturk University,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,Ataturk University0000,30-Oct-20,1-Sep-20,59,30-Sep-20,13-May-21,,18-May-21,"Ataturk University, Erzurum, Turkey",,https://ClinicalTrials.gov/show/NCT04885777
1114,NCT04871386,#Stayhealthy - Monitoring and Maintenance of Mental Health Under Conditions of Social Isolation During the Corona Crisis,stayhealthy,Completed,No Results Available,Mental Health Wellness 1,Behavioral: Acceptance and commitment therapy (ACT) exercises|Behavioral: Positive psychology (PP) exercises,General stress level (change from baseline/day 1 to post-measurement/day 14)|General stress level (change from post-measurement/day 14 to follow-up/day 28)|Symptoms of depression (change from baseline/day 1 to post-measurement/day 14)|Symptoms of depression (change from post-measurement/day 14 to follow-up/day 28)|Anxiety (change from baseline/day 1 to post-measurement/day 14)|Anxiety (change from post-measurement/day 14 to follow-up/day 28)|Subjective vitality (change from baseline/day 1 to post-measurement/day 14)|Subjective vitality (change from post-measurement/day 14 to follow-up/day 28)|Overall well-being (change from baseline/day 1 to post-measurement/day 14)|Overall well-being (change from post-measurement/day 14 to follow-up/day 28)|Coping strategies|Daily questionnaire,University Hospital Tuebingen,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Not Applicable,138,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,228/2020BO2,18-May-20,15-Apr-20,33,18-May-20,4-May-21,,4-May-21,"Department of Psychiatry and Psychotherapy, University Hospital Tuebingen, Tuebingen, Baden-WÃ¼rttemberg, Germany",,https://ClinicalTrials.gov/show/NCT04871386
1115,NCT04806477,Diagnostic Accuracy Comparison Between Telemedicine and Face-to-face Consultations in Respiratory Infection Patients.,,Completed,No Results Available,Respiratory Tract Infections,Other: Telemedicine Consultation|Other: Face-to-face Consultation,Final evaluation ICD 10-code diagnosis.|Time of medical care|Rate of indication for complementary exams|Type of requested exams|Medical prescription|Proposed destination after completion of the service,Hospital Israelita Albert Einstein,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,98,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,3.42E+16,1-Nov-20,1-Sep-20,61,1-Nov-20,19-Mar-21,,19-Mar-21,"Hospital Israelita Abert Einstein, SÃ£o Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT04806477
1116,NCT04406194,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Favipiravir,Completed,Has Results,Bioequivalence,Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets,AUC0-tlast of Favipiravir|Cmax of Favipiravir|AUC0-inf of Favipiravir|Tmax of Favipiravir,Atabay Kimya Sanayi Ticaret A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Male,20 Years to 40 Years Â  (Adult),Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,NOV2020/1917,19-Jun-20,14-May-20,36,22-May-20,28-May-20,12-Aug-20,14-Aug-20,"Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04406194
1117,NCT04400682,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Favipiravir,Completed,Has Results,Bioequivalence,Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,AUC0-tlast|Favipiravir Cmax|AUC0-inf of Favipiravir|Tmax of Favipiravir,Novelfarma IlaÃ§ San. ve Tic. Ltd. Sti.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Male,20 Years to 40 Years Â  (Adult),Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,NOV2020/1923|FARGE 367,18-Jun-20,28-May-20,21,5-Jun-20,22-May-20,11-Aug-20,11-Aug-20,"Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04400682
1118,NCT04339842,Eating Habits of Adults During the Quarantine,,Completed,No Results Available,Health Behavior|Eating Behavior,Other: Assessment of Dietary Changes in Adults in the Quarantine,Changes in the Eating Habits of Adults during the Quarantine,Eliz Arter|Cyprus Science University|Eastern Mediterranean University,All,"18 Years to 80 Years Â  (Adult, Older Adult)",,673,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Nutr2020,31-May-20,10-Apr-20,51,31-May-20,9-Apr-20,,22-Jul-20,"Online, Nicosia, Cyprus","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04339842
1119,NCT04407000,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions",Favipiravir,Completed,No Results Available,Bioequivalence,Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan),Primary PK End Points AUC0-tlast|Primary PK End Points Cmax|Secondary PK End Points AUC0-inf|Secondary PK End Points tmax,World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Male,20 Years to 40 Years Â  (Adult),Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,NOV2020/01925,8-Aug-20,23-Jun-20,46,20-Jul-20,29-May-20,,11-Aug-20,"Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",,https://ClinicalTrials.gov/show/NCT04407000
1120,NCT04763304,Self-contamination Following Removal of Two Personal Protective Equipment Suits: a Crossover Trial,,Completed,No Results Available,Personal Protective Equipment|Self Contamination,Other: Gown personal protective equipment (PPE-G) suit|Other: Coverall personal protective equipment (PPE-C) suit,Mean within-participant difference in self-contamination between PPE-G and PPE-C suits|Correlation between self-contamination and adherence to the PPE removal protocol,Hospital Italiano de Buenos Aires,All,"18 Years and older Â  (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,5646,18-Nov-20,1-Sep-20,78,29-Oct-20,21-Feb-21,,21-Feb-21,"Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT04763304
1121,NCT04386876,"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions",Orvical,Completed,No Results Available,Bioequivalence,Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet,Primary PK End Points,World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Male,20 Years to 40 Years Â  (Adult),Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,NOV2020/01911|FARGE365,11-Jun-20,30-Apr-20,42,22-May-20,13-May-20,,31-Dec-20,"Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04386876/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04386876/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04386876
1123,NCT04761510,Mindfulness-SOS: Stress Reduction for Refugees,,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Stress Related Disorder",Behavioral: Mindfulness-SOS for Refugees,Harvard Trauma Questionnaire according to DSM-5 (HTQ-5)|Brief Patient Health Questionnaire (PHQ-9)|Beck's Anxiety Inventory (BAI)|Post-Migration Living Difficulties Checklist (PMLD)|Brief Inventory of Thriving (BIT)|Dimensions of Anger Reactions-5 (DAR-5)|Parenting Scale (PS)|Modified 5-item Extended-Hurt/Insult/Threaten/Scream (Modified E-HITS)|Positive and Negative Affect Schedule (PANAS)|Brief assessment of mindful awareness|Brief assessment of self-compassion|Brief weekly assessment of formal and informal mindfulness practice|Brief weekly assessment of post-traumatic stress|Brief weekly assessment of depression|Brief weekly assessment of anxiety,University of Haifa,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Mindfulness-SOS for Refugees,14-Jan-21,14-Sep-20,122,14-Jan-21,21-Feb-21,,21-Feb-21,"Assaf, Tel Aviv, Merkaz, Israel",,https://ClinicalTrials.gov/show/NCT04761510
